<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="500" offset="1500" totalResults="4191"><SearchResults><Trial Id="170472"><Indications><Indication>Ewing sarcoma</Indication><Indication>Liposarcoma</Indication><Indication>Osteosarcoma</Indication><Indication>Rhabdomyosarcoma</Indication><Indication>Soft tissue sarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Caspase-3 stimulator</Action><Action>Caspase-9 stimulator</Action><Action>FGF receptor antagonist</Action><Action>Kit tyrosine kinase inhibitor</Action><Action>PDGF receptor beta modulator</Action><Action>RET tyrosine kinase receptor family inhibitor</Action><Action>Raf 1 protein kinase inhibitor</Action><Action>Raf B protein kinase inhibitor</Action><Action>TIE tyrosine kinase receptor inhibitor</Action><Action>Tek tyrosine kinase receptor inhibitor</Action><Action>VEGF-1 receptor antagonist</Action><Action>VEGF-2 receptor antagonist</Action><Action>VEGF-3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Sarcoma Alliance for Research through Collaboration</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-18T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2014-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02048371</Identifier><Identifier>SARC024</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Fatigue</Indication><Indication>Hypertension</Indication><Indication>Hypokalemia</Indication><Indication>Hypophosphatemia</Indication><Indication>Muscle weakness</Indication><Indication>Neutropenia</Indication><Indication>Oral mucositis</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>regorafenib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the safety and efficacy of oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas. A total of 30 patients were enrolled between September 2014 and March 2016 at 14 US sites [ 1931886 ]. The primary objective of the study was to determine the PFS according to RECIST 1.1. The secondary objectives were: To determine the AEs, ORR, TTP, PFS at 8, 12 and 16 weeks, OS and DSS. To evaluate the PFS, RR, TTP, OS</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bone tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Bone tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bone tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Bone tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Bone tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas</TitleDisplay><PatientSegmentTerms><PatientSegment>Bone tumor - Advanced Bone Cancer</PatientSegment><PatientSegment>Bone tumor - Subjects with Ewing's Sarcoma Family of Tumors - Subjects with Ewing's sarcoma</PatientSegment><PatientSegment>Bone tumor - Subjects with Osteosarcoma</PatientSegment><PatientSegment>Bone tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Ewings family of Tumors</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Liposarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Stage IV Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> CIC-DUX4 fusion protein </BiomarkerName><BiomarkerName> Lipase </BiomarkerName><BiomarkerName> RNA-binding protein EWS</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Comprehensive Cancer Center</Name><Name>Daniel Rushing, MD</Name><Name>David Boody-Alter</Name><Name>David Liebner, MD</Name><Name>Elizabeth Loggers, MD, PhD</Name><Name>Elizabeth Smith</Name><Name>Kristen Ganjoo, MD</Name><Name>Lara Davis, MD</Name><Name>Magnolia Manzano</Name><Name>Maria Ahern</Name><Name>Mark Agulnik, MD</Name><Name>Melissa Sindler</Name><Name>Michael Livingston, MD</Name><Name>Michele Niland</Name><Name>Michelle Treadwell</Name><Name>Rasima Cehic</Name><Name>Robert Maki, MD, PhD</Name><Name>Roxanne Moore</Name><Name>SARC Office</Name><Name>Sant Chawla, MD</Name><Name>Scott Okuno, MD</Name><Name>Steven Attia, DO</Name><Name>Torie Fechner</Name><Name>Vicky Keedy, MD</Name><Name>Victoria Chua</Name><Name>Warren Chow, MD</Name></ContactNames></Trial><Trial Id="169666"><Indications><Indication>Asthma</Indication></Indications><CompaniesCollaborator><Company>National Institute for Health Research (NIHR)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Alder Hey Children's NHS Foundation Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-05-11T00:00:00Z</DateChangeLast><DateEnd>2016-09-01T00:00:00Z</DateEnd><DateStart>2013-11-25T00:00:00Z</DateStart><Identifiers><Identifier>13/NW/0738</Identifier><Identifier>15768</Identifier><Identifier>Humox Study</Identifier><Identifier>ISRCTN62616194</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard oxygen therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Fisher and Paykel MR850 humidifier alone</Intervention><Intervention>OxygenTherapy System alone</Intervention><Intervention>cold humidified oxygen alone</Intervention><Intervention>warm humidified oxygen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would receive either standard oxygen therapy, warm humidified oxygen or &lt;b&gt;cold&lt;/b&gt; humidified oxygen. Heated humidified oxygen will be delivered by a Fisher and Paykel MR850 humidifier and a RT408 OxygenTherapy System through a System facemask...pilot, randomized, controlled trial in which pateints would receive either: standard oxygen therapy; warm humidified oxygen; &lt;b&gt;cold&lt;/b&gt; humidified oxygen. A range of outcomes pateints be measured which have previously been assessed as relevant and important</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Asthma - Health Economic Assessments</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Humox Study: To assess whether humidified oxygen is more effective than standard oxygen therapy in treating children with acute severe asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with uncontrolled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Paul Liverpool</Name><Name>Paul Mcnamara</Name></ContactNames></Trial><Trial Id="169115"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2017-07-13T00:00:00Z</DateChangeLast><DateEnd>2007-08-31T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2006-003181-34</Identifier><Identifier>NCT00408395</Identifier><Identifier>V70P2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Fluad alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>281</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>other vaccine component, or impairment/alteration of immune function Experience of a severe acute infectious disease in the month prior to study start or experience of a mild acute infection disease in the week prior the study start (untreated common &lt;b&gt;cold&lt;/b&gt; is acceptable) Fever within the 7 days before enrollment Known or suspected impairment/alteration of immune function, for example, resulting from receipt of immunosuppressive, immunostimulants, parenteral immunoglobulin preparation, blood products,</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Immunogenicity of Two Commercially Available Influenza Vaccines in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Novartis Vaccines (formerly Chiron Vaccines)</Name></ContactNames></Trial><Trial Id="168668"><Indications><Indication>Hepatocellular carcinoma</Indication></Indications><CompaniesCollaborator><Company>The Princess Margaret Hospital Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>The University Health Network</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-09-26T00:00:00Z</DateChangeLast><DateEnd>2019-08-31T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>COLD 2</Identifier><Identifier>NCT00914355</Identifier><Identifier>UHN REB 07-0346-C</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Stereotactic body radiation therapy (SBRT) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>47</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumor size, slow progression of the disease, prolong life and improve quality of life of patients with hepatocellular carcinoma, that cannot be removed surgically (unresectable) and cannot be treated with ablative therapy (eg, radio-frequency ablation) or trans-arterial chemo-embolization (TACE) therapy (delivery of chemotherapy through an artery that feeds into the liver). It is hoped that knowledge</Teaser><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Biomarkers - Assessment of alfa-feto protein (AFP) markers</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of radiographic response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability - Assessment of complication rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COLD 2: Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Unresectable Hepato-biliary Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>144 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Laura Dawson, MD</Name></ContactNames></Trial><Trial Id="168014"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>City of Hope Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-02T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2011-03-14T00:00:00Z</DateStart><Identifiers><Identifier>09101</Identifier><Identifier>BC095002</Identifier><Identifier>NCI-2010-00322</Identifier><Identifier>NCT01093612</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>18F-FDG alone</Intervention><Intervention>64Cu-DOTA-trastuzumab alone</Intervention><Intervention>PET/CT alone</Intervention><Intervention>trastuzumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Eligibility part I (determination of the &lt;b&gt;cold&lt;/b&gt; dose): Participants must be women who have histological confirmation of metastatic invasive breast cancer that...cancer. Primary objectives: To determine the dose of pre-administered &lt;b&gt;cold&lt;/b&gt; antibody that optimizes image quality of 64Cu-DOTA-trastuzumab PET without increasing...PET/CT scan. Patients received 5 or 45 (n = 16) or 50 mg of &lt;b&gt;cold&lt;/b&gt; trastuzumab prior to the injection of 64Cu-trastuzumab. PET/CT scans were obtained at 21 to 25</Teaser><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of signaling pathway</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Breast Cancer Subjects with Bone Metastasis</PatientSegment><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Phosphatidylinositol 3-Kinase </BiomarkerName><BiomarkerName> RAC-alpha serine/threonine-protein kinase </BiomarkerName><BiomarkerName> Standardized uptake value</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>105 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joanne Mortimer</Name></ContactNames></Trial><Trial Id="16796"><Indications><Indication>Asthma</Indication><Indication>Common cold</Indication><Indication>Skin burns</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Bradykinin receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Scios Inc</Company></CompaniesSponsor><DateChangeLast>2008-06-11T00:00:00Z</DateChangeLast><DateStart>1991-12-31T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>NPC-567 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Patients with asthma, common &lt;b&gt;cold&lt;/b&gt; and skin burns</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase II, double-blind, placebo-controlled, efficacy study of intranasal administration of NPC-567 on the response to nasal provocation with bradykinin</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="167951"><Indications><Indication>Throat disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action><Action>Oxidoreductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Prostaglandin synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Yeungnam University College of Medicine</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2014-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02039427</Identifier><Identifier>YUH-3368-sore throat</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention><Intervention>ketorolac alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>192</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to evaluate the effect of ketorolac on sore throat in comparison to dexamethasone after thyroidectomy in female adult patients. The investigator would explore how the analgesic and anti-inflammatory effects of ketorolac influence airway symptoms following general anesthesia with tracheal intubation.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Hyperthyroidism - Hyperthyroid Subjects Scheduled for Thyroidectomy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sung Mee Jung, M.D.</Name></ContactNames></Trial><Trial Id="167221"><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Rigshospitalet, Denmark</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2019-01-29T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2014-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-004462-33</Identifier><Identifier>NCT02033356</Identifier><Identifier>SM3-PJ-13</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Adductor canal block alone</Intervention><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this prospective, dose finding study was to estimate the minimal effective volume (ED95) for lidocaine 1.0% for filling the adductor canal when placing an adductor canal block. Investigators would apply the Continual Reassesment Method (CRM) for estimating the ED95 and use an MRI scan to evaluate the main objective and ensure spread to the distal part of the adductor canal. Secondary objectives were to investigate the effect on volume on spread to the femoral tiangle, muscle strength and</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ED95 of Lidocaine 1.0% for Filling the Adductor Canal</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pia Jaeger, MD</Name></ContactNames></Trial><Trial Id="167214"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>MediQuest Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-03-25T00:00:00Z</DateChangeLast><DateStart>2006-07-31T00:00:00Z</DateStart><Identifiers><Identifier>06-001</Identifier><Identifier>NCT00378521</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MQX-503 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the response to two different strengths of a topical gel containing nitroglycerin ( MQX-503 ) in patients with Raynaud's disease.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Assessment of blood flow to return cold exposure.</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Time required for skin temperature to return after cold exposure</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Indices or Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Dose-Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Leslie Klaff, MD</Name></ContactNames></Trial><Trial Id="166487"><Indications><Indication>Breast tumor</Indication></Indications><CompaniesSponsor><Company>Dignitana Ab</Company><Company>Target Health Inc.</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-02-06T00:00:00Z</DateChangeLast><DateEnd>2014-09-01T00:00:00Z</DateEnd><DateStart>2013-07-01T00:00:00Z</DateStart><Identifiers><Identifier>DIG-001</Identifier><Identifier>NCT01831024</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Dignicap alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>investigational agents, drugs, device or procedure that may cause hair loss Intercurrent life-threatening malignancy A history of &lt;b&gt;cold&lt;/b&gt; agglutinin disease or cryoglobulinemia. Evidence of untreated or poorly controlled hyper or hypothyroidism A history of silicon...at each chemotherapy cycle. Hair loss will be evaluated by patient self assessment of five standardized photographs taken prior to each chemotherapy cycle. A concurrent control group not using a &lt;b&gt;cold&lt;/b&gt; cap will also be evaluated.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alopecia - Assessment of Clinical Response - Assessment of hair loss</EndpointIndex><EndpointIndex>Alopecia - Assessment of Hair Growth &amp; Characteristics</EndpointIndex><EndpointIndex>Alopecia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Alopecia - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Alopecia - Assessment of adverse events</EndpointIndex><EndpointIndex>Alopecia - Patient Reported Outcomes/Quality of Life Assessments - European Organization for Research and Treatment of Cancer-Quality of Life-BR23 questionnaire</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-BR23</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dean Scale for alopecia</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-BR</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Alopecia - Subjects with/at Risk of Chemotherapy/Radiotherapy Induced Alopecia</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Cancer supportive care - Cancer- Aloplecia/Hair loss</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>14 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Eva Jurewicz</Name><Name>Glen Park</Name><Name>Hope Rugo</Name><Name>Margarita Gilyadova</Name><Name>Paula Klein</Name><Name>Susan Melin</Name><Name>Tessa Cigler</Name></ContactNames></Trial><Trial Id="166155"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><CompaniesSponsor><Company>Chinese University of Hong Kong</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country></Countries><DateChangeLast>2017-08-01T00:00:00Z</DateChangeLast><DateStart>2004-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ICM/CTS/03/333</Identifier><Identifier>NCT00456755</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Shi-Bi-Lin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>126</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Pregnant women and women at risk of conception Received allergen injections in previous two years Regular medications for AR or &lt;b&gt;cold&lt;/b&gt; and other allergic disorder Seasonal allergic rhinitis, vasomotor rhinitis and rhinitis medicamentosa Nasal structure deformities, nasal polyps and hypertrophic rhinitis Systematic cortisosteroid used within recent 3 months or nasal cortisosteroid with 15 days Other active respiratory disorders</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of rhinorrhoea</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of life</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Herbal Treatment for Perennial Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Zhao Yu, PhD</Name></ContactNames></Trial><Trial Id="16609"><Indications><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Cough</Indication><Indication>Pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Fibrosuppressant</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation local</Technology><Technology>Peptide</Technology><Technology>Transmucosal formulation</Technology></Technologies><CompaniesCollaborator><Company>Texas Tech University</Company></CompaniesCollaborator><CompaniesSponsor><Company>Amarillo Biosciences Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2012-04-30T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>07HUCO01</Identifier><Identifier>NCT00690885</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>interferon-alpha, Amarillo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough - Assessment of cough intensity/frequency</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Cough</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Therapy Related Outcomes - Assessment of use of rescue intervention</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Interferon-Alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 1/Mild COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with comorbid conditions</PatientSegment><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lorenz Lutherer</Name></ContactNames></Trial><Trial Id="165910"><Indications><Indication>Metastatic esophageal cancer</Indication><Indication>Metastatic stomach cancer</Indication></Indications><CompaniesCollaborator><Company>US Department of Defense</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-09T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>13-165</Identifier><Identifier>NCT02023996</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>89Zr-DFO-trastuzumab alone</Intervention><Intervention>Positron-emission tomography (PET) imaging alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Patients would receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab which would be given iv over 5 to 10 min. Injection of &lt;b&gt;cold&lt;/b&gt; trastuzumab would be mixed with 89Zr-DFO-trastuzumab so that total mass was equal to 50 mg. In the first ten patients the investigators wish to obtain normal organ dosimetry, pharmacokinetics and determine optimal imaging time, therefore these patients would undergo imaging at</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment><PatientSegment>Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with HER2 Positive Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage IV Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Standardized uptake value</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>84 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Neeta Pandit-Taskar, MD</Name><Name>Yelena Janjigian, MD</Name></ContactNames></Trial><Trial Id="165601"><Indications><Indication>Diarrhea</Indication><Indication>Lower respiratory tract infection</Indication><Indication>Malnutrition</Indication></Indications><CompaniesSponsor><Company>International Centre For Diarrhoeal Disease Research, Bangladesh</Company></CompaniesSponsor><Countries><Country>Bangladesh</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2007-12-31T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2005033</Identifier><Identifier>NCT00388921</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vitamin A alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>260</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> height Z score&amp;lt; -3 of the National Center for Health Statistics (NCHS) reference Written informed consent of respective parents/ guardians for participation of the children in the study Children having diarrhea (watery or invasive) or cough and &lt;b&gt;cold&lt;/b&gt; or both for the last 48 h</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diarrhea - Anthropometric Assessments</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Co-morbidity - Assessment of respiratory infections</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Resolution of Diarrhoea</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pneumonia - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM</TitleDisplay><BiomarkerNames><BiomarkerName>Retinol-binding proteins</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Samima Sattart, MBBS</Name></ContactNames></Trial><Trial Id="164261"><Indications><Indication>Stage III melanoma</Indication><Indication>Stage IV melanoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF2 gene stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Live attenuated viral vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intratumoral formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Amgen Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-04-19T00:00:00Z</DateEnd><DateStart>2014-04-07T00:00:00Z</DateStart><Identifiers><Identifier>20120324</Identifier><Identifier>NCT02014441</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>talimogene laherparepvec alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>61</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective was to estimate the proportion of subjects with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first three cycles.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Melanoma - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Melanoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate</EndpointIndex><EndpointIndex>Melanoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Melanoma - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec</TitleDisplay><PatientSegmentTerms><PatientSegment>Melanoma - Subjects with Advanced/Metastatic Cancer</PatientSegment><PatientSegment>Melanoma - Subjects with Evidence of Metastasis</PatientSegment><PatientSegment>Melanoma - Subjects with Stage III Melanoma - Subjects with stage IIIB melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Stage III Melanoma - Subjects with stage IIIC melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Stage IV Melanoma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-01-25T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>15</NumberOfSites><ContactNames><Name>MD</Name></ContactNames></Trial><Trial Id="163995"><Indications><Indication>Pulpitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Consejo Nacional de Ciencia y Tecnología</Company></CompaniesSponsor><Countries><Country>Mexico</Country></Countries><DateChangeLast>2017-01-02T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>ibuprofen alone</Intervention><Intervention>epinephrine plus mepivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of the trial was to evaluate the effect of preoperative oral ibuprofen on the success of inferior alveolar nerve blocks (IANBs) with mepivacaine containing 1 : 100000 epinephrine for patients with symptomatic irreversible pulpitis (SIP) [ 1509526 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A randomized trial for efficacy of preoperative ibuprofen on the success of inferior alveolar nerve block in patients with symptomatic irreversible pulpitis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="162800"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Verona Pharma plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-07-02T00:00:00Z</DateChangeLast><DateStart>2013-03-25T00:00:00Z</DateStart><Identifiers><Identifier>CCRN 2257 (IPF)</Identifier><Identifier>EPOCh</Identifier><Identifier>EudraCT 2012-005794-31</Identifier><Identifier>UKCRN 14558</Identifier><Identifier>VRP700-002-2012</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carcainium chloride (inhaled, cough), Verona Pharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to assess the efficacy of a single dose of 100 mg of VRP-700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis (IPF).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Cough</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Therapy Related Outcomes - Assessment of efficacy/effectiveness of therapy</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TitleDisplay>EPOCh: A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy of a Single Dose of 100 mg of VRP-700 by Inhalation in Reducing the Frequency and Severity of Cough in Adult Patients With Idiopathic Pulmonary Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with idiopathic interstitial pneumonia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jacky Smith</Name><Name>Lui Franciosi</Name></ContactNames></Trial><Trial Id="162751"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytotoxic T-lymphocyte protein-4 stimulator</Action><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein conjugated</Technology><Technology>Protein fusion</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Immune Tolerance Network</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2019-01-16T00:00:00Z</DateChangeLast><DateEnd>2018-03-01T00:00:00Z</DateEnd><DateStart>2014-03-19T00:00:00Z</DateStart><Identifiers><Identifier>DAIT ITN059AI</Identifier><Identifier>ITN059AI</Identifier><Identifier>NCT01999868</Identifier><Identifier>PAUSE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>abatacept alone</Intervention><Intervention>ustekinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>lt; 150000 /microl Hemoglobin&amp;lt; 10 g/dl Females who are pregnant, lactating, planning on pregnancy during the study period, or unwilling to use FDA-approved method of birth control Receipt of a live vaccine (eg, varicella, measles, mumps, rubella, &lt;b&gt;cold&lt;/b&gt;-attenuated intranasal influenza vaccine, and smallpox) in the 6 weeks before enrollment BCG (Bacillus-Calmette-Guerin) vaccines one year prior to enrollment</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Psoriasis Recurrence</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PAUSE: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body surface area</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>James Krueger, MD, PhD</Name></ContactNames></Trial><Trial Id="162637"><Indications><Indication>Asthma attack</Indication></Indications><CompaniesSponsor><Company>CHU de Quebec-Universite Laval</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>12140</Identifier><Identifier>DIVA-pilot</Identifier><Identifier>NCT01999907</Identifier><Identifier>VD0001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vitamin D alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objectives of this 6-month, pilot, randomized, controlled, double-blind study were to: show that a vitamin D bolus is superior to placebo in raising vitamin D levels; record the number of asthma attacks and viral infections and in enrolled subjects; and identify problems that may call for protocol changes. The investigators hypothesized that a vitamin D bolus given in clinic will sufficiently increase the blood level of vitamin D to prevent the expected winter decline, compared with placebo, in</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum cytokines/interleukins/chemokines</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>DIVA-pilot: Vitamin D to Reduce Colds and Asthma Attacks in Young Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Calcium/Creatinine ratio </BiomarkerName><BiomarkerName> Chemokines </BiomarkerName><BiomarkerName> Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elizabeth Rousseau</Name><Name>Francine M Ducharme</Name><Name>Genevieve Mailhot</Name><Name>Jacques Corbeil</Name><Name>Megan Jensen</Name></ContactNames></Trial><Trial Id="162489"><Indications><Indication>Hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Aldosterone antagonist</Action><Action>Calcium channel inhibitor L-type</Action><Action>Mineralocorticoid receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Cardioprotectant</Action><Action>Diuretic agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>University of Texas Southwestern Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-17T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01996449</Identifier><Identifier>R01HL113738</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amlodipine alone</Intervention><Intervention>eplerenone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise. Muscle blood flow will be measured before and after hand grip exercises. &lt;b&gt;Cold&lt;/b&gt; pressor test: subjects will place hand in &lt;b&gt;cold&lt;/b&gt; water with ice for 3 min. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 min after the test. A subgroup of subjects</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Normotensive Subjects</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 1 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Cardiac Output </BiomarkerName><BiomarkerName> Muscle sympathetic nerve activity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Debbie Arbique, DNP</Name><Name>Poghni Peri-Okonny, MD</Name><Name>Wanpen Vongpatanasin, MD</Name></ContactNames></Trial><Trial Id="161700"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Fungicide</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Inhalant formulation</Technology><Technology>Natural product</Technology><Technology>Oligosaccharide</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>AlgiPharma AS</Company><Company>Technology Strategy Board</Company></CompaniesCollaborator><CompaniesSponsor><Company>Bio-Images Drug Delivery Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-06-28T00:00:00Z</DateChangeLast><DateEnd>2014-09-30T00:00:00Z</DateEnd><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-003774-27</Identifier><Identifier>BC-180-12</Identifier><Identifier>NCT01991028</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>OligoG CF-5/20 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to study the distribution of OligoG CF-5/20 dry powder and nebulized solution in the lungs of patients with cystic fibrosis and to find out how much of the formulation gets to the deep lung and how much of the formulation remains in the devices used for administration. Main objective of the trial: To determine the lung deposition of OligoG when administered to cystic fibrosis patients either as a nebulised solution or as a dry powder for inhalation. Secondary objectives</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Investigate Lung Deposition of Radiolabelled OligoG</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Howard NE Stevens, PhD</Name><Name>Lee Hodges</Name><Name>Sian Roberts</Name></ContactNames></Trial><Trial Id="161695"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Genentech Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Canada</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-003233-15</Identifier><Identifier>GX29107</Identifier><Identifier>NCT01987947</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>quilizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> investigational agent within 30 days of screening, and previous treatment with monoclonal antibody therapies used to treat CSU 9 months prior to screening Chronic urticarias other than CSU, including the following: Acute, solar, cholinergic, heat, &lt;b&gt;cold&lt;/b&gt;, aquagenic, delayed pressure or contact Other diseases and conditions with symptoms of urticaria Routine doses of the following medications within 30 days prior to screening: Systemic or topical corticosteroids (prescription or over the counter), hydroxychloroquine</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin E</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="160943"><Indications><Indication>Herpesvirus infection</Indication></Indications><CompaniesCollaborator><Company>Benu BioPharma Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Topical Remedy LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2014-07-31T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01985321</Identifier><Identifier>TR-H-211</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Merlin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>469</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the &lt;b&gt;cold&lt;/b&gt; sore would be completely healed or 14 days from the start of treatment, whichever comes first. At each clinic visit the &lt;b&gt;cold&lt;/b&gt; sore...the &lt;b&gt;cold&lt;/b&gt; sore or might impair accurate evaluation of the &lt;b&gt;cold&lt;/b&gt; sore lesion Subject has had a vaccine for herpes...previous &lt;b&gt;cold&lt;/b&gt; sore episodes Subject must have a history of at least half of their &lt;b&gt;cold&lt;/b&gt; sore episodes producing classical lesions (ie, episodes that progressed through macule</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>8</NumberOfSites></Trial><Trial Id="160647"><Indications><Indication>Cardiac failure</Indication></Indications><CompaniesCollaborator><Company>Innogene Kalbiotech Pte Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Nepean Blue Mountains Local Health District</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2013-11-18T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01981655</Identifier><Identifier>SOLACE1</Identifier><Identifier>SOLACE1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sodium lactate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> for cardiac pump failure Right heart failure: as evidenced by 1 out of 2: Bilateral leg oedema above ankles RV failure (low tricuspid annular plane systolic excursion (TAPSE), dilated floppy RV) Poor peripheral perfusion as evidenced by 2 out of 3 &lt;b&gt;Cold&lt;/b&gt; mottled skin low urine output acutely clouded sensorium/poor mentation: Consent obtained from patient or patients next of kin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Assessment of cardiac output</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function - Serum electrolytes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SOLACE1: A Study of 0.5 M Na Lactate Solution in Acute Heart Failure (AHF)</TitleDisplay><PatientSegmentTerms><PatientSegment>Cardiac failure - Subjects with Other Types of Heart Failure</PatientSegment><PatientSegment>Cardiac failure - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Cardiac failure - Systolic Heart Failure Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marek Nalos, MD</Name></ContactNames></Trial><Trial Id="160410"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesCollaborator><Company>Creative Concepts and Solutions Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Theranor Sprl</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2018-01-15T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-000057-31</Identifier><Identifier>ESTUAR</Identifier><Identifier>ESTUAR001</Identifier><Identifier>NCT01651715</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>TAO1 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>232</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>dispensed to patients who have signed informed consent. Upon contracting a common &lt;b&gt;cold&lt;/b&gt;, they would start the treatment immediately and take contact with the doctor...Any of the common &lt;b&gt;cold&lt;/b&gt; symptoms persisting since &amp;gt; 36 h Use of other homeopathic drugs designed to treat URTIs Use of antibiotics, anti-histaminergic drugs or...years Ability and willingness to adhere to the study protocol Signed informed consent Self-reported recently emerged symptoms of common &lt;b&gt;cold&lt;/b&gt;: answer 'Yes' to</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ESTUAR: Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections</TitleDisplay><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>33</NumberOfSites><ContactNames><Name>Luc Moriau, PhD</Name><Name>Michel Thiry, PhD</Name><Name>Stéphane Heijmans, MD</Name></ContactNames></Trial><Trial Id="160152"><Indications><Indication>Atopic dermatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-13 receptor antagonist</Action><Action>IL-4 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2019-02-22T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01979016</Identifier><Identifier>R668-AD-1307</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dupilumab alone</Intervention><Intervention>topical emollient alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to assess the efficacy of dupilumab , compared to placebo, in adult patients with moderate-to-severe atopic dermatitis.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dermatitis - Assessment of Clinical Response - Assessment of pruritus</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Dermatitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Dermatitis - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Dermatitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by patient-oriented eczema measure (POEM)</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Eczema Area and Severity Index (EASI) score</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Scoring Atopic Dermatitis (SCORAD) Index</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Determine the Safety and Effectiveness of Dupilumab (REGN-668/SAR-231893) for Treatment of Atopic Dermatitis (AD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD) - Subjects with moderate to severe atopic dermatitis</PatientSegment><PatientSegment>Dermatitis - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> C-C motif chemokine 17 </BiomarkerName><BiomarkerName> C-C motif chemokine 18 </BiomarkerName><BiomarkerName> C-C motif chemokine 26 </BiomarkerName><BiomarkerName> Claudins </BiomarkerName><BiomarkerName> Cytotoxic T-lymphocyte protein 4 </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Elongation of very long chain fatty acids protein 3 </BiomarkerName><BiomarkerName> Filaggrin </BiomarkerName><BiomarkerName> Immunoglobulin E </BiomarkerName><BiomarkerName> Inducible T-cell costimulator </BiomarkerName><BiomarkerName> Integrin alpha-X </BiomarkerName><BiomarkerName> Interleukin-13 </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-22 </BiomarkerName><BiomarkerName> Interleukin-31 </BiomarkerName><BiomarkerName> Keratin, type I cytoskeletal 16 </BiomarkerName><BiomarkerName> Loricrin </BiomarkerName><BiomarkerName> Periostin </BiomarkerName><BiomarkerName> Protein S100-A1 </BiomarkerName><BiomarkerName> T helper 17 cells </BiomarkerName><BiomarkerName> T-Helper 22 cells </BiomarkerName><BiomarkerName> T-lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Clinical Trial Management</Name></ContactNames></Trial><Trial Id="159559"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Germany</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2015-09-28T00:00:00Z</DateEnd><DateStart>2014-01-16T00:00:00Z</DateStart><Identifiers><Identifier>1750/2013</Identifier><Identifier>DRKS00005021</Identifier><Identifier>EudraCT 2013-002359-14</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ropivacaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this study was to evaluate, if the already implemented anesthetic procedure of ultrasound guided cauld blocks for operations below the umbilicus, in contrast to the literature, also could be implemented in children with a body weight &gt; 30 kg [ 1494846 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TitleDisplay>Ultrasound Guided Caudal Blockade in Children Between 30 and 50 kg: A Feasibility Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Maya Keplinger</Name></ContactNames></Trial><Trial Id="159515"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>NeRRe Therapeutics Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Italy</Country></Countries><DateChangeLast>2015-12-20T00:00:00Z</DateChangeLast><DateStart>2013-10-11T00:00:00Z</DateStart><Identifiers><Identifier>2013-002763-25</Identifier><Identifier>EUCTR2013-002763-25-IT</Identifier><Identifier>NT2013/Orv/Prot001</Identifier><Identifier>RELIEVE 1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects (the 'RELIEVE 1' study) [ 1495062 ]. Secondary objectives of the trial were: To assess the effects of orvepitant (10 and 30 mg qd) compared with placebo on quality of life measures using the Skindex-16 Questionnaire. To assess the effects of orvepitant (10 and 30 mg qd) compared with placebo on quality of sleep</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Sleep - Assessment by Leeds Sleep Evaluation Questionnaire (LSEQ)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Skindex16</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Verbal Rating Scale (VRS)</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by skindex score</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by skindex questionnaire</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints - Assessment of Other Treatment Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RELIEVE 1: A Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy of Two Different Dose Levels of Orvepitant (10 and 30 mg) Compared With Placebo on EGFRi-Induced Intense Pruritus in Oncology Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events - Chemotherapy induced skin reactions</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Pruritus - Subjects with Drug Induced Pruritus</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>PROJECT MANAGEMENT DEPARTMENT</Name></ContactNames></Trial><Trial Id="159463"><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Fibrosuppressant</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation local</Technology><Technology>Peptide</Technology><Technology>Transmucosal formulation</Technology></Technologies><CompaniesCollaborator><Company>Western Australia Department of Health- State Health Research Advisory Council [SHRAC]</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sir Charles Gairdner Hospital</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-10T00:00:00Z</DateChangeLast><DateStart>2009-05-04T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12609000976280</Identifier><Identifier>ANZCTR83791</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>interferon-alpha, Amarillo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>placebo, on the frequency and severity of winter &lt;b&gt;cold&lt;/b&gt; and flu-like symptoms (WCFLS) during the main winter colds and flu season in Australia. Frequency and severity of WCFLS will be assessed using a questionnaire submitted on a weekly basis by study subjects. The secondary objectives would be to compare Veldona and placebo treatment with respect to changes in days of work missed, &lt;b&gt;cold&lt;/b&gt;/flu medication usage, number of physician visits required due to &lt;b&gt;cold&lt;/b&gt;/flu symptoms, number of pharmacy visits required</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Influenza/Influenza Like Illness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alayne Bennett</Name><Name>David Smith</Name></ContactNames></Trial><Trial Id="158813"><Indications><Indication>Endometriosis</Indication><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Brigham &amp; Women's Hospital</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2010P002903</Identifier><Identifier>NCT01968694</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main aim of the study was to determine the efficacy of iv lidocaine on endometriosis pain.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Endometriosis - Assessment of Endometriosis Symptoms</EndpointIndex><EndpointIndex>Endometriosis - Assessment of Pain - Assessment by Short-form McGill Pain Questionnaire (SF-MPQ)</EndpointIndex><EndpointIndex>Endometriosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Endometriosis - Patient Reported Outcomes/Quality of Life Assessments - Numerical rating scale(NRS)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Intravenous Lidocaine on Endometriosis Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Endometriosis - Subjects with History of/Scheduled for Disease Specific Therapy - Women with history of/scheduled for medical therapy</PatientSegment><PatientSegment>Endometriosis - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Endometriosis - Subjects with Symptomatic Disease - Women with dysmenorrhea</PatientSegment><PatientSegment>Endometriosis - Women with Protocol Specified Menstrual Status - Pre-menopausal subjects</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with dysmenorrhoea</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with pelvic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antje Barreveld, MD</Name></ContactNames></Trial><Trial Id="15867"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus novel</Technology></Technologies><CompaniesSponsor><Company>BioDiem Ltd</Company></CompaniesSponsor><DateChangeLast>2017-07-10T00:00:00Z</DateChangeLast><DateStart>2004-04-15T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This phase II trial was to evaluate the safety and efficacy of H5N1 influenza vaccine (CoVaccine adjuvant) delivered by nasal spray for the potential prevention of influenza virus [ 553143 ].</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase II trial to evaluate the safety and efficacy of H5N1 influenza vaccine (CoVaccine adjuvant) delivered by nasal spray for the potential prevention of influenza</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="158541"><Indications><Indication>Influenza virus infection</Indication><Indication>Neisseria meningitidis meningitis</Indication><Indication>Streptococcus pneumoniae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Freeze drying</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Rockefeller University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2022-03-31T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01967238</Identifier><Identifier>TWA-0804</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Menveo alone</Intervention><Intervention>Pneumovax 23 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>140</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Bioavailability</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pneumococcal Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Open-Label Study of IgG Fc Glycan Composition in Human Immunity</TitleDisplay><BiomarkerNames><BiomarkerName>Fucose </BiomarkerName><BiomarkerName> Galactose </BiomarkerName><BiomarkerName> N-acetylneuraminic acid</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>108 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Recruitment Specialist</Name><Name>Rockefeller University Recruitment Office</Name><Name>Taia T Wang, MD PhD</Name></ContactNames></Trial><Trial Id="158434"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Janssen Research &amp; Development LLC</Company><Company>Janssen-Cilag International NV (BE)</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Hungary</Country><Country>UK</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Malaysia</Country><Country>Germany</Country><Country>China</Country><Country>Taiwan</Country><Country>South Korea</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-003607-36</Identifier><Identifier>CNTO6785OPD2001</Identifier><Identifier>CR102318</Identifier><Identifier>NCT01966549</Identifier><Identifier>NMRR-12-1372-14065</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>CNTO-6785 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>187</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>study visit 1; COPD exacerbation that required systemic steroids and/or antibiotics or required hospitalization and was not associated with pneumonia within 6 weeks prior to study visit 1; upper or lower respiratory tract infection (including common &lt;b&gt;cold&lt;/b&gt; or sinusitis) that was not associated with either pneumonia or COPD exacerbation within 4 weeks prior to study visit 1</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of FEV1/FVC Ratio</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Flow (FEF)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC post bronchodilator administration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC pre bronchodilator administration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements - PEFR post bronchodilator administration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements - PEFR pre bronchodilator administration</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Effectiveness and Safety of CNTO-6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>56</NumberOfSites><ContactNames><Name>Clinical Registry Group</Name><Name>Lim Xiu Wei</Name><Name>Samira Shetye</Name></ContactNames></Trial><Trial Id="157943"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>University of British Columbia</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>H13-01551</Identifier><Identifier>LipTRP</Identifier><Identifier>NCT01963910</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin cream alone</Intervention><Intervention>mannitol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Diet containing capsaicin (Cayenne pepper, capsicum) (spicy foods), more than once a week Meal containing capsaicin (spicy foods) within 5 days prior to the experiment Any lesion, cracking, &lt;b&gt;cold&lt;/b&gt; sore or abrasion on the lips Inability to tolerate capsaicin containing 'spicy foods' Wearing lipstick or lip balm on the upper lip Inability to fill out an NRS pain scale Use of painkilling medication, within 24 h of the study Allergy to any of the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LipTRP: Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream</TitleDisplay><PrimaryCompletionDate type="Actual">2014-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Helene Bertrand, MD, CM, CCFP</Name></ContactNames></Trial><Trial Id="156395"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Guanylate cyclase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Bayer AG</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-11-21T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>16787</Identifier><Identifier>2013-001899-38</Identifier><Identifier>DIGIT</Identifier><Identifier>NCT01926847</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspepsia</Indication><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>riociguat alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>23</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>mean digital blood flow by 40.6 and 15.1% at room temperature and after &lt;b&gt;cold&lt;/b&gt; water exposure, respectively compared to baseline. Overall, 60% of patients responded...led to mean increase in digital blood flow of 135.7 and 38.9% at room temperature and &lt;b&gt;cold&lt;/b&gt; water exposure, respectively compared to baseline. At 1, 2, 3 and 4 h, mean...Placebo-corrected changes in digital blood flow at room temperature (RT)&amp;nbsp; and after &lt;b&gt;cold&lt;/b&gt; exposure (CE) were + 46 and 9%, with high inter-individual variability. At</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiac Function - Blood pressure change</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma drug concentration</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Safety and Tolerability - Assessment of adverse effects</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex><EndpointIndex>Peripheral vascular disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Scleroderma - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Scleroderma - Assessment of adverse events</EndpointIndex><EndpointIndex>Scleroderma - Clinical Assessments</EndpointIndex><EndpointIndex>Scleroderma - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>DIGIT: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Bayer Study Director</Name></ContactNames></Trial><Trial Id="156159"><Indications><Indication>Lower respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Alfred Health</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2018-10-10T00:00:00Z</DateChangeLast><DateEnd>2017-08-23T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>342/13</Identifier><Identifier>NCT01952470</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to evaluate the safety and efficacy of dornase alfa , compared to isotonic saline on quantitative and qualitative respiratory outcomes and the need for antibiotics, length of stay and exacerbation/re-admission rates. Investigators hypothesize that dornase alfa would be more effective than isotonic saline.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung transplantation - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Lung transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Lung transplantation - Assessment of Pulmonary Function - Forced expiratory volume in the first second (FEV1)</EndpointIndex><EndpointIndex>Lung transplantation - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Lung transplantation - Health Economic Assessments</EndpointIndex><EndpointIndex>Lung transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Leicester Cough Questionnaire (LCQ)</EndpointIndex><EndpointIndex>Lung transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment by St Georges Respiratory Questionnaire (SGRQ) activity scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung transplantation - Lung Transplant Recipients</PatientSegment><PatientSegment>Lung transplantation - Lung Transplant Recipients - Double lung transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-08-23T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Anne Holland</Name><Name>Benjamin J Tarrant, B.Physio</Name><Name>Brenda Button</Name><Name>Bruce Thompson</Name><Name>Greg Snell</Name><Name>Louise Fuller</Name><Name>Steven Ivulich</Name></ContactNames></Trial><Trial Id="155991"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Menlo Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Ireland</Country></Countries><DateChangeLast>2018-04-12T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-001581-10</Identifier><Identifier>NCT01951274</Identifier><Identifier>TCP 101</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Drowsiness</Indication><Indication>Spontaneous abortion</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>serlopitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>257</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this multicenter, randomized, placebo-controlled study was to evaluate several doses of a novel treatment for chronic itch compared to placebo for subjects whose condition had not responded to other treatments. Main objective of the trial was to compare the efficacy and safety of VPD-737 tablets (at concentrations of 0.25, 1 or 5 mg) and placebo given once-daily for 8 weeks for the treatment of prurigo nodularis (PN) [ 1621441 ], [ 1787170 ], [ 2006853 ], [ 2006876 ]. </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pruritus - Pruritus Assessed by Visual Analog Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>VPD-737 for Treatment of Chronic Pruritus</TitleDisplay><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Edward F Schnipper, MD</Name></ContactNames></Trial><Trial Id="155687"><Indications><Indication>Growth hormone deficiency</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Growth hormone ligand</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Growth hormone ligand</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cloning technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>PEGylated formulation</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Ascendis Pharma A/S</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Egypt</Country><Country>Germany</Country><Country>Greece</Country><Country>Bulgaria</Country><Country>Slovenia</Country><Country>Ukraine</Country><Country>Romania</Country><Country>Belarus</Country><Country>Russian Federation</Country><Country>Turkey</Country><Country>Hungary</Country><Country>Czech Republic</Country><Country>Poland</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-002787-27</Identifier><Identifier>ACP-001_CT-004</Identifier><Identifier>NCT01947907</Identifier></Identifiers><InterventionsControlDisplay><Intervention>somatropin, Pfizer alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ACP-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>growth hormone (GH) phase II study. The aim of this analysis was to evaluate the efficacy of dose increment of  ACP-001 auto-injector with bracketed dosing using dual chamber cartridges (DCC) which provided weekly weight-based dosing, while eliminating &lt;b&gt;cold&lt;/b&gt; storage, primings, air shots, dose settings and GH waste, for treatment of growth hormone deficiency in children. In sensitivity analyses, robust growth with minimal variation was observed with the proposed 20% DCC dose increment. Over the dose range</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Auxological Measures - Assessment of height velocity</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Biomarkers - Assessment of IGF-I</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypopituitarism - Subjects with Growth hormone (GH) Deficiency</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Height velocity </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Somatotropin </BiomarkerName><BiomarkerName> Thyroid hormones</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>47</NumberOfSites><ContactNames><Name>Clinical Trials Info</Name><Name>Michael Beckert, MD</Name><Name>Pierre Chatelain, Prof, MD</Name></ContactNames></Trial><Trial Id="154305"><CompaniesCollaborator><Company>St Olavs Hospital</Company><Company>University of Iceland</Company></CompaniesCollaborator><CompaniesSponsor><Company>Norwegian University of Science and Technology (NTNU)</Company></CompaniesSponsor><Countries><Country>Norway</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-004989-18</Identifier><Identifier>NCT01939444</Identifier><Identifier>OPI-12-001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>naloxone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> History of liver disease Taking any medications including herbal medicines the last week history of drug abuse Any local nasal disease or nasal surgery or recent &lt;b&gt;cold&lt;/b&gt; for the last week Any history of drug allergies</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Bioavailability</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Pilot Study of the Bioavailability of Nasal Naloxone</TitleDisplay><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Øyvind Ellingsen, MD PhD</Name></ContactNames></Trial><Trial Id="154296"><Indications><Indication>Metabolic disorder</Indication></Indications><CompaniesSponsor><Company>Imperial College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-04-19T00:00:00Z</DateChangeLast><DateEnd>2020-07-31T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>13HH0688</Identifier><Identifier>NCT01935791</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>18F-FDG alone</Intervention><Intervention>glucagon (Glucagen) alone</Intervention><Intervention>infrared thermography alone</Intervention><Intervention>positron emission tomography–computed tomography alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>after &lt;b&gt;cold&lt;/b&gt; exposure (+0.44degC; p &amp;lt; 0.001 versus control), In subjects with a &lt;b&gt;cold&lt;/b&gt;-induced increase in the metabolic activity...detected. Sympathetic activation measured by circulating norepinephrine levels were increased after &lt;b&gt;cold&lt;/b&gt; exposure, but not after glucagon infusion [ 1732392 ]. In March... Subjects with &lt;b&gt;cold&lt;/b&gt;-induced BAT activation on 18F-FDG positron emission tomography (PET)/computed tomography (CT) (n = 8) were randomized to a second 18F-FDG</Teaser><TrialCategories><Category>Biological</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Investigating Brown Adipose Tissue Activation in Humans</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Brown adipose tissue </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Norepinephrine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>84 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Waljit Dhillo</Name></ContactNames></Trial><Trial Id="152405"><Indications><Indication>HIV infection</Indication></Indications><CompaniesCollaborator><Company>Medical Research Council</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Cape Town</Company></CompaniesSponsor><Countries><Country>South Africa</Country></Countries><DateChangeLast>2018-12-20T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2005-06-01T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN21322548</Identifier><Identifier>TB-IRIS-RCT</Identifier><Identifier>TB-IRIS-RCT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>prednisone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> HAART is documented and the patient was on anti-tuberculous therapy when HAART commenced There are new or recurrent constitutional symptoms PLUS one or more of: New or expanding lymph nodes (&gt; 20 mm or &gt; 50% in volume) New or expanding tuberculous &lt;b&gt;cold&lt;/b&gt; abscesses (eg, paraspinal) New or expanding pulmonary infiltrates (radiographically confirmed) New or enlarging serous effusions (pericardial, pleural or ascitic) Patients presenting with other manifestations of TB-IRIS (eg, central nervous system </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Anthropometric Assessments</EndpointIndex><EndpointIndex>HIV infection - Assessment of AIDS Defining Events(CDC Criteria)</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Morbidity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Performance Status - Assessment by Karnofsky Performance Status</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Clinical Assessments - Assessment of liver function</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Medical Outcomes Study HIV Health Survey (MOSHIV)</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Clinical Response - Assessment of signs and symptoms</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Disease Relapse/Recurrence - Assessment of recurrence rate</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Immune Response - Assessment of CD4/CD8 count</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Laboratory/Diagnostic Measures - Liver function tests</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Mycobacterium tuberculosis infection - Patient Reported Outcomes/Quality of Life Assessments - Karnofsky score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TB-IRIS-RCT: A Randomized Controlled Trial of Prednisone Versus Placebo in the Management of Human Immunodeficiency Virus (HIV)-Infected Patients Presenting With Mild to Moderate Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome After Commencing Highly Active Antiretroviral Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Subjects with comorbid conditions</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment><PatientSegment>Mycobacterium tuberculosis infection - Subjects at risk of developing disease - Immunocompromised state as a risk factor</PatientSegment><PatientSegment>Mycobacterium tuberculosis infection - Subjects at risk of developing disease - Subjects with high risk medical conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gary Maartens</Name></ContactNames></Trial><Trial Id="152342"><Indications><Indication>Periodontitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Corporacion de Fomento de la Produccion</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Los Andes</Company></CompaniesSponsor><Countries><Country>Chile</Country></Countries><DateChangeLast>2014-07-31T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CORFO-13IDL1-18270</Identifier><Identifier>NCT01929135</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>atorvastatin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>38</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the present study was to develop statin ( atorvastatin 2%) medicated toothpaste and evaluate its effectiveness, as complement to non-surgical conventional periodontal treatment. Clinical as well as molecular examination would be made at the beginning and after 1 month of treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Short-term Effect of 2% Atorvastatin Dentifrice in Periodontal Status</TitleDisplay><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Neutrophil collagenase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>David R Rosenberg</Name></ContactNames></Trial><Trial Id="152229"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin sensitizer</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2013-12-13T00:00:00Z</DateChangeLast><DateEnd>2000-05-30T00:00:00Z</DateEnd><DateStart>1998-05-09T00:00:00Z</DateStart><Identifiers><Identifier>49653/055</Identifier><Identifier>BRL49653C/055</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Bronchitis</Indication><Indication>Constipation</Indication><Indication>Edema</Indication><Indication>Injury</Indication><Indication>Leukopenia</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including rosiglitazone , rosiglitazone 2 mg + sulphonylurea , rosiglitazone 4 mg + sulphonylurea , rosiglitazone 8 mg + sulphonylurea , sulphonylurea</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>163</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>15.4%), injury (7.5, 3 versus 6.2%), leukopenia (4.5, 7.6 versus 4.6%), edema (3, 6.1 versus 4.6%), bronchitis (4.5, 4.5 versus 4.6%), constipation (4.5, 1.5 versus 4.6%), abdominal pain (3, 4.5 versus 1.5), weight gain (4.5, 9.1 versus 15.4%), common &lt;b&gt;cold&lt;/b&gt; syndrome (13.4, 18.2 versus 18.5%) and increased creatine phosphokinase (6, 10.6 versus 13.8%) in 2, 4 versus 8 mg of rosiglitazone , respectively. Angina pectoris, hyperglycemia, bronchitis, malaise, pneumonia were the serious adverse events in patients</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of C-peptide Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Fructosamine Levels/Glycoalbumin Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of immuno reactive insulin (IRI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Clinical Evaluation of BRL 49653C in Type 2 Diabetes Mellitus (Combination Therapy with Sulphonylurea) - Double-blind, Dose-finding Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects on other single antidiabetic agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1,5-Anhydroglucitol </BiomarkerName><BiomarkerName> D-Isoglucosamine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Total cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="152023"><Indications><Indication>Pleural disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Inhalant formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Medical Research Council</Company><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Oxford University Hospitals NHS Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-07-23T00:00:00Z</DateChangeLast><DateEnd>2007-10-11T00:00:00Z</DateEnd><DateStart>2003-10-11T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2004-000658-22</Identifier><Identifier>ISRCTN57454527</Identifier><Identifier>MIST2</Identifier><Identifier>MREC N: 04/mre5/53</Identifier><Identifier>UKCRN ID: 4037</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>alteplase plus dornase alfa</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>210</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to test the safety of alteplase and DNase (dornase alfa) drugs, and whether they could help to drain the fluid around the lungs [ 1469495 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sepsis - Assessment of Biomarkers - Protein C</EndpointIndex><EndpointIndex>Sepsis - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Sepsis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Sepsis - Assessment of Survival - Assessment of Survival Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MIST2: The Second Multicenter Intra-Pleural Sepsis Trial (MIST2), to Assess Whether DNase or Alteplase, Improve Pleural Fluid Drainage in Pleural Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Sepsis - Subjects with Sepsis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Najib Rahman</Name><Name>Robert Davies</Name></ContactNames></Trial><Trial Id="151416"><Indications><Indication>Allergic rhinitis</Indication></Indications><CompaniesCollaborator><Company>National Institute on Deafness and Other Communication Disorders</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Pittsburgh</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2019-03-22T00:00:00Z</DateEnd><DateStart>2013-10-01T00:00:00Z</DateStart><Identifiers><Identifier>2P50DC007667-07</Identifier><Identifier>NCT01925729</Identifier><Identifier>PRO13040386</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>histamine alone</Intervention><Intervention>oxymetazoline alone</Intervention><Intervention>pseudoephedrine alone</Intervention><Intervention>ragweed alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>84</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Individuals with abnormally low tympanic membrane mobility, eg type B tympanogram Individuals reporting a previous adverse experience with breathing gas mixtures containing N2O (eg, during dental procedures) Individuals who have upper respiratory ('&lt;b&gt;cold&lt;/b&gt;') symptoms or allergic rhinitis symptoms (may be rescheduled) Individuals with single or multiple allergic sensitivities by screening history (experiment 2 only)</Teaser><TrialCategories><Category>Borderline product</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>TransMEM Gas Exchange - Project I, Aim II</TitleDisplay><BiomarkerNames><BiomarkerName>Blood flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2019-03-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>65 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cuneyt M Alper, MD</Name></ContactNames></Trial><Trial Id="151394"><Indications><Indication>Tendon disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Dermatological agent</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Patch formulation</Technology><Technology>Plaster</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Institut Biochimique SA</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2016-04-11T00:00:00Z</DateChangeLast><DateEnd>2014-04-24T00:00:00Z</DateEnd><DateStart>2013-02-11T00:00:00Z</DateStart><Identifiers><Identifier>12I-BMT08</Identifier><Identifier>EUCTR2012-005030-11-IT</Identifier><Identifier>EudraCT 2012-005030-11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> tendinopathy Patients having received a local corticosteroid injection for their tendinopathy or an intra-articular corticosteroid injection&amp;lt; 6 months before inclusion Patients having undergone a standard physiotherapeutic treatment (except for &lt;b&gt;cold&lt;/b&gt; or hot patch application and/or use of braces for casting), an electro-medical tecar therapy, a laser therapy, Iontophoresis therapy or eccentric training for the treatment of their tendinopathy&amp;lt; 3 months before inclusion Patients having taken systemic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of self efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Short-Term Efficacy and Safety of Two Different Treatment Regimens of Betamethasone Valerate 2.25 Mg Medicated Plaster in Patients With Chronic Tendinopathies of the Upper and Lower Limbs</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="149898"><Indications><Indication>Herpesvirus infection</Indication></Indications><CompaniesSponsor><Company>Lif-Hlaup EHF Bio-Gels Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Iceland</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2007-05-01T00:00:00Z</DateEnd><DateStart>2005-09-29T00:00:00Z</DateStart><Identifiers><Identifier>2005-001097-27</Identifier><Identifier>MONO-01</Identifier><Identifier>MONO-01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>monocaprin + doxycycline alone</Intervention><Intervention>monocaprin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to investigate the effect of a hydrogel containing monocaprin and doxycycline or hydrogel containing monocaprin alone on herpes labialis infection compared to placebo, by evaluating the effect of treatment on the development of the disease during treatment. Time to healing. The size of lesion and assessment of pain, tenderness, edema and amount of crust would be analyzed. A sample swab for viral culture and/ or detection of HSV DNA by PCR would be made initially</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Appearance</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of acceptability of therapy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MONO-01: A Study of the Clinical Activity of Monocaprin/Doxycycline Gel on Cold Sores</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="149656"><Indications><Indication>Common cold</Indication></Indications><CompaniesCollaborator><Company>Marinomed Biotechnologie GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>St Anna Children's Hospital</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2019-02-15T00:00:00Z</DateChangeLast><DateEnd>2009-12-23T00:00:00Z</DateEnd><DateStart>2009-01-21T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN52519535</Identifier><Identifier>PMID: 22950667</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Coldamaris prophylactic gel nasal spray alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>153</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>combination &lt;b&gt;cold&lt;/b&gt; products, antiviral, steroids, all nasal sprays, any &lt;b&gt;cold&lt;/b&gt;-directed herbal treatment, and any supplement or...or their parents considered that the subjects were in an early stage of a common &lt;b&gt;cold&lt;/b&gt; with symptoms no more than 36 h duration Subjects had a symptom score of at...combination &lt;b&gt;cold&lt;/b&gt; products, antivirals, oral or nasal steroids, all nasal sprays, any &lt;b&gt;cold&lt;/b&gt;-directed herbal treatment (eg andrographis</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza virus infection - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Symptom score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Prevention and Therapy of Respiratory Disease in Children Using Nasal Sprays</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Subjects with Influenza</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 2 </BiomarkerName><BiomarkerName> C-C motif chemokine 3 </BiomarkerName><BiomarkerName> C-C motif chemokine 4 </BiomarkerName><BiomarkerName> C-C motif chemokine 7 </BiomarkerName><BiomarkerName> Eotaxin </BiomarkerName><BiomarkerName> Fibroblast growth factor 3 </BiomarkerName><BiomarkerName> Fractalkine </BiomarkerName><BiomarkerName> Granulocyte colony-stimulating factor </BiomarkerName><BiomarkerName> Granulocyte-macrophage colony-stimulating factor </BiomarkerName><BiomarkerName> Interferon alpha-1/13 </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-12 </BiomarkerName><BiomarkerName> Interleukin-13 </BiomarkerName><BiomarkerName> Interleukin-15 </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-3 </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> Interleukin-5 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Interleukin-9 </BiomarkerName><BiomarkerName> Pro-epidermal growth factor </BiomarkerName><BiomarkerName> Transforming growth factor alpha </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Tamas Fazekas</Name></ContactNames></Trial><Trial Id="146952"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Tabriz University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-06-06T00:00:00Z</DateChangeLast><DateStart>2010-04-01T00:00:00Z</DateStart><Identifiers><Identifier>5/4/9503</Identifier><Identifier>IRCT138903064041N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fentanyl alone</Intervention><Intervention>bupivacaine, AstraZeneca plus clonidine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>140</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Coexisting diseases like sever common &lt;b&gt;cold&lt;/b&gt;, anemia</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACES Pain Rating Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Local Injection in Decreasing Post Tonsillectomy Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Mahin Seyedhejazi</Name><Name>Mahin Seyedhejazi</Name></ContactNames></Trial><Trial Id="146507"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Kelch like ECH associated protein 1 modulator</Action><Action>Nuclear erythroid 2-related factor 2 stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunomodulator</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Biogen Inc</Company></CompaniesSponsor><Countries><Country>Poland</Country></Countries><DateChangeLast>2014-02-04T00:00:00Z</DateChangeLast><IndicationsAdverse><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Inflammatory disease</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>dimethyl fumarate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>144</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to assess safety and efficay of BG-12 ( BG-00012 )in patients with patients with the chronic plaque, exanthematic guttate, erythrodermic, palmoplantar, or pustular types of psoriasis [ 1453615 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-50 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex></EndpointIndex><TitleDisplay>Fumaric Acid Esters Emerging as Treatment for Severe Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Erythrodermic Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Generalized Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Guttate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Localized Psoriasis - Subjects with palmoplantar psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Pustular Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="146475"><Indications><Indication>Cardiogenic shock</Indication><Indication>Myocardial infarction</Indication></Indications><CompaniesSponsor><Company>Hospices Civils De Lyon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2012.754</Identifier><Identifier>CLOTILDE</Identifier><Identifier>NCT01901471</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cyclosporine A (cremophor-free IV cyclosporine A formulation) alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Planned, not Initiated</Reason></ReasonForTrialDiscontinuation><Teaser>admission in the catheterism laboratory Patient presenting a cardiogenic shock defined by a SBP (systolic blood presuure)&amp;lt; 90 mmHg for a period over 30 min and do not answering to a test of vascular charge associated with signs peripheral hypoperfusion (&lt;b&gt;cold&lt;/b&gt; extremities, cyanosis, oliguria with urine output &amp;lt; 50 ml/h or alteration of higher mental functions) Clear information is delivered to the patient or a legal representative if present and preliminary oral consent obtained, followed by obtaining</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Markers - Creatine kinase (CK)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Echocardiography Findings</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Infarct Parameters - Limitation/Reduction of infarct size</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Creatine kinase (CK) levels</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Area of infarction (percentage)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CLOTILDE: Ciclosporine In Acute Myocardial Infarction Complicated By Cardiogenic Shock</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Non-ST Segment Elevation Myocardial Infarction(NSTEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention - PTCA alone</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 0</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 1</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - Off pump coronary artery bypass grafting (CABG)</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Complications of the Underlying IHD</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 0</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 1</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Non ST elevation myocardial infarction (NSTEMI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bicarbonates </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Cardiac Output </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Left ventricle </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Partial pressure of oxygen </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urinary flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-10-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>19</NumberOfSites><ContactNames><Name>Eric Bonnefoy-Cudraz, MD, PhD</Name></ContactNames></Trial><Trial Id="145945"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Voltage gated sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>North West Lung Centre Charity</Company></CompaniesCollaborator><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-11-06T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>117270</Identifier><Identifier>NCT01899768</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including GSK-2339345 , capsaicin , citric acid</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This randomized, double-blind study was designed to evaluate the effect of GSK-2339345 relative to placebo on the number of coughs in patients with Chronic Idiopathic Cough (CIC) administered by an Aqueous Droplet Inhaler (ADI). The primary aim was to investigate the efficacy of GSK-2339345 on reducing objective cough frequency in CIC patients. The secondary aim of this study was to investigate the efficacy of GSK-2339345 in inhibiting a hypertussive cough response elicited by capsaicin and citric</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>GSK-2339345 Hypertussive Challenge Study</TitleDisplay><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="145797"><Indications><Indication>Neisseria meningitidis infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology></Technologies><CompaniesSponsor><Company>JN-International Medical Corp</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>JN-NM-002</Identifier><Identifier>NCT01897402</Identifier></Identifiers><InterventionsControlDisplay><Intervention>meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>NmVac4-A/C/Y/W-135-DT alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>525</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>might interfere with the evaluation of the study objectives History of chronic or severe headaches, myalgia, arthralgia, malaise, fatigue or other systemic disorder commonly observed as AEs for licensed meningococcal vaccines Currently experiencing a &lt;b&gt;cold&lt;/b&gt;, flu or other acute illness (subject may be deferred until after recovery)</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Meningitis - Assessment of Immune Response - Assessment of anti-meningococcal antibody concentration</EndpointIndex><EndpointIndex>Meningitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Immune Response - Assessment of anti-meningococcal antibody concentration</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of local reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of systemic reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Immunogenicity And Safety Of Group A, C, Y and W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine</TitleDisplay><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Alberto Yataco, MD</Name><Name>Jeffrey E Atkinson, MD</Name><Name>Kendra Barton</Name><Name>Lisa Dreszer</Name><Name>Myron I Murdock, MD</Name><Name>Wendy Paxton</Name></ContactNames></Trial><Trial Id="143657"><Indications><Indication>Menopause</Indication></Indications><CompaniesSponsor><Company>Naturalendo Tech Co Ltd</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-14T00:00:00Z</DateChangeLast><DateEnd>2010-01-20T00:00:00Z</DateEnd><DateStart>2009-05-26T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN95953457</Identifier><Identifier>NET-ESTROG-100-001</Identifier></Identifiers><IndicationsAdverse><Indication>Fatigue</Indication><Indication>Insomnia</Indication><Indication>Melancholia</Indication><Indication>Paresthesia</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>EstroG-100 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>64</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women [ 1446666 ].</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Anthropometric Assessments</EndpointIndex><EndpointIndex>Insomnia - Assessment of Co-morbidity - Assessment of menopause</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep</EndpointIndex><EndpointIndex>Insomnia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Insomnia - Assessment of adverse events</EndpointIndex><EndpointIndex>Menopause - Assessment of Sleep</EndpointIndex><EndpointIndex>Menopause - Patient Reported Outcomes/Quality of Life Assessments - Assessment of hot flashes</EndpointIndex><EndpointIndex>Menopause - Patient Reported Outcomes/Quality of Life Assessments - Assessment of vulvar and vaginal atrophy symptoms</EndpointIndex><EndpointIndex>Menopause - Patient Reported Outcomes/Quality of Life Assessments - Kupperman menopause index(KMI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>African Ancestry</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>EstroG-100 on Menopausal Women</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Albert Chang</Name></ContactNames></Trial><Trial Id="143265"><Indications><Indication>Raynauds disease</Indication></Indications><CompaniesSponsor><Company>Royal National Hospital For Rheumatic Diseases</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-09-08T00:00:00Z</DateChangeLast><DateStart>2010-09-29T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2009-013468-37</Identifier><Identifier>MREC 09/H0101/81</Identifier><Identifier>Protocol code BA7</Identifier><Identifier>UKCRN 9654</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aspirin plus dipyridamole</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>discoloration, in conjunction with pain upon &lt;b&gt;cold&lt;/b&gt; exposure or emotional stress within the one week of examination in the absence of other features of connective...assessment of treatment effects on: The clinical severity of Raynaud's phenomenon. The finger blood flow response to &lt;b&gt;cold&lt;/b&gt; stress test (assessed using thermal...oxidative stress. Secondary objectives: To assess the reproducibility of the &lt;b&gt;cold&lt;/b&gt; challenge test assessed using thermal imaging and laser contrast speckle imaging</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Diagnosis</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Short-term Open-label Single Site Pilot Study Evaluating the Use of Asasantin Retard Therapy in the Management of Raynaud’s Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain due to dermatological conditions</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>John Pauling</Name></ContactNames></Trial><Trial Id="14324"><Indications><Indication>HIV infection</Indication><Indication>Papillomavirus infection</Indication><Indication>Verruca vulgaris</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Fibrosuppressant</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation local</Technology><Technology>Immuno-oncology</Technology><Technology>Peptide</Technology><Technology>Transmucosal formulation</Technology></Technologies><CompaniesCollaborator><Company>Amarillo Biosciences Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>TOLMAR Therapeutics Inc</Company></CompaniesSponsor><DateChangeLast>2008-05-20T00:00:00Z</DateChangeLast><DateStart>2002-03-20T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>interferon-alpha, Amarillo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>A phase II trial to evaluate the efficacy of low-dose Veldona for the treatment of oral warts caused by HPV in HIV-infected patients [ 444293 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A Phase II Efficacy Study of Veldona for the Potential Treatment of Oral Warts Caused by HPV in HIV-Infected Patients</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="143134"><Indications><Indication>Idiopathic pulmonary fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Verona Pharma plc</Company></CompaniesSponsor><DateChangeLast>2013-06-27T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>carcainium chloride (inhaled, cough), Verona Pharma alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The aim of this phase II, randomized, double-blind, placebo-controlled study was to assess the efficacy of VRP-700 in patients with idiopathic pulmonary fibrosis [ 1443484 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase II, randomized, double-blind, placebo-controlled study to assess the efficacy of VRP-700 in patients with idiopathic pulmonary fibrosis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Smith</Name></ContactNames></Trial><Trial Id="143088"><Indications><Indication>Liver transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Republican Scientific and Practical Center for Organ and Tissue Transplantation</Company></CompaniesSponsor><Countries><Country>Belarus</Country></Countries><DateChangeLast>2017-12-28T00:00:00Z</DateChangeLast><DateEnd>2014-07-31T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1633</Identifier><Identifier>NCT01887171</Identifier><Identifier>PATAC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tacrolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Donor: Age 15 to 65 years Macrovesicular steatosis&amp;lt; 40% (macroscopy or biopsy) Sodium&amp;lt; 165 mmol/l ICU (intensive care unit) stay and ventilation&amp;lt; 11 days &lt;b&gt;Cold&lt;/b&gt; ischemia time&amp;lt; 13 h AST (aspartate transaminase)&amp;lt; 200 U/l ALT (alanine transaminase)&amp;lt; 200 U/l Bilirubin&amp;lt; 50 micromol/l Application of norepinephrine is allowed Recipient age: 18 to 69 years</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Dysfunction</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Post Transplant Complications</EndpointIndex><EndpointIndex>Liver transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Liver transplantation - Pharmacoeconomic Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PATAC: Evaluation Of Preimplantation Portal Vein And Hepatic Artery Flushing With Tacrolimus</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> C-C motif chemokine 3 </BiomarkerName><BiomarkerName> Elastase-1 </BiomarkerName><BiomarkerName> Fibrin </BiomarkerName><BiomarkerName> High mobility group protein B1 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Macrosialin </BiomarkerName><BiomarkerName> P-selectin </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> VEGF/SEMA ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Aliaksei E Shcherba, PhD</Name><Name>Oleg O Rumo, MD PhD</Name></ContactNames></Trial><Trial Id="142988"><Indications><Indication>Xerophthalmia</Indication></Indications><CompaniesCollaborator><Company>Ministerio De Sanidad, Politica Social e Igualdad</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundacion Publica Andaluza para la Investigacion de Malaga en Biomedicina y Salud</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-30T00:00:00Z</DateChangeLast><DateStart>2012-11-08T00:00:00Z</DateStart><Identifiers><Identifier>COL_SCU_2011</Identifier><Identifier>EudraCT 2012-001556-19</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous serum alone</Intervention><Intervention>heterologous serum alone</Intervention><Intervention>umbilical cord serum alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>123</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to valuate tear film and ocular surface changes after autologous serum therapy, heterologous serum therapy and umbilical cord serum therapy in patients with severe dry eye syndrome and to accomplish clinical comparison of the effects between the three therapies. Secondary objectives were to determine by Enzyme-linked immunosorbent assay (ELISA) in autologous, heterologous and umbilical cord: Growth factors: EGF, transforming growth factor (TGF) and platelet-derived growth</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sjoegrens syndrome - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulins (in particular IgG)/cryoglobulins</EndpointIndex><EndpointIndex>Sjoegrens syndrome - Assessment of Lacrimal Gland Function</EndpointIndex><EndpointIndex>Sjoegrens syndrome - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Tear Dynamics</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of ocular function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Prospective, Randomized, Doubled-masked, Single-Center, Clinical Comparison of Autologous Serum, Heterologous Serum and Umbilical Cord Serum Eye Drops in the Management of Dry Eye Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Xerophthalmia - Subjects with Severe Dry Eye</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cysteine/serine-rich nuclear protein 1 </BiomarkerName><BiomarkerName> Fibronectin </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Platelet-derived growth factor </BiomarkerName><BiomarkerName> Pro-epidermal growth factor </BiomarkerName><BiomarkerName> Vitamin A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="142947"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pharmaxis Ltd</Company></CompaniesSponsor><Countries><Country>France</Country><Country>UK</Country><Country>Canada</Country><Country>Spain</Country><Country>Europe</Country><Country>Austria</Country><Country>Netherlands</Country><Country>Belgium</Country><Country>Argentina</Country><Country>Italy</Country></Countries><DateChangeLast>2019-06-17T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-002699-14</Identifier><Identifier>DPM-CF-204</Identifier><Identifier>NCT01883531</Identifier><Identifier>NTR4453</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>mannitol (inhaled, CF), Pharmaxis/ Chiesi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>95</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this multicenter, randomized, double‐blind, crossover, placebo‐controlled, crossover study was to assess the safey and efficacy of dry powder mannitol to improve lung function in cystic fibrosis patients aged 6 to 17 years. The hypothesis was that inhaled mannitol 400 mg bid would lead to a significant improvement in the absolute change in percentage of predicted FEV1 from baseline following 8-weeks of trial treatment compared to treatment with inhaled placebo twice-daily [ 1721852</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of FEV1 % predicted</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of FVC % predicted</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum production/composition</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6 to 17 Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for treatment with Medications</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Alexander Möller, MD</Name><Name>Anne Munck, Dr</Name><Name>Christiane De Boeck</Name><Name>Dr. H.A.W.M. Tiddens</Name><Name>European Regional Director</Name><Name>Harm Tiddens, MD</Name><Name>Jeremy Hull, Dr</Name><Name>Joachim Riethmuller, Dr</Name><Name>Larry Lands, MD</Name><Name>R&amp;D Manager Kristen Morgan</Name><Name>Sonia Volpi, MD</Name></ContactNames></Trial><Trial Id="142632"><Indications><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Bionorica SE</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2011-01-04T00:00:00Z</DateEnd><DateStart>2010-08-04T00:00:00Z</DateStart><Identifiers><Identifier>AlRhi-IIa</Identifier><Identifier>EudraCT 2010-018786-33</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BNO-1355 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>weeks prior to study inclusion Treatment with oral H1-Antihistamines or cromoglycates within 72 h before study inclusions Treatment with antiinflammatory analgesics, mucolytics/secretolytics, or alternative medicine preparations for treatment of common &lt;b&gt;cold&lt;/b&gt; like symptoms or with immunomodulating properties within the last 7 days prior to study inclusion Treatment with medication that might interfere with rescue medication for allergic shock (eg, beta blocker, ACE blocker). Subjects requiring immunosuppressive</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Dose Comparison</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Phase IIa/b Study to Assess the Efficacy and Safety of two Dosages of a Herbal Medicinal Product (Dry Extract BNO-1355) in Patients with Seasonal Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="142560"><Indications><Indication>Anxiety disorder</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anxiolytic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Guilan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-06T00:00:00Z</DateChangeLast><DateStart>2013-01-02T00:00:00Z</DateStart><Identifiers><Identifier>3910354611</Identifier><Identifier>IRCT201302031861N4</Identifier></Identifiers><InterventionsControlDisplay><Intervention>midazolam hydrochloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>midazolam (iranian drug) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>82</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Hypertrophic tonsils /adenoids (Brodsky&gt; 2) Weight&gt; 24 kg History of allergy to Benzodiazepines Sleep apnea History of common &lt;b&gt;cold&lt;/b&gt;/ Respiratory disease during the past 2 weeks</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment of behavior</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Sleep</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Symptoms of Phobic Disorders</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Midazolam Efficacy and Safety</TitleDisplay><PatientSegmentTerms><PatientSegment>Anxiety disorder - Subjects with Phobic Disorders - Subjects with specific phobias</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Katayoun Salem</Name><Name>Komaiee</Name><Name>Sara Ataee</Name><Name>Sara Ataee, Dental nurse,</Name></ContactNames></Trial><Trial Id="142347"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Umea University</Company></CompaniesSponsor><Countries><Country>Sweden</Country></Countries><DateChangeLast>2016-01-07T00:00:00Z</DateChangeLast><DateEnd>2013-09-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>GOCOLDU&amp;B2013</Identifier><Identifier>NCT01883453</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>glucose plus glucose oxidase</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>146</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>they have caught a common &lt;b&gt;cold&lt;/b&gt;. Subjects would be randomized to receive a nasal spray with 200 U/ml of glucose oxidase + 5% glucose or nasal spray with isotonic saline + 5% glucose. Treatment would start with five puffs in each nostril at the... The aim of the study was to investigate whether a nasal spray with glucose oxidase could shorten an episode of common &lt;b&gt;cold&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold</TitleDisplay><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Krister Tano, MD,PhD</Name></ContactNames></Trial><Trial Id="142344"><Indications><Indication>Otitis media</Indication><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Umea University</Company></CompaniesSponsor><Countries><Country>Sweden</Country></Countries><DateChangeLast>2015-05-05T00:00:00Z</DateChangeLast><DateEnd>2013-06-01T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>GOBARN2013</Identifier><Identifier>NCT01883427</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>glucose plus glucose oxidase</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to investigate if use of glucosoxidas nasal spray would reduce the number of days with rhinitis and/or otitis in children beyond four years.</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Otitis media - Assessment of Incidence/Prevalence of Otitis Media - Incidence/prevalence of acute otitis media</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Otitis media - Subjects with Acute Otitis Media</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Anders Niklasson, MD</Name><Name>Eva Westman, MD, PhD</Name><Name>Helena Toolanen, MD</Name><Name>Marie Ryding, MD, PhD</Name></ContactNames></Trial><Trial Id="142332"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Umea University</Company></CompaniesSponsor><Countries><Country>Sweden</Country></Countries><DateChangeLast>2016-02-26T00:00:00Z</DateChangeLast><DateEnd>2013-09-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>GOCOLDSY2013</Identifier><Identifier>NCT01883440</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>glucose alone</Intervention><Intervention>glucose plus glucose oxidase</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Persons that were convinced of that they have caught an episode of common &lt;b&gt;cold&lt;/b&gt; would be included into the study within 24 h after the onset of symptoms. Before... Symptoms of a common &lt;b&gt;cold&lt;/b&gt; within the last 24 h...study aim was to investigate if a nasal spray with glucose oxidase could treat a common &lt;b&gt;cold&lt;/b&gt;, when the treatment was started even after the onset of the symptoms.</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Glucose Oxidase as Treatment Against Common Cold</TitleDisplay><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Helena Toolanen, MD</Name></ContactNames></Trial><Trial Id="14194"><Indications><Indication>Seasonal allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2006-11-30T00:00:00Z</DateEnd><DateStart>2006-03-15T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2006-000215-22</Identifier><Identifier>HH3104994</Identifier><Identifier>NCT00400998</Identifier></Identifiers><IndicationsAdverse><Indication>Conjunctivitis</Indication><Indication>Cough</Indication><Indication>Gastrointestinal infection</Indication><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> (5% each in phases I and II), cough (3% in phase II), conjunctivitis (3% in phase III) and intestinal infection (3% in phase II). Some of the most common adverse events experienced by placebo treated patients were headache (3% in phase II), common &lt;b&gt;cold&lt;/b&gt; (3% in phase II) and bronchospasm (3% in phase III). No serious adverse events were observed [ 1308780 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Nasal lavage fluid and nasal secretions analysis</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Other nasal examinations(unspecified)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of rhinorrhoea</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of individual ocular symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function - Assessment of nasal obstruction/resistance</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function - Forced expiratory volume in the first second (FEV1)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability - Assessment of serious/treatment emergent adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Change from baseline in total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of life</EndpointIndex><EndpointIndex>Pruritus - Assessment of Therapy Related Outcomes - Assessment of treatment effectiveness</EndpointIndex><EndpointIndex>Pruritus - Assessment of adverse events</EndpointIndex><EndpointIndex>Pruritus - Investigator's Global Assessment (IGA)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Investigate Two Trial Models; Vienna Challenge Chamber (in and Out of Season) and Park Study (in Season) Using a Drug for Seasonal Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Systemic Disorders - Subjects with allergic disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2006-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="141840"><Indications><Indication>Back pain</Indication></Indications><CompaniesSponsor><Company>Shahrekord University of Medical Sciences and Health Services</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-27T00:00:00Z</DateChangeLast><DateStart>2013-03-15T00:00:00Z</DateStart><Identifiers><Identifier>90-10-32</Identifier><Identifier>IRCT201303106480N5</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>naproxen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>87</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> The aim of this study was to determine the effect of both, warm and &lt;b&gt;cold&lt;/b&gt; therapy on pain in patients with low back pain treatment [ 1442508 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effectiveness of Heat and Cold Therapy on Acute Back Pain in Patients Referred to Orthopedic Clinic of Kashani Hospital in Shahrekord</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with back pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Morteza Dehghan</Name><Name>Mahmoud Mobasheri</Name><Name>Mohammadtaghi Moradi</Name><Name>Morteza Dehghan</Name></ContactNames></Trial><Trial Id="141415"><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Sweden</Country></Countries><DateChangeLast>2018-01-15T00:00:00Z</DateChangeLast><DateStart>2005-01-27T00:00:00Z</DateStart><Identifiers><Identifier>A6431079</Identifier><Identifier>EudraCT 2004-004575-11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mint nicotine mouth strip alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> subject consumes different types of alcoholic beverages Treatment with an investigational drug within 3 months preceding the first dose of trial medication History or current complaints of dry mouth Acute or chronic oral or lips disease, including &lt;b&gt;cold&lt;/b&gt; sores, impairing chewing function or sensory functions of the oral mucosa Upper respiratory infection Work in any of the following areas: marketing, market research, advertising, public relations, pharmacy, pharmaceutical industry or journalism</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Smoking Cessation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Smoking Cessation - Assessment of craving</EndpointIndex><EndpointIndex>Smoking Cessation - Patient Reported Outcomes/Quality of Life Assessments - Assessment of acceptability of therapy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Perception and Tolerability of Nicotine Films for Use in the Mouth. A Randomized, Crossover, Phase-II, Study in Healthy Smokers</TitleDisplay><PatientSegmentTerms><PatientSegment>Smoking Cessation - Healthy Smokers</PatientSegment><PatientSegment>Smoking Cessation - Smoking Cessation in Heavy Smokers</PatientSegment><PatientSegment>Smoking Cessation - Smoking Cessation in Moderate Smokers</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="141141"><Indications><Indication>Dermatitis</Indication></Indications><CompaniesSponsor><Company>Ahvaz Jundishapur University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-01-15T00:00:00Z</DateChangeLast><DateStart>2011-09-23T00:00:00Z</DateStart><Identifiers><Identifier>IRCT201112128388N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Shallomin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Patients would receive Shallomin 0.5 % or ethanol as placebo applied each 2 h on the &lt;b&gt;cold&lt;/b&gt; score for 48 h[ 1442616 ].... Age&amp;lt; 18 and &amp;gt; 28 years Other sore &lt;b&gt;Cold&lt;/b&gt; sore &amp;gt; 24 h old... Age from 18 to 28 &lt;b&gt;Cold&lt;/b&gt; sore</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Shallomin (Active Fraction of Shallot) to Be Effective to Treat Cold Sore of Face in Students of Ahvaz University of Medical Sciences</TitleDisplay><PatientSegmentTerms><PatientSegment>Dermatitis - Subjects with unspecified/other forms of dermatitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Seyed Mohamad Radmanesh</Name><Name>Mansour Amin</Name><Name>Mostafa Feghee</Name><Name>Seyed Radmanesh</Name></ContactNames></Trial><Trial Id="140551"><Indications><Indication>Myocardial infarction</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Leukotriene A4 hydrolase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Cardioprotectant</Action><Action>Leukotriene B4 synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>deCODE genetics ehf</Company></CompaniesSponsor><Countries><Country>Iceland</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2008-04-15T00:00:00Z</DateStart><Identifiers><Identifier>DG-051-CV-202</Identifier><Identifier>EudraCT 2007-004913-32</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>DG-051 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>performed within 6 weeks prior to scheduled day of randomization Any other intercurrent illness or other condition, which, in the investigator’s judgment, will interfere with the patient’s participation in this study or interpretation of the data (eg, &lt;b&gt;cold&lt;/b&gt; and/or flu symptoms at randomization) Patients not willing to return for follow-up or with known history of non-compliance Patients who consume &gt; 2 alcoholic drinks/day or &gt;/= 10 drinks/week, or have a history of alcohol abuse within the past two years</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Coronary artery disease - Gene variants involved in outcome measures</EndpointIndex><EndpointIndex>Coronary artery disease - Gene variants involved in outcome measures - ALOX5AP_HUMAN_Mutation</EndpointIndex><EndpointIndex>Coronary artery disease - Gene variants involved in outcome measures - LTA4H_HUMAN_Mutation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind, Placebo-controlled Evaluation of the Pharmacodynamics, Pharmacokinetics, and Safety of DG-051 in Patients With a History of MI</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with Abnormal Echo/ECG findings</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Elevated Cardiac Biomarkers - Elevated serum troponins</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Elevated Cardiac Biomarkers - Elevation of cardiac enzymes</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Prior history of myocardial infarction (MI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 2 </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Cell adhesion molecules </BiomarkerName><BiomarkerName> Leukotriene B4 </BiomarkerName><BiomarkerName> Myeloperoxidase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="140318"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Institute on Drug Abuse</Company><Company>National Institutes of Health Clinical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute on Alcohol Abuse and Alcoholism</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-13T00:00:00Z</DateChangeLast><DateEnd>2017-04-27T00:00:00Z</DateEnd><DateStart>2013-06-13T00:00:00Z</DateStart><Identifiers><Identifier>13-AA-0061</Identifier><Identifier>130061</Identifier><Identifier>NCT01878006</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>(11C)raclopride alone</Intervention><Intervention>PET scanning alone</Intervention><Intervention>morphine alone</Intervention><Intervention>remifentanil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>visit 2, participants would test their pain sensitivity by placing one hand in &lt;b&gt;cold&lt;/b&gt; water. Pupil diameter would be measured after the sensitivity test. After a blood...respiratory rate, oxygen saturation and a pain rating from putting a hand in &lt;b&gt;cold&lt;/b&gt; water and blood chemistries. In addition, during this visit, participants would wear...These include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-&lt;b&gt;cold&lt;/b&gt; preparations that contain anti-histamines or opiate, pain medicines will</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Metabolic function assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - OPRM1_HUMAN_rs1799971(A)</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - OPRM1_HUMAN_rs1799971(G)</EndpointIndex><EndpointIndex>Pain - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints - Assessment of pupil size</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Genetic Effects on Dopamine Response to an Opiate</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with gene variants - OPRM1_HUMAN_rs1799971(A)</PatientSegment><PatientSegment>Pain - Subjects with gene variants - OPRM1_HUMAN_rs1799971(G)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adrenocorticotropic hormone </BiomarkerName><BiomarkerName> Dopamine </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Mu-Type opioid receptor </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Pupil </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Skin conductance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-04-27T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alane Kimes</Name><Name>Vijay A Ramchandani, Ph.D.</Name></ContactNames></Trial><Trial Id="14003"><Indications><Indication>Migraine</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Netherlands</Country><Country>Australia</Country><Country>UK</Country></Countries><DateChangeLast>2018-01-19T00:00:00Z</DateChangeLast><DateStart>2006-01-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2005-004480-37</Identifier><Identifier>NCT00269022</Identifier><Identifier>SB-705498/008</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>705498 (oral, pain/migraine/IBS), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamids of SB-705498 for the treatment of migraine pain.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of 2-hr pain-free response</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of headache relief</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of medication consumption</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of other migraine-associated symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Use Of SB-705498 In The Acute Treatment Of Migraine</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Migraine - Subjects with migraine with aura</PatientSegment><PatientSegment>Pain - Subjects with Migraine - Subjects with migraine without aura</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with specific disease - Subjects with acute migraine attacks</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>4</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="13983"><Indications><Indication>Cystic fibrosis</Indication><Indication>Sinusitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Genentech Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Vermont</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-23T00:00:00Z</DateChangeLast><DateEnd>2012-06-30T00:00:00Z</DateEnd><DateStart>2006-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00416182</Identifier><Identifier>Z3297S</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine whether Pulmozyme would maintain sinus health (compared to placebo) in patients with cystic fibrosis who have recently undergone sinus surgery. This trial was to evaluate the effectiveness of Pulmozyme in decreasing post-operative sinusitis symptoms in patients with cystic fibrosis.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures - Assessment of organ function by imaging techniques</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Respiratory System/Symptoms - Assessment of sino-nasal system/signs &amp; symptoms</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of use of Rescue Medication - Assessment by duration/frequency of antibiotic use</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by quality of life (short form-36 and chronic respiratory questionnaire)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sandra Diehl, MS</Name><Name>Thomas Lahiri</Name><Name>Thomas Lahiri, MD</Name></ContactNames></Trial><Trial Id="139258"><Indications><Indication>Cheynes Stokes breathing</Indication></Indications><ActionsPrimaryInterventionsControl><Action>PGI2 agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Bayer AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ruhr Universitat Bochum</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2017-07-05T00:00:00Z</DateChangeLast><DateEnd>2011-11-26T00:00:00Z</DateEnd><DateStart>2010-07-19T00:00:00Z</DateStart><Identifiers><Identifier>4036184</Identifier><Identifier>43/2009</Identifier><Identifier>DRKS00000467</Identifier><Identifier>EudraCT: 2010-018892-20</Identifier><Identifier>Gly-CS</Identifier><Identifier>HDZKA-2010-01</Identifier></Identifiers><InterventionsControlDisplay><Intervention>iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>glyceryl trinitrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Ongoing nitrate-therapy Hypotension (RR&amp;lt; 90/60 mmHg) Significant &lt;b&gt;COLD&lt;/b&gt; (FEV1/VC&amp;lt; 70%) Respiratoric insufficiency indicating a long-term O2-therapy Daytime hypercapnia (pCO2&gt; 45 mmHg) Ongoing ventilation therapy Cardiothoracic surgery within the last 3 months Myocardial infarction within the last 6 months Implantation</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pulmonary Function - Change in Oxygen saturation SO(2)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pulmonary Function - Pulmonary capillary wedge pressure (PCWP)</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen desaturation</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms - Assessment of apneic episodes</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms - Assessment of hypoapneic episodes</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms - Assessment of respiratory arousal</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Disease Progression - Assessment by apnea-hypopnea index [AHI]</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Sleep</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Gly-CS: Pathophysiology of Cheyne-Stokes Respiration: Lowering of the Pulmonary Capillary Wedge Pressure as a Causal Therapeutic Option</TitleDisplay><PatientSegmentTerms><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Mild /NYHA Functional Class II Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects</PatientSegment><PatientSegment>Sleep apnea - Subjects with Central Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Severe Sleep Apnea</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Pulmonary arterial pressure </BiomarkerName><BiomarkerName> Pulmonary wedge pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Astrid Kleemeyer</Name><Name>Thomas Bitter</Name></ContactNames></Trial><Trial Id="13884"><Indications><Indication>Neuropathic pain</Indication><Indication>Neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>GABA modulator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action><Action>GABA modulator</Action><Action>Glutamate release inhibitor</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Harvard University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-10T00:00:00Z</DateChangeLast><DateEnd>2008-07-31T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>Facial Neuropathy/lamotrigine</Identifier><Identifier>NCT00243152</Identifier></Identifiers><InterventionsControlDisplay><Intervention>gabapentin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>gabapentin alone</Intervention><Intervention>lamotrigine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>6</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Half of the patients received placebo first while the other half received lamotrigine first (based on the blinding protocol) and underwent two fMRI sessions. Brush, &lt;b&gt;cold&lt;/b&gt;, and heat was applied to the affected and mirror-unaffected sides of their faces of all patients [ 1478670 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of lamotrigine on neuropathic facial pain using fMRI</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Borsook</Name></ContactNames></Trial><Trial Id="138656"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Topical dermatological antiviral product</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Glycoprotein</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Novotech (Australia) Pty Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Marine Biotechnology Australia Pty Ltd</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-04-12T00:00:00Z</DateChangeLast><DateStart>2011-08-25T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12611000920998</Identifier><Identifier>ANZCTR343395</Identifier><Identifier>HREC: 2011-05-262</Identifier><Identifier>MBA-001-010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>abalone haemocyanin (topical, herpes infections), Marine Biotechnology Australia/Bio-Link alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>210</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Male or female with history of recurrent &lt;b&gt;cold&lt;/b&gt; sores and have experienced at least three episodes in the previous 12 months</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Appearance</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Safety and Efficacy of Topical Abalone Hemocyanin Once-Daily for the Treatment of Herpes Labialis in Immunocompetent Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Adrian Cuthbertson</Name><Name>Alek Safarian</Name><Name>Serena King</Name></ContactNames></Trial><Trial Id="138171"><Indications><Indication>Osteoarthritis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bone modulator</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Hamsoa Pharmaceutical Co., Ltd.</Company><Company>Kyung Hee University Gangdong Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Kyunghee University Medical Center</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2016-01-01T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>KCT0000732</Identifier><Identifier>KR-KHNMC-OA02</Identifier><Identifier>NCT01873053</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>WIN-34B alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this randomized, double-blind was to evaluate the efficacy and safety of WIN-34B in patients with osteoarthritis of the knee.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain - Assessment of Pain by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on WOMAC scale</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects with Osteoarthritis of Knee</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dong-Suk Park</Name></ContactNames></Trial><Trial Id="136586"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Haukeland University Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Bergen</Company></CompaniesSponsor><Countries><Country>Norway</Country></Countries><DateChangeLast>2017-07-19T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-002848-24</Identifier><Identifier>LAIV-TONSILSV2 VERSION 2</Identifier><Identifier>NCT01866540</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man and children [ 1704808 ].</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Immune Response To Intranasal Influenza Vaccination</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adenomatous polyposis coli protein </BiomarkerName><BiomarkerName> B-lymphocyte antigen CD20 </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Leukocyte common antigen </BiomarkerName><BiomarkerName> MHC class I polypeptide-related sequence B </BiomarkerName><BiomarkerName> Receptor-interacting serine/threonine-protein kinase 2 </BiomarkerName><BiomarkerName> Suppressor of cytokine signaling 1 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> TCR gamma alternate reading frame protein </BiomarkerName><BiomarkerName> Toll-like receptor 1 </BiomarkerName><BiomarkerName> Transforming growth factor beta 1 </BiomarkerName><BiomarkerName> Tumor necrosis factor ligand superfamily member 6</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>62 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hans Jørgen Aarstad</Name><Name>Rebecca Cox</Name></ContactNames></Trial><Trial Id="134310"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Tehran University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-08-27T00:00:00Z</DateChangeLast><DateEnd>2013-06-30T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01860248</Identifier><Identifier>TUMS 4341</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Vapocoolant spray alone</Intervention><Intervention>Water spray alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>medication used within 24 h of enrollment Any sign of decreased consciousness History of skin hypersensitivity Inability to report a pain score History of a known neurological problem that changes pain perception History of &lt;b&gt;cold&lt;/b&gt; related reactions (eg, raynaud's phenomenon, &lt;b&gt;cold&lt;/b&gt; urticaria) Abnormal allen's test</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vapocoolant Spray Effectiveness On Arterial Puncture Pain: Randomized, Double-Blind, Placebo-Controlled Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Shervin Farahmand, M.D.</Name></ContactNames></Trial><Trial Id="13275"><Indications><Indication>Verruca vulgaris</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Fibrosuppressant</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation local</Technology><Technology>Peptide</Technology><Technology>Transmucosal formulation</Technology></Technologies><CompaniesSponsor><Company>Amarillo Biosciences Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-24T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2007-02-28T00:00:00Z</DateStart><Identifiers><Identifier>03HUHI19</Identifier><Identifier>NCT00454181</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>interferon-alpha, Amarillo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>59</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults. The hypothesis of this study was that interferon-alpha would be safe and that a higher percentage of subjects given interferon-alpha would experience a complete or nearly complete remission of their oral warts compared to subjects given placebo.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Papillomavirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Papillomavirus infection - Resolution/Progression of HPV Infections/Lesions - Resolution/progression of genital warts</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Treatment of Oral Warts in HIV+ Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Subjects with comorbid conditions - Subjects with opportunistic/other infections</PatientSegment><PatientSegment>Papillomavirus infection - Subjects at risk of developing disease - Subjects with HIV infection</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Oral Papillomas</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Deborah Greenspan</Name></ContactNames></Trial><Trial Id="132201"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Benzodiazepine receptor agonist</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Injectable emulsion</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Siriraj Hospital</Company></CompaniesSponsor><Countries><Country>Thailand</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2015-11-30T00:00:00Z</DateEnd><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01845376</Identifier><Identifier>SIRB035</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Arcoxia (etoricoxib) alone</Intervention><Intervention>acetaminophen alone</Intervention><Intervention>bupivacaine, AstraZeneca alone</Intervention><Intervention>morphine alone</Intervention><Intervention>sevoflurane alone</Intervention><Intervention>Variable regimens including adrenaline , bupivacaine, AstraZeneca , fentanyl , lidocaine , midazolam hydrochloride , propofol, AstraZeneca/Fresenius</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> In the SA group, patients would be positioned in the lateral position and a Whitacre 25 G needle would be inserted at L3 to 4 intervertebral space and then heavy bupivacaine 0.5 % 15 mg would be injected. Sensory block (T4 and below dermatomes) to &lt;b&gt;cold&lt;/b&gt; and pinprick would be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 microg of fentanyl would be given iv if patients in the LA and SA group require. In the GA group, patients would be induced with propofol</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Local or Regional or General Anesthesia for Hernia Repair: A Randomized, Controlled Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mingkwan Wongyingsinn, MD, MSc</Name></ContactNames></Trial><Trial Id="131949"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pharmaxis Ltd</Company><Company>The Children's Hospital at Westmead</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2019-06-21T00:00:00Z</DateChangeLast><DateStart>2007-11-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612001167853</Identifier><Identifier>ANZCTR363220</Identifier><Identifier>HREC: 2007/016</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mannitol (inhaled, CF), Pharmaxis/ Chiesi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to see if the addition of dry mannitol as an extra therapy during hospitalization for an acute pulmonary exacerbation in young people with cystic fibrosis improves outcomes from that admission [ 1423190 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Clinical Symptoms - Assessment of CF symptoms/other clinical symptoms/outcomes</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study Examining the Utility of Inhaled Mannitol as an Additional Therapy During an Admission to Hospital for an Acute Pulmonary Exacerbation in Children With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hiran Selvadurai</Name></ContactNames></Trial><Trial Id="13124"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-04T00:00:00Z</DateChangeLast><DateEnd>2001-12-01T00:00:00Z</DateEnd><DateStart>2001-09-30T00:00:00Z</DateStart><Identifiers><Identifier>D153-P005</Identifier><Identifier>NCT00192387</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to determine the proportion of subjects, seronegative to all three strains of influenza, as defined by a serum hemagglutination inhibition antibodies (HAI) antibody titer of &amp;lt; 1:10, who shed each vaccine virus strain following a single dose of CAIV-T .</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term></TermsPatientSelection><TitleDisplay>Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Robert Walker, MD</Name></ContactNames></Trial><Trial Id="130962"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Hamadan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-15T00:00:00Z</DateChangeLast><DateStart>2008-03-19T00:00:00Z</DateStart><Identifiers><Identifier>72229/9/35/16/پ</Identifier><Identifier>IRCT201103303289N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fentanyl plus lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>140</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this study was to compare the duration of sensory and motor block and side effects of adding different doses of intrathecal fentanyl to lidocaine 5% in spinal anesthesia [ 1422052 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Opioid on Duration of Spinal Anesthesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Abbas Zamanian</Name><Name>Ebrahim Khoshraftar</Name><Name>Ebrahim Khoshraftar,MD</Name><Name>Esmail Moshiri</Name></ContactNames></Trial><Trial Id="130960"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-04-09T00:00:00Z</DateChangeLast><DateStart>2005-07-14T00:00:00Z</DateStart><Identifiers><Identifier>C2380329</Identifier><Identifier>EudraCT 2005-001384-60</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>history which may require treatment or make the subject unlikely to finish the study Subjects for whom Zovirax is contra-indicated Subjects presenting with a non-classical &lt;b&gt;cold&lt;/b&gt; sore lesion or a significant history of &lt;b&gt;cold&lt;/b&gt; sores which abort Prior...this &lt;b&gt;cold&lt;/b&gt; sore episode with topical Zovirax cream at first signs or symptoms of the lesion Only subjects who have reached the papular/oedematous (stage 2) of their &lt;b&gt;cold&lt;/b&gt; sore will be included Compliance Understands and is willing, able</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Exploratory, Observational Cohort Study Investigating Commercially Available Treatments Which May Reduce the Scab Stage of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="13086"><Indications><Indication>Androgen deficiency</Indication><Indication>Hypogonadism</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Androgen receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal gel formulation</Technology></Technologies><CompaniesSponsor><Company>Boston University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2006-04-30T00:00:00Z</DateStart><Identifiers><Identifier>H-27995</Identifier><Identifier>NCT00351819</Identifier><Identifier>TAP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>testosterone gel, Solvay/Bayer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>84</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> scores were significantly different from placebo. In comparison to placebo, patients who received testosterone experienced significant improvements in sexual desire, pressure pain threshold (p &amp;lt; 0.031), mechanical pain intensity (p = 0.049) and &lt;b&gt;cold&lt;/b&gt; presser pain after-sensations (p = 0.08). Patients who received testosterone showed a trend toward improvement in aspects of role limitation due to emotional problems as measured by MOS-SF-36 [ 1436841 ]. In February 2015, similar results were published</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypogonadism - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TAP: Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypogonadism - Subjects with Secondary Hypogonadism</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Prostate-specific antigen </BiomarkerName><BiomarkerName> Sex hormone-binding globulin </BiomarkerName><BiomarkerName> Testosterone </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>79 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Shehzad Basaria, MD</Name></ContactNames></Trial><Trial Id="130294"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel inhibitor L-type</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Class IV antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Radboud University</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2016-09-16T00:00:00Z</DateChangeLast><DateStart>2010-11-01T00:00:00Z</DateStart><Identifiers><Identifier>NCCC</Identifier><Identifier>NL31484.091.10CCMO</Identifier><Identifier>NTR2591</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nifedipine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>diary kept up to date daily by the participant for the complete research period. Experienced perniones complaints (itch or pain) and limitations in daily life are scored daily. For the complete research period of each individual patient the exposure to &lt;b&gt;cold&lt;/b&gt; would be registered by asking for the average day temperature as measured in 'de Bilt' at the KNMI.There would be six contact moments: Intake (t1), end of week 1 (t2), end of week 3 (t3), end of week 7 (t4), end of week 9 (t5) and end of week 13 (t6</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of adverse events</EndpointIndex><EndpointIndex>Pruritus - Pruritus Assessed by Visual Analog Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NCCC: Does Nifedipine 60 mg Per Day Per Os Reduce the Complaints of Chronic Chilblains</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>I. Souwer</Name></ContactNames></Trial><Trial Id="129521"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Barrier Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Czech Republic</Country><Country>Belgium</Country></Countries><DateChangeLast>2013-11-22T00:00:00Z</DateChangeLast><DateStart>2007-07-18T00:00:00Z</DateStart><Identifiers><Identifier>BT0800NED001</Identifier><Identifier>EudraCT 2005-002749-38</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vapitadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Erythematosus, hepatitis, vasculitis, hyperthyroidism with physical urticaria (&lt;b&gt;cold&lt;/b&gt;, heat, sun-induced, pressure or dermographism, aquagenic), with cholinergic urticaria, with hereditary angioedema or with urticaria due to medications, insect bites, food or any other known etiology Subjects, previously unresponsive to at least two different antihistamines for the treatment of chronic idiopathic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of duration and severity of pruritus</EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind, Placebo-controlled Exploratory Trial to Evaluate a 1-Week Oral Treatment With R-129160 (60 mg qd) in Patients With Chronic Idiopathic Urticaria</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Subjects with chronic idiopathic urticaria(CIU)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites></Trial><Trial Id="129281"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ORL1 receptor agonist</Action><Action>Opioid receptor mu partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Antidepressant</Action><Action>Muscle relaxant</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Dr Reddy's Laboratories Ltd</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-09-07T00:00:00Z</DateChangeLast><DateStart>2012-06-08T00:00:00Z</DateStart><Identifiers><Identifier>CHDR1209</Identifier><Identifier>EudraCT 2012-002302-43</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buprenorphine (sublingual, opioid dependence), Indivior plus milnacipran</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to determine if co-administration of acute milnacipran with acute buprenorphine potentiates or synergises with the analgesic effects of buprenorphine in healthy volunteers or vice versa. The secondary objectives were: To determine if co-administration of multiple-dose milnacipran with acute buprenorphine potentiates or synergises with the analgesic effects of buprenorphine in healthy volunteers. To investigate the safety and tolerability of co-administration of iv</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of other neurological function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>A Study to Investigate the Analgesic Effects of Buprenorphine and Milnacipram in Healthy Volunteers</TitleDisplay><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Geert Groeneveld</Name></ContactNames></Trial><Trial Id="12903"><Indications><Indication>Hypersensitivity</Indication><Indication>Irritable bowel syndrome</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Glaxo Group Research Ltd</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2007-09-01T00:00:00Z</DateEnd><DateStart>2007-01-26T00:00:00Z</DateStart><Identifiers><Identifier>2006-002632-21</Identifier><Identifier>NCT00461682</Identifier><Identifier>VRA107438</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>705498 (oral, pain/migraine/IBS), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>This study would investigate the efficacy of SB-705498 in patients with rectal pain. This was a double-blind, placebo-controlled, two-way crossover study. 21 patients with fecal urgency (Group 1), and 21 patients with IBS (Group 2) would complete this study. The main objective of this study was to  investigate the effects of a single dose of SB-705498 on rectal pain thresholds and ongoing pain in patients with rectal hypersensitivity associated with faecal urgency (group 1) and IBS (group 2). The</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments - Quality Of Life (QOL) questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of Life (Unspecified)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Sb-705498 Rectal Pain Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with abdominal pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Evoked potentials</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-09-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="12887"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><DateChangeLast>2015-11-04T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2006_518</Identifier><Identifier>2295-005</Identifier><Identifier>MK2295-005</Identifier><Identifier>NCT00387140</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ibuprofen alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>MK-2295 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>89</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was conducted to evaluate the safety and tolerability of MK-2295, and to evaluate its efficacy compared to placebo and to ibuprofen, in the treatment of post-operative dental pain in male patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A study to evaluate the safety and efficacy of an investigational drug in the treatment of post-operative dental pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Medical Monitor</Name></ContactNames></Trial><Trial Id="128570"><ActionsPrimaryInterventionsPrimary><Action>Low molecular weight heparin</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Golestan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-13T00:00:00Z</DateChangeLast><DateStart>2012-05-04T00:00:00Z</DateStart><Identifiers><Identifier>533/35/گ پ</Identifier><Identifier>IRCT201201158731N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enoxaparin sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>receive &lt;b&gt;cold&lt;/b&gt; apply to injection site for 5 min before, 10 s injection duration. Arm 3: this group would receive 10 s injection duration and waiting 10 s before exit needle. Arm 4: this group would receive &lt;b&gt;cold&lt;/b&gt; apply for 5... The main objective of the trial was to determine and compare the effect of local &lt;b&gt;cold&lt;/b&gt; application and injection duration on occurrence of pain and bruising injection site in patients who received sc enoxaparin sodium injections [ 1416986 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Pain scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Local Cold Application and Injection Duration on the Occurrence of Bruising and Pain at the Injection Site in sc Enoxaparin Sodium Injections</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hossein Anaraki</Name><Name>Mohsen Aarabi</Name></ContactNames></Trial><Trial Id="127668"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ministry of Economic Affairs, Agriculture and Innovation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Academic Hospital Maastricht</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2019-05-06T00:00:00Z</DateChangeLast><DateEnd>2008-04-10T00:00:00Z</DateEnd><DateStart>2006-04-10T00:00:00Z</DateStart><Identifiers><Identifier>BSIK03016</Identifier><Identifier>ISRCTN71968956</Identifier><Identifier>NTR651</Identifier><Identifier>SYMBLOC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>124</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to assess percutaneous sympathetic blockade in complex regional pain syndrome type 1 (CRPS1). The study was based on the hypothesis that &lt;b&gt;cold&lt;/b&gt; fenotype of CRPS1 was associated with a better respons to percutaneous sympathetic blockade as opposed to the warm type of CRPS1 [ 1416213 ]</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SYMBLOC: Percutaneous Sympathetic Blockade in Complex Regional Pain Syndrome Type 1: a Prospective Clinical Investigation on Predictors of Sympatheticaly Maintained Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with reflex sympathetic dystrophy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>J. Geurts</Name></ContactNames></Trial><Trial Id="12696"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>South Korea</Country><Country>Italy</Country></Countries><DateChangeLast>2019-01-29T00:00:00Z</DateChangeLast><DateEnd>2007-10-03T00:00:00Z</DateEnd><DateStart>2005-12-07T00:00:00Z</DateStart><Identifiers><Identifier>2005-004481-16</Identifier><Identifier>NCT00281684</Identifier><Identifier>VRA105345</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>705498 (oral, pain/migraine/IBS), GSK alone</Intervention><Intervention>codeine phosphate plus paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>145</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This clinical trial was a multicenter, randomized, single-blind, parallel-group, placebo-controlled, single oral dose study with a positive control arm. Participants previously scheduled for third molar tooth extraction, who were otherwise healthy would be recruited. Upon completion of surgery, eg, prior to established pain, participants would be randomized to treatment, SB-705498 , placebo or co-codamol and dosed with the study medication.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>SB-705498 Dental Pain Study After Tooth Extraction</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Ketones </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Mean corpuscular hemoglobin </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> Phosphate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> QRS complex </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> R-R interval </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urobilinogen </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-10-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="126761"><Indications><Indication>Cough</Indication></Indications><CompaniesCollaborator><Company>Medical Research Council</Company></CompaniesCollaborator><CompaniesSponsor><Company>South Manchester University Hospitals NHS Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-02-15T00:00:00Z</DateChangeLast><DateEnd>2012-01-04T00:00:00Z</DateEnd><DateStart>2011-01-04T00:00:00Z</DateStart><Identifiers><Identifier>9727</Identifier><Identifier>DNIC</Identifier><Identifier>DNIC1</Identifier><Identifier>G0900449</Identifier><Identifier>ISRCTN31901405</Identifier><Identifier>MREC Number 10/H1003/104</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>conditions: during both blocks of capsaicin inhalation (block 1 and block 2) subjects would place their hand in a non-painful warm water bath (37degC) and would be instructed to cough freely. &lt;b&gt;Cold&lt;/b&gt; water conditions: during one of the blocks of capsaicin inhalation (block 1 or 2) subjects would place their hand in a painful &lt;b&gt;cold&lt;/b&gt; water bath (10degC). During the other block subjects would place their hand in a non-painful warm water bath (37degC). The order of the blocks would be randomized. Subjects would be </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Cough</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Assessment of response to therapy</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough - Assessment of cough reflex</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DNIC: Diffuse Noxious Inhibitory Controls in Chronic Cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Emma Young</Name></ContactNames></Trial><Trial Id="12665"><Indications><Indication>Neuropathic pain</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>GABA receptor agonist</Action><Action>NMDA receptor antagonist</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticonvulsant agent</Action><Action>Anxiolytic</Action><Action>CNS modulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action><Action>Antihypertensive</Action><Action>Antitussive</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Bead formulation</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Granule</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>National Institutes of Health</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-09-14T00:00:00Z</DateChangeLast><DateEnd>2002-01-31T00:00:00Z</DateEnd><DateStart>1997-12-31T00:00:00Z</DateStart><Identifiers><Identifier>98-D-0042</Identifier><Identifier>980042</Identifier><Identifier>NCT00001725</Identifier></Identifiers><InterventionsControlDisplay><Intervention>lorazepam alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dextromethorphan hydrobromide (sustained release) alone</Intervention><Intervention>topiramate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was designed to evaluate the safety and effectiveness of two drugs - dextromethorphan and topiramate - in treating orofacial (mouth and face) pain. Dextromethorphan , a commonly used cough suppressant, and topiramate , an anti-seizure medicine, block certain receptors on brain and spinal nerve cells that may cause the cells to produce electrical discharges and pain. Patients 18 years of age and older with oral and facial pain with trigeminal nerve damage and who had had pain daily for at</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>49 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="12626"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>Belgium</Country></Countries><DateChangeLast>2017-12-02T00:00:00Z</DateChangeLast><DateEnd>2001-01-22T00:00:00Z</DateEnd><DateStart>2000-10-02T00:00:00Z</DateStart><Identifiers><Identifier>D153-P503</Identifier><Identifier>FluMist</Identifier><Identifier>NCT00192270</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Rhinitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>498</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the number of doses of CAIV-T required to effectively immunize children and adolescents in the 6 to 17 years age group.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>FluMist: Trial to Assess Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-Adapted (CAIV-T) in Healthy Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2001-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Matti Uhari</Name><Name>Prof Karel Hoppenbrouwers</Name><Name>Prof Pierre Van Damme</Name><Name>Prof Ulrich Behre</Name><Name>Raburn Mallory</Name><Name>Robert Walker</Name></ContactNames></Trial><Trial Id="125591"><Indications><Indication>Renal injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Solute carrier family 12A1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Cardiac agent</Action><Action>Diuretic agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Tabriz University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-16T00:00:00Z</DateChangeLast><DateStart>2012-06-21T00:00:00Z</DateStart><Identifiers><Identifier>9133</Identifier><Identifier>IRCT201205092582N8</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>furosemide (tablets), sanofi-aventis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>106</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose was to evaluate the effect of Lasix therapy on prevention of acute kidney injury and the level of neutrophil gelatinase (N-gal) associated lipocalin [ 1411771 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal failure - Assessment of Acute Renal Failure</EndpointIndex><EndpointIndex>Renal failure - Assessment of Biomarkers - Assessment of neutrophil gelatinase-associated lipocalin(NGAL)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of Blood Urea Nitrogen (BUN)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Effect of Lasix Therapy in Preventing Acute Kidney Injury And on the Level of Neutrophil Gelatinase Associated Lipocalin in Critically Hospitalized Patients in Intensive Care Unit</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal failure - Subjects with Acute Renal Failure(ARF) - Subjects in failure(F) category</PatientSegment><PatientSegment>Renal failure - Subjects with Acute Renal Failure(ARF) - Subjects in risk(R) category</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Urinary flow </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alireza Rahimi</Name><Name>Ata Mahmoodpoor</Name><Name>Vahid Fattahi</Name></ContactNames></Trial><Trial Id="12546"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>Poland</Country><Country>UK</Country></Countries><DateChangeLast>2017-12-02T00:00:00Z</DateChangeLast><DateEnd>2003-07-23T00:00:00Z</DateEnd><DateStart>2003-06-30T00:00:00Z</DateStart><Identifiers><Identifier>D153-P526</Identifier><Identifier>FluMist</Identifier><Identifier>NCT00192179</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Appetite loss</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Nasal congestion</Indication><Indication>Rhinitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this prospective, randomized, double-blind, placebo-controlled study was to compare, over a 7-day period, the fever rates following one dose of either influenza virus vaccine ( CAIV-T ) or placebo administered outside the influenza season to healthy children and adolescents aged 6 to &amp;lt; 18 years.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>FluMist: A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children - Children more than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2003-07-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>6</NumberOfSites><ContactNames><Name>Dr Andre Vertruyen</Name><Name>Dr Bhavesh Bodalia</Name><Name>Dr Douglas McKeith</Name><Name>Dr Jerzy Pejcz</Name><Name>Prof Dr Pierre Van Damme</Name><Name>Prof Dr. Karel Hoppenbrowers</Name><Name>Raburn Mallory, M.D.</Name></ContactNames></Trial><Trial Id="125346"><Indications><Indication>Obesity</Indication></Indications><CompaniesSponsor><Company>Universiteit Maastricht</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-07-02T00:00:00Z</DateChangeLast><DateEnd>2012-04-01T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN21413505</Identifier><Identifier>NL 31762.068.10</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>isoproterenol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Mild &lt;b&gt;cold&lt;/b&gt; experiment, in which the participants would be subject to mild &lt;b&gt;cold&lt;/b&gt; exposure via airconditioning until they start shivering. Then the temperature would be increased by two degrees to avoid further shivering. This intervention would...study the effects of isoprenaline and food intake on brown fat activity compared to brown fat activity during &lt;b&gt;cold&lt;/b&gt; exposure (control experiment). The hypotheses: a single high-caloric, carbohydrate-rich meal would increase energy expenditure and was</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Assessment of Laboratory/Diagnostic Measures - Body temperature</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters - Assessment of energy expenditure</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Role Of Brown Adipose Tissue In Meal-Induced Thermogenesis And The Involvement Of The Sympathetic Nervous System</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Wouter Lichtenbelt</Name></ContactNames></Trial><Trial Id="125046"><Indications><Indication>Asthma</Indication></Indications><CompaniesCollaborator><Company>Kyorin Pharmaceutical Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Dokkyo Medical University</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-07-17T00:00:00Z</DateChangeLast><DateStart>2007-11-01T00:00:00Z</DateStart><Identifiers><Identifier>JPRN-UMIN000006234</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carbocisteine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The aim of this study was to evaluate the effect of carbocisteine on the frequency of the common &lt;b&gt;cold&lt;/b&gt; and acute exacerbations in asthma patients [ 1410776 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Severity of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Time to first exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Assessment of response to therapy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Carbocisteine on Common Cold Morbidity in Asthma Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ritsuko Kondo</Name><Name>Takeshi Fukuda</Name></ContactNames></Trial><Trial Id="12479"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-02T00:00:00Z</DateChangeLast><DateEnd>2001-10-01T00:00:00Z</DateEnd><DateStart>2001-07-31T00:00:00Z</DateStart><Identifiers><Identifier>D153 P003</Identifier><Identifier>NCT00192153</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this clinical study was to evaluate immunological responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to develop assays for application in investigating potential immunological correlates of protection and/or establishing assays to measure vaccine take.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>2 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Robert Walker, MD</Name></ContactNames></Trial><Trial Id="12478"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-02T00:00:00Z</DateChangeLast><DateEnd>2006-01-31T00:00:00Z</DateEnd><DateStart>2005-05-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP123</Identifier><Identifier>NCT00111579</Identifier></Identifiers><IndicationsAdverse><Indication>Fever</Indication><Indication>Hepatomegaly</Indication><Indication>Nasal congestion</Indication><Indication>Otitis media</Indication><Indication>Rhinorrhea</Indication><Indication>Seizure disorder</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Fluzone alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>52</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to describe the level of serum antibody conferred by CAIV-T and TIV ( Fluzone ) against homotypic and heterotypic influenza virus strains.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate>2006-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Robert Walker, MD</Name></ContactNames></Trial><Trial Id="124289"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company><Company>Roche Nederland BV</Company></CompaniesCollaborator><CompaniesSponsor><Company>Erasmus MC - Sophia</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-06-07T00:00:00Z</DateChangeLast><DateEnd>2008-01-01T00:00:00Z</DateEnd><DateStart>2006-02-01T00:00:00Z</DateStart><Identifiers><Identifier>DIEPTE</Identifier><Identifier>ISRCTN50584238</Identifier><Identifier>MEC-2005-308</Identifier><Identifier>NTR553</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Akita nebulizer alone</Intervention><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose was to evaluate the efficacy of RhDNase ( dornase alfa ) targeted to the peripheral airways in Cystic Fibrosis (CF) exacerbations [ 1409428 ], [ 1493286 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment of mucociliary clearance</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>DIEPTE: DIEPTE-Study: DNase Inhalation in Cf Exacerbations, Peripherally Targeted</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation</PatientSegment><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>E. Bakker</Name><Name>H. Tiddens</Name></ContactNames></Trial><Trial Id="123969"><Indications><Indication>Seasonal allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Cytokine modulator</Action><Action>Immunostimulant</Action><Action>T-lymphocyte modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Novotech (Australia) Pty Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Anzamune Limited</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2013-10-29T00:00:00Z</DateChangeLast><DateStart>2007-10-14T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12607000494437</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>CMP-1 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>anti-histamines HIV protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir) Potent inhibitors of P450 cytochrome CYP 3A4 Within 7 days prior to screening: Cetirizine, fexofenadine HCL, all other antihistamines (includes sleep and diet aids and &lt;b&gt;cold&lt;/b&gt; preparations)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of symptom free days</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of symptoms and medication score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM instantaneous total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Rhinoconjunctivitis Quality of life questionnaire(RQLQ)</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of disease interference with sleep and daily activities of living</EndpointIndex><EndpointIndex>Allergic rhinitis - Physician Global Assessment of Disease Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of the Safety and Effectiveness of Chitin Microparticles (CMP) Nasal Spray in People With 'Hay Fever' Due to Spring Allergy</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>5</NumberOfSites><ContactNames><Name>Sharon Parkes</Name><Name>Stuart Mclachlan</Name></ContactNames></Trial><Trial Id="123200"><Indications><Indication>Dyspepsia</Indication></Indications><CompaniesSponsor><Company>Japanese Ministry of Health, Labor and Welfare</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-10-01T00:00:00Z</DateChangeLast><DateEnd>2013-06-30T00:00:00Z</DateEnd><DateStart>2011-02-01T00:00:00Z</DateStart><Identifiers><Identifier>JPRN-UMIN000003954</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>rikkunshito alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>430</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>case), tinnitus (one case), skin dysesthesia (one case), oral dysesthesia (one case), dizziness (one case), and urticaria (one case) in rikkunshito group. In the placebo group, the following mild symptoms were reported: c-GTP elevation (four cases), &lt;b&gt;cold&lt;/b&gt; symptoms (three cases), dermatitis (two cases), diarrhea (one case), upper abdominal pain (one case), abdominal bloating (one case), lower back pain (one case), and sudden deafness (one case) [ 1589386 ]. Similar results were presented in May 2014.</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dyspepsia - Assessment of Functional Dyspepsia Symptoms Using Protocol Specified Scales/Scores</EndpointIndex><EndpointIndex>Dyspepsia - Assessment of Functional Dyspepsia Symptoms Using Protocol Specified Scales/Scores - Assessment of symptoms by Dyspepsia symptom Score (DSS)</EndpointIndex><EndpointIndex>Dyspepsia - Assessment of Other Symptoms of Functional Dyspepsia</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Gastro-intestinal disease related outcomes</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Double-blind, Randomized, Placebo-controlled Trial To Examine The Efficacy And The Safety Of Rikkunshito For Functional Dyspepsia</TitleDisplay><PatientSegmentTerms><PatientSegment>Dyspepsia - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with abdominal pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Appetite regulating hormone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hidekazu Suzuki</Name><Name>Mami Okada</Name><Name>Naoki Tomotsugu</Name></ContactNames></Trial><Trial Id="123132"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Cytotoxic T-lymphocyte protein-4 modulator</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Protein fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Bristol-Myers Squibb Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Mount Sinai School of Medicine</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-04-18T00:00:00Z</DateChangeLast><DateEnd>2017-06-30T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>13-00174</Identifier><Identifier>IM103-057</Identifier><Identifier>NCT01837043</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cyclosporine alone</Intervention><Intervention>tacrolimus alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>belatacept alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>over the age of 60 or age 50 to 60 with two of the following risk factors: Terminal creatinine&gt; 1.5 mg/dl History of hypertension Death due to cerebrovascular accident Donations after cardiac death (DCD) kidney recipients Donor organs with an actual &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT)&gt; 19 h Recipients of donor organs with a terminal creatinine&gt; 1.5 mg/day Only patients who receive thymoglobulin induction and CNI maintenance at time of randomization will be considered for the study Men and women, 18 to 70 years</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Virology Markers</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Other Laboratory Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Clusterin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Rap guanine nucleotide exchange factor 5 </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Barbara Murphy, MD</Name><Name>Brandy Haydel, CCRC</Name><Name>Brandy M Haydel, CCRC</Name><Name>Peter Heeger, MD</Name><Name>Sander Florman, MD</Name><Name>Vinay Nair, D.O.</Name></ContactNames></Trial><Trial Id="123103"><Indications><Indication>Mouth ulcer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Shahid Sadoughi University of Medical Sciences and Health Services</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-21T00:00:00Z</DateChangeLast><DateStart>2009-04-05T00:00:00Z</DateStart><Identifiers><Identifier>IRCT138708191442N1</Identifier></Identifiers><InterventionsControlDisplay><Intervention>aciclovir alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>melissan gel alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose was to compare the treatment efficacy of melissan gel with cream of aciclovir in the treatment of recurrent herpes labialis in this study [ 1407742 ].</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Appearance</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Gel of Mellissan in the Treatment of the Cold Sore</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Hakimeh Ahadian</Name><Name>Fatemeh Ardakani</Name><Name>Hakimeh Ahadian</Name></ContactNames></Trial><Trial Id="122822"><Indications><Indication>Pulpitis</Indication></Indications><CompaniesSponsor><Company>Kerman University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-13T00:00:00Z</DateChangeLast><DateStart>2009-09-11T00:00:00Z</DateStart><Identifiers><Identifier>IRCT138803192016N1</Identifier><Identifier>KA/88-05</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ibuprofen alone</Intervention><Intervention>indomethacin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> No response to &lt;b&gt;cold&lt;/b&gt; test Having sensitivity to percussion and palpation Having radiographic changes such as PDL widening Lack of vital pulp in coronal pulp chamber access cavity preparation, teeth with evidence of crack in their crown Having advanced periodontal disease</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of the Effect Of Pretreatment with Ibuprofen, Indomethacin, and Placebo on the Success of Inferior Alveolar Nerve Block for Teeth with Irreversible Pulpitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr.Masoud Parirokh</Name><Name>Hasani</Name><Name>Nozar Nakhaee</Name><Name>Rezvan Ashouri</Name><Name>masoud Parirokh</Name></ContactNames></Trial><Trial Id="122623"><Indications><Indication>Papillomavirus infection</Indication><Indication>Verruca vulgaris</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Gastric secretion inhibitor</Action><Action>Histamine H2 antagonist antiulcerant product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Islamic Azad University of Khorasgan</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-14T00:00:00Z</DateChangeLast><DateStart>2007-04-21T00:00:00Z</DateStart><Identifiers><Identifier>1342</Identifier><Identifier>IRCT201008134128N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cimetidine alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>81</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Raynaud’s phenomen Peripheral vascular disease Previous wart treatment and &lt;b&gt;cold&lt;/b&gt; urticaria</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Disease Relapse/Recurrence - Relapse/recurrence of warts</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Tumor Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison the therapeutic efficacy of cimetidine and cryotherapy in treatment of warts</TitleDisplay><PatientSegmentTerms><PatientSegment>Papillomavirus infection - Subjects with Skin Warts - Subjects with common warts</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Majid Mogaddam</Name><Name>Majid Rostami</Name><Name>Seiied Hashemein</Name></ContactNames></Trial><Trial Id="122528"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>AJA University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-19T00:00:00Z</DateChangeLast><DateStart>2009-08-11T00:00:00Z</DateStart><Identifiers><Identifier>81/1955</Identifier><Identifier>IRCT201105095536N3</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Male sex Non-smoker Not suffering from any disease related to air ways like asthma Bronchitis and amphysma Not having &lt;b&gt;cold&lt;/b&gt; during last 6 weaks Not using corticosteroids and analgesics before operation</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Evalution of Intracuff Dexamethasone on Post-extubation Reactions</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Mohamad Reza Rafiei</Name><Name>Drmohamad Rafiei</Name><Name>Mohamad Rafiei</Name><Name>Mohamadreza Rafiei</Name></ContactNames></Trial><Trial Id="12093"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Vaccines</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-01T00:00:00Z</DateChangeLast><DateEnd>2001-12-01T00:00:00Z</DateEnd><DateStart>2001-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CAIVT</Identifier><Identifier>D153-P002</Identifier><Identifier>NCT00192322</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>173</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>was designed to perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by CAIV-T (influenza virus vaccine, trivalent, types A and B, live, &lt;b&gt;cold&lt;/b&gt;-adapted liquid Wyeth Lederle Vaccines, Marietta, PA). Also to assess nasal swab specimens to detect vaccine virus shedding.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Viral Load/Viral Shedding</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Viral Load/Viral Shedding</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>CAIVT: Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2001-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Robert Walker</Name></ContactNames></Trial><Trial Id="120844"><Indications><Indication>Breast tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Public Health Research Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Tokai Breast Cancer Clinical Research Group</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-07-20T00:00:00Z</DateChangeLast><DateEnd>2009-09-01T00:00:00Z</DateEnd><DateStart>2007-07-01T00:00:00Z</DateStart><Identifiers><Identifier>JPRN-UMIN000000806</Identifier><Identifier>TBCRG 03 trial</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cyclophosphamide plus docetaxel</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Heart disease As neoadjuvant and adjuvant therapy, treated hormone therapy and chemotherapy HER2/neu gene overexpressed or amplified A history of whitlow and &lt;b&gt;cold&lt;/b&gt; allergy Bilateral breast cancer and inflammatory breast cancer Uncontrolled medical conditions Hepatitis B A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TBCRG 03 trial: Multicenter, Phase II Trial to Prevent Docetaxel-induced Nail Change Using A Frozen Glove with Docetaxel (T) And Cyclophosphamide(C) As Adjuvant Chemotherapy for Patients With High Risk, Node Negative, Early Stage Breast Cancer: Tokai Breast Cancer Clinical Research Group</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with node negative breast cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hiroji Iwata</Name></ContactNames></Trial><Trial Id="120687"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesCollaborator><Company>South Manchester University Hospitals NHS Trust</Company></CompaniesCollaborator><CompaniesSponsor><Company>Department of Health</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-07-19T00:00:00Z</DateChangeLast><DateEnd>2007-07-31T00:00:00Z</DateEnd><DateStart>2005-03-01T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2004-003833-15</Identifier><Identifier>ISRCTN50541811</Identifier><Identifier>N0226156349</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the last 12 months or congestive cardiac failure Subjects with other significant pulmonary, cardiovascular, neurological, hepatic, renal, endocrine or hematological diseases Female subjects who intend to become pregnant Subjects who have experienced &lt;b&gt;cold&lt;/b&gt; or flu-like symptoms or a respiratory infection within 4 weeks of the study start Subjects who have received an investigational drug within 30 days or within five drug half-lives of the drug Subjects with a history (or suspected history) of alcohol</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Functional Residual Capacity (FRC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Leukotriene B4 (LTB4) assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inspiratory Capacity (IC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Lung Volumes - Residual volume (RV)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function - Assessment of total lung capacity (TLC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum - Cell counts in sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum - Cytokine IL-8 concentration in induced sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessments of Airway Status/Obstruction - Assessment of airway conductance (sGaw)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessments of Airway Status/Obstruction - Assessment of airway resistance (Raw)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements - Maximum Expiratory Flow (MEF)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Pharmacogenetic/Pharmacogenomics Analysis - Pharmacogenetics/genomics/pharmacoepigenetic analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Parallel-Group Trial to Investigate the Effect of Seretide Withdrawal in Chronic Obstructive Pulmonary Disease (COPD) Using Non-Invasive Biomarkers and Physiological Measurements</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucocorticoid receptor </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Leukotriene B4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>29 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>David Singh</Name></ContactNames></Trial><Trial Id="120304"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Erasmus University Medical Center Rotterdam</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-06-06T00:00:00Z</DateChangeLast><DateEnd>2008-01-01T00:00:00Z</DateEnd><DateStart>2006-09-01T00:00:00Z</DateStart><Identifiers><Identifier>2006-002337-20</Identifier><Identifier>2412325-2</Identifier><Identifier>IDOL</Identifier><Identifier>ISRCTN71537084</Identifier><Identifier>NTR671</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this randomized, double-blind, placebo-controlled, parallel study was to investigate the effect of treatment with nebulized Pulmozyme on pulmonary function in children with asthma and persistent obstructive pulmonary function. The secondary objectives were to investigate the effect of treatment with nebulized Pulmozyme on gas mixing, FENO values and symptom scores in children with asthma and persistent obstructive pulmonary function [ 1403128 ], [ 1403137 ], [ 1403133 ]. The</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Cough</EndpointIndex><EndpointIndex>Asthma - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Asthma - Assessment of Exercise Capacity/Tolerance - Effect of exercise therapy on symptoms or biomarkers</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Flow (FEF)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>IDOL: Efficacy of Peripherally Targeted Inhaled rhDNase for Persistent Obstructive Asthma in Childhood</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Stable Asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>H. Tiddens</Name><Name>H.A.W.M. Tiddens</Name></ContactNames></Trial><Trial Id="119755"><Indications><Indication>Reperfusion injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement cascade inhibitor</Action><Action>Complement receptor 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intra-articular formulation</Technology><Technology>Protein conjugated</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesCollaborator><Company>Medical Research Council</Company></CompaniesCollaborator><CompaniesSponsor><Company>King's College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-05-22T00:00:00Z</DateChangeLast><DateEnd>2018-05-30T00:00:00Z</DateEnd><DateStart>2012-10-18T00:00:00Z</DateStart><Identifiers><Identifier>2011-000958-30</Identifier><Identifier>EMPIRIKAL</Identifier><Identifier>ISRCTN49958194</Identifier><Identifier>MD-001</Identifier><Identifier>UKCRN 16181</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mirococept alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>560</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>of the kidney and whether this might extend the life of the kidney [ 1401129 ]. Study hypothesis was to test the superiority of mirococept in the prevention of ischemia-reperfusion injury (IRI) in cadaveric renal allografts, as compared to standard &lt;b&gt;cold&lt;/b&gt; perfusion fluid (Soltran).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EMPIRIKAL: An Investigation Into the Treatment of the Donor Kidney to See if This Improves the Recovery of the Kidney After Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>67 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Laura Nicols</Name><Name>Marie Thornhill</Name><Name>Martin Drage</Name></ContactNames></Trial><Trial Id="11965"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Vaccines</Company><Company>WYETH LEDERLE</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country><Country>Singapore</Country></Countries><DateChangeLast>2017-12-02T00:00:00Z</DateChangeLast><DateEnd>2003-05-31T00:00:00Z</DateEnd><DateStart>2002-10-31T00:00:00Z</DateStart><Identifiers><Identifier>D153-P522</Identifier><Identifier>HKUCTR-277</Identifier><Identifier>IRB 02-25 R/292</Identifier><Identifier>NCT00192166</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Priorix alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1200</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to determine if intranasally administered influenza virus vaccine, CAIV-T ( FluMist ), when administered concomitantly with a subcutaneous combination live, attenuated mumps, measles, and rubella ( MMR vaccine ) virus vaccine to children, interferes with the immune responses to the measles, mumps, and rubella components of the MMR vaccine.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of complications</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of complications</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to assess safety, efficacy, tolerability and immunogenicity of influenza virus vaccine, liquid formulation (CAIV-T), administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11 to 24 months</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>MMR Vaccine - Subjects Naive to Other Vaccines</PatientSegment><PatientSegment>MMR Vaccine - Subjects Naive to Other Vaccines - Subjects Naive to MMR Vaccine</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin E</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>HKUCTR Administrator</Name><Name>Lucy Lum</Name><Name>Prof. Yu-lung Lau</Name></ContactNames></Trial><Trial Id="119629"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Roche Nederland BV</Company></CompaniesCollaborator><CompaniesSponsor><Company>Erasmus University Medical Center Rotterdam</Company><Company>The Aghia Sophia Children's Hospital</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-06-06T00:00:00Z</DateChangeLast><DateEnd>2007-09-15T00:00:00Z</DateEnd><DateStart>2005-09-15T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN81874766</Identifier><Identifier>NTR240</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to evaluate the efficacy of inhaled rhDNase ( dornase alfa ) for acute asthma in childhood. The study hypothesized that rhDNase can liquefy sputum in acute asthma resulting in less airways obstruction, reduced work of breathing, and diminished ventilation-perfusion mismatch, thereby improving symptoms, reducing the number of patients who need to be admitted, and shorten the duration of admission [ 1400560 ], [ 1400563 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Reduction/improvement of symptoms</EndpointIndex><EndpointIndex>Asthma - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Asthma - Assessment of Exercise Capacity/Tolerance - Assessment of oxygen consumption</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs - Respiratory rate</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Readmission rates</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Beta agonist usage</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use</EndpointIndex><EndpointIndex>Asthma - Health Economic Assessments - Assessment of direct cost</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Inhaled rhDNase for Acute Asthma in Childhood</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>R. Boogaard</Name></ContactNames></Trial><Trial Id="119007"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Leiber Company</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-04-03T00:00:00Z</DateChangeLast><DateEnd>2011-05-12T00:00:00Z</DateEnd><DateStart>2010-10-15T00:00:00Z</DateStart><Identifiers><Identifier>ISRCTN16094368</Identifier><Identifier>LEI/K/00810</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Yestimun alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>224</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>congestion, &lt;b&gt;cold&lt;/b&gt; related sleeping difficulties, and body temperature above 38degC. During an episode, the subjects recorded and assessed their &lt;b&gt;cold&lt;/b&gt; symptoms in the subject diary, for a period of...weeks. In addition, one episode visit was conducted on the 5th day of each &lt;b&gt;cold&lt;/b&gt; episode. The number, severity and duration of colds, use of antibiotics and analgesics...control methods) At least three common &lt;b&gt;cold&lt;/b&gt; infections within the last 6 months Written consent of the subject to study participation, subject understands the</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Social and Occupational Functioning</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and efficacy of insoluble (1,3)-(1,6)-beta-glucan made from brewers’ yeast (Saccharomyces cerevisiae)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with other types of headache</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>6 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Annegret Auinger</Name></ContactNames></Trial><Trial Id="118891"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Zanjan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-06-06T00:00:00Z</DateChangeLast><DateStart>2011-04-04T00:00:00Z</DateStart><Identifiers><Identifier>8912315</Identifier><Identifier>IRCT201205169664N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>indomethacin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Patients would receive 100 mg indomethacin suppository 1 h before chest tube removal with either 4degC &lt;b&gt;cold&lt;/b&gt; pack or &lt;b&gt;cold&lt;/b&gt; pack with room temprature placed it on chest tube site 20 min before removing chest tube [ 1399197 ].... The aim of this study was to examine the effect of &lt;b&gt;cold&lt;/b&gt; application in combination with indomethacin suppository on chest tube removal pain in patients who had undergone open heart surgery [ 1399197 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effectiveness Of Cold Application In Combination With Indomethacin Suppository On Chest Tube Removal Pain Undergone Open Heart Surgery Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alireza Biglari</Name><Name>Eskanndar Nourizadeh</Name><Name>Mitra Bousari</Name></ContactNames></Trial><Trial Id="118794"><Indications><Indication>Allergic rhinitis</Indication><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>Medisch Spectrum Twente Enschede</Company></CompaniesCollaborator><CompaniesSponsor><Company>Stichting Pediatrisch Onderzoek Enschede</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-07-23T00:00:00Z</DateChangeLast><DateEnd>2009-04-05T00:00:00Z</DateEnd><DateStart>2009-03-05T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2009-010563-17</Identifier><Identifier>FF1</Identifier><Identifier>ISRCTN90761040</Identifier><Identifier>NL26953.044.09</Identifier><Identifier>YSCO</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>91</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this trial was to evaluate the protective effect of a nasal corticosteroid fluticasone furoate (Avamys) on exercise induced airway obstruction in &lt;b&gt;cold&lt;/b&gt; air in children [ 1398685 ], [ 1399954 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function - Forced expiratory volume in the first second (FEV1)</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Asthma Control Questionnaire (ACQ)</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Paediatric Asthma Quality of Life Questionnaire(PAQLQ)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in FEV1 after challenge test</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function - Peak expiratory flow</EndpointIndex><EndpointIndex>Asthma - Assessments of Airway Status/Obstruction - Airway conductance (sGaw)</EndpointIndex><EndpointIndex>Asthma - Assessments of Airway Status/Obstruction - Airway resistance (Raw)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>YSCO: The Protective Effect of a Nasal Corticosteroid (Avamys) On Exercise Induced Airway Obstruction in Cold Air in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with comorbid conditions</PatientSegment><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Stable Asthma</PatientSegment><PatientSegment>Asthma - Subjects with specific disease - Subjects with Exercise Induced Asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Janneke Van Leeuwen</Name></ContactNames></Trial><Trial Id="118675"><Indications><Indication>Cold injury</Indication></Indications><CompaniesSponsor><Company>Defence Research &amp; Development Organisation</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-04-22T00:00:00Z</DateChangeLast><DateStart>2006-10-11T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2010/091/001442</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>salbutamol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>of clinician in charge) Patients with skin disease in the area of &lt;b&gt;cold&lt;/b&gt; injury/other lesions Patients with clinically significant renal, respiratory (other than...Mild &lt;b&gt;cold&lt;/b&gt; injury: Painful &lt;b&gt;cold&lt;/b&gt; periphery (hands and feet) attributed to &lt;b&gt;cold&lt;/b&gt; injury in appropriate weather conditions Age group: 18... The purpose of this study was to evaluate salbutamol ointment for &lt;b&gt;cold&lt;/b&gt; injuries [ 1398297 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Clinical Trial With 0.5% Salbutamol Ointment for Cold Injuries</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Aseem Bhatnagar</Name></ContactNames></Trial><Trial Id="118514"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Elastase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Expectorant</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Imperial College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2013-09-19T00:00:00Z</DateChangeLast><DateStart>2008-01-24T00:00:00Z</DateStart><Identifiers><Identifier>05102006</Identifier><Identifier>EudraCT 2006-005534-20</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>erdosteine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective was to demonstrate that erdosteine has anti-oxidative placebo-different effect that can be demonstrated by measuring the proposed sputum biomarkers. The secondary objectives were to demonstrate that anti-oxidative effect of erdosteine is also reflected by the improvement of phagocytotic activity of peripheral blood mononuclear cells (PBMC), oxidative biomarkers in exhaled breath and condensate, peripheral blood, lung function, symptoms and quality of life [ 1397938 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea - Dyspnea assessed by Borg Scale/Modified Borg Scale (MBS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of FEV1/FVC Ratio</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Leukotriene B4 (LTB4) assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Anxiety scores</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Erdosteine on Inflammatory and Oxidative Biomarkers in Sputum and Exhaled Breath in Patients with COPD</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Leukotriene B4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="118477"><Indications><Indication>Hyperalgesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>National Institute on Drug Abuse</Company></CompaniesCollaborator><CompaniesSponsor><Company>Georgetown University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01821430</Identifier><Identifier>Pro00000669</Identifier><Identifier>U01DA029580</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>disability (Brief Pain Inventory). Opioid-induced hyperalgesia would be measured at each time point using a standardized &lt;b&gt;Cold&lt;/b&gt; Pressor trial, and performance at baseline would be compared to performance following pregabalin /placebo administration over...buprenorphine (6 to 24 mg/day) at least 10 days Provide urine sample absent of any non-prescribed drugs of abuse at screening Screening &lt;b&gt;cold&lt;/b&gt;-pressor pain tolerance&amp;lt; 70 s Have chronic lower back pain or arthritis pain (duration 6 or more months). Be otherwise</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Increase Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Peggy Compton, RN, PhD</Name></ContactNames></Trial><Trial Id="118101"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NMDA receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Gedeon Richter Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2013-09-18T00:00:00Z</DateChangeLast><DateStart>2005-05-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2005-001201-25</Identifier><Identifier>RGH-896-004</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>radiprodil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>prior to the screening visit and &gt;/= 40 mm on the pain VAS during the baseline week prior to randomisation The presence of neuropathy will be confirmed by: A combined (both feet) score of &gt;/= 3 on the neuropathy deficit score (vibration, pin prick, hot/&lt;b&gt;cold&lt;/b&gt; and ankle reflexes) Elevated vibration perception threshold (&gt; 10 V) and Sural sensory nerve action potential amplitude reduced to&amp;lt;/= 8 microV</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Phase II, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of RGH-896 in Patients With Pain Due to Diabetic Sensorimotor Peripheral Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117938"><Indications><Indication>Cancer</Indication></Indications><CompaniesCollaborator><Company>Cypress Systems</Company><Company>Danish Cancer Society</Company><Company>Pharma Nord ApS</Company><Company>The Dagmar Marshall Foundation</Company><Company>The Danish Directory of Food and Agriculture</Company><Company>The Foundation of Clinical Experimental Cancer Research, Odense</Company><Company>The Foundation of Lily Benthine Lund</Company><Company>The Memory Foundation of Merchant Brogaard</Company><Company>University of Southern Denmark</Company></CompaniesCollaborator><CompaniesSponsor><Company>Odense University Hospital</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2019-03-08T00:00:00Z</DateChangeLast><DateEnd>2004-06-30T00:00:00Z</DateEnd><DateStart>1998-11-30T00:00:00Z</DateStart><Identifiers><Identifier>DK PRECISE</Identifier><Identifier>NCT01819649</Identifier><Identifier>OUH-DK-PILOT-PRECISE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>SelenoPRECISE alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>491</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this pilot study was to assess the viability of a full scale randomized trial. Amendment to study objective: mortality analysis during intervention and follow-up as specified in the sections concerning study design and outcome measures. Hypothesis: daily intake of selenium supplementation in the form of selenium-enriched yeast tablets would reduce the risk of cancer in healthy individuals.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>DK PRECISE: Selenium in the Prevention of Cancer</TitleDisplay><BiomarkerNames><BiomarkerName>Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2004-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>67 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Soren Cold</Name></ContactNames></Trial><Trial Id="117710"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Chloride channel modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Genaera Corp</Company></CompaniesSponsor><Countries><Country>Ireland</Country></Countries><DateChangeLast>2018-08-06T00:00:00Z</DateChangeLast><DateStart>2005-04-08T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2004-004334-13</Identifier><Identifier>MSI-1995-203</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>talniflumate (mucoregulator), Genaera alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>220</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objectives of the study was to evaluate the safety profile and efficacy of talniflumate (Somalgen) compared with that of placebo when administered as two 370 mg tablets, tid for 52 weeks. The secondary objectives of this study were: To evaluate at weeks 2, 4, 8, 20, 32, 46, 48, 50 and 52, and follow-up: change from baseline in (pre- and post-bronchodilator) spirometric measurements of forced vital capacity (FVC) and FEV1. Change from baseline in respiratory rate. Change from baseline</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of change from baseline in FVC</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment of total lung capacity/residual volume</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Carbon monoxide diffusing capacity (DLCO)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Respiratory System/Symptoms</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_rs113993960(-)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Carbon monoxide diffusing capacity </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Oxyhemoglobins</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117676"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Consumer Healthcare Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-01-02T00:00:00Z</DateChangeLast><DateStart>2007-06-06T00:00:00Z</DateStart><Identifiers><Identifier>A2720382</Identifier><Identifier>EudraCT 2006-004790-10</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>paracetamol alone</Intervention><Intervention>AG-1321001 plus paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this trial was to compare the analgesic efficacy of theobromine (AG-1321001) + paracetamol versus paracetamol alone [ 1396307 ]. The secondary objectives were: To summarize pharmacokinetic data (AUC[0 to 6 h], Cmax, tmax) for theobromine and for paracetamol (alone and in combination with theobromine ). To summarize the frequency of micturation for theobromine + paracetamol and for paracetamol alone. To summarize safety data for theobromine + paracetamol and for paracetamol alone</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Proof-of-Principle Analgesic Adjuvant Pilot Study in Post-Operative Dental Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117640"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable emulsion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Ankara Training and Research Hospital</Company></CompaniesSponsor><Countries><Country>Turkey</Country></Countries><DateChangeLast>2017-03-24T00:00:00Z</DateChangeLast><DateStart>2011-09-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000435886</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>propofol, AstraZeneca/Fresenius alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>40degC hot application for 2 min with a bair hugger device through the vein trace which the cannula were attached. Local cooling group (Group II): before anesthesia induction patients were subjected to + 2 to 4degC cooling application for 2 min with &lt;b&gt;cold&lt;/b&gt; water bags kept in refrigerator, through the infusion vein trace. No intervention group (Group III): patients in this group were accepted as control group and were not subjected to any procedure. Propofol prepared in room temperature (10 mg/ml ampoule</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Local Warming Versus Local Cooling on Injection Pain After Propofol Administration During Anesthesia Induction</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hale Uysal</Name></ContactNames></Trial><Trial Id="117608"><Indications><Indication>Psoriasis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Topical antipsoriatic product</Action><Action>Vitamin D analog</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Agis Industries (1983) Ltd</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2013-09-24T00:00:00Z</DateChangeLast><DateStart>2005-08-15T00:00:00Z</DateStart><Identifiers><Identifier>240213BS</Identifier><Identifier>EudraCT 2004-004740-51</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>calcipotriol alone</Intervention><Intervention>paroxetine hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>medications which are known to provoke or aggravate psoriasis, eg, b-blocker, antimalarial drugs within 2 weeks before the beginning of the study and during the study Medications which do not influence the study aim for example for treatment of headache or &lt;b&gt;cold&lt;/b&gt; may be used at the discretion of the investigator Known allergic reactions to the active ingredients or other components of the study preparations, comparators or control Evidence of drug abuse Known positive HIV-test Pregnancy or nursing UV-therapy</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion</EndpointIndex><EndpointIndex>Psoriasis - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Psoriasis - Protocol Specified Other Endpoints - Therapy/Intervention Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Determination of Anti-Psoriatic Efficacy of Topical Paroxetine Hydrochloride Ointments in a Psoriasis Plaque Test</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117354"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Roche Products Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Royal Liverpool University Hospital</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-05-21T00:00:00Z</DateChangeLast><DateEnd>2009-06-24T00:00:00Z</DateEnd><DateStart>2002-11-26T00:00:00Z</DateStart><Identifiers><Identifier>101177/ML17309</Identifier><Identifier>ISRCTN74336394</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cyclosporine plus mycophenolate mofetil</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>steroid therapy alone</Intervention><Intervention>Variable regimens including daclizumab , mycophenolate mofetil , sirolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate whether a calcineurin inhibitor (CNI) free regimen offers equivalent safety and efficacy to that of a CNI regimen and may offer improved long-term graft survival [ 1395385 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of vascular structure/function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Survival</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Transplantation</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment Acute Tubular Necrosis - Incidence/rate of acute tubular necrosis</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment Acute Tubular Necrosis - Rate of recovery of acute tubular necrosis</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Hypertension</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR) - Time to CGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance - Creatinine clearance using Cockcroft-Gault formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular endothelial growth factor (VEGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A randomized, prospective trial of daclizumab induction followed by sirolimus in association with mycophenolate mofetil and steroids versus standard cyclosporin based triple therapy for rejection prophylaxis in renal transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>End stage renal disease - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>78 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Abdel Hammad</Name></ContactNames></Trial><Trial Id="117000"><Indications><Indication>Nocturia</Indication></Indications><CompaniesSponsor><Company>SagaMedica</Company></CompaniesSponsor><Countries><Country>Iceland</Country></Countries><DateChangeLast>2018-01-10T00:00:00Z</DateChangeLast><DateEnd>2011-02-11T00:00:00Z</DateEnd><DateStart>2010-05-11T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2010-019668-35</Identifier><Identifier>Saga-001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>SagaPro alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results demonstrated that SagaPro was safe. There were no severe adverse events reported, and the number of reports was similar in both treatment groups, 24 in the placebo group and 21 in the SagaPro group. The most frequent adverse events were common &lt;b&gt;cold&lt;/b&gt; (n = 4 in the placebo group and n = 3 in the SagaPro group), diarrhea (n = 3 in each group), vomiting (n = 2 in each group) and sore throat (n = 2 in the SagaPro group and n = 1 in the placebo group). No other adverse events were reported by more than</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate hyperplasia - Assessment of Therapy Related Outcomes - Assessment of treatment efficacy(unspecified)</EndpointIndex><EndpointIndex>Prostate hyperplasia - Subjective Assessment of BPH Symptoms - Assessment of voiding symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Parallel, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of SagaPro on Nocturia in Men</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate hyperplasia - Subjects with Symptomatic Disease - Subjets with Moderately Symptomatic BPH</PatientSegment><PatientSegment>Prostate hyperplasia - Subjects with Symptomatic Disease - Subjets with Severely Symptomatic BPH</PatientSegment><PatientSegment>Prostate hyperplasia - Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH) - Subjects with lower urinary tract symptoms(LUTS)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116890"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>STAT-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Oligonucleotide</Technology></Technologies><CompaniesSponsor><Company>Avontec GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2007-01-23T00:00:00Z</DateStart><Identifiers><Identifier>AVT-01/2/AST/04</Identifier><Identifier>EudraCT 2006-004191-13</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AVT-01 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>Nedocromil Cromolyn sodium Antihistamines NSAIDs Immunosuppressant agents Antitussive drugs (eg, codeine or other morphine derivatives) Medical history or presence of any of the following organic diseases: Acute respiratory infection (including “common &lt;b&gt;cold&lt;/b&gt;”) in the past 4 weeks prior to screening and during the entire study Chronic obstructive pulmonary disease (COPD) Acute episode of COPD Clinically relevant chronic cardiovascular disease Chronic kidney disease Gastrointestinal or liver diseases, such</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Methacholine( PC20/PD20) challenge tests</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of AVT-01 10 mg Single Dose in Patients With Mild Asthma Challenged With Inhaled Tumor Necrosis Factor Alpha – A Double-Blind, Randomized, Placebo-Controlled Clinical Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116832"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>STAT-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Oligonucleotide</Technology></Technologies><CompaniesSponsor><Company>Avontec GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2013-09-17T00:00:00Z</DateChangeLast><DateStart>2007-01-23T00:00:00Z</DateStart><Identifiers><Identifier>AVT-01/2/AST/03</Identifier><Identifier>EudraCT 2006-004190-94</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AVT-01 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>or inhaled long-acting beta-agonists Leukotriene modifiers Nedocromil Cromolyn sodium NSAIDs Immunosuppressant agents Antihistamines Medical history or presence of any of the following organic diseases: Acute respiratory infection (including 'common &lt;b&gt;cold&lt;/b&gt;') in the past 4 weeks prior to screening and during the entire study Chronic obstructive pulmonary disease (COPD) Acute episode of COPD Clinically relevant chronic cardiovascular disease Chronic kidney disease Gastrointestinal or liver diseases, such</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Methacholine( PC20/PD20) challenge tests</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of AVT-01 10 mg qd Over 7 Days in Patients With Moderate Persistent Atopic Asthma – A Double-Blind, Randomized, Placebo-Controlled Clinical Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116784"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon beta ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Synairgen plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-02-15T00:00:00Z</DateChangeLast><DateStart>2010-10-08T00:00:00Z</DateStart><Identifiers><Identifier>2010-022110-29</Identifier><Identifier>SG006</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>inhaled interferon beta (lung disorders/influenza), Synairgen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>166</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> The objective of this study was to see if SNG-001 was better than placebo at controlling chronic obstructive pulmonary disease (COPD) symptoms during common &lt;b&gt;cold&lt;/b&gt; infections. SNG-001 was given by a nebulizer, and the solution contains interferon-beta, which is an antiviral protein. The investigators tested the drug by looking to see if their COPD symptom (EXACT-Pro) peak score was lower in the SNG-001 treated</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Efficacy and Safety of Inhaled SNG-001 to Placebo Administered to COPD Patients After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of COPD Symptoms Caused by Respiratory Viruses</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116693"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>STAT-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Oligonucleotide</Technology></Technologies><CompaniesSponsor><Company>Avontec GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2013-09-18T00:00:00Z</DateChangeLast><DateStart>2007-01-23T00:00:00Z</DateStart><Identifiers><Identifier>AVT-01/2/AST/02</Identifier><Identifier>EudraCT 2006-004187-32</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AVT-01 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>or inhaled long-acting beta-agonists Leukotriene modifiers Nedocromil Cromolyn sodium NSAIDs Immunosuppressant agents Antihistamines Medical history or presence of any of the following organic diseases: Acute respiratory infection (including “common &lt;b&gt;cold&lt;/b&gt;”) in the past 4 weeks prior to screening and during the entire study Chronic obstructive pulmonary disease (COPD) Acute episode of COPD Clinically relevant chronic cardiovascular disease Chronic kidney disease Gastrointestinal or liver diseases, such</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Methacholine( PC20/PD20) challenge tests</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of AVT-01 5 mg qd Over 7 Days in Patients With Moderate Persistent Atopic Asthma – A Double-Blind, Randomized, Placebo-Controlled Clinical Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116451"><Indications><Indication>Lymphoplasmacytic lymphoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>B-lymphocyte antigen CD20 inhibitor</Action><Action>Proteasome inhibitor</Action><Action>Ubiquitin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Onyx Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hackensack University Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-07T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>IST-CAR-531</Identifier><Identifier>IST-CAR-531</Identifier><Identifier>NCT01813227</Identifier><Identifier>PRO 3596 (CAR-531)</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including carfilzomib , dexamethasone , rituximab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Waldenstrom's Macroglobulinemia (IWWM), includes the following criteria: Hemoglobin&amp;lt; 10 g/dl, platelet count &amp;lt; 100,000 microl, bulky adenopathy or organomegaly, symptomatic hyperviscosity syndrome, severe neuropathy, amyloidosis, cryoglobulinemia, &lt;b&gt;cold&lt;/b&gt; agglutinin disease, or evidence of transformation high-grade non-Hodgkin's lymphoma Patients must not be receiving concurrent steroids&gt; 10 mg prednisone (or equivalent) per day Prior irradiation is allowed if&gt; 28 days prior to registration have elapsed</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lymphoma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IST-CAR-531: A Phase II Study of Carfilzomib in Relapsed Waldenstrom's Macroglobulinemia (WM)</TitleDisplay><PatientSegmentTerms><PatientSegment>Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia) (Immunocytoma)</PatientSegment><PatientSegment>Lymphoma - Subjects with Other Lymphoid Malignancies - Subjects with transformed lymphoma</PatientSegment><PatientSegment>Lymphoma - Subjects with Relapse/Recurrent Lymphoma</PatientSegment><PatientSegment>Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma</PatientSegment><PatientSegment>Lymphoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2015-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Ann Mcneill</Name><Name>David H Vesole, MD, PhD</Name><Name>David Siegel</Name><Name>Elizabeth Bilotti</Name><Name>Joshua Richter</Name><Name>Kristin Ivanovski</Name></ContactNames></Trial><Trial Id="116404"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin sensitizer</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-08-14T00:00:00Z</DateChangeLast><DateStart>1996-06-10T00:00:00Z</DateStart><Identifiers><Identifier>49653/050</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Edema</Indication><Indication>Weight gain</Indication><Indication>Weight loss</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>rosiglitazone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>In March 2006, results were published. Common &lt;b&gt;cold&lt;/b&gt; syndrome, edema, decreased and increased weight were the most frequently reported adverse events. No drug related serious adverse events (fatal/non-fatal) were reported [ 1393136 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A multicenter, open-label, phase II study to evaluate the safety and efficacy of rosiglitazone (BRL-49653C) as monotherapy in Japanese type-2 diabetes mellitus patients</TitleDisplay><BiomarkerNames><BiomarkerName>1,5-Anhydroglucitol </BiomarkerName><BiomarkerName> C-peptide </BiomarkerName><BiomarkerName> D-Isoglucosamine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Nonesterified fatty acids </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="113755"><Indications><Indication>Cluster headache</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1b receptor agonist</Action><Action>5-HT 1d receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Nasal systemic formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Poland</Country><Country>Denmark</Country><Country>Sweden</Country></Countries><DateChangeLast>2014-02-11T00:00:00Z</DateChangeLast><DateEnd>1990-03-23T00:00:00Z</DateEnd><DateStart>1989-08-24T00:00:00Z</DateStart><Identifiers><Identifier>S2BT23</Identifier><Identifier>SUM30015</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Nausea</Indication><Indication>Pruritus</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sumatriptan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>49</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>tingling at the site of injection, were observed in 7 and 11 placebo-treated and sumatriptan -treated patients, respectively. Neurological symptoms such as dizziness, tiredness, numbness of hands, tingling, paresthesia, a feeling of paralysis in the face, &lt;b&gt;cold&lt;/b&gt; and hot sensations, were reported by 8 and 12 patients after the injections of placebo and sumatriptan , respectively. There were no drug-related abnormalities in the hematological or biochemical tests. No electrocardiographic abnormalities were detected</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of headache relief</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase II, randomized, double-blind, placebo-controlled, two-attack crossover, inpatient study to evaluate the safety and efficacy of sc GR-43175C (6 mg) in patients with cluster headache</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with other types of headache</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urea</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>4</NumberOfSites></Trial><Trial Id="11324"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-09-14T00:00:00Z</DateChangeLast><DateEnd>2001-12-31T00:00:00Z</DateEnd><DateStart>2001-09-30T00:00:00Z</DateStart><Identifiers><Identifier>D153 P004</Identifier><Identifier>NCT00192309</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Erythema</Indication><Indication>Headache</Indication><Indication>Myalgia</Indication><Indication>Pain</Indication><Indication>Rhinitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>TIV alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>31</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by CAIV-T , live &lt;b&gt;cold&lt;/b&gt;-adapted trivalent influenza virus vaccine types A and B, (liquid formulation, Wyeth , Marietta, PA).</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine</TitleDisplay><BiomarkerNames><BiomarkerName>B-cell antigen receptor complex-associated protein alpha chain </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Interferon gamma</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2001-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr David Radin</Name><Name>Robert Walker</Name></ContactNames></Trial><Trial Id="11259"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Utah</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-19T00:00:00Z</DateChangeLast><DateEnd>2008-01-31T00:00:00Z</DateEnd><DateStart>2004-09-30T00:00:00Z</DateStart><Identifiers><Identifier>50301066</Identifier><Identifier>NCT00297011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>clobetasol plus valaciclovir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age 18 years or older A history typical for recurrent herpes labialis. The subject must have experienced three or more &lt;b&gt;cold&lt;/b&gt; sores in the last 12 months In general good health, without other serious medical conditions, as determined by the patient's account of his/her medical history Signature on the informed consent document</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Appearance</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Valaciclovir plus Temovate Gel for the Treatment of Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christopher Hull</Name></ContactNames></Trial><Trial Id="111752"><Indications><Indication>Insomnia</Indication><Indication>Pain</Indication></Indications><CompaniesCollaborator><Company>National Institute on Drug Abuse</Company></CompaniesCollaborator><CompaniesSponsor><Company>Johns Hopkins University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-02-25T00:00:00Z</DateChangeLast><DateEnd>2018-01-31T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>1R01DA032922-01</Identifier><Identifier>ESP2</Identifier><Identifier>NA_00071465</Identifier><Identifier>NCT01794689</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>morphine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the effects of disrupted sleep patterns on mood, inflammation, the perception of pain, and pain relief. This study would help to understand the relationship between sleep and pain, and how sleep disturbance might influence chronic pain conditions.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>ESP2: Mechanisms of Sleep Disruption Hyperalgesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>56 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michael Smith, Ph.D</Name></ContactNames></Trial><Trial Id="111705"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TLR-2 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesCollaborator><Company>European Commission</Company></CompaniesCollaborator><CompaniesSponsor><Company>Opsona Therapeutics Ltd</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>UK</Country><Country>Germany</Country><Country>Switzerland</Country><Country>US</Country><Country>Netherlands</Country><Country>Poland</Country><Country>Belgium</Country><Country>Austria</Country><Country>France</Country><Country>Spain</Country></Countries><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-001455-39</Identifier><Identifier>MABSOT</Identifier><Identifier>NCT01794663</Identifier><Identifier>OPN305-102</Identifier><Identifier>UKCRN 14763</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tomaralimab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>252</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>a &lt;b&gt;cold&lt;/b&gt; ischaemic time &amp;gt; 18 h at time of arrival in the recipient's hospital in phase 0 or at randomization in parts...in &lt;b&gt;cold&lt;/b&gt; storage with or without machine perfusion For donor kidney in part B: The donor kidney must be considered...lt;/= 1.5mg/dl. Note: maximum terminal creatinine &amp;lt;/= 3 mg/dl (265.25 micromol/l) Kidney allograft maintained in &lt;b&gt;cold&lt;/b&gt; storage with or without machine perfusion</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MABSOT: Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> Glutathione S-transferase A3 </BiomarkerName><BiomarkerName> Glutathione S-transferase P </BiomarkerName><BiomarkerName> Hepatitis A virus cellular receptor 1 </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Metalloproteinase inhibitor 1 </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Osteopontin </BiomarkerName><BiomarkerName> Serum amyloid A protein 2 </BiomarkerName><BiomarkerName> Toll-like receptor 2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>58</NumberOfSites><ContactNames><Name>Caroline  Matthews</Name><Name>Neil  Sheerin</Name><Name>Rachel  Forrest</Name><Name>Robert M Miller, FRCS MBBS</Name><Name>VP Pharmaceutical Dev. &amp; Operations</Name></ContactNames></Trial><Trial Id="111473"><Indications><Indication>Pulpitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Islamic Azad University of Tehran-Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-09-07T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>18050</Identifier><Identifier>NCT01794533</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including epinephrine , fentanyl (transdermal), Janssen/ALZA , lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>64</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Individuals requiring urgent root canal treatment of maxillary first or second molars Hot painful teeth with irreversible pulpitis (moderate to severe spontaneous pain), with a positive response to thermal vitality tests (a long painful response to a &lt;b&gt;cold&lt;/b&gt; test) and no clinical or radiographic signs or symptoms of acute or chronic apical periodontitis No history of taking analgesics in the previous 12 h</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Level/Depth of block</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Fentanyl on the Rate of Anesthesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="108981"><Indications><Indication>Alcoholism</Indication></Indications><CompaniesCollaborator><Company>National Institutes of Health Clinical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute on Alcohol Abuse and Alcoholism</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-22T00:00:00Z</DateChangeLast><DateEnd>2017-06-01T00:00:00Z</DateEnd><DateStart>2012-12-13T00:00:00Z</DateStart><Identifiers><Identifier>13-AA-0043</Identifier><Identifier>130043</Identifier><Identifier>NCT01779024</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Functional MRI alone</Intervention><Intervention>ethanol plus ghrelin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Narcotics including darvocet, percocet and hydrocodone Drugs known to inhibit or induce enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram Cough-and-&lt;b&gt;cold&lt;/b&gt; preparations, which contain antihistamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least 72 h prior to each study session Current or prior history of alcohol-induced</Teaser><TrialCategories><Category>Borderline product</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alcoholism - Assessment of Brain Structure and Function</EndpointIndex><EndpointIndex>Alcoholism - Assessment of Substance Use/Abuse</EndpointIndex><EndpointIndex>Alcoholism - Assessment of adverse events</EndpointIndex><EndpointIndex>Alcoholism - Assessment of craving</EndpointIndex><EndpointIndex>Alcoholism - Imaging/Radiological Assessments - Assessment of imaging modalities</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers</TitleDisplay><PatientSegmentTerms><PatientSegment>Alcoholism - Subjects with Hazardous Levels of Alcohol Consumption - Heavy drinkers</PatientSegment><PatientSegment>Alcoholism - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-06-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lorenzo Leggio, M.D.</Name></ContactNames></Trial><Trial Id="107725"><Indications><Indication>Obesity</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 3 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Diabetes, Digestive and Kidney Diseases</Company><Company>National Institutes of Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>Beth Israel Deaconess Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2013-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2012-P-000309</Identifier><Identifier>2P30DK036836-26</Identifier><Identifier>NCT01783470</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mirabegron alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>during &lt;b&gt;cold&lt;/b&gt; exposure. &lt;b&gt;Cold&lt;/b&gt; exposure would consist of wearing a cooling vest at 55 to 61degF, a temperature shown to be cool enough to activate brown adipose tissue but warm enough not to lead to...to test the hypothesis that human brown adipose tissue (BAT) can be activated using a beta-3-adrenergic receptor (AR) agonist ( mirabegron ). The efficacy of beta-3-AR agonist would be compared with &lt;b&gt;cold&lt;/b&gt; exposure, as well as a placebo control.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Assessment of fat</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments - Changes in hormonal parameters</EndpointIndex><EndpointIndex>Obesity - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of beta-3-Adrenergic Receptor Agonists on Brown Adipose Tissue</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basal metabolic rate </BiomarkerName><BiomarkerName> Brown adipose tissue </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Skeletal muscle mass </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Aaron M Cypess, MD PhD</Name></ContactNames></Trial><Trial Id="107347"><Indications><Indication>Myocardial infarction</Indication></Indications><CompaniesCollaborator><Company>Fonds zur Förderung der wissenschaftlichen Forschung</Company></CompaniesCollaborator><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2019-03-15T00:00:00Z</DateChangeLast><DateEnd>2019-01-31T00:00:00Z</DateEnd><DateStart>2013-02-28T00:00:00Z</DateStart><Identifiers><Identifier>KLI209</Identifier><Identifier>NCT01777750</Identifier><Identifier>STATIM</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Standard treatment alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>EMCOOLS flex pad alone</Intervention><Intervention>Philips InnerCool RTx alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>or surface cooling with EMCOOLS flex pads (out-of-hospital) followed by an infusion of 1000 to 2000 ml of &lt;b&gt;cold&lt;/b&gt; saline (out-of-hospital) and central-venous cooling with Philips InnerCool RTx endovascular system. In the cath-lab a endovascular cooling...in patients with ST-elevation myocardial infarction by strategic temperature management with the use of external cooling pads in the out-of-hospital setting and the continuation with &lt;b&gt;cold&lt;/b&gt; saline and central venous catheter cooling in hospital.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Major adverse cardiovascular events (MACE)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of MRI Imaging Findings</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of MRI Imaging Findings - Evaluation of infarct size</EndpointIndex><EndpointIndex>Acute coronary syndrome - Hematological Assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Area of infarction (percentage)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Coronary artery disease - Hematological Assessments</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiac Function - MRI assessment of cardiac structure/function</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>STATIM: Cooling in Myocardial Infarction</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - ST segment changes (elevation /depression)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Echo/ECG findings - ST segment abnormalities</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Macrophages </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> ST segment</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>71 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christoph Testori, MD</Name></ContactNames></Trial><Trial Id="106835"><Indications><Indication>Traumatic brain injury</Indication></Indications><CompaniesCollaborator><Company>Eastern Association for the Surgery of Trauma</Company><Company>Vanderbilt Institute for Clinical and Translational Research</Company></CompaniesCollaborator><CompaniesSponsor><Company>Vanderbilt University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2011-08-31T00:00:00Z</DateStart><Identifiers><Identifier>110429</Identifier><Identifier>DASH After TBI</Identifier><Identifier>NCT01322048</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>clonidine plus propranolol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>severe traumatic brain Injury (TBI). The primary hypothesis was that adrenergic blockade after severe TBI would be associated with increased ventilator-free days, decreased catecholamine levels, normalization of HRV, and decreased autonomic response to &lt;b&gt;cold&lt;/b&gt; pressor testing. The study aimed to determine feasibility and investigate safety and outcomes associated with adrenergic blockade in patients with severe TBI [ 1365101 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>DASH After TBI: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Catecholamines </BiomarkerName><BiomarkerName> Cerebral blood flow </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Norepinephrine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>64 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mayur B Patel, MD, MPH</Name></ContactNames></Trial><Trial Id="106021"><Indications><Indication>Pharyngitis</Indication></Indications><CompaniesSponsor><Company>Boehringer Ingelheim Corp</Company></CompaniesSponsor><Countries><Country>South Africa</Country></Countries><DateChangeLast>2018-05-08T00:00:00Z</DateChangeLast><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>18.504</Identifier><Identifier>NCT01361802</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ambroxol spray alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>494</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients with drug dependence and/or alcohol abuse Use of any throat lozenge, throat spray, cough drop, menthol-containing product, or any product with demulcent properties within last 2 h Use of any analgesic/anti-pyretic within last 4 h Use of any '&lt;b&gt;cold&lt;/b&gt; medication' (eg, decongestant, antihistamine, expectorant, anti-tussive) within last 8 h Use of an antibiotic for an acute illness within last 24 h Use of inhaled steroids or beta-agonists on a continuous basis during the last week Use of any investigational</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Ambroxol Spray Sore Throat Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-08-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>10</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name></ContactNames></Trial><Trial Id="10594"><Indications><Indication>Adult onset Stills disease</Indication><Indication>Inflammatory disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin-1 alpha ligand inhibitor</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Protein fusion</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institutes of Health Clinical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute of Arthritis and Musculoskeletal and Skin Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-18T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>05-AR-0014</Identifier><Identifier>050014</Identifier><Identifier>NCT00094900</Identifier></Identifiers><IndicationsAdverse><Indication>Bursitis</Indication><Indication>Mycobacterium infection</Indication><Indication>Skin infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>rilonacept alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>11</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Trap, Regeneron) in the treatment of adult subjects with diseases known to respond to IL-1 blockade, including the following autoinflammatory disorders: Neonatal Onset Multisystem Inflammatory Disease (NOMID), Muckle-Wells Syndrome (MWS), and Familial &lt;b&gt;Cold&lt;/b&gt; Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF), and Adult Still's disease. This protocol (from the NIH standpoint) was a continuation of the ongoing protocol 05-AR-0014, with a new change in study sponsor, the NIH replacing rilonacept</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Hematological Assessments - Erythrocyte sedimentation rate (ESR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Interleukin-1 Trap To Treat Autoinflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Juvenile Rheumatoid Arthritis (JRA)</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy - Biological DMARDs</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects with gene variants - MEFV_HUMAN_Mutation</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects with gene variants - NLRP3_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Ferritin </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Serum amyloid A protein 1 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>74 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="105317"><Indications><Indication>Raynauds disease</Indication></Indications><CompaniesSponsor><Company>VSM Geneesmiddelen b.v.</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2006-04-30T00:00:00Z</DateEnd><DateStart>2005-11-30T00:00:00Z</DateStart><Identifiers><Identifier>523052.01.002</Identifier><Identifier>NCT00251238</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>EGb-761 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Secondary Raynaud's phenomenon Connective tissue disease Large vessel disease Cryoglobulinemia, &lt;b&gt;cold&lt;/b&gt; agglutinins disease, thrombocytosis Concomitant pharmacological treatment with effects on the vasculature Pregnancy or lactation Severe internal or systemic disease</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud's Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Study Department</Name></ContactNames></Trial><Trial Id="104098"><Indications><Indication>Vibrio cholerae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Inactivated bacterial vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology></Technologies><CompaniesSponsor><Company>International Centre For Diarrhoeal Disease Research, Bangladesh</Company></CompaniesSponsor><Countries><Country>Bangladesh</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01762930</Identifier><Identifier>PR-12030</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oral cholera vaccine, VABIOTECH/Shantha Biotechnics/International Vaccine Institute alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1015</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>immunogenicity studies on temperature stability of ShanChol would be done. The vaccines would be stored at different temperatures: 25degC for 14 days, 37degC for 14 days and 42degC for 14 days. After that vaccine would be stored at the recommended tempature in &lt;b&gt;cold&lt;/b&gt; chain until their administration to the participants. The second dose would be administered 14 days after the first dose, as currently recommended. These three groups would be compared to those receiving the same vaccine maintained at standard conditions</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cholera Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Cholera Vaccine - Assessment of Immune Response - Assessment of T-cell responses</EndpointIndex><EndpointIndex>Cholera Vaccine - Assessment of Immune Response - Assessment of vibriocidal antibodies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Field Application of Shanchol in Adults in Bangladesh</TitleDisplay><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amit Saha, M.Med</Name></ContactNames></Trial><Trial Id="103291"><Indications><Indication>Cardiovascular disease</Indication></Indications><CompaniesCollaborator><Company>National Heart Lung and Blood Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Maryland</Company></CompaniesSponsor><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2006-08-29T00:00:00Z</DateEnd><DateStart>2003-05-31T00:00:00Z</DateStart><Identifiers><Identifier>1404</Identifier><Identifier>H-22773</Identifier><Identifier>HAPI</Identifier><Identifier>HP-00040375</Identifier><Identifier>NCT00664040</Identifier><Identifier>U01 HL072515-05</Identifier><Identifier>U01HL072515</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cold Pressor Test alone</Intervention><Intervention>Dietary Salt alone</Intervention><Intervention>High Fat Meal alone</Intervention><Intervention>aspirin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>868</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>quantitative traits would be measured. The interventions and responses would be: &lt;b&gt;Cold&lt;/b&gt; pressor stress and changes in blood pressure and changes in endothelial function...intervention. Platelet aggregation would be measured 1 h after the last dose of aspirin. &lt;b&gt;Cold&lt;/b&gt; pressor test: this would consist of the participant placing his or her hand and...agents, nitrates, systemic glucocorticoids, adrenergic or cholinergic-acting agents including &lt;b&gt;cold&lt;/b&gt; formulas and antidepressants, and diet/weight loss agents Is taking</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Artery Plaque /Atheroma - Coronary Artery Calcification</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Platelet Function Tests (PFT) Findings</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Determination of the value of brachial artery reactivity</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Flow mediated dilation (FMD)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HAPI: Heredity and Phenotype Intervention (HAPI) Heart Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>38 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Alan Shuldiner</Name></ContactNames></Trial><Trial Id="101220"><Indications><Indication>Insomnia</Indication></Indications><CompaniesCollaborator><Company>Autism Treatment Network</Company><Company>Health Resources and Services Administration</Company><Company>Massachusetts General Hospital</Company><Company>The EMMES Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Colorado at Denver and Health Sciences Center</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2015-08-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>12-0466</Identifier><Identifier>NCT01745497</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ferrous sulfate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>promazine, triflupromazine, methotrimeprazine, fluphenazine, mesoridazine, perphenazine, thioridazine, and trifluoperazine), antidepressants that increase serotonin only if the onset of sleep issues was associated with starting the medication, and some &lt;b&gt;cold&lt;/b&gt; and allergy medications-that contain sedating antihistamines(methdilazine, promethazine, trimeprazine) A child taking a medication that has a significant drug interaction with iron that cannot be addressed by the timing of administration such as Cholestyramine</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Autism - Assessment of Neuropsychological Function - Assessment of attention</EndpointIndex><EndpointIndex>Autism - Assessment of Sleep</EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Neuropsychological Function - Assessment of attention/concentration</EndpointIndex><EndpointIndex>Insomnia - Assessment of Neuropsychological Function - Assessment of behavior</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Neuropsychological Function - Assessment of attention/concentration</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of RLS Symptoms with Protocol Specified Scales - Assessment by Periodic Limb Movements during time in Bed index (PLMI)</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Autism - Subjects with Asperger's Syndrome</PatientSegment><PatientSegment>Autism - Subjects with Autistic Disorder</PatientSegment><PatientSegment>Autism - Subjects with Pervasive Developmental Disorders (NOS)</PatientSegment><PatientSegment>Autism - Subjects with comorbid conditions - Subjects with sleep disorders</PatientSegment><PatientSegment>Insomnia - Insomnia in Children and Adolescents</PatientSegment><PatientSegment>Insomnia - Subjects with Sleep Maintenance Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with Sleep Onset Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with comorbid conditions - Subjects co-morbid with neurological disorders</PatientSegment><PatientSegment>Restless legs syndrome - RLS Subjects with Sleep Disturbances</PatientSegment><PatientSegment>Restless legs syndrome - Subjects with Early Onset Restless Legs Syndrome</PatientSegment><PatientSegment>Restless legs syndrome - Subjects with Secondary Restless Legs Syndrome</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ferritin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Ann Halbower</Name><Name>Ann Reynolds, MD</Name><Name>Beth Malow</Name><Name>Debbie Wofford</Name><Name>Diane Fawkes</Name><Name>Heide Connolly</Name><Name>Jennifer Foley</Name><Name>Pam Green</Name><Name>Rachel Hundley</Name><Name>Shelly Weiss</Name><Name>Sheryl Faut</Name><Name>Stephanie Huston</Name><Name>Terry Katz</Name></ContactNames></Trial><Trial Id="100062"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Velomedix LLC</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2014-09-30T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01655433</Identifier><Identifier>VELOCITY</Identifier><Identifier>VMXP-2490</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Velomedix APLS device alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>This study was to look at the safety and feasibility of treating patients with heart attack with mild hypothermia induced using a system of automated peritoneal lavage. The hypothesized that the Velomedix Automated Peritoneal Lavage System (APLS) can treat patients with heart attack safely and with adequate performance. By November 2012, the trial received approval to include a control arm for a randomized comparison, thus doubling the number of patients, and to increase the number of U.S. trial</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Major adverse cardiovascular events (MACE)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Hemorrhagic Complications - Bleeding rate /events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of MRI Imaging Findings - Evaluation of infarct size</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Renal Function</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of Left ventricular function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Area of infarction (percentage)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>VELOCITY: Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Acute coronary syndrome - Unstable Angina (UA) Subjects</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Angina - Subjects with unstable angina</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Graham Nichol, MD</Name><Name>Gregg Stone, MD</Name></ContactNames></Trial><Trial Id="9787"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Antiviral</Action><Action>Topical antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Royalmount Pharma</Company></CompaniesSponsor><DateChangeLast>2015-06-01T00:00:00Z</DateChangeLast><DateEnd>2007-01-25T00:00:00Z</DateEnd><DateStart>2007-01-25T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>resveratrol (topical, psoriasis/herpes simplex virus infection), Royalmount Pharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>115</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A multi-center, phase IIa clinical trial of a topical formulation of resveratrol (RM-1812) for the treatment of recurrent herpes simplex labialis (HSV-1 or &lt;b&gt;cold&lt;/b&gt; sores) [ 760588 ], [ 760661 ].</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A multi-center, phase IIa study of topical formulation of resveratrol for the treatment of herpes simplex labialis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="9359"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Biolex Therapeutics Inc</Company><Company>Dr Reddy’s Research and Development BV</Company></CompaniesSponsor><DateChangeLast>2012-02-22T00:00:00Z</DateChangeLast><DateStart>2007-01-30T00:00:00Z</DateStart><Identifiers><Identifier>SELECT-1</Identifier><Identifier>SELECT-1</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hypothermia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Otitis media</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>interferon alpha (controlled release, PolyActive), Biolex/OctoPlus plus ribavirin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase IIa, open-label, randomized study, was to evaluate the safety, tolerability and viral response of Locteron in combination with oral ribavirin in treatment-naive hepatitis C (HCV) patients with the geneotype-1 variant of the virus [ 761663 ], [ 761898 ], [ 1180835 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TitleDisplay>SELECT-1: A phase IIa, multicenter, randomized, open-label study to evaluate the safety, tolerability and viral response of Locteron, for treatment-naive hepatitis C virus patients</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="7816"><Indications><Indication>Postherpetic neuralgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA A receptor agonist</Action><Action>KCNQ voltage-gated potassium channel stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Bausch Health Companies Inc</Company></CompaniesSponsor><Countries><Country>South Africa</Country><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2009-12-31T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00612105</Identifier><Identifier>VRX-RET-E22-NP201</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>retigabine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>187</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to evaluate the efficacy of retigabine versus placebo in reducing pain associated with post-herpetic neuralgia (PHN).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Average pain intensity score</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Disease Relapse/Recurrence - Assessment of breakthrough pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=30% response</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=50% response</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by diary scores</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and efficacy study of retigabine versus placebo in postherpetic neuralgia (PHN)</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>David Lineberry</Name><Name>Nathan Ternus</Name></ContactNames></Trial><Trial Id="75540"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 2C adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>CNS modulator</Action><Action>Psychomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Orion Corp</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024005-13</Identifier><Identifier>3098009</Identifier><Identifier>NCT01315899</Identifier><Identifier>REINO</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>DB-105 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason><Reason>Safety Issues</Reason></ReasonForTrialDiscontinuation><Teaser>history of &lt;b&gt;cold&lt;/b&gt; sensitivity associated with colour changes of cyanosis or pallor, as well as of at least six attacks weekly during the winter months. Diagnosis... Results were presented in November 2012. Placebo treatment showed higher recovery rate from &lt;b&gt;cold&lt;/b&gt; challenge...doses of ORM-12741 , respectively. ORM-12741 did not expedite recovery from a &lt;b&gt;cold&lt;/b&gt; challenge in the fingers of patients with systemic sclerosis [ 1343266 ], [ 1350041</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>REINO: Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ariane L Herrick</Name></ContactNames></Trial><Trial Id="75262"><Indications><Indication>Overactive bladder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Ario Pharma Ltd</Company></CompaniesSponsor><Countries><Country>Estonia</Country><Country>UK</Country><Country>Belgium</Country><Country>Russian Federation</Country><Country>Romania</Country></Countries><DateChangeLast>2011-03-07T00:00:00Z</DateChangeLast><DateStart>2011-01-13T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>XEN-D0501 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The study was designed to evaluate the safety and efficacy of XEN-D0501 in patients with overactive bladder [ 1160936 ], [ 1172896 ]. By January 2011, the study was initiated in Europe [ 1160936 ]. By March 2011, the first patients have been enrolled [ 1172896 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A multicenter phase IIa study to evaluate the safety and efficacy of XEN-D0501 in patients with overactive bladder</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>5</NumberOfSites></Trial><Trial Id="70680"><Indications><Indication>Bacterial skin infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>MAO inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Peptide deformylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Ribosome binding agent</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2011-01-18T00:00:00Z</DateEnd><DateStart>2010-08-17T00:00:00Z</DateStart><Identifiers><Identifier>113414</Identifier><Identifier>NCT01209078</Identifier></Identifiers><InterventionsControlDisplay><Intervention>linezolid alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>lanopepden alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>84</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to determine the safety, tolerability and efficacy of GSK-1322322 versus linezolid in subjects with acute bacterial skin and skin structure infection (ABSSSI) [ 1180470 ], [ 1219993 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bacterial skin infection - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>GSK-1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Subjects with Uncomplicated Skin and Skin Structure Infections - Subjects with uncomplicated gram positive infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Bicarbonates </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Carbon dioxide </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Estradiol </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mean corpuscular hemoglobin </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> QRS complex </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> R-R interval </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Reticulocytes </BiomarkerName><BiomarkerName> Sialin </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-01-18T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="6503"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Protein synthesis modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Fortovia Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Puerto Rico</Country><Country>US</Country></Countries><DateChangeLast>2017-11-01T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>DTCL100</Identifier><Identifier>NCT00474916</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>KRN-5500 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>decrease in pain intensity with increase in dose (p = 0.009). In patients with CIPN, KRN-5500 was effective in reducing pain [ 1129346 ]. In December 2010, results published showed that a larger median decrease in pain associated with both touch and &lt;b&gt;cold&lt;/b&gt; was shown by patients treated with KRN-5500 (both 33%) when compared to placebo (0 and 8%, respectively) [ 1156019 ]. In May 2012, further results from an analysis that was based on self-reported daily pain scores from patients' diaries were presented</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Anthropometric Assessments</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Treatment Withdrawal</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by IVRS 11-Point Numeric Rating Scale (NRS) pain score</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Physical Examination - Assessment of anthropometric measurements</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pain</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of subject withdrawals</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of pain</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Ovary tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Anthropometric Assessments</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of pain</EndpointIndex><EndpointIndex>Solid tumor - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Solid tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Solid tumor - Assessment of pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Neuropathic Pain in Patients With Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Cancer supportive care - Cancer/Treatment-related Pain</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Cancer Resistant or Refractory to Non-Platinum Therapies</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment><PatientSegment>Pain - Subjects with Intractable Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Solid tumor - Subjects with Advanced/Metastatic Solid Tumors</PatientSegment><PatientSegment>Solid tumor - Subjects with Relapsed/Recurrent Solid Tumors</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Agnes Ponce</Name><Name>Linda Jett</Name><Name>Luis Rivera-Colon, MD</Name><Name>Richard Penson</Name><Name>Sharon Weinstein</Name></ContactNames></Trial><Trial Id="6328"><Indications><Indication>Albuminuria</Indication><Indication>Hypertension</Indication><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Renin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Protectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Speedel Pharma AG</Company></CompaniesSponsor><Countries><Country>Ireland</Country><Country>Hungary</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2008-09-30T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2007-004559-12</Identifier><Identifier>NCT00561171</Identifier><Identifier>SPP635CRD05</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Common cold</Indication><Indication>Dizziness</Indication><Indication>Dysphonia</Indication><Indication>Headache</Indication><Indication>Hypertension</Indication><Indication>Hypotension</Indication><Indication>Nausea</Indication><Indication>Polydipsia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>SPP-635 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase IIa, double-blind, randomized, parallel-design, 4-week study to investigate the efficacy, safety and tolerability of two different doses of SPP-635 in type 2 diabetic patients with mild to moderate hypertension and albuminuria. The total study duration for patients completing the entire study was approximately 7 weeks including a 2-week screening phase, 1-week wash-out phase, 4-week treatment phase and 1-week follow-up phase. All treatments other than certain anti-hypertensive</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Blood Pressure (BP) - Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Blood Pressure (BP) - Seated BP</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory diastolic blood pressure (ADBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory systolic blood pressure (ASBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - Morning BP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - Nighttime BP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - Seated BP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Clinic/office DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hypertension - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Concentration of study drug in body fluids</EndpointIndex><EndpointIndex>Hypertension - Assessment of Renal Function - Urinary albumin excretion/albuminuria</EndpointIndex><EndpointIndex>Hypertension - Assessment of Renal Function - Urinary albumin to creatinine ratio (UACR)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Renin, Angiotensin, Aldosterone (RAS) Biomarkers - Renin</EndpointIndex><EndpointIndex>Hypertension - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Clinic/office SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of adverse events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP) - Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP) - Seated BP</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Phase IIa Study to Investigate the Efficacy and Safety of SPP-635 in Diabetic and Hypertensive Patients With Albuminuria</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects With Hypertension, Type 2 Diabetes and Renal Impairment</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 1 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with type 2 diabetes mellitus</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with hypertension</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic nephropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Renin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate>2008-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Maria Nicolaides, Dr.</Name></ContactNames></Trial><Trial Id="63257"><Indications><Indication>Gastroesophageal reflux</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-08-13T00:00:00Z</DateChangeLast><DateEnd>2010-05-31T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>D9120C00032</Identifier><Identifier>NCT01043185</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lesogaberan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to estimate what effect four different doses of lesogaberan (AZD-3355) would have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms - Assessment of acid regurgitation/reflux</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms - Assessment of frequency of symptoms</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of Laboratory/Diagnostic Measures - Assessment of pH</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Estimate Effect of Four Different Doses of AZD-3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) may Experience</TitleDisplay><PatientSegmentTerms><PatientSegment>Gastroesophageal reflux - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Debra G Silberg</Name><Name>Philip Miner</Name></ContactNames></Trial><Trial Id="60971"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease modulator</Action><Action>Unspecified enzyme modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Recombinant enzyme</Technology></Technologies><CompaniesCollaborator><Company>Genentech Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aradigm Corp</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-01-24T00:00:00Z</DateChangeLast><DateEnd>2000-10-12T00:00:00Z</DateEnd><DateStart>2000-01-24T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>dornase alpha (inhaled, AERx), Aradigm/Genentech alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This phase IIa, multicenter study was designed to evaluate if a bolus delivery of dornase alpha delivered via the AERx system improves lung function in cystic fibrosis patients [ 353318 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase IIa, multicenter study to evaluate the efficacy of dornase alpha in patients with cystic fibrosis</TitleDisplay><PrimaryCompletionDate/><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="49388"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CFTR modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Vertex Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>US</Country><Country>Canada</Country><Country>Germany</Country><Country>Netherlands</Country></Countries><DateChangeLast>2018-06-28T00:00:00Z</DateChangeLast><DateEnd>2009-12-31T00:00:00Z</DateEnd><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-006446-25</Identifier><Identifier>NCT00865904</Identifier><Identifier>VX08-809-101</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lumacaftor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>93</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>therapeutic clinical study, or prior participation in an investigational drug study without appropriate washout Illness within 14 days before receiving the first dose of study drug. 'Illness'is defined as a recent non-serious, non-acute condition, eg, common &lt;b&gt;cold&lt;/b&gt; Treatment with systemic antibiotics for an acute illness within 14 days before receiving the first dose of study drug Concomitant use of any inhibitors or inducers of CYP3A4</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemistry/hematology</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures - Assessment of sodium conductance/nasal potential difference</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures - Assessment of sweat/serum chloride/sodium</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination - Assessment of cardiac status</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of VX-809 in Cystic Fibrosis Subjects With the DeltaF508-CFTR Gene Mutation</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_rs113993960(-)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Chlorides </BiomarkerName><BiomarkerName> Cystic fibrosis transmembrane conductance regulator </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>25</NumberOfSites><ContactNames><Name>J.P. Clancy, M.D</Name><Name>Medical Monitor</Name></ContactNames></Trial><Trial Id="43548"><Indications><Indication>Gastroesophageal reflux</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2019-06-05T00:00:00Z</DateChangeLast><DateEnd>2008-05-31T00:00:00Z</DateEnd><DateStart>2007-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2006-004501-25</Identifier><Identifier>D9120C00020</Identifier><Identifier>NCT00743444</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Paresthesia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lesogaberan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to compare the effect of AZD-3355 on frequency and content of reflux episodes in patients with gastroesophageal reflux disease.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms - Assessment of acid regurgitation/reflux</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms - Assessment of frequency of symptoms</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TLESR-Impedance Study in Patients</TitleDisplay><PrimaryCompletionDate type="Actual">2008-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Daniel Sifrim, MD, PhD</Name><Name>Eva Ersdal, PhD</Name></ContactNames></Trial><Trial Id="375905"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Smooth muscle relaxant</Action><Action>Surfactant</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>SolAeroMed Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-04-21T00:00:00Z</DateChangeLast><DateEnd>2020-08-31T00:00:00Z</DateEnd><DateStart>2019-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT03903913</Identifier><Identifier>SAMI-03-1-01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carbon dioxide + perfluorooctyl bromide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a single-center, open-label, phase IIa, multiple-ascending dose study in which subjects with mild to moderate cystic fibrosis (n &amp;lt;/= 12) will be enrolled. The safety and tolerability of S-1226 composed of perfluorooctylbromide (PFOB) with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered up to three successive doses, twice daily in subjects with cystic fibrosis (CF) will be evaluated. The primary aim of this study of S-1226 is to capture information to inform follow-up</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment by lung clearance index</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum</EndpointIndex><EndpointIndex>Cystic fibrosis - Clinical Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Cystic fibrosis questionnaire (CFQ)</EndpointIndex><EndpointIndex>Cystic fibrosis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, tolerability and efficacy of S-1226 in cystic fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Inspiratory capacity </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Lung clearance index </BiomarkerName><BiomarkerName> Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Bryce Oslanski, RT</Name><Name>Francis Green, MBChB, MD</Name><Name>Grishma Shrestha, MD</Name><Name>John Dennis, Phd</Name><Name>Mark Montgomery, MD</Name></ContactNames></Trial><Trial Id="373459"><Indications><Indication>Dengue virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Monocyte differentiation antigen CD14 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Implicit Bioscience Ltd</Company></CompaniesSponsor><DateChangeLast>2019-03-20T00:00:00Z</DateChangeLast><DateStart>2019-05-31T00:00:00Z</DateStart><Identifiers><Identifier>EDF-01</Identifier><Identifier>NCT03875560</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>IC-14 alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>baseline or normal for age Abrupt drop in platelets Respiratory discomfort One or more of the following signs and symptoms of severe dengue, such as: Severe plasma extravasation, leading to shock evidenced by one or more of the following: Tachycardia &lt;b&gt;Cold&lt;/b&gt; distal extremities Weak, thready pulse Slow capillary refill (&gt; 2 s) Pulse pressure&amp;lt; 20 mmHg Tachypnea; or Oliguria (&amp;lt;1.5 mL/kg/hr) Systolic blood pressure&amp;lt; 90 mmHg or decrease &gt; 40 mmHg Cyanosis Fluid accumulation with respiratory discomfort</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of hospitalization</EndpointIndex><EndpointIndex>Dengue virus infection - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Dengue virus infection - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>IC-14 in Adult Patients With Dengue Fever</TitleDisplay><PatientSegmentTerms><PatientSegment>Dengue virus infection - Subjects with Dengue Fever</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-01-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites><ContactNames><Name>Jan Agosti, MD</Name></ContactNames></Trial><Trial Id="371958"><Indications><Indication>Allergy</Indication><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Metalloprotease-12 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Foresee Pharmaceuticals Co Ltd</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2019-03-08T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-07-02T00:00:00Z</DateStart><Identifiers><Identifier>FP02C-18-001</Identifier><Identifier>NCT03858686</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FP-025 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>phase of any immunotherapy) Subject regularly used alcohol (intake of&gt; 21 units/wk for males and &gt; 14 units/wk for females) and/or recreational drugs within the last 6 months prior to screening Subject had any respiratory (viral) infections (eg, common &lt;b&gt;cold&lt;/b&gt;) within 3 weeks of Screening Day 1 or on Day -1 Subject is using maintenance asthma therapy or long-acting bronchodilators or any other anti-asthma or anti-allergic medications (as detailed in the protocol) other than infrequent use of SABA prn only</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Blood eosinophils</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Allergen challenge test</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Methacholine( PC20/PD20) challenge tests</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Stable Asthma</PatientSegment><PatientSegment>Asthma - Subjects with comorbid conditions - Subjects with allergic disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Fractional concentration of exhaled nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Cindy Lopez</Name><Name>David Lau, Ph.D.</Name><Name>Rene Lutter MD</Name><Name>Rene Lutter, MD</Name><Name>Zuzana Diamant, MD, PhD</Name></ContactNames></Trial><Trial Id="368317"><Indications><Indication>Atopic dermatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin 1 like receptor 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Japan</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2020-10-19T00:00:00Z</DateEnd><DateStart>2019-02-12T00:00:00Z</DateStart><Identifiers><Identifier>1368-0032</Identifier><Identifier>JapicCTI-194780</Identifier><Identifier>NCT03822832</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BI-655130 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>administered trial medication agent or its excipients Active systemic infections (fungal and bacterial disease) during the last 2 weeks prior to first drug administration, per investigator assessment Relevant chronic or acute infections (exception: common &lt;b&gt;cold&lt;/b&gt;) including human immunodeficiency virus (HIV) or viral hepatitis. A patient can be re-screened if the patient was treated and is cured from the acute infection Active or latent tuberculosis (TB): Patients with active tuberculosis are excluded Patients</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atopic Dermatitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Atopic Dermatitis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Atopic Dermatitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Eczema Area Severity Index (EASI) score</EndpointIndex><EndpointIndex>Atopic Dermatitis - Physician Global Assessment of Disease Activity - Assessment by Investigator Global Assessment (IGA) score</EndpointIndex><EndpointIndex>Atopic Dermatitis - Physician Global Assessment of Disease Activity - Assessment by SCORAD (Scoring Atopic Dermatitis) Severity Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study in Patients With Atopic Eczema to Test How Effective BI-655130 is and How Well it is Tolerated</TitleDisplay><PatientSegmentTerms><PatientSegment>Atopic Dermatitis - Patients enrolled based on EASI scores</PatientSegment><PatientSegment>Atopic Dermatitis - Patients enrolled based on Investigator global assessment [IGA] Scores - Score of 3-4</PatientSegment><PatientSegment>Atopic Dermatitis - Patients with Moderate to Severe Atopic Dermatitis</PatientSegment><PatientSegment>Atopic Dermatitis - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-02-14T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>19</NumberOfSites><ContactNames><Name>Adam Bennett</Name><Name>Anais Badia</Name><Name>Boehringer Ingelheim</Name><Name>Cheryl Hull</Name><Name>Etienne Saint-Cyr Proulx</Name><Name>Gary McCracken</Name><Name>Hirohiko Sueki</Name><Name>Jarad Levin</Name><Name>Lilia Rodriguez-Ables</Name><Name>Mark Lee</Name><Name>Norito Ishii</Name><Name>Norito Kato</Name><Name>Patricia Lee</Name><Name>Robert Buka</Name><Name>Scott Guenthner</Name><Name>Seth Forman</Name><Name>Shinichi Imafuku</Name><Name>Wayne Gulliver</Name><Name>William Abramovits</Name></ContactNames></Trial><Trial Id="367252"><Indications><Indication>Non-alcoholic steatohepatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Farnesoid X receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antihypercholesterolemic agent</Action><Action>Antiviral</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>ENYO Pharma SA</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Belgium</Country><Country>US</Country><Country>France</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2020-01-31T00:00:00Z</DateEnd><DateStart>2019-01-30T00:00:00Z</DateStart><Identifiers><Identifier>2018-003119-22</Identifier><Identifier>EYP001-202</Identifier><Identifier>NCT03812029</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>EYP-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>160</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to assess the effects of EYP-001a with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with Nonalcoholic Steatohepatitis (NASH).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, Tolerability, Pharmacokinetics and Efficacy of EYP-001a in Patients With Nonalcoholic Steatohepatitis (NASH)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gastrointestinal disease - Subjects with specific disease - Nonalcoholic steatohepatitis (NASH) subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Collagen type III </BiomarkerName><BiomarkerName> Fibronectin </BiomarkerName><BiomarkerName> Hepatic fat </BiomarkerName><BiomarkerName> Hyaluronic acid</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>41</NumberOfSites><ContactNames><Name>Couchoux Harold</Name><Name>Gary Reiss, MD</Name><Name>Ghalib Reem, Dr.</Name><Name>Harrison Stephen, MD</Name><Name>John Lentz, MD</Name><Name>Naim Alkhouri, MD</Name><Name>Stephen Harrison, MD</Name></ContactNames></Trial><Trial Id="366436"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis B large envelope protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>GC Pharma</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2019-03-12T00:00:00Z</DateChangeLast><DateEnd>2021-12-31T00:00:00Z</DateEnd><DateStart>2019-02-11T00:00:00Z</DateStart><Identifiers><Identifier>GC1102B_P2A</Identifier><Identifier>NCT03801798</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>GC-1102 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>/= 400 ml within 8 weeks before the screening Patient who have active infection (other than chronic hepatitis B infection) requiring continual treatment with antibiotics or antivirals (except for clinically insignificant temporary infection such as &lt;b&gt;cold&lt;/b&gt;)</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of HBV Viral Response - Assessment of HBV viral load</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Liver Functions - Alanine transaminase (ALT) levels</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBeAg changes</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBsAg changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of GC-1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis B virus infection - Hepatitis B Treatment Experienced Subjects</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - HBsAG positive subjects</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - Subjects with Chronic Hepatitis B Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Hepatitis B virus DNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Jayoung Shon</Name><Name>S.H Ahn, M.D.</Name><Name>Sang Hoon Ahn</Name></ContactNames></Trial><Trial Id="351896"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>New Zealand</Country><Country>Spain</Country><Country>Chile</Country><Country>Russian Federation</Country><Country>US</Country><Country>Puerto Rico</Country><Country>Poland</Country><Country>Australia</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2020-06-16T00:00:00Z</DateEnd><DateStart>2018-09-11T00:00:00Z</DateStart><Identifiers><Identifier>034-00</Identifier><Identifier>2018-001098-26</Identifier><Identifier>7264-034</Identifier><Identifier>MK-7264-034</Identifier><Identifier>NCT03654326</Identifier></Identifiers><InterventionsControlDisplay><Intervention>naproxen alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>gefapixant plus naproxen</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>166</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in premenopausal female participants with moderate to severe endometriosis-related pain. The primary hypothesis: gefapixant is superior to placebo in reducing the average daily pelvic pain score (cyclic and non-cyclic) during treatment cycle 2.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pelvic pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by diary scores</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Endometriosis - Women with Protocol Specified Menstrual Status - Pre-menopausal subjects</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with pelvic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-06-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>58</NumberOfSites><ContactNames><Name>Medical Director</Name><Name>Study Coordinator</Name><Name>Toll Free Number</Name></ContactNames></Trial><Trial Id="347268"><Indications><Indication>Cystic fibrosis</Indication><Indication>Lung infection</Indication><Indication>Mycobacterium avium infection</Indication><Indication>Mycobacterium infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action><Action>GM-CSF ligand</Action><Action>GM-CSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Aminoglycoside antibiotic</Action><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Ribosome binding agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Ribosome inactivator</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Savara Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-27T00:00:00Z</DateChangeLast><DateEnd>2021-07-15T00:00:00Z</DateEnd><DateStart>2019-06-20T00:00:00Z</DateStart><Identifiers><Identifier>ENCORE</Identifier><Identifier>NCT03597347</Identifier><Identifier>SAV008-02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>PARI eFlow nebulizer system alone</Intervention><Intervention>Variable regimens including dornase alfa , molgramostim (inhaled, cystic fibrosis/pneumonia/pulmonary alveolar proteinosis/respiratory distress syndrome), Savara , tobramycin (nebulized), Novartis</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of the study was to evaluate the efficacy of inhaled molgramostim (recombinant human GM-CSF) administered open-label to adult cystic fibrosis subjects with chronic pulmonary non-tuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy [ 2130027 ], [ 2057327 ], [ 2093298 ]. In July 2018, Savara Inc planned to initiate this trial in the first quarter of 2019 [ 2057327 ]. In April 2019, study was initiated [ 2137373 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination - Assessment of growth/anthropometric measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum microbiology</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ENCORE: Trial of Inhaled Molgramostim in CF Subjects With NTM Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with respiratory tract infections</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-01-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Alexandria "Alex" Nesbit</Name><Name>Alexandria Leonhardt</Name><Name>Amy Beasley</Name><Name>Andrea Sookchan</Name><Name>Cecilia Ganslandt</Name><Name>Daniel T. Layish, MD</Name><Name>Janice Wang, MD</Name><Name>Jennifer Goralski, MD</Name><Name>Jerry Nick</Name><Name>Jerry Nick, MD</Name><Name>Jessica Jackson</Name><Name>Kenneth (Bert) Kesser</Name><Name>Susan Galvin</Name></ContactNames></Trial><Trial Id="347223"><Indications><Indication>Paroxysmal nocturnal hemoglobinuria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Apellis Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Serbia</Country><Country>Poland</Country><Country>Greece</Country><Country>Bulgaria</Country><Country>Romania</Country></Countries><DateChangeLast>2019-03-25T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-07-18T00:00:00Z</DateStart><Identifiers><Identifier>2017-005140-16</Identifier><Identifier>APL2-202</Identifier><Identifier>NCT03593200</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The primary objective of this phase IIa, open-label, multiple-dose, study to assess the safety, tolerability, preliminary  efficacy and Pharmacokinetics (PK) of multiple  subcutaneously administered APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not received eculizumab ( Soliris ) in the past. A single cohort of patients will be planned for evaluation. An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of APL-2 when</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With PNH</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with paroxysmal nocturnal hemoglobinuria</PatientSegment><PatientSegment>Anemia - Subjects with History of/Scheduled for Disease Specific Therapy</PatientSegment><PatientSegment>Anemia - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>AP-2 complex subunit mu </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Complement hemolytic activity </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Haptoglobin </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Reticulocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Federico Grossi</Name><Name>Head of Clinical Operations</Name></ContactNames></Trial><Trial Id="344390"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-02-06T00:00:00Z</DateChangeLast><DateEnd>2018-11-19T00:00:00Z</DateEnd><DateStart>2018-07-04T00:00:00Z</DateStart><Identifiers><Identifier>2017-000472-28</Identifier><Identifier>7264-013</Identifier><Identifier>IND 123007</Identifier><Identifier>MK-7264-013</Identifier><Identifier>NCT03569033</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gefapixant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) on acute cough in adult participants with induced viral upper respiratory tract infections (URTI). Secondary objectives of the trial: To evaluate the efficacy of MK-7264 on the perception of cough severity. To evaluate the efficacy of MK-7264 on cough-specific quality of life. To evaluate the safety and tolerability of MK-7264. Sub-study: Future Biomedical Research. Merck would conduct Future</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment><PatientSegment>Respiratory tract infection - Others - Healthy Subjects</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-11-04T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Medical Director</Name><Name>Study Coordinator</Name></ContactNames></Trial><Trial Id="3350"><Indications><Indication>Diabetic neuropathy</Indication><Indication>Non-insulin dependent diabetes</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>MAO A inhibitor</Action><Action>MAO B inhibitor</Action><Action>NMDA receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>Antiparkinsonian</Action><Action>Antitussive</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Vernalis plc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2007-04-30T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>DRN329</Identifier><Identifier>NCT00375960</Identifier><Identifier>V3381-2DPNP01</Identifier></Identifiers><IndicationsAdverse><Indication>Nausea</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>indantadol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this study was to investigate the safety and efficacy of an investigational drug, indantadol , for the treatment of diabetic peripheral neuropathic (DPN) pain.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events - Dizziness</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events - Nausea &amp; vomiting</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events - Dizziness</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events - Nausea &amp; vomiting</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Christine Sang, M.D., MPH</Name></ContactNames></Trial><Trial Id="325918"><Indications><Indication>Sickle beta 0 thalassemia</Indication><Indication>Sickle cell anemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 9 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood system agent</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Imara Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>US</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2018-01-26T00:00:00Z</DateStart><Identifiers><Identifier>2017-000653-39</Identifier><Identifier>EHA-3095</Identifier><Identifier>IMR-SCD-102</Identifier><Identifier>NCT03401112</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Common cold</Indication><Indication>Fever</Indication><Indication>Gastroesophageal reflux</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Pain</Indication><Indication>Sickle cell crisis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>IMR-687 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>adverse events [ 2165755 ], [ 2165567 ], [ 2166305 ], [ 2164515 ]. In June 2019, results were presented. Most frequent adverse events were pain in extremities/back etc (10 [number of events]), vaso-occlusive crisis (VOC; 6), sickle cell pain crisis (6), &lt;b&gt;cold&lt;/b&gt;/flu symptoms (3), anemia (3), fever (2), nausea (2), headache (2) and gastroesophageal reflux disease (GERD; 2). Most frequent serious adverse events were sickle cell pain crisis (3) and VOC (2). No myelosuppression was seen in any patient [ 2164515</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-beta-0 Thalassemia)</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Sickle Cell Anemia</PatientSegment><PatientSegment>Anemia - Subjects with Thalassemia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>E-selectin </BiomarkerName><BiomarkerName> Fetal hemoglobin </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Myeloperoxidase </BiomarkerName><BiomarkerName> P-selectin </BiomarkerName><BiomarkerName> Reticulocytes </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Anna Price</Name><Name>Biree Andemariam</Name><Name>Dr. Shivan Pancham</Name><Name>Elizabeth Green</Name><Name>Emily Warner</Name><Name>Jaspreet Kaur</Name><Name>Jitka Fucikova</Name><Name>Kacie Smith</Name><Name>Kaitlyn Walker</Name><Name>Kelsey Gates</Name><Name>Lanetta Bronte</Name><Name>Lani Krauz</Name><Name>Linda Sawyer</Name><Name>Maina Palumbo</Name><Name>Sasia Jon</Name><Name>Sasia Jones</Name><Name>ShiYin Foo, MD PhD MMSc</Name><Name>Timothy Mant, MB, FFPM,FRCP</Name></ContactNames></Trial><Trial Id="31563"><Indications><Indication>Lymphoplasmacytic lymphoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>26S proteasome complex inhibitor</Action><Action>Proteasome inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Apoptosis stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Assistance Publique Hopitaux de Paris</Company><Company>National Cancer Institute, France</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-02-21T00:00:00Z</DateChangeLast><DateEnd>2012-08-31T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2006-004218-42</Identifier><Identifier>NCT00777738</Identifier><Identifier>P060207</Identifier><Identifier>WM2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bortezomib alone</Intervention><Intervention>bortezomib plus dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>34</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>but &gt; 1) x E + 10(9)/l, and/or platelets &amp;lt; 150 (but &gt; 100) x E + 10(9)/l Complications of monoclonal immunoglobulin Ig M: the Physical chemical (hyperviscosity, type I cryoglobulin symptomatic, severe disorders of hemostasis), autoimmune diseases (&lt;b&gt;cold&lt;/b&gt; hemagglutinin, cryoglobulin symptomatic type II, etc ) Strong tumor mass: tumor mass &gt; 7 cm, and/or presence of more than three nodes of diameter &gt; 3 cm, and/or serous effusion and / or compressive syndrome, and/or symptomatic splenomegaly Increased</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lymphoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Remission - Assessment of complete remission</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Remission - Assessment of partial remission</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>WM2: Efficacy of Bortezomib (Velcade) in Patients With Advanced Waldenstrom Macroglobulinemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia) (Immunocytoma)</PatientSegment><PatientSegment>Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Véronique LEBLOND, MD, PhD</Name></ContactNames></Trial><Trial Id="30822"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anti-inflammatory</Action><Action>Immunostimulant</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Immune Response BioPharma Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-03T00:00:00Z</DateChangeLast><DateStart>1995-08-09T00:00:00Z</DateStart><IndicationsAdverse><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>IR-501 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>99</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>, anxiety attack, laryngeal cancer, inguinal abscess, migraine headache, postsurgical foot infection, gangrenous bowel and tooth infections). The most frequent adverse events were infections (mostly in the upper respiratory tract as well as flu and &lt;b&gt;cold&lt;/b&gt; symptoms) and aseptic local injection reactions; both categories were evenly distributed across the three study arms. None of the patients discontinued because of treatment-related adverse events [ 338781 ]. In November 1999, similar results were presented</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A double-blind, placebo-controlled, multicenter, phase II trial to evaluate the safety and efficacy of IR-501 in rheumatoid arthritis patients</TitleDisplay><BiomarkerNames><BiomarkerName>Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>4</NumberOfSites><ContactNames><Name>Larry Moreland</Name></ContactNames></Trial><Trial Id="304583"><Indications><Indication>Ankylosing spondylitis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>TNF alpha ligand inhibitor</Action><Action>TNF antagonist</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>PEGylated formulation</Technology><Technology>Protein conjugated</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>US</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>Netherlands</Country><Country>Moldova, Republic of</Country><Country>Russian Federation</Country><Country>Greece</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2020-06-30T00:00:00Z</DateEnd><DateStart>2017-10-04T00:00:00Z</DateStart><Identifiers><Identifier>2017-000957-37</Identifier><Identifier>AS0013</Identifier><Identifier>NCT03215277</Identifier></Identifiers><InterventionsControlDisplay><Intervention>certolizumab pegol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>76</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>or a diagnosis of any other inflammatory arthritis eg, rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus, or reactive arthritis Subjects with any current sign or symptom that may indicate an active infection (except for the common &lt;b&gt;cold&lt;/b&gt;) Subject has received previous or current biological treatment other than TNF-alpha inhibitor treatment Subject has chronic, recurrent, recent serious/life-threatening or current infection, as defined in the protocol Subject has history of certain </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Pain - Spinal pain/Back pain (assessed by VAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Stiffness - Duration of morning stiffness</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Imaging/Radiological Assessments - Computed tomography (CT) assessment</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Imaging/Radiological Assessments - Magnetic resonance imaging (MRI) of bone &amp; soft tissue</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Ankylosing spondylitis disease activity score (ASDAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Physician Global Assessment of Disease Activity - Physician's assessment of local disease activity as measured by joint swelling/pain</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (BASDAI criteria)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Active Ankylosing Spondylitis</PatientSegment><PatientSegment>Ankylosing spondylitis - Moderate Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Severe Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Anti-TNF therapy</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Stable medication</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="274079"><Indications><Indication>Focal segmental glomerulosclerosis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>CD40 ligand receptor antagonist</Action><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Inc</Company><Company>Kyowa Hakko Kirin Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Global Development Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2019-02-12T00:00:00Z</DateChangeLast><DateEnd>2021-04-30T00:00:00Z</DateEnd><DateStart>2017-05-22T00:00:00Z</DateStart><Identifiers><Identifier>7163-CL-3201</Identifier><Identifier>NCT02921789</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including basiliximab , methylprednisone , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , bleselumab , methylprednisone , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>most current graft failure(s) is not due to the recurrence of FSGS Subject will receive a kidney as part of a multi-organ transplant Subject will receive a dual kidney transplant from a deceased donor Subject will receive a kidney with an anticipated &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT) of&gt; 30 h Subject will receive a kidney that meets BOTH Extended Criteria Donor (ECD) and Donation after cardiac death (DCD) criteria. (A kidney that meets either ECD OR DCD criteria may be eligible for inclusion) Subject will receive</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Transplantation</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Urine Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Clinical Assessments</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Assessment of urinary protein to creatinine ratio (UPCR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Other Post Transplant Complications</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Recurrence of original disease</EndpointIndex><EndpointIndex>Other genitourinary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genitourinary disease - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>End stage renal disease - Subjects with Glomerular Disorder</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment><PatientSegment>Other genitourinary disease - Subjects with specific disease - Subjects with Glomerulonephritis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Astellas Pharma Global Development - US</Name><Name>Medical Director</Name></ContactNames></Trial><Trial Id="273068"><Indications><Indication>Erythromelalgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>SCN9A sodium channel subunit inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Psychomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Biogen Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-01-31T00:00:00Z</DateEnd><DateStart>2016-09-09T00:00:00Z</DateStart><Identifiers><Identifier>1014802-205</Identifier><Identifier>NCT02917187</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vixotrigine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>8</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to investigate the efficacy of repeat oral dosing of BIIB-074 (raxatrigine) on paroxysmal pain in participants with primary inherited erythromelalgia (EM). The secondary objective of the study was to investigate the efficacy of repeat oral dosing of BIIB-074 on varying additional aspects of pain in participants with EM; and to investigate the safety and tolerability of repeat oral dosing of BIIB-074 in participants with EM.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase IIa Study of BIIB-074 in the Treatment of Erythromelalgia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-12-27T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="272419"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Catalase stimulator</Action><Action>Interleukin-1 ligand inhibitor</Action><Action>Interleukin-6 ligand inhibitor</Action><Action>Interleukin-8 ligand inhibitor</Action><Action>Superoxide dismutase stimulator</Action><Action>TNF alpha ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunomodulator</Action><Action>Macrophage modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>PAREXEL International</Company></CompaniesCollaborator><CompaniesSponsor><Company>MetrioPharm AG</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2017-02-28T00:00:00Z</DateEnd><DateStart>2016-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-005159-28</Identifier><Identifier>MP1032-CT02</Identifier><Identifier>NCT02908347</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Pruritus</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>MP-1032 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>By October 2016, results were presented. Serious adverse events were not observed [ 1871121 ]. In March 2017, results were presented. Common &lt;b&gt;cold&lt;/b&gt;, headache, and itching were the most frequently reported adverse events. All events were mild to moderate and were observed in both the placebo and MP-1032 group. There were no effects on lymphocytes or other blood-count parameters. Treatment-related gastro-intestinal adverse effects were not reported. Serious or severe adverse events were not reported </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Nail psoriasis severity index (NAPSI) and modified NAPSI score</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-50 response</EndpointIndex><EndpointIndex>Psoriasis - Hematological Assessments</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - EuroQol-5D (EQ-5D)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate Safety and Efficacy of Oral MP-1032 in Psoriasis Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood cells </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Anke Gauliard, MD</Name><Name>Dr Petra Schulz</Name><Name>Dr. Petra Schulz</Name><Name>Wolfgang Vanscheidt</Name></ContactNames></Trial><Trial Id="268895"><Indications><Indication>Kartagener syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CFTR stimulator</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Parion Sciences Inc</Company><Company>Vertex Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Sweden</Country><Country>Canada</Country><Country>Netherlands</Country><Country>US</Country><Country>Poland</Country><Country>Denmark</Country><Country>UK</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2019-05-27T00:00:00Z</DateChangeLast><DateEnd>2018-11-20T00:00:00Z</DateEnd><DateStart>2016-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-004917-26</Identifier><Identifier>CLEAN-PCD</Identifier><Identifier>NCT02871778</Identifier><Identifier>PS-G202</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>VX-371 alone</Intervention><Intervention>hypertonic saline alone</Intervention><Intervention>ivacaftor alone</Intervention><Intervention>Variable regimens including VX-371 , hypertonic saline , ivacaftor</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>123</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the trial was to evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor , and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD) [ 1974710 ], [ 1917590 ]. Main objective of the trial : Part A : to evaluate the safety and efficacy of treatment with VX-371, administered with and without 4.2% hypertonic saline (HS) in subjects with primary ciliary dyskinesia (PCD) who were &gt;/= 18 years</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CLEAN-PCD: Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease - Subjects with Kartagener Syndrome (Primary ciliary dyskinesia)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-11-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Clinical Operations</Name></ContactNames></Trial><Trial Id="255795"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CFTR stimulator</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Parion Sciences Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Vertex Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Czech Republic</Country><Country>France</Country><Country>Ireland</Country><Country>US</Country></Countries><DateChangeLast>2019-05-23T00:00:00Z</DateChangeLast><DateEnd>2017-09-30T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2015-004841-13</Identifier><Identifier>NCT02709109</Identifier><Identifier>VX15-371-101</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>VX-371 plus lumacaftor + ivacaftor (cystic fibrosis), Vertex/Cystic Fibrosis Foundation Therapeutics</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>142</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the safety and efficacy of treatment with VX-371 in saline compared to saline alone in subjects with cystic fibrosis (CF) who were &gt;/= 12 years of age, homozygous for the F508del-CFTR mutation, and being treated with Orkambi . Secondary objectives of the trial was to investigate the pharmacokinetics (PK) of VX-371 in subjects with CF who are &gt;/= 12 years of age, homozygous for the F508del-CFTR mutation and being treated with Orkambi.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination - Assessment of cardiac status</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_rs113993960(-)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cystic fibrosis transmembrane conductance regulator </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>43</NumberOfSites><ContactNames><Name>Clinical Trials and Medical Info</Name><Name>Clinical Trials and Medical Info.</Name></ContactNames></Trial><Trial Id="243082"><Indications><Indication>Cervix infection</Indication><Indication>Papillomavirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HPV structural protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Adjuvant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Prophylactic vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein fusion</Technology></Technologies><CompaniesCollaborator><Company>Clinical Research Management Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>TheVax Genetics Vaccine Co Ltd</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2018-09-30T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02576561</Identifier><Identifier>VAX 02-01</Identifier></Identifiers><InterventionsControlDisplay><Intervention>GPI-0100 alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>TVGV-1 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Normal electrocardiogram (ECG), laboratory values (chemistry, complete blood count) and urinalysis, as judged Grade 0 to 1 by per National Cancer Institute Common Toxicity Criteria (NCI-CTC) Agrees to Loop Electrosurgical Excision Procedure (LEEP), &lt;b&gt;Cold&lt;/b&gt; Knife Conization (CKC) or Hysterectomy being performed at the end of study according to the standard-of-care</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL</TitleDisplay><PrimaryCompletionDate type="Anticipated">2018-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Frank L Douglas, PhD, MD</Name></ContactNames></Trial><Trial Id="235050"><Indications><Indication>Congestive heart failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TRP cation channel V4 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Cardiovascular agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2017-08-21T00:00:00Z</DateEnd><DateStart>2016-04-13T00:00:00Z</DateStart><Identifiers><Identifier>201881</Identifier><Identifier>NCT02497937</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>GSK-2798745 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>11</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This single-center, randomized, double-blind, sponsor-unblinded, placebo-controlled, 2 x 2 crossover study was designed to investigate the effect of repeat administration of GSK-2798745 on pulmonary gas exchange and pulmonary function in adults with heart failure.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Blood Pressure (BP) - Diastolic blood pressure (DBP)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Blood Pressure (BP) - Systolic blood pressure (SBP)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Electrocardiography (ECG) Findings</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Exercise Capacity/Tolerance - Ventilatory response (VE/VCO2) [Ventilatory efficiency (VE/VCO2 slope)]</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Elimination half-life time (T1/2)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma Drug Concentrations</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Time to maximum concentration (Tmax)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pulmonary Function - Carbon monoxide diffusing capacity (DLCO)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pulmonary Function - Vital capacity (VC)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Vital Signs - Respiratory rate</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Cardiac failure - Hematological Assessments</EndpointIndex><EndpointIndex>Cardiac failure - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK-2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure</TitleDisplay><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Carbon monoxide diffusing capacity </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Diffusing capacity of the lung for nitric oxide </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mean corpuscular hemoglobin </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Pulmonary blood flow </BiomarkerName><BiomarkerName> QRS complex </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Ventilatory efficiency/Carbon dioxide output</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-08-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="234276"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon beta ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca AB</Company><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>France</Country><Country>Argentina</Country><Country>South Korea</Country><Country>Spain</Country><Country>Colombia</Country><Country>UK</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2016-11-24T00:00:00Z</DateEnd><DateStart>2015-07-21T00:00:00Z</DateStart><Identifiers><Identifier>2014-005084-32</Identifier><Identifier>D6230C00001</Identifier><Identifier>INEXAS</Identifier><Identifier>NCT02491684</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>inhaled interferon beta (lung disorders/influenza), Synairgen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>121</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>common &lt;b&gt;cold&lt;/b&gt; or the flu. When the patient answers yes to the question that he/she would be coming down with a common &lt;b&gt;cold&lt;/b&gt; or...but no later than 48 h after the onset of the first of the common &lt;b&gt;cold&lt;/b&gt; or flu symptoms. Patients would be assessed with regards to exacerbations and changes in respiratory...patient that these aforementioned exacerbations would be triggered by an upper respiratory tract infection (ie, related to symptoms of a common &lt;b&gt;cold&lt;/b&gt; or the flu).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Daytime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Nighttime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Severity of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Time to first exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of morning/evening FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Change from baseline in PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Change in rescue medication use</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Electronic patient reported outcome</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>INEXAS: A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once-Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> C-X-C motif chemokine 10 </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Mean corpuscular hemoglobin </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> Peak expiratory flow rate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> QRS complex </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> R-R interval </BiomarkerName><BiomarkerName> Sodium</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-11-24T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Per Gustafson, MD PhD</Name><Name>Unidad de Investigación Clínica</Name></ContactNames></Trial><Trial Id="226401"><Indications><Indication>Cough</Indication><Indication>Idiopathic pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>G protein coupled receptor 35 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Patara Pharma LLC</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Netherlands</Country></Countries><DateChangeLast>2019-06-14T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2014-004025-40</Identifier><Identifier>NCT02412020</Identifier><Identifier>PA101-CC-02</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Dyspnea</Indication><Indication>Fatigue</Indication><Indication>Gastrointestinal disease by location</Indication><Indication>Headache</Indication><Indication>Pharynx disease</Indication><Indication>Respiratory disease</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>cromolyn sodium (inhalant, chronic cough), Respivant Sciences alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>52</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a double-blind, randomized, placebo-controlled, two-period, crossover, two-cohort study in adult patients with refractory chronic cough. The purpose of the study was to assess the efficacy and safety of inhaled PA-101-B (PA-101) delivered via eFlow high efficiency nebulizer for treating refractory chronic cough [ 1702291 ], [ 1964003 ], [ 2073036 ]. The main objective of the trial was to assess whether PA-101 (inhaled cromolyn sodium) was an effective treatment for chronic cough when</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Cough</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Leicester Cough Questionnaire (LCQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Treatment of Refractory Chronic Cough With PA-101</TitleDisplay><PatientSegmentTerms><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with idiopathic interstitial pneumonia</PatientSegment><PatientSegment>Interstitial lung disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Chief Mecical Officer</Name></ContactNames></Trial><Trial Id="220578"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Parion Sciences Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Vertex Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CLEAN-CF</Identifier><Identifier>NCT02343445</Identifier><Identifier>PS-G201</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>VX-371 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>142</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The goal of this phase IIa study was to evaluate the safety and tolerability of P-1037 and to determine whether the combination of P-1037 with hypertonic saline or P-1037 alone had a greater effect on lung function in patients (pediatric also) with Cystic Fibrosis (CF) than placebo (0.17% saline) [ 1693932 ], [ 1666997 ], [ 1886000 ]. In May 2015, the first patient was enrolled in the trial [ 1657502 ]. In September 2015, as recommended by the Data Monitoring Committee, the trial was expanded to</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of change from baseline in FVC</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CLEAN-CF: Clearing Lungs With ENAC Inhibition in Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>33</NumberOfSites></Trial><Trial Id="219612"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Smooth muscle relaxant</Action><Action>Surfactant</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>SolAeroMed Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-02-20T00:00:00Z</DateChangeLast><DateEnd>2015-11-25T00:00:00Z</DateEnd><DateStart>2015-02-06T00:00:00Z</DateStart><Identifiers><Identifier>NCT02334553</Identifier><Identifier>SAMI-02-1-02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carbon dioxide + perfluorooctyl bromide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this phase IIa, placebo-controlled, randomized, double-blind, crossover, single-dose study was to evaluate the safety, tolerability and efficacy of S-1226 (8%) administered by nebulization in subjects with mild atopic asthma [ 1631245 ], [ 1618510 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Allergen challenge test</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination - Cardiac evaluation</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination - Physical activity assessment</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Drug related adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Asthma - Spirometry Unspecified</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Single-dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects at risk of developing disease - Ex-Smokers</PatientSegment><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with specific cigarette smoking activity - Non-smokers</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-11-25T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Richard Leigh, MD, PhD</Name><Name>Veronica Swystun, PhD</Name></ContactNames></Trial><Trial Id="21254"><Indications><Indication>Dyspepsia</Indication><Indication>Gastroesophageal reflux</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-07T00:00:00Z</DateChangeLast><DateEnd>2009-01-31T00:00:00Z</DateEnd><DateStart>2008-05-31T00:00:00Z</DateStart><Identifiers><Identifier>C27</Identifier><Identifier>D9120C00027</Identifier><Identifier>NCT00703534</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lesogaberan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>478</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This research study is being done to gather information about how to do further clinical studies using AZD-3355 as an add-on treatment to proton pump inhibitors (PPI).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>C27: Validation of Patient-Reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms</TitleDisplay><PrimaryCompletionDate type="Actual">2009-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>84</NumberOfSites><ContactNames><Name>Debra Silberg</Name><Name>Nimish Vakil</Name></ContactNames></Trial><Trial Id="209927"><Indications><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ario Pharma Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Xention Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-10-19T00:00:00Z</DateChangeLast><DateEnd>2015-02-28T00:00:00Z</DateEnd><DateStart>2014-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2013-004041-17</Identifier><Identifier>NCT02233686</Identifier><Identifier>XEN-D0501-CL-05</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>XEN-D0501 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase IIa study was to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD). Secondary objectives of the trial was to evaluate the effectiveness of XEN-D0501 placebo in reducing capsaicin cough responses, objective 24 h cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale [VAS]), urge to cough (via VAS), global rating of change scale, Clinical</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough - Assessment of cough intensity/frequency</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Clinical COPD Questionnaire (CCQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD</TitleDisplay><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Chief Medical Officer</Name><Name>Dave Singh</Name><Name>Dr Jacky Smith</Name></ContactNames></Trial><Trial Id="209866"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ario Pharma Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Xention Ltd</Company></CompaniesSponsor><Countries><Country>Ireland</Country><Country>UK</Country></Countries><DateChangeLast>2018-03-01T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2014-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-000306-36</Identifier><Identifier>NCT02233699</Identifier><Identifier>XEN-D0501-CL-04</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>XEN-D0501 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough. The effectiveness of XEN-D0501 over placebo in reducing capsaicin cough responses, objective 24-h cough frequency, hourly change in cough frequency, cough severity, urge to cough (via Visual Analog Scale [VAS]), global rating of change scale and Leicester Cough Questionnaire (LCQ) would be evaluated. The secondary objectives were</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough</TitleDisplay><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Dr Lorcan McGarvey</Name><Name>Jacky Smith</Name><Name>Patrick Round</Name></ContactNames></Trial><Trial Id="209306"><Indications><Indication>Raynauds disease</Indication><Indication>Scleroderma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PGE1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Vasodilator</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Absorption enhancer transdermal</Technology><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Quick release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Apricus Biosciences Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-13T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2014-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02228850</Identifier><Identifier>NEXMED 2014-RPS-001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>alprostadil cream (NexACT, erectile dysfunction), Seelos/Allergan/Ferring alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>35</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>placebo-controlled, dose-ranging study was to evaluate the pharmacodynamic (PD) effects of topical alprostadil (RayVa ) on digital perfusion by laser Doppler capillary velocimetry and digital temperature recovery with thermography following standardized &lt;b&gt;cold&lt;/b&gt; challenge and to assess the safety and tolerability of three doses of alprostadil topical cream and placebo cream in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc) [ 1557605 ], [ 1695825 ], [ 1957947 ]</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacodynamics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis</TitleDisplay><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Barbara Troupin, MD, MBA</Name><Name>Dr. Elena Schiopu</Name></ContactNames></Trial><Trial Id="201000"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Cystic Fibrosis Trust</Company><Company>Health Science Scotland</Company><Company>NHS Grampian</Company><Company>University of Aberdeen</Company></CompaniesCollaborator><CompaniesSponsor><Company>NovaBiotics Ltd</Company></CompaniesSponsor><DateChangeLast>2015-06-17T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>mercaptamine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of the study was to determine levels of Lynovex in the blood and sputum of cystic fibrosis patients after it was administered in tablet form and would monitor levels of bacteria in sputum, lung function and weight as well as general health and quality of life parameters. In June 2014, this Phase IIa trial was initiated [ 1573007 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A Phase IIa Clinical Study of Lynovex in Stable Adult Cystic Fibrosis Patients</TitleDisplay><BiomarkerNames><BiomarkerName>Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Graham Devereu</Name></ContactNames></Trial><Trial Id="19274"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pharmaxis Ltd</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>Canada</Country></Countries><DateChangeLast>2019-06-21T00:00:00Z</DateChangeLast><DateEnd>2008-08-31T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>DPM-CF-202</Identifier><Identifier>NCT00251056</Identifier></Identifiers><IndicationsAdverse><Indication>Barotrauma</Indication><Indication>Bronchospasm</Indication><Indication>Cough</Indication><Indication>Dyspnea</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Lung infection</Indication><Indication>Nasal congestion</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Rhinorrhea</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>mannitol (inhaled, CF), Pharmaxis/ Chiesi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to determine the optimal dose of mannitol (Bronchitol) to generate clinical improvement in patients with cystic fibrosis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Dose Comparison</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Respiratory System/Symptoms</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum microbiology</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum rheology</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by quality of life (short form-36 and chronic respiratory questionnaire)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Mannitol Dose Response Study in Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for treatment with Medications</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate>2008-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Brett Charlton</Name><Name>Elizabeth Tullis</Name></ContactNames></Trial><Trial Id="17620"><Indications><Indication>Gastroesophageal reflux</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>France</Country><Country>Australia</Country><Country>Belgium</Country><Country>Germany</Country><Country>Norway</Country><Country>Hungary</Country><Country>Netherlands</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2007-06-30T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>D9120C00011</Identifier><Identifier>EUDRACT No 2006-003541-16</Identifier><Identifier>NCT00394472</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Fatigue</Indication><Indication>Nausea</Indication><Indication>Paresthesia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lesogaberan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>306</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to estimate the effect of AZD-3355 as an add-on treatment to a PPI (proton pump inhibitor) on GERD (gastroesophageal reflux disease) symptoms in patients with an incomplete response to PPI treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Symptom Improvements in GERD Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Gastroesophageal reflux - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Guy Boeckxstaens, MD</Name><Name>Göran Hasselgren, MD</Name></ContactNames></Trial><Trial Id="164523"><Indications><Indication>Muscle weakness</Indication><Indication>Muscular dystrophy</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Muscle system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Bioblast Pharma Ltd</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2014-02-28T00:00:00Z</DateStart><Identifiers><Identifier>BBCO-001</Identifier><Identifier>HOPEMD</Identifier><Identifier>NCT02015481</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>trehalose (iv, OPMD/SCA3/Sanfilippo syndrome), Seelos Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>treatment [ 1720019 ]. In March 2016, final results were presented. In the &lt;b&gt;cold&lt;/b&gt; water drinking test, from baseline a mean reduction in time to complete the test...h [ 1799236 ]. In October 2016, results were presented. An improvement in dysphagia&amp;nbsp; was observed in time to swallow 80 ml &lt;b&gt;cold&lt;/b&gt; water in patients treated ...drinking time as compared to baseline. The 'p' values and median reduction in drinking time of &lt;b&gt;cold&lt;/b&gt; water, nectar, honey thickened were &amp;lt; .01, &amp;lt; .01, &amp;lt; .01, respectively</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HOPEMD: Safety, Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients</TitleDisplay><BiomarkerNames><BiomarkerName>Blood cells </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Forearm rotation </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hip motion </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Knee motion </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Shoulder motion </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Bernard Brais, MD</Name><Name>Yoseph Caraco, M.D</Name></ContactNames></Trial><Trial Id="152209"><Indications><Indication>Hepatitis C virus infection</Indication><Indication>Liver fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institutes of Health Clinical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-06T00:00:00Z</DateChangeLast><DateEnd>2015-08-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>13-I-0066</Identifier><Identifier>130066</Identifier><Identifier>NCT01805882</Identifier><Identifier>SYNERGY</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention><Intervention>Variable regimens including GS-7977 + GS-5885 + GS-9451 , GS-7977 + GS-5885 + GS-9669 , radalbuvir , ribavirin , sofosbuvir , sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead , vedroprevir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>229</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>included pain-related to post-treatment liver biopsy and vertigo. Headache (25, 25 and 0%), fatigue (10, 10 and 20%), diarrhea (5, 25 and 15%), rash (15, 5 and 0%), constipation (0, 10 and 5%), vomiting (5, 10 and 0%), nausea (5, 10 and 5%), common &lt;b&gt;cold&lt;/b&gt; (20, 5 and 5%), night sweats (0, 10 and 0%) and shoulder pain (10, 0 and 0%) were the adverse events reported in &gt; 10% of patients in arm 1, 2 and 3, respectively. Elevated AST, ALT, LDL, hyperglycemia and hypoglycemia were reported in arm 1 (5%, each</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SYNERGY: Combination Therapy for Chronic Hepatitis C Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 4</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cytotoxic T-lymphocyte protein 4 </BiomarkerName><BiomarkerName> Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Hepatitis A virus cellular receptor 2 </BiomarkerName><BiomarkerName> Hepatitis C virus RNA </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Programmed cell death protein 1 </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Henry Masur, M.D.</Name></ContactNames></Trial><Trial Id="142492"><Indications><Indication>Peripheral neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu modulator</Action><Action>Opioid receptor sigma antagonist 1</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antipsychotic</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Laboratorios Dr Esteve SA</Company></CompaniesSponsor><Countries><Country>Greece</Country><Country>Spain</Country></Countries><DateChangeLast>2018-02-08T00:00:00Z</DateChangeLast><DateStart>2012-06-21T00:00:00Z</DateStart><Identifiers><Identifier>2012-000398-21</Identifier><Identifier>ESTEVE-SIGM-202</Identifier></Identifiers><IndicationsAdverse><Indication>Neuropathy</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>MR-309 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>both &lt;b&gt;cold&lt;/b&gt; pain threshold and supra-threshold &lt;b&gt;cold&lt;/b&gt; stimulus–evoked pain intensity; and these effects were noticed from the first cycle over all cycles and also across the whole chemotherapy period. E-52862 notably reduced the signs...E-52862 versus placebo (mean treatment effect difference [SE]: 5.29 [1.60] degC; p = 0.001) and suprathreshold &lt;b&gt;cold&lt;/b&gt; stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032]. Total neuropathy score, health-related</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Clinical Total Neuropathy Score (cTNS)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-CIPN20</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Disease/Symptom Assesment</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pain</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment by chemotherapy-induced neuropathy (QLQ-CIPN20) scale</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC- QLQ</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical trial to evaluate the efficacy and safety of E-52862 for reducing oxaliplatin-induced peripheral neuropathy in patients treated for colorectal cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Motor nerve action potential </BiomarkerName><BiomarkerName> Motor nerve conduction velocity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Dr. Bruna</Name><Name>Study Medical Monitor</Name></ContactNames></Trial><Trial Id="130823"><Indications><Indication>Obesity</Indication></Indications><CompaniesSponsor><Company>Riemser Pharma GmbH</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-08-27T00:00:00Z</DateChangeLast><DateEnd>2012-05-22T00:00:00Z</DateEnd><DateStart>2010-09-13T00:00:00Z</DateStart><Identifiers><Identifier>2708/10</Identifier><Identifier>4036050</Identifier><Identifier>BfArM 4036050</Identifier><Identifier>DRKS00000543</Identifier><Identifier>EudraCT 2009-010116-15</Identifier><Identifier>U1111-1116-7751</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cathine hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> off limit in patients with coexisting risk factors like hyperlipidaemia and type 2 diabetes mellitus. Fasting glucose: 200mg/dL HbA1c: 9% Triglycerides: 800mg/dl Intake of drugs which increase blood pressure and heart rate eg, drugs against cough, &lt;b&gt;cold&lt;/b&gt; and allergies like ephedrine and pseudoephedrine and drugs with a decongestant effect like xylometazoline. Application of adrenergic amines, concurrent or less than two weeks back application of monoaminooxidase inhibitor (MAO-inhibitor), amantadine</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist circumference</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist to hip ratio</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex><EndpointIndex>Obesity - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Obesity - Assessment of Laboratory/Diagnostic Measures - Assessment of pulse</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>A Multicentre, Double-Blind, Placebo-Controlled, Dose - Finding Clinical Study for Three Doses of Antiadipositum X 112 T (Cathine-Hydrochloride) versus Placebo in 240 Patients With a Body Mass Index (BMI) Between 27 and 40 Kg/m2</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Diabetes</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Dyslipidemia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Waist circumference </BiomarkerName><BiomarkerName> Waist to Hip Ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dietmar Schroeder</Name></ContactNames></Trial><Trial Id="130702"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TLR-7 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunostimulant</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Immuno-oncology</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Anadys Pharmaceuticals Inc</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2011-05-10T00:00:00Z</DateStart><Identifiers><Identifier>ANA773-602</Identifier><Identifier>EudraCT 2011-000728-14</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>RG-7795 plus ribavirin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser> or Clinically significant abnormalities Donated or lost&gt; 500 ml of blood &amp;lt; 30 days prior to enrollment into this study Participated in other clinical studies of a new chemical entity within 30 days prior to study randomization Active infection (&lt;b&gt;cold&lt;/b&gt;, flu) within 14 days prior to the start of study or had a febrile illness within 5 days prior to administration of the first dose of study medication Any medical contraindications to Peg-INF or RBV therapy</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Treatment-emergent adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Clinical Investigation In The Early Stages Of Drug Development To Evaluate The Safety And Tolerability Of A New Drug For The Treatment Of Hepatitis C When It Is Given To Hepatitis C Patients Together With Ribavirin</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with gene variants - IFNL3_HUMAN_Mutation</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin 28B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117318"><Indications><Indication>Pruritus</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Systemic antipruritic product</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Maruho Co Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2013-09-18T00:00:00Z</DateChangeLast><DateStart>2006-08-09T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2006-001564-22</Identifier><Identifier>M5161/-02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>M-516102 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>history, physical examination and clinical laboratory safety tests Patients who have taken antiallergic drugs, antihistamines, nonsteroidal anti- inflammatory drugs, gamma-globulins, anti-cholinergic drugs, tranquilizers, hypnotics, antipsychotic drugs, &lt;b&gt;cold&lt;/b&gt; remedies containing antihistamine component, and any other systemic antiallergic or antipruritic drugs within 1 day prior to visit 1 Patients who have been treated with steroids (except inhaled preparations) or immunosuppressive drugs within 2 weeks</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dermatitis - Assessment of Clinical Response - Assessment of pruritus</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase IIa, Multiple-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of M-5161 in Relieving Pruritus Associated With Atopic Dermatitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD)</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with dermatitis/eczema</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116678"><Indications><Indication>Overactive bladder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Xention Ltd</Company></CompaniesSponsor><Countries><Country>Estonia</Country><Country>UK</Country><Country>Russian Federation</Country><Country>Belgium</Country></Countries><DateChangeLast>2014-08-18T00:00:00Z</DateChangeLast><DateEnd>2011-10-20T00:00:00Z</DateEnd><DateStart>2011-01-07T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2010-022611-19</Identifier><Identifier>XEN-D0501-CL-03</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>XEN-D0501 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of the study was to evaluate the efficacy of twice daily dosing with two doses of XEN-D0501 on the urinary symptoms of subjects with OAB compared to placebo [ 1393922 ]. Secondary objectives of the study were: To determine the safety and tolerability of twice daily dosing with two doses of XEN-D0501 in subjects with OAB compared to placebo. To evaluate the efficacy of twice daily dosing with two doses of XEN-D0501 on the urinary symptoms of subjects with OAB compared to placebo</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urinary incontinence - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase IIa, Multicenter, Parallel-group, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Two Doses of XEN-D0501 in the Treatment of Idiopathic Overactive Bladder (OAB)</TitleDisplay><PatientSegmentTerms><PatientSegment>Urinary incontinence - Subjects with Urge Incontinence/Overactive Bladder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>9 Months</TrialDuration><NumberOfSites>14</NumberOfSites></Trial><Trial Id="106826"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>CD40 ligand receptor antagonist</Action><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Inc</Company><Company>Kyowa Hakko Kirin Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Global Development Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2017-01-27T00:00:00Z</DateEnd><DateStart>2013-03-05T00:00:00Z</DateStart><Identifiers><Identifier>7163-CL-0108</Identifier><Identifier>NCT01780844</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including basiliximab , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , bleselumab , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>149</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>initial immunosuppressive regimen Subject has previously received or is receiving an organ transplant other than a kidney Subject will receive a solitary kidney from a deceased donor&amp;lt; 5 years of age Subject will receive a kidney with an anticipated &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT) of&gt; 30 h Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion Subject will receive</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Assess the Efficacy and Safety of ASKP-1240 in de Novo Kidney Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Senior Medical Director</Name></ContactNames></Trial><Trial Id="10000"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2Y2 purinoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Inspire Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2012-02-21T00:00:00Z</DateChangeLast><DateStart>2002-05-08T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>denufosol tetrasodium (intranasal, upper respiratory disorder), Inspire alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2a Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser> This was phase II multi-center, double-blind, placebo-controlled, dose-ranging study of INS-37217 intranasal in patients with upper respiratory infection (common &lt;b&gt;cold&lt;/b&gt;) [ 469286 ], [ 450637 ]. </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A Phase IIa Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of INS-37217 Intranasal In Patients With Upper Respiratory Infection (Common Cold)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Birgit Winther</Name></ContactNames></Trial><Trial Id="9719"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Thymidine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Transport Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2012-03-07T00:00:00Z</DateChangeLast><DateStart>2006-08-15T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>aciclovir (transdermal, iontophoretic), Transport Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser> Non-immunocompromised patients with a history of recurrent &lt;b&gt;cold&lt;/b&gt; sore outbreaks (three or more annually)...of &lt;b&gt;cold&lt;/b&gt; sores at specified stages of infection.The study would enroll 200 non-immunocompromised patients with a history of recurrent &lt;b&gt;cold&lt;/b&gt; sore outbreaks (three... Based on physical presentation, &lt;b&gt;cold&lt;/b&gt; sore lesions were assessed (swelling, ulcer, crusting, etc) and scored by an investigator or trained designee prior to dosing</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase IIb Study To Assess The Safety And Efficacy of acyclovir (dermatological, iontophoretic)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Spotswood Spruance</Name></ContactNames></Trial><Trial Id="94687"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>C-reactive protein inhibitor</Action><Action>Chemokine CC22 ligand inhibitor</Action><Action>GM-CSF receptor antagonist</Action><Action>Hemoglobin scavenger receptor antagonist</Action><Action>Metalloprotease-1 inhibitor</Action><Action>Metalloprotease-3 inhibitor</Action><Action>Small inducible cytokine A17 ligand inhibitor</Action><Action>VEGF gene inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>IL-6 modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>Serbia</Country><Country>Germany</Country><Country>Hungary</Country><Country>Chile</Country><Country>France</Country><Country>Ukraine</Country><Country>Bulgaria</Country><Country>Czech Republic</Country><Country>Estonia</Country><Country>Poland</Country><Country>South Africa</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Argentina</Country><Country>Colombia</Country></Countries><DateChangeLast>2019-02-18T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2012-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-005634-19</Identifier><Identifier>CD-IA-CAM-3001-1071</Identifier><Identifier>EARTH EXPLORER-1</Identifier><Identifier>NCT01706926</Identifier></Identifiers><IndicationsAdverse><Indication>Adenocarcinoma</Indication><Indication>Bronchitis</Indication><Indication>Cholelithiasis</Indication><Indication>Dacryocystocele</Indication><Indication>Dyspepsia</Indication><Indication>Headache</Indication><Indication>Hyperlipidemia</Indication><Indication>Hypertension</Indication><Indication>Influenza virus infection</Indication><Indication>Lower limb fracture</Indication><Indication>Neutropenia</Indication><Indication>Osteoarthritis</Indication><Indication>Pneumonia</Indication><Indication>Rheumatoid arthritis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Squamous cell carcinoma</Indication><Indication>Supraventricular tachycardia</Indication><Indication>Tachycardia</Indication><Indication>Tendon injury</Indication><Indication>Uterus tumor</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>methotrexate alone</Intervention><Intervention>mavrilimumab plus methotrexate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>420</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In May 2014, results were published. Results showed that, the most common adverse events (&gt; 3%) reported were headache, nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), hypertension, bronchitis and worsening of RA [ 1555853 ]. Similar results were presented in November 2014 [ 1612971 ], [ 1608758 ]. In November 2014, the results were presented. Hyperlipidemia, influenza and neutropenia were the treatment emergent adverse events (AEs) reported for mavrilimumab 150, 100, 30 mg and placebo, groups respectively. There</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 50 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 70 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Fatigue - Assessment of Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Treatment Response by EULAR Criteria</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of pain</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response - Clinical response (Decrease in DAS28 score of &gt; 1.2)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EARTH EXPLORER-1: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Moderate Rheumatoid Arthritis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> C-C motif chemokine 22 </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Carbon monoxide diffusing capacity </BiomarkerName><BiomarkerName> Chitinase-3-like protein 1 </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Gamma-glutamyltranspeptidase 1 </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Interleukin-22 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interstitial collagenase </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> Matrix metalloproteinase-9 </BiomarkerName><BiomarkerName> Myeloid cells </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Pro-epidermal growth factor </BiomarkerName><BiomarkerName> Protein-arginine deiminase type-2 </BiomarkerName><BiomarkerName> Resistin </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Serum amyloid A protein 1 </BiomarkerName><BiomarkerName> Stromelysin-1 </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 1A </BiomarkerName><BiomarkerName> Type IV collagen </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factor A </BiomarkerName><BiomarkerName> Vimentin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>46</NumberOfSites><ContactNames><Name>Marius Albulescu, MD</Name></ContactNames></Trial><Trial Id="88393"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Superoxide dismutase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Antioxidant agent</Action><Action>Chemoprotectant</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Pharma Consulting Group</Company></CompaniesCollaborator><CompaniesSponsor><Company>PledPharma AB</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Bulgaria</Country><Country>Denmark</Country><Country>Europe</Country><Country>Georgia</Country><Country>US</Country><Country>Portugal</Country><Country>Serbia</Country><Country>Sweden</Country></Countries><DateChangeLast>2018-11-08T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-001367-76</Identifier><Identifier>NCT01619423</Identifier><Identifier>PLIANT</Identifier><Identifier>PP095, (PLIANT)</Identifier></Identifiers><IndicationsAdverse><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-fluorouracil , PledOx + FOLFOX6 , calmangafodipir , folinic acid , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>186</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>patients (all three doses pooled) reported less physician graded neurotoxicity (odds ratio; p = 0.16), significantly less problems with &lt;b&gt;cold&lt;/b&gt; allodynia (mean 1.6 versus 2.3, p &amp;lt; 0.05) and significantly fewer sensory symptoms in the Leonard scale (cycle...0.84, 0.57 and 0.55 in placebo, PledOx 2, 5 and 10 micromol groups, respectively (primary endpoint). The patient reported outcomes &lt;b&gt;Cold&lt;/b&gt; Allodynia Test score at the end of treatment was 2.4, 1.3, 1.5 and 1.63; Leonard Scale (LS) score was 5.4, 2.8</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain - Numerical Rating Scale (NRS-11, NRS-101)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Imaging/Radiological Assessments - Assessment by Computed tomography (CT)/ PET scans</EndpointIndex><EndpointIndex>Cancer supportive care - Imaging/Radiological Assessments - Assessment by Magnetic Resonance Imaging (MRI)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Survival</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Laboratory Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Physician related outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PLIANT: A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Pain - Subjects with Cancer Related Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Manganese </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Zinc</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>41</NumberOfSites><ContactNames><Name>Bengt Glimelius</Name><Name>Clinical Operations</Name><Name>Marie Bengtson</Name><Name>Mary Cheli</Name><Name>Nicholas Iannotti</Name></ContactNames></Trial><Trial Id="8829"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Isotechnika Pharma Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2009-07-31T00:00:00Z</DateEnd><DateStart>2006-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ISA05-01</Identifier><Identifier>NCT00270634</Identifier><Identifier>PROMISE</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Hypertension</Indication><Indication>Insomnia</Indication><Indication>Tremor</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>tacrolimus alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>voclosporin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>334</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Receiving a lymphocytic antigen (HLA) identical living related transplant &lt;b&gt;Cold&lt;/b&gt; ischemic time&gt; 24 h Peak PRA (panel reactive antibodies)&gt; 30% Cadaveric donors who are over age 60 years, non-heart beating donors or any cadaveric donors positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) Transplantation of multiple</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Hypertension</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR) - Biopsy-proven CGR (BPCR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of neurotoxicity</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PROMISE: Study of ISA-247 (Voclosporin) in De Novo Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Calcineurin </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>A Gaber</Name><Name>Arthur Matas</Name><Name>Arthur Matas, MD</Name><Name>Daniel Abramowicz</Name><Name>Flavio Vincenti</Name><Name>Mark Pescovitz</Name><Name>Philip Belitsky</Name><Name>Stephan Busque</Name></ContactNames></Trial><Trial Id="83117"><Indications><Indication>Schizophrenia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Nicotinic ACh receptor alpha 7 subunit stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antipsychotic</Action><Action>Antitussive</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Targacept Inc</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Serbia</Country><Country>US</Country><Country>Ukraine</Country><Country>Romania</Country><Country>Hungary</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2013-11-01T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2011-005138-21</Identifier><Identifier>NCT01488929</Identifier><Identifier>TC-5619-23-CRD-003</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bradanicline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>603</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy of TC-5619 as an adjunctive therapy in combination with atypical antipsychotics to treat subjects with negative symptoms and cognitive dysfunction in schizophrenia (CDS) [ 1383336 ],[ 1428289 ]. By April 2013, recruitment was completed [ 1406241 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Functional Disability/Physical Function - UCSD Performance-based Skills Assessment (UPSA)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by SANS (Schedule for Assessment of Negative Symptoms)</EndpointIndex><EndpointIndex>Schizophrenia - Cognitive, Global and Functional Assessments - Assessment of subjects by CogState Schizophrenia test battery (CSTB)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients with Schizophrenia</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Subjects with Adverse Effects of Therapy</PatientSegment><PatientSegment>Schizophrenia - Subjects with Different Clinical Forms of Schizophrenia - Subjects with stable schizophrenia</PatientSegment><PatientSegment>Schizophrenia - Subjects with Negative Symptoms</PatientSegment><PatientSegment>Schizophrenia - Subjects with Positive Symptoms</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>71</NumberOfSites><ContactNames><Name>David P Walling, PhD</Name></ContactNames></Trial><Trial Id="72181"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-5 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Apoptosis stimulator</Action><Action>Bronchodilator</Action><Action>Eosinophil inhibitor</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Mexico</Country><Country>Peru</Country><Country>Colombia</Country><Country>Argentina</Country><Country>Poland</Country><Country>US</Country><Country>Brazil</Country></Countries><DateChangeLast>2019-03-05T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-020126-17</Identifier><Identifier>D3250L00001</Identifier><Identifier>MI-CP220</Identifier><Identifier>NCT01238861</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Dermatitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>benralizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>964</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In October 2014, results were published. Similar frequency of adverse events including treatment-emergent serious adverse events were observed in both placebo and benralizumab groups. Compared to placebo, benralizumab had shown more frequent common &lt;b&gt;cold&lt;/b&gt; and skin reactions at the injection site [ 1600836 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Immune Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Assessment of response to therapy</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Asthma control</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adenosine receptor A3 </BiomarkerName><BiomarkerName> Arachidonate 15-lipoxygenase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> C-C motif chemokine 24 </BiomarkerName><BiomarkerName> Chemokines </BiomarkerName><BiomarkerName> Eosinophil lysophospholipase </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Eotaxin </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Fractional concentration of exhaled nitric oxide </BiomarkerName><BiomarkerName> High affinity immunoglobulin epsilon receptor subunit alpha </BiomarkerName><BiomarkerName> Histamine H4 receptor </BiomarkerName><BiomarkerName> Immunoglobulin E </BiomarkerName><BiomarkerName> Interleukin-5 receptor subunit alpha </BiomarkerName><BiomarkerName> Oligodendrocyte transcription factor 2 </BiomarkerName><BiomarkerName> P2Y purinoceptor 14 </BiomarkerName><BiomarkerName> Peak expiratory flow rate </BiomarkerName><BiomarkerName> Serine protease 33</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>74</NumberOfSites><ContactNames><Name>Angi Gillen</Name><Name>David Gossage</Name><Name>Donald Raible, MD</Name><Name>Julie Nafziger</Name></ContactNames></Trial><Trial Id="68826"><Indications><Indication>Asthma</Indication><Indication>Rhinovirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action><Action>Virus uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Aviragen Therapeutics Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Biota Scientific Management</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-23T00:00:00Z</DateChangeLast><DateEnd>2012-03-01T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>BTA798-202</Identifier><Identifier>NCT01175226</Identifier><Identifier>RHINO</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>vapendavir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results showed that the study met the primary endpoint, resulting in a statistically significant reduction in the severity score of &lt;b&gt;cold&lt;/b&gt; symptoms when compared to placebo (p = 0.028). The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) scores...were decreased compared to placebo on day 3 onwards and statistically significanct differences were observed daily form days 5 to 14. &lt;b&gt;Cold&lt;/b&gt; symptoms across all HRV species A, B and C were reduced with BTA-798 . Greater reduction in the asthma ACQ</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RHINO: A Phase II Study of BTA-798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Intermittent/Episodic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>44</NumberOfSites><ContactNames><Name>John Lambert, PhD</Name></ContactNames></Trial><Trial Id="62293"><Indications><Indication>Cervical dysplasia</Indication><Indication>Papillomavirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Human papillomavirus E6 protein modulator</Action><Action>Human papillomavirus E7 protein modulator</Action><Action>IL2 gene stimulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Pox virus based gene therapy</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Belgium</Country><Country>Puerto Rico</Country><Country>Finland</Country><Country>Germany</Country><Country>US</Country><Country>Spain</Country></Countries><DateChangeLast>2019-06-14T00:00:00Z</DateChangeLast><DateEnd>2013-09-30T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-006946-24</Identifier><Identifier>NCT01022346</Identifier><Identifier>NV25025</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tipapkinogene sovacivec alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>206</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein barr virus (EBV) within 30 days of receiving study treatment. Mild viral infections such as Herpes Simplex Virus 1 (HSV-1) or common &lt;b&gt;cold&lt;/b&gt; are not excluded Have participated in another experimental protocol/use of investigational drug during the prior 6 months Are unable to comply with the protocol requirements Have any condition that, in the judgment of the investigator, might prevent</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 16) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Survival - Assessment of objective response (OR)</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of adverse events</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Immune Response - Anti-HPV antibodies</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Viral Load - HPV viral load</EndpointIndex><EndpointIndex>Papillomavirus infection - Resolution/Progression of HPV Infections/Lesions</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Immune Function</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of RO-5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions - Subjects with cervical cancer/cervical dysplasia</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Pre-cancerous Lesions - Subjects with cervical intraepithelial neoplasia</PatientSegment><PatientSegment>Uterine cervix tumor - Human Papilloma Virus (HPV) Positive Women</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects at risk of developing disease</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Cervical Intraepithelial Neoplasia (CIN) - Subjects with CIN II/moderate to marked dysplasia</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Cervical Intraepithelial Neoplasia (CIN) - Subjects with CIN III/severe dysplasia to carcinoma in situ</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>66</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="61523"><Indications><Indication>Gastroesophageal reflux</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-04-06T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-012935-13</Identifier><Identifier>D9120C00019</Identifier><Identifier>NCT01005251</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Nausea</Indication><Indication>Paresthesia</Indication><Indication>Pruritus</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lesogaberan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>661</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This phase IIb, multicenter study was being carried out to see whether AZD-3355 is an effective treatment as an add-on to Proton Pump Inhibitor (PPI) therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with PPI treatment alone. Another goal of the study was to examine which of the investigated doses of AZD-3355 is optimal for treatment of these patients. This study would also measure levels of drug in the blood and see how well it</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of GERD Symptoms by Protocol Specified Scales/Scores</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of Therapy Related Outcomes - Assessment of treatment response</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Assessment of adverse events</EndpointIndex><EndpointIndex>Gastroesophageal reflux - Patient Reported Outcomes/Quality of Life Assessments - Reflux Symptom Questionnaire Electronic Diary</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Investigate the Effect of Different Doses of Lesogaberan (AZD-3355) as add-on to Proton Pump Inhibitor (PPI) in Gastroesophageal Reflux Disease (GERD) Patients With Partial Response to PPI</TitleDisplay><PatientSegmentTerms><PatientSegment>Gastroesophageal reflux - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Debra Silberg, MD</Name><Name>Nicholas Shaheen, MD, MPH</Name></ContactNames></Trial><Trial Id="61325"><Indications><Indication>Post traumatic stress disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-25T00:00:00Z</DateChangeLast><DateEnd>2010-06-28T00:00:00Z</DateEnd><DateStart>2009-11-02T00:00:00Z</DateStart><Identifiers><Identifier>113211</Identifier><Identifier>NCT01000493</Identifier><Identifier>NKG113211</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Diarrhea</Indication><Indication>Drowsiness</Indication><Indication>Dyspepsia</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Seizure disorder</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>132</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a 12-week, randomized, multicenter, double-blind, placebo-controlled, fixed-dose, parallel-group study to assess the efficacy and safety of orvepitant (60 mg/day) versus placebo in subjects with a diagnosis of non-combat-related post traumatic stress disorder (PTSD), whose symptoms are considered moderate or severe.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment of executive functions</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Remission - Assessment of remission rate</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Response Rates (RR) - Assessment of response rate</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Response Rates (RR) - Assessment of time to response</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Sleep - Assessment by Pittsburgh Sleep Quality Index (PSQI)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Symptoms of Post Traumatic Stress Disorder - Assessment by Clinician-Administered PTSD Scale [CAPS]</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Symptoms of Post Traumatic Stress Disorder - Assessment by Davidson Trauma Scale (DTS)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Symptoms of Post Traumatic Stress Disorder - Assessment by Short PTSD Rating Interview (SPRINT)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of the Symptoms of Anxiety Disorder - Assessment of affective symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Orvepitant (GW-823296) in Adult Post Traumatic Stress Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Anxiety disorder - Subjects with Post Traumatic Stress Disorder - Subjects with moderate to severe post traumatic stress disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-06-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="59386"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer hormone antagonist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Dermatological gel formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal gel formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Northwestern University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-26T00:00:00Z</DateChangeLast><DateEnd>2011-09-30T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000650556</Identifier><Identifier>CDR0000674368</Identifier><Identifier>N01CN35157</Identifier><Identifier>NCI 07-9-02</Identifier><Identifier>NCI-2013-00452</Identifier><Identifier>NCT00952731</Identifier><Identifier>NU-NWU07-9-02</Identifier><Identifier>NWU07-9-02</Identifier><Identifier>P30CA060553</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>afimoxifene (gel, breast cancer/gynecomastia/mastalgia), BHR alone</Intervention><Intervention>tamoxifen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>DCNB and TSE samples would be acquired by the recruiting institution and ten sections from each specimen submitted to the NU Pathology Core Facility (NU PCF). The sections would be cut in batches (with pre- and post-samples in the same batch), shipped &lt;b&gt;cold&lt;/b&gt;, and processed for immunohistochemistry within a week of sectioning. Compliance assessment would occur through patient diaries, pill counts and the weighing of returned drug (gel) canisters. Participants would be assessed for adverse events at the </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of markers of estrogen metabolism</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of polymorphisms of drug metabolizing enzymes/transporters/nuclear receptors</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Breast tumor - Assessment of markers of drug resistance/metabolism</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects at Risk of Developing Invasive Breast Cancer - Ductal carcinoma in situ/Intraductal carcinoma (DCIS)</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Coagulation factor VIII </BiomarkerName><BiomarkerName> Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Estrogens </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Sex hormone-binding globulin </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Julie Margenthaler</Name><Name>Lee Wilke</Name><Name>Raymond Bergan</Name><Name>Seema Khan</Name></ContactNames></Trial><Trial Id="51505"><Indications><Indication>Depression</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2010-06-16T00:00:00Z</DateEnd><DateStart>2009-03-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT00880399</Identifier><Identifier>NKG111733</Identifier><Identifier>orvepitant MDD</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>328</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>This was a 6-week, randomized, multicenter, double-blind, placebo-controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in patients with a diagnosis of a major depressive disorder, whose symptoms were considered moderate or severe. Following an initial screening visit, patients fulfilling the study inclusion and exclusion criteria would enter a pre-treatment screening phase to permit evaluation of the laboratory and ECG</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms - Assessment of anxiety symptoms</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms - Assessment of sexual dysfunction</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms - Assessment of suicidal ideation/suicide attempts</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Bech Melancholia Scale (BMS)</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Hamilton Depression Rating Scale (HDRS)</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Quick Inventory Depressive Symptoms (QIDS)</EndpointIndex><EndpointIndex>Depression - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function - Assessment of cognitive symptoms</EndpointIndex><EndpointIndex>Depression - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Depression - Assessment of Remission</EndpointIndex><EndpointIndex>Depression - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Depression - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Depression - Assessment of Sleep</EndpointIndex><EndpointIndex>Depression - Assessment of adverse events</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Sexual Function - Assessment by Sexual Function Questionnaire (SFQ)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Underlying Condition - Assessment of neuropsychiatric conditions</EndpointIndex><EndpointIndex>Female sexual dysfunction - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Patient Reported Outcomes/Quality of Life Assessments - Cognitive and physical function questionnaire(CPFQ)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Patient Reported Outcomes/Quality of Life Assessments - Discontinuation emergent signs and symptoms scale(DESS)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Patient Reported Outcomes/Quality of Life Assessments - Hamilton depression rating scale(HDRS-17/HAMD/HRSD)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Patient Reported Outcomes/Quality of Life Assessments - Quick inventory of depressive symptomatology(QIDS-SR 16)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>orvepitant MDD: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Depression - Subjects with Major Depressive Disorder</PatientSegment><PatientSegment>Depression - Subjects with Relapse/Recurrent Depression</PatientSegment><PatientSegment>Female sexual dysfunction - Subjects with History of Neuropsychiatric Disorders</PatientSegment><PatientSegment>Female sexual dysfunction - Subjects with History of Neuropsychiatric Disorders - Subjects with history of/concurrent neuropsychiatric therapy</PatientSegment><PatientSegment>Female sexual dysfunction - Subjects with history/Scheduled for Hormonal Therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-06-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>20</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="372430"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>G protein coupled receptor 35 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Respivant Sciences</Company></CompaniesCollaborator><CompaniesSponsor><Company>Respivant Sciences GmbH</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country><Country>Netherlands</Country><Country>UK</Country><Country>Italy</Country><Country>Turkey</Country><Country>Belgium</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-19T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2019-03-29T00:00:00Z</DateStart><Identifiers><Identifier>NCT03864328</Identifier><Identifier>RVT1601-CC-04</Identifier><Identifier>SCENIC</Identifier></Identifiers><InterventionsControlDisplay><Intervention>eFlow nebulizer alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cromolyn sodium (inhalant, chronic cough), Respivant Sciences alone</Intervention><Intervention>eFlow nebulizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow Closed System (CS) nebulizer, was being evaluated in this Phase IIb study for the treatment of persistent cough in patients with IPF (idiopathic pulmonary fibrosis). In May 2019, first patient was dosed [ 2153350 ].</Teaser><TrialCategories><Category>Biomarker identification</Category><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Cough</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Interstitial lung disease - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Leicester Cough Questionnaire (LCQ)</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by St Georges Respiratory Questionnaire (SGRQ) activity scale</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - King's brief interstitial lung disease questionnaire</EndpointIndex><EndpointIndex>Interstitial lung disease - Patient Reported Outcomes/Quality of Life Assessments - UCSD shortness of breath questionnaire scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SCENIC: A Phase IIb Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF</TitleDisplay><PatientSegmentTerms><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment><PatientSegment>Interstitial lung disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Lung</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>59</NumberOfSites><ContactNames><Name>Ahmet Tutuncu, MD, PhD</Name><Name>Carlo Albera, MD</Name><Name>Carlo Vancheri, MD</Name><Name>Charles Fogarty, MD</Name><Name>Christopher Ryerson</Name><Name>Craig Glazer, MD</Name><Name>Daniel Culver, MD</Name><Name>Daniel Dilling</Name><Name>Elena Bargagli, MD</Name><Name>Elizabeth Belloli, MD</Name><Name>Esther Nossent, MD</Name><Name>Francesco Bonella, MD</Name><Name>Gerard Criner, MD</Name><Name>Gulfer Okumus, MD</Name><Name>Hannah Mannem, MD</Name><Name>Helen Parfrey, MD</Name><Name>Hyun Kim</Name><Name>Ismail Hanta, MD</Name><Name>Ivan Rosas</Name><Name>Jeffrey Golden, MD</Name><Name>Jeffrey Swigris, MD</Name><Name>Joseph Lasky</Name><Name>Julie Morisset, MD</Name><Name>Justin Oldham</Name><Name>Kerri Johannson, MD</Name><Name>Lake Morrison, MD</Name><Name>Lawrence Ho, MD</Name><Name>Leo Ginns, MD</Name><Name>Lisa Lancaster, MD</Name><Name>Lisa Spencer, MD</Name><Name>Luca Richeldi, MD</Name><Name>Marcel Veltkamp, MD</Name><Name>Marilyn Glassberg</Name><Name>Marlies Wijsenbeek, MD</Name><Name>Martin Kolb, MD</Name><Name>Martina Vasakova, MD</Name><Name>Mary Beth Scholand, MD</Name><Name>Maureen Horton, MD</Name><Name>Meena Kalluri, MD</Name><Name>Michael Kreuter, MD</Name><Name>Nazia Chaudhuri, MD</Name><Name>Neil Ettinger, MD</Name><Name>Nesrin Mogulkoc, MD</Name><Name>Nikhil Hirani</Name><Name>Paolo Spagnolo, MD</Name><Name>Paul Bresser, MD</Name><Name>Paul Hernandez, MD</Name><Name>Pilar Acosta, MD</Name><Name>Remy Mostard, MD</Name><Name>Robert Kaner, MD</Name><Name>Sanjay Agrawal, MD</Name><Name>Selwyn Spangenthal, MD</Name><Name>Shane Shapera, MD</Name><Name>Simon Hart, MD</Name><Name>Sophie Fletcher, MD</Name><Name>Stefano Nava, MD</Name><Name>Steven Nathan, MD</Name><Name>Timothy Whelan, MD</Name><Name>Toby Maher, MD</Name><Name>Vivek Iyer</Name><Name>Wim Wuyts, MD</Name></ContactNames></Trial><Trial Id="368460"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Fungicide</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Inhalant formulation</Technology><Technology>Natural product</Technology><Technology>Oligosaccharide</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>AlgiPharma Pty Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>AlgiPharma AS</Company></CompaniesSponsor><Countries><Country>Norway</Country></Countries><DateChangeLast>2019-06-17T00:00:00Z</DateChangeLast><DateEnd>2019-10-30T00:00:00Z</DateEnd><DateStart>2019-04-03T00:00:00Z</DateStart><Identifiers><Identifier>NCT03822455</Identifier><Identifier>ORDCF205</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>OligoG CF-5/20 alone</Intervention><Intervention>standard-of-care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>33</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This was a double-blind, randomized study of Oligo-G dry powder inhalation (DPI) (alginate oligosaccharide ie, OligoG CF-5/20 ) compared to placebo DPI, both on top of standard-of-care, to assess safety, efficacy and tolerability [ 2163097 ].</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase IIb, Randomized, Placebo-Controlled Study of Oligo-G in Patients With Cystic Fibrosis (CFmized, Double-blind, Parallel-group Study of Alginate Oligosaccharide)</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with respiratory tract infections</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for treatment with Medications</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hilde Morris</Name><Name>Marieta Ryan</Name></ContactNames></Trial><Trial Id="36472"><Indications><Indication>Diabetic peripheral neuropathy</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>MAO A inhibitor</Action><Action>MAO B inhibitor</Action><Action>NMDA receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>Antiparkinsonian</Action><Action>Antitussive</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Vernalis plc</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>UK</Country><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2016-06-10T00:00:00Z</DateChangeLast><DateEnd>2009-12-31T00:00:00Z</DateEnd><DateStart>2008-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-007978-38</Identifier><Identifier>IN-STEP</Identifier><Identifier>NCT00794430</Identifier><Identifier>V3381-2DPNP-02</Identifier></Identifiers><IndicationsAdverse><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>indantadol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>161</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of oral doses of V-3381 , titrated to effect. A 2-week, single-blind, placebo run-in period would be followed by a 13-week, double-blind titration and maintenance phase. Doses would be titrated up in 100 mg bid increments every 1 or 2 weeks, starting from 100 mg bid. A 2-week, follow-up period would conclude patient participation in the study. In September 2009, enrollment was completed [ 1041837 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>IN-STEP: Study of the Safety, Tolerability and Efficacy of V-3381 in Patients With Diabetic Peripheral Neuropathic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>33</NumberOfSites><ContactNames><Name>Christine Sang</Name></ContactNames></Trial><Trial Id="352955"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>CD40 ligand receptor antagonist</Action><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farmaceutica SA</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>France</Country><Country>Hungary</Country><Country>Sweden</Country><Country>US</Country><Country>Norway</Country><Country>Japan</Country><Country>Argentina</Country><Country>Italy</Country><Country>Australia</Country><Country>UK</Country><Country>Czech Republic</Country><Country>Spain</Country><Country>Netherlands</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><DateEnd>2022-09-09T00:00:00Z</DateEnd><DateStart>2018-11-20T00:00:00Z</DateStart><Identifiers><Identifier>2017-003607-22</Identifier><Identifier>CCFZ533A2201</Identifier><Identifier>CIRRUS I</Identifier><Identifier>JapicCTI-194637</Identifier><Identifier>NCT03663335</Identifier></Identifiers><InterventionsControlDisplay><Intervention>corticosteroid therapy alone</Intervention><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>corticosteroid therapy alone</Intervention><Intervention>Variable regimens including iscalimab (intravenous, solid organ transplantation/Sjoegrens syndrome), Novartis , mycophenolate mofetil , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>325</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of three CFZ-533 dose regimens in kidney transplant recipients [ 2119637 ], [ 2159665 ]. The main trial objectives were: Cohort 1: to demonstrate that two CFZ-533 dosing regimens were non-inferior to a tacrolimus-based regimen with respect to the proportion of patients who experience the composite efficacy failure event (BPAR, graft loss or death) over 12 months posttransplantation. Cohort</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Proportion/percentage of patients with AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure - Incidence/proportion of patients with graft loss</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma drug/drug metabolite concentration</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Thrombotic/Thromboembolic Events</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Assessment of Number of Patients Withdrawn From Immunosuppression</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CIRRUS I: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ-533, in Kidney Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Heart beating donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Expanded Criteria Donor (ECD) Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-09-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>16</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Information&amp;Communication Médicales</Name><Name>Medical information</Name><Name>Medizinischer Infoservice (MCC)</Name><Name>Novartis Pharma Corporation</Name><Name>Novartis Pharmaceuticals</Name><Name>Public Information Desk</Name><Name>Trial Monitoring Organization (TMo)</Name></ContactNames></Trial><Trial Id="349618"><Indications><Indication>Respiratory syncytial virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Respiratory syncytial virus protein F modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intramuscular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>Universitair Medisch Centrum Utrecht</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-10-06T00:00:00Z</DateChangeLast><DateEnd>2020-04-30T00:00:00Z</DateEnd><DateStart>2018-11-15T00:00:00Z</DateStart><Identifiers><Identifier>2018-002742-37</Identifier><Identifier>66735.041.18</Identifier><Identifier>NL66735.041.18</Identifier><Identifier>NTR7403</Identifier><Identifier>Narsyn</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>palivizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>348</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Study A: Adults with a nasal &lt;b&gt;cold&lt;/b&gt; or obstructions in the nasal cavity that could interfere with administration of the study vaccine are excluded History of any respiratory symptoms or clinically significant infectious disease within 4 weeks prior to drug administration or immunocompromised</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory syncytial virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Respiratory syncytial virus infection - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Narsyn: Nasal Administration of Palivizumab to Prevent RSV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory syncytial virus infection - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Louis Bont</Name><Name>Narsyn trial information</Name></ContactNames></Trial><Trial Id="344633"><Indications><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication><Indication>Viral respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon beta ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Synairgen plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-06-11T00:00:00Z</DateChangeLast><DateEnd>2020-04-30T00:00:00Z</DateEnd><DateStart>2018-01-29T00:00:00Z</DateStart><Identifiers><Identifier>2017-003679-75</Identifier><Identifier>NCT03570359</Identifier><Identifier>SG015</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>inhaled interferon beta (lung disorders/influenza), Synairgen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>130</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>inhalation). In part 2 COPD patients would contact the research team when they experience &lt;b&gt;cold&lt;/b&gt; or flu symptoms or a deterioration of their COPD symptoms. At this point, eligible...and OAS1) were previously observed in studies in asthma patients; in these studies, lung function was improved in patients with &lt;b&gt;cold&lt;/b&gt; or flu that had been treated with inhaled IFN-beta [ 2153829 ]....assess efficacy and safety of inhaled SNG-001 in 80 patients with COPD with a &lt;b&gt;cold&lt;/b&gt; or COPD exacerbation. The aim of this two-part&amp;nbsp;trial was to study the safety and</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - CXC chemokines assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interferon-gamma (IFN-gamma) assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of breathlessness, cough and sputum scale (BCSS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Influenza virus infection - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Influenza virus infection - Protocol Specified Other Endpoints - Antiviral efficacy</EndpointIndex><EndpointIndex>Influenza virus infection - Protocol Specified Other Endpoints - Medications usage</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment><PatientSegment>Influenza virus infection - Subjects with Influenza</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>2'-5'-oligoadenylate synthetase 1 </BiomarkerName><BiomarkerName> C-X-C motif chemokine 10 </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Interferon-induced GTP-binding protein Mx1 </BiomarkerName><BiomarkerName> Interferon-induced guanylate-binding protein 1 </BiomarkerName><BiomarkerName> Interferon-induced protein with tetratricopeptide repeats 2 </BiomarkerName><BiomarkerName> Interferons </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Dave Singh, Prof</Name><Name>Geoff Nash, James Thompson</Name><Name>Helen Francis</Name><Name>Jody Brookes</Name><Name>Richard Marsden</Name><Name>Rukhsana Shaikh-Zaidi</Name><Name>Tim Harris</Name><Name>Tom Wilkinson</Name></ContactNames></Trial><Trial Id="343178"><Indications><Indication>Bladder cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer alkylating agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Gel formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>UroGen Pharma Ltd</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>US</Country></Countries><DateChangeLast>2019-05-24T00:00:00Z</DateChangeLast><DateEnd>2020-09-30T00:00:00Z</DateEnd><DateStart>2018-10-25T00:00:00Z</DateStart><Identifiers><Identifier>NCT03558503</Identifier><Identifier>TC-BC-12</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mitomycin C (high-dose/sustained release intravesical formulation/RTGel, low grade non-muscle invasive bladder cancer), Urogen Pharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Age &gt;/= 18 years Willing and able to sign an informed consent and comply with the protocol Has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by &lt;b&gt;cold&lt;/b&gt; cup biopsy at screening or within 6 weeks of screening Is at intermediate risk for progression, defined as having 1 or 2 of the following: Presence of multiple tumors Solitary tumor&gt; 3 cm Recurrence (&gt;/= 1 occurrence of LG NMIBC within one year of </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Histopathological Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Newly Diagnosed Tumor</PatientSegment><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bicarbonates </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Phosphorus </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Alexander Sankin, MD</Name><Name>Alon Weizer, MD</Name><Name>Angela Smith, MD</Name><Name>Arnold Cinman, MD</Name><Name>Boris Fridman, MD</Name><Name>Bryan Mehlhaff, MD</Name><Name>Carmela Graci-Pipitone</Name><Name>Chamie Karim, MD</Name><Name>Daniel Saltzstein, MD</Name><Name>David Morris, M.D.</Name><Name>Douglas Scherr, MD</Name><Name>Hilla Cohen</Name><Name>Huang William, MD</Name><Name>Jay Raman, MD</Name><Name>Jennifer Linehan, MD</Name><Name>Kathleen Lehman</Name><Name>Katie O'Brien</Name><Name>Kelly Garver</Name><Name>Kent Chevli, MD</Name><Name>Kethsaly Salinas</Name><Name>Kim Ganzel</Name><Name>Krystal Payton</Name><Name>Lawrench Karsh, M.D.</Name><Name>Lindsey Rabon</Name><Name>Max Kates, MD</Name><Name>Michael O'Donnell, MD</Name><Name>Natali Oginets</Name><Name>Neil Shore, MD</Name><Name>Nimrod Gabai, BSc</Name><Name>Richard Emanuel D'Anna, MD</Name><Name>Robert Kirshoff, MS, CNS, CCRC</Name><Name>Robert Robert, MS, CNS, CCRC</Name><Name>Roxie Felton</Name><Name>Seth Lerner, MD</Name><Name>Shiblee Nomanee</Name><Name>Stephanie Kerns</Name><Name>Stephanie Malczewski</Name><Name>Steven Kester, M.D.</Name><Name>Thomas Flynn</Name><Name>Trainer Andrew, MD</Name><Name>Yaron Erlich, CM</Name></ContactNames></Trial><Trial Id="329947"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Canada</Country><Country>Germany</Country><Country>Belgium</Country><Country>Taiwan</Country><Country>Switzerland</Country><Country>Turkey</Country><Country>Argentina</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2021-06-16T00:00:00Z</DateEnd><DateStart>2018-08-01T00:00:00Z</DateStart><Identifiers><Identifier>2017-004207-52</Identifier><Identifier>CQGE031C2202</Identifier><Identifier>NCT03437278</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ligelizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Clearly defined underlying etiology for chronic urticarias other than CSU. This includes the following: Inducible urticaria: urticaria factitia, &lt;b&gt;cold&lt;/b&gt;, heat, solar, pressure, delayed pressure, aquagenic, cholinergic, or contact-urticaria Diseases with possible symptoms of urticaria or angioedema such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of number of hives</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum immunoglobulin levels</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Investigate the Efficacy and Safety of QGE-031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Immunoglobulin E </BiomarkerName><BiomarkerName> QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-02-26T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>22</NumberOfSites><ContactNames><Name>Medizinischer Infoservice (MCC)</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="322744"><Indications><Indication>Respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR complex 2 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Immunosuppressant</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>resTORbio Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-22T00:00:00Z</DateChangeLast><DateEnd>2018-07-31T00:00:00Z</DateEnd><DateStart>2017-11-15T00:00:00Z</DateStart><Identifiers><Identifier>NCT03373903</Identifier><Identifier>RTB-BEZ235-202</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dactolisib alone</Intervention><Intervention>dactolisib plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>652</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>235 alone and in combination with everolimus (RAD-001) to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly patients [ 2057168 ], [ 2057174 ], [ 2130891 ]. This trial was conducted during the winter &lt;b&gt;cold&lt;/b&gt; and flu season in the southern hemisphere (Part 1) and northern hemisphere (Part 2). Patients enrolled were those at increased risk of morbidity and mortality from RTIs [ 2057168 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma Drug Concentrations</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Efficacy parameter - unspecified</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Lung infections</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Protocol Specified Other Endpoints - Efficacy - unspecified</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Dose Finding Study to Determine if BEZ-235 Alone or in Combination With RAD-001 Decreases the Incidence of Respiratory Tract Infections in the Elderly</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Others - Healthy Subjects</PatientSegment><PatientSegment>Cardiac failure - Others - Healthy Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Mild /NYHA Functional Class I/Asymptomatic Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Mild /NYHA Functional Class II Heart Failure Subjects</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 1/Mild COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Others - Healthy Subjects</PatientSegment><PatientSegment>Respiratory tract infection - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CREB-regulated transcription coactivator 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-05-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sarb Shergill, PhD</Name></ContactNames></Trial><Trial Id="313623"><Indications><Indication>Cough</Indication><Indication>Idiopathic pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>G protein coupled receptor 35 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Patara Pharma LLC</Company><Company>Roivant Sciences Ltd</Company></CompaniesSponsor><DateChangeLast>2018-09-21T00:00:00Z</DateChangeLast><DateStart>2019-03-31T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>cromolyn sodium (inhalant, chronic cough), Respivant Sciences alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>This is a robust phase IIb clinical trial to identify the optimal dose of RVT-1601 for the treatment of idiopathic pulmonary fibrosis patients with persistent cough [ 1964003 ], [ 2069276 ]. In September 2018, Roivant Sciences Ltd planned to initiate the trial in first quarter of 2019 [ 2073036 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A robust phase IIb clinical trial to identify the optimal dose of RVT-1601 for the treatment of idiopathic pulmonary fibrosis patients with persistent cough</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="312573"><Indications><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Haemophilus influenzae infection</Indication><Indication>Moraxella catarrhalis infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Biologicals</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>France</Country><Country>UK</Country><Country>Spain</Country><Country>Italy</Country><Country>US</Country><Country>Canada</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2020-04-10T00:00:00Z</DateEnd><DateStart>2017-11-27T00:00:00Z</DateStart><Identifiers><Identifier>2017-000880-34</Identifier><Identifier>207489</Identifier><Identifier>NCT03281876</Identifier><Identifier>NTHI MCAT-002</Identifier><Identifier>NTHI MCAT-002</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>COPD vaccine (COPD exacerbations associated with non-typeable Haemophilus influenzae and Moraxella catarrhalis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>608</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of phase IIb, proof-of-concept (POC) study is to test if the vaccine ( GSK-3277511A ) is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ('exacerbations') and to gather further information on safety and immune response Main objective of the trial is to assess efficacy of the investigational vaccine as compared to the placebo control with respect to the rate of moderate and severe acute exacerbations of COPD (AECOPDs). Secondary objectives</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of time to first exacerbation</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Fatigue</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interferon-gamma (IFN-gamma) assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum - Sputum weight and volume</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Vital Signs - Temperature changes</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Fatigue</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization</EndpointIndex><EndpointIndex>Influenza Vaccine - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Influenza Vaccine - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Influenza Vaccine - Protocol Specified Other Endpoints - Medications usage</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NTHI MCAT-002: A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Treatment Naive Subjects</PatientSegment><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza Vaccine - Vaccination Naive Subjects - Influenza vaccine naive subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-Protein D antibodies </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> CD40 ligand </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-13 </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-03-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>73</NumberOfSites><ContactNames><Name>Centro de Información</Name><Name>Clinical Disclosure Advisor</Name><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="309282"><Indications><Indication>Lung disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IGF binding protein-3 stimulator</Action><Action>Insulin sensitizer</Action><Action>Insulin-like growth factor 1 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer hormone</Action><Action>Hypoglycemic agent</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein chimeric</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Shire plc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Sweden</Country></Countries><DateChangeLast>2019-05-31T00:00:00Z</DateChangeLast><DateEnd>2023-02-22T00:00:00Z</DateEnd><DateStart>2019-05-09T00:00:00Z</DateStart><Identifiers><Identifier>2018-001393-16</Identifier><Identifier>IND number: 133076</Identifier><Identifier>NCT03253263</Identifier><Identifier>SHP607-202</Identifier><Identifier>SHP607-301</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Standard neonatal care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>mecasermin rinfabate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this randomized, multicenter, open-label, controlled study was to determine if an investigational drug ( SHP-607 ) can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone [ 1961493 ], [ 1961184 ]. The first patient first visit was planned on December 2017 and completion was estimated on March 2022 [ 1961184 ]. The primary objective of this study</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Hemorrhagic Complications - Assessment of intraventricular hemorrhage (IVH)</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments - Assessment of Retinopathy of prematurity (ROP)</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>A Clinical Efficacy and Safety Study of SHP-607 in Preventing Chronic Lung Disease in Extremely Premature Infants</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Birth weight </BiomarkerName><BiomarkerName> Fraction of inspired oxygen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Abhay Bhatt, MD</Name><Name>Basharat Buchh, MD</Name><Name>Charlotte Almeida</Name><Name>Shire Contact</Name><Name>Site Contact</Name><Name>Study Director</Name></ContactNames></Trial><Trial Id="296583"><Indications><Indication>Stage III melanoma</Indication><Indication>Stage IV melanoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL12 gene stimulator</Action><Action>Programmed cell death protein 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Immunostimulant</Action><Action>Plasmid based gene therapy</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intramuscular formulation</Technology><Technology>Intratumoral formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Intravesical formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesCollaborator><Company>Merck &amp; Co Inc</Company><Company>University of California Los Angeles</Company></CompaniesCollaborator><CompaniesSponsor><Company>OncoSec Medical Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country><Country>Australia</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2017-10-03T00:00:00Z</DateStart><Identifiers><Identifier>KEYNOTE-695</Identifier><Identifier>NCT03132675</Identifier><Identifier>OMS-I103</Identifier><Identifier>OMS-I103 (KEYNOTE 695)</Identifier><Identifier>PISCES</Identifier></Identifiers><IndicationsAdverse><Indication>Pain</Indication><Indication>Respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Electroporation alone</Intervention><Intervention>Immunopulse alone</Intervention><Intervention>pembrolizumab plus tavokinogene telseplasmid</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this phase IIb, global, simon two-stage, non-comparative, open-label, single-arm, multicenter study study was to evaluate the effect of IT-pIL12-EP plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who were progressing on either pembrolizumab or nivolumab treatment [ 1926088 ], [ 1935920 ], [ 1969578 ], [ 1965889 ], [ 1970520 ], [ 1972873 ], [ 1974486 ], [ 1974411 ], [ 1979837 ], [ 1981574 ], [ 1985806 ], [ 1994600 ], [ 1998650 ], [ 2001783</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Melanoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Melanoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate</EndpointIndex><EndpointIndex>Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PISCES: Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Melanoma - Subjects with Advanced/Metastatic Cancer</PatientSegment><PatientSegment>Melanoma - Subjects with Evidence of Metastasis</PatientSegment><PatientSegment>Melanoma - Subjects with Stage III Melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Stage IV Melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Surgically Non-resectable Melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>23</NumberOfSites><ContactNames><Name>Adil Daud</Name><Name>Chris Baker</Name><Name>Dr. Roger S. Lo</Name><Name>Kellie Malloy</Name><Name>Kellie Malloy Foerter</Name></ContactNames></Trial><Trial Id="291663"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Beijing Da-an Bio-technology</Company></CompaniesSponsor><DateChangeLast>2017-03-28T00:00:00Z</DateChangeLast><DateEnd>2018-03-31T00:00:00Z</DateEnd><DateStart>2017-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT03089138</Identifier><Identifier>REGAN TANGJIANG PHASE 2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Regan Tangjiang plus shufengjiere capsules</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>psychosis and so on Participants who had used other drugs to treat common &lt;b&gt;cold&lt;/b&gt; after the onset of the disease, including antivirals, antibiotics and traditional Chinese...common &lt;b&gt;cold&lt;/b&gt; according to Western Medicine, with symptoms onset and fever&amp;lt; 24 h prior to randomization After the onset of the disease, with the following symptoms... The purpose of this study is to evaluate the efficacy and safety of Regan Tangjiang for treating the common &lt;b&gt;cold&lt;/b&gt; with wind-heat</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="283198"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Agility Clinical</Company><Company>PSR Orphan Experts</Company></CompaniesCollaborator><CompaniesSponsor><Company>NovaBiotics Ltd</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Italy</Country><Country>UK</Country></Countries><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><DateEnd>2018-04-30T00:00:00Z</DateEnd><DateStart>2016-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CARE-CF-1</Identifier><Identifier>NBTCS02</Identifier><Identifier>NCT03000348</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mercaptamine alone</Intervention><Intervention>standard of care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>91</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a multicenter, double-blind, randomized, placebo-controlled, six-arm study to investigate the optimal dose regimen, efficacy, and safety benefits of cysteamine ( Lynovex ) as adjunct therapy to standard of care antibiotic and other interventions in Cystic Fibrosis (CF) infectious exacerbations in the treatment of adult patients with CF who were experiencing an exacerbation of CF-associated lung disease [ 1893078 ], [ 1926838 ], [ 1950017 ], [ 1978002 ], [ 2012547 ], [ 2053266 ], [ 2160266</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Physical Examination - Assessment of growth/anthropometric measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum inflammatory markers/cell Counts</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum microbiology</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CARE-CF-1: A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with respiratory tract infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Cysteamine </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Leukocyte elastase </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Professor Graham Devereux</Name></ContactNames></Trial><Trial Id="282434"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>NeRRe Therapeutics Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>US</Country></Countries><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><DateEnd>2019-02-25T00:00:00Z</DateEnd><DateStart>2017-05-10T00:00:00Z</DateStart><Identifiers><Identifier>NCT02993822</Identifier><Identifier>VOLCANO-2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>315</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this multicenter, 12-week, double-blind, randomized, parallel-group, placebo-controlled, phase IIb dose-ranging study was to determine the effectiveness of three doses of orvepitant , taken once a day, in the treatment of chronic refractory cough [ 2160349 ]. The hypothesis being tested in this trial was that orvepitant could suppress the dysfunctional cough reflex and neuronal hypersensitivity which was thought to cause excessive coughing in patients with refractory chronic cough</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2019-02-11T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>40</NumberOfSites></Trial><Trial Id="281138"><Indications><Indication>Psoriatic arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Sun Pharma Global Fze</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>US</Country><Country>Spain</Country><Country>Hungary</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>Mexico</Country><Country>Ukraine</Country><Country>Chile</Country><Country>UK</Country></Countries><DateChangeLast>2019-06-17T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2017-05-17T00:00:00Z</DateStart><Identifiers><Identifier>2016-003937-62</Identifier><Identifier>CLR_16_23</Identifier><Identifier>NCT02980692</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tildrakizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>a low and comparable rate of adverse events to placebo. In 2.2 and 2.5% of subjects treated with SUNPG-1623 and placebo reported serious treatment-emergent adverse events, respectively. No subject discontinued treatment due to serious TEAEs. Common &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis), upper respiratory tract infection, and headache were the most commonly adverse events through week 24. No subject reported candidiasis, inflammatory bowel disease, major adverse cardiac events, malignancy, or deaths [ 2163039 ]. </Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Psoriatic arthritis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of SUNPG-1623</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2019-03-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>27</NumberOfSites><ContactNames><Name>Philip J. Mease, MD, MACR</Name><Name>Shravanti Bhowmik, MD</Name></ContactNames></Trial><Trial Id="281109"><Indications><Indication>Cancer</Indication><Indication>Hematological disease</Indication></Indications><CompaniesSponsor><Company>Nohla Therapeutics Inc</Company></CompaniesSponsor><DateChangeLast>2017-10-04T00:00:00Z</DateChangeLast><Identifiers><Identifier>NLA-101</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NLA-101 alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this multicenter, randomized, open-label, phase IIb study was to study the efficacy of NLA-101 in patients receiving a cord blood transplant [ 1880148 ]. As of October 2017, this study was ongoing [ 1966749 ].</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A multicenter, randomized, open-label, phase IIb study of NLA-101 in patients receiving a cord blood transplant</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="279861"><Indications><Indication>Psoriatic arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>US</Country><Country>Czech Republic</Country><Country>Russian Federation</Country><Country>Hungary</Country><Country>Germany</Country><Country>Poland</Country></Countries><DateChangeLast>2019-06-11T00:00:00Z</DateChangeLast><DateEnd>2018-07-31T00:00:00Z</DateEnd><DateStart>2016-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2016-001103-23</Identifier><Identifier>BE ACTIVE</Identifier><Identifier>NCT02969525</Identifier><Identifier>PA0008</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Esophagitis</Indication><Indication>Liver disease</Indication><Indication>Neutropenia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>206</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results were presented. Bimekizumab was generally well-tolerated with no new safety signals. Compared to placebo, the common &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis) was the most frequently reported adverse event with bimekizumab [ 1993054 ]. In October 2018, results... Subjects with any current sign or symptom that may indicate an active infection (with the exception of the common &lt;b&gt;cold&lt;/b&gt;) or has had an infection requiring systemic antibiotics within 2 weeks of baseline/day 1 Subjects with a history of chronic</Teaser><TrialCategories><Category>Biological</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 20 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 50 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 70 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Skin Disease Activity - Psoriasis area and severity index (PASI)score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE ACTIVE: A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with History of Treatment - Subjects on DMARDs</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with History of Treatment - Subjects on stable medication</PatientSegment><PatientSegment>Psoriatic arthritis - Treatment Naive Subjects - Biologic-naive subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body surface area </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>42</NumberOfSites><ContactNames><Name>Clin Trial Reg &amp; Results Disclosure</Name><Name>Clin Trial Reg and Results Disclosure</Name><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="279172"><Indications><Indication>Ankylosing spondylitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>US</Country><Country>UK</Country><Country>Ukraine</Country><Country>Hungary</Country><Country>Canada</Country><Country>Czech Republic</Country><Country>Germany</Country><Country>Bulgaria</Country><Country>Spain</Country><Country>Russian Federation</Country><Country>Poland</Country></Countries><DateChangeLast>2019-06-18T00:00:00Z</DateChangeLast><DateEnd>2018-08-31T00:00:00Z</DateEnd><DateStart>2016-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2016-001102-42</Identifier><Identifier>AS0008</Identifier><Identifier>BE AGILE</Identifier><Identifier>NCT02963506</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Headache</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>303</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In December 2017, positive first results were presented. Bimekizumab was well-tolerated with no unexpected safety signs. Common &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis) was the most common adverse event observed [ 1991754 ]. In June 2018, week 12 results were...reactive arthritis Subjects with any current sign or symptom that may indicate an active infection (except for the common &lt;b&gt;cold&lt;/b&gt;) Subjects with a history of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Functional Disability/Physical Function - Bath ankylosing spondylitis functional index (BASFI)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Ankylosing spondylitis disease activity score (ASDAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 5/6</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS20</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS40</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (BASDAI criteria)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE AGILE: A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Active Ankylosing Spondylitis</PatientSegment><PatientSegment>Ankylosing spondylitis - Moderate Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Severe Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Anti-TNF therapy</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - DMARDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - NSAIDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Stable medication</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment><PatientSegment>Ankylosing spondylitis - Treatment Naive Subjects - Anti-TNF therapy naive subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17F</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>68</NumberOfSites><ContactNames><Name>Clin Trial Reg &amp; Results Disclosure</Name><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="277611"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Dermatological agent</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Innovation Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-30T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2016-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CTIX-PRU-005</Identifier><Identifier>NCT02949388</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>KM-133 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>199</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>keratoses that have been treated or excised with no evidence of recurrence in the past 12 weeks; cervical carcinoma in situ or non-invasive malignant colon polyps that have been removed Active systemic infections during the past 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to start of study treatment or any infection that reoccurs on a regular basis Past medical history of infection with HIV, hepatitis B or hepatitis C History of any allergic reaction to any formulation of abacavir Previous treatment with any </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Clinical Response - Assessment of erythema</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Body surface area (BSA%) involvement</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Change in size/area of skin lesion</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by itch severity scale(ISS)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of treatment satisfaction</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - EuroQol-5D (EQ-5D)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for phototherapy</PatientSegment><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for systemic therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>33</NumberOfSites></Trial><Trial Id="272069"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>PAREXEL International</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Japan</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Hungary</Country><Country>US</Country></Countries><DateChangeLast>2019-03-29T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2016-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2016-001891-31</Identifier><Identifier>BE ABLE 1</Identifier><Identifier>NCT02905006</Identifier><Identifier>PS0010</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>250</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>were presented. Favourable safety profile was observed without any new safety signals . Runny nose (nasopharyngitis) and common &lt;b&gt;cold&lt;/b&gt; (upper-respiratory tract infection) were the most common adverse events observed [ 1947282 ]. In February 2018, results...biological response modifier (limited to anti-tumor necrosis factor [TNF] or IL-12/23) for psoriatic arthritis or psoriasis prior to the baseline Subject has any current sign or symptom that may indicate an active infection (except for common &lt;b&gt;cold&lt;/b&gt;)</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE ABLE 1: Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17F</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Andrew Blauvelt</Name><Name>Clin Trial Reg &amp; Results Disclosure</Name><Name>Kim Pap</Name><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="25749"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pharmaxis Ltd</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>New Zealand</Country></Countries><DateChangeLast>2019-06-21T00:00:00Z</DateChangeLast><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>MANCOT</Identifier><Identifier>Study B 202</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mannitol (inhaled, CF), Pharmaxis/ Chiesi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>A double-blind, placebo-controlled, cross-over, phase IIb study to determine the effect of a twice-daily dose of Bronchitol on patients' quality of life [ 613835 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>MANCOT: A phase IIb study to evaluate the safety and efficacy of Bronchitol in the treatment of bronchiectasis in children and adults</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites></Trial><Trial Id="247261"><Indications><Indication>Acute decompensated heart failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Na+ K+ ATPase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Inotropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>CVie Therapeutics Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Lee's Pharmaceutical Holdings Limited</Company></CompaniesSponsor><Countries><Country>China</Country><Country>Italy</Country></Countries><DateChangeLast>2019-06-24T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-000540-26</Identifier><Identifier>CVIE2015002</Identifier><Identifier>CVT-CV-002</Identifier><Identifier>EudraCT 2013-000540-26</Identifier><Identifier>NCT02617446</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiac failure</Indication><Indication>Cardiovascular disease</Indication><Indication>Gastrointestinal disease</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>istaroxime alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>episode with dyspnea at rest or minimal exertion and need of intravenous diuretic therapy (&gt;/= 40 mg iv furosemide) Systolic blood pressure between 90 and 125 mmHg (limits included) without signs or symptoms of hypoperfusion including cardiogenic shock, &lt;b&gt;cold&lt;/b&gt; extremities and peripheral vasoconstriction, oliguria/anuria, signs of cerebral hypo perfusion such as confusion Left ventricular (LV) Ejection fraction (EF)&amp;lt;/= 40% measured by 2D-Echocardiography E/Ea ratio&gt; 10 BNP &gt;/= 350 pg/ml or NT-pro-BNP &gt;</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Assessment of left ventricular ejection fraction (LVEF)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Left ventricular end-systolic volume (LVESV)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Stroke volume index (SVI)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Markers - Cardiac isoform of TnT (cTnT)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Clinical Symptoms - Assessment of arrhythmia</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Electrocardiography (ECG) Findings</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma Drug Concentrations</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Transmitral Flow (TMF) Parameters - A-wave velocity</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Transmitral Flow (TMF) Parameters - E-wave velocity</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Transmitral Flow (TMF) Parameters - E-wave/A-wave velocity ratio (E/A ratio)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Transmitral Flow (TMF) Parameters - E/E' ratio [E/Em ratio] [E/EA ratio] [E/e ratio]</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Ventricular Structure/Dimension/Function - Left ventricular end-diastolic volume (LVEDV)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Cardiac failure - Hematological Assessments</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Hemodynamic parameter - unspecified</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure</TitleDisplay><PatientSegmentTerms><PatientSegment>Cardiac failure - Acute Decompensated Heart Failure (ADHF) Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>A-wave </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> E-wave </BiomarkerName><BiomarkerName> E/A </BiomarkerName><BiomarkerName> Left ventricle </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Stroke volume </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Troponin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Lee's Pharmaceutical Limited</Name><Name>Paola Minguzzi</Name><Name>Yuhui Zhang, MD</Name></ContactNames></Trial><Trial Id="222504"><Indications><Indication>Asthma</Indication><Indication>Rhinovirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action><Action>Virus uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Vaxart Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aviragen Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Georgia</Country><Country>Bulgaria</Country><Country>US</Country><Country>Czech Republic</Country><Country>Romania</Country><Country>Poland</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2014-001785-95</Identifier><Identifier>BTA798-203</Identifier><Identifier>NCT02367313</Identifier><Identifier>SPIRITUS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vapendavir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>455</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the safety of the patient or the validity of the study Use of &lt;b&gt;cold&lt;/b&gt; preparations, anti-cholinergics, nasal lavage preparations or sprays, or prescription or over-the-counter...within 3 days following the Screening Visit Upon presentation to the clinic with &lt;b&gt;cold&lt;/b&gt; symptoms, subjects will be required to be randomized and treated within 48 h...for randomization and study treatment: Patient presents to clinic reporting symptoms of a &lt;b&gt;cold&lt;/b&gt; (eg, hey can be randomized and dosed preferably within 24 h but up</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Wisconsin upper respiratory symptom survey (WURSS)</EndpointIndex><EndpointIndex>Asthma - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>SPIRITUS: A Phase II Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>59</NumberOfSites><ContactNames><Name>Anna Novotney-Barry</Name><Name>VP, Clinical Development</Name></ContactNames></Trial><Trial Id="220717"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Afferent Pharmaceuticals</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-01T00:00:00Z</DateChangeLast><DateEnd>2016-02-09T00:00:00Z</DateEnd><DateStart>2015-03-09T00:00:00Z</DateStart><Identifiers><Identifier>7264-010</Identifier><Identifier>AF219-010</Identifier><Identifier>NCT02349425</Identifier></Identifiers><IndicationsAdverse><Indication>Ageusia</Indication><Indication>Dysgeusia</Indication><Indication>Rhinitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>gefapixant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this randomized, double-blind, placebo-controlled, crossover, dose-escalation study was to evaluate the safety and efficacy of AF-219 in subjects with refractory chronic cough [ 1764926 ]. In July 2015, enrollment was completed [ 1676222 ]. This study was conducted at ten clinical sites in US [ 1764926 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Dose-Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough</TitleDisplay><PrimaryCompletionDate type="Actual">2016-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michael Kitt, MD</Name></ContactNames></Trial><Trial Id="194811"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Fungicide</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Inhalant formulation</Technology><Technology>Natural product</Technology><Technology>Oligosaccharide</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>European Eurostars Programme</Company><Company>Smerud Medical Research International AS</Company></CompaniesCollaborator><CompaniesSponsor><Company>AlgiPharma AS</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Sweden</Country><Country>UK</Country><Country>Denmark</Country><Country>Norway</Country></Countries><DateChangeLast>2018-11-16T00:00:00Z</DateChangeLast><DateEnd>2017-09-30T00:00:00Z</DateEnd><DateStart>2014-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-000844-13</Identifier><Identifier>ALGIPHARMA AS</Identifier><Identifier>NCT02157922</Identifier><Identifier>SMR-2984</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>OligoG CF-5/20 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this randomized, double-blind, placebo-controlled, multicenter, crossover, phase IIb study was to assess the efficacy and safety of Oligo-G as a dry powder formulation, in adult subjects with cystic fibrosis [ 1778642 ], [ 1890557 ]. The primary objective was to demonstrate efficacy of inhaled Oligo-G measured by FEV1, and supported by secondary endpoints including mucociliary clearance, rheology, microbiology and quality-of-life. The secondary objectives were: To demonstrate the safety</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment of mucociliary clearance</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase IIb Study of Oligo-G in Subjects With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cystic fibrosis transmembrane conductance regulator </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Lung clearance index </BiomarkerName><BiomarkerName> Mucociliary clearance </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> cough clearance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>21</NumberOfSites><ContactNames><Name>Project Manager</Name><Name>Tacjana Pressler, PhD MD</Name></ContactNames></Trial><Trial Id="174111"><Indications><Indication>Common cold</Indication></Indications><CompaniesCollaborator><Company>Shenzhen Bei Ke Lian Pharmaceutical Sci-Tech Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sichuan University</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-22T00:00:00Z</DateChangeLast><DateEnd>2015-04-01T00:00:00Z</DateEnd><DateStart>2014-04-01T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR-TRC-14004255</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gantong granules alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Patients who used drugs to treat the common &lt;b&gt;cold&lt;/b&gt;; 6.Body temperature &amp;gt; 38.5degC Pregnant or lactating women, or women who have birth plan Allergic constitution... Corresponding to the western medicine diagnostic criteria for the common &lt;b&gt;cold&lt;/b&gt; Corresponding to chinese medcine symptoms... The purpose of this study was to assess the efficacy and safety of Gantong granules in the treatment of common &lt;b&gt;cold&lt;/b&gt; (Wind-Heat Syndrome) [ 1674276 ].</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blinded and Placebo-controlled, Multicenter, Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Gantong Granules in the Treatment of Common Cold (Wind-Heat Syndrome)</TitleDisplay><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Mao Bing</Name></ContactNames></Trial><Trial Id="16602"><Indications><Indication>Cervix infection</Indication><Indication>Papillomavirus infection</Indication><Indication>Uterine cervix tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Protein recombinant</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company><Company>MedImmune LLC</Company></CompaniesSponsor><DateChangeLast>2017-07-12T00:00:00Z</DateChangeLast><DateEnd>2003-04-30T00:00:00Z</DateEnd><DateStart>2001-01-31T00:00:00Z</DateStart><Identifiers><Identifier>580299-001 (HPV-001)</Identifier><Identifier>580299/001</Identifier><Identifier>HPV-001</Identifier><Identifier>NCT00689741</Identifier></Identifiers><IndicationsAdverse><Indication>Central nervous system disease</Indication><Indication>Gastrointestinal disease</Indication><Indication>Musculoskeletal disease</Indication><Indication>Reproductive disorder</Indication><Indication>Respiratory disease</Indication><Indication>Skin appendage disease</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Cervarix alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1113</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>cervical cytology (Pap smear) test (other than a single prior report of ASCUS with a subsequent normal report) Treatment for cervical disease by ablative therapy (cryotherapy or laser ablation) or excisional therapy (laser cone biopsy, loop excision, &lt;b&gt;cold&lt;/b&gt;-knife conization) Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection A family history of congenital or hereditary immunodeficiency Major congenital defects or serious chronic</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of the Human Papillomavirus Associated Cancer</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Human Papillomavirus Infection - Assessment of frequency/incidence/persistence of human papillomavirus infection</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Human Papillomavirus Infection - Assessment of human papillomavirus titer</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Other Human Papillomavirus Associated Conditions</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Other Human Papillomavirus Associated Conditions - Assessment of frequency/incidence/persistence of human papillomavirus associated conditions</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Other Human Papillomavirus Associated Conditions - Assessment of the human papillomavirus associated other lesions</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Viral Load - HPV viral load</EndpointIndex><EndpointIndex>Papillomavirus infection - Incidence/Prevalence of HPV Infections/Diseases</EndpointIndex><EndpointIndex>Papillomavirus infection - Incidence/Prevalence of HPV Infections/Diseases - Incidence/prevalence of cervical intraepithelial neoplasia</EndpointIndex><EndpointIndex>Papillomavirus infection - Resolution/Progression of HPV Infections/Lesions - Resolution/progression of cervical lesions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy Study of HPV-16/18 Vaccine (GSK-580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women</TitleDisplay><PatientSegmentTerms><PatientSegment>Human Papillomavirus Vaccine - Subjects at risk of developing disease - Subjects with multiple sexual partners/unprotected sex</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects with Prior Other Vaccination</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2003-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="159062"><Indications><Indication>Cystic fibrosis</Indication></Indications><CompaniesCollaborator><Company>Universitat Duisburg Essen</Company><Company>Universitat Ulm</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Children's Hospital Tuebingen</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2017-07-10T00:00:00Z</DateChangeLast><DateEnd>2011-05-31T00:00:00Z</DateEnd><DateStart>2009-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-002673-13</Identifier><Identifier>APA-IIB</Identifier><Identifier>APA-IIb</Identifier><Identifier>NCT01309178</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Gastroenteritis</Indication><Indication>Headache</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Mannit alone</Intervention><Intervention>amitriptyline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>group. Sixty-eight AEs were observed in 30 out of 40 patients. Thirty-one AEs were related or possibly related to the medication. Xerostomia (82 versus 18%; p = 0.053), gastroenteritis (33 versus 67%; p = 0.11), headache (33 and 67%; p = 0.11), common &lt;b&gt;cold&lt;/b&gt; (65 versus 35%; p = 0.44) and tiredness (71 versus 29%; p = 0.28) were observed in amitriptyline and placebo groups, respectively. The effect was mostly transient. Because of the low-dose administered, none of the other typical adverse effects of amitriptyline</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of change from baseline in FVC</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of nasal lavage/epithelial cells /airway Inflammatory markers</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures - Assessment of microbiological/serological parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment by lung clearance index</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment of maximum expiratory flow (MEF)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Carbon monoxide diffusing capacity (DLCO)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum production/composition</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of complications - Assessment by episodes/number/frequency/rate of infection</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Laboratory/Diagnostic Measures - Inflammatory markers</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Pulmonary Function - Forced expiratory volume(FEV)</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>APA-IIb: Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with respiratory tract infections</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for treatment with Medications</PatientSegment><PatientSegment>Pneumonia - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2011-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Joachim Riethmueller, Dr</Name><Name>Joachim Riethmueller, Dr.</Name><Name>Jochen Mainz</Name><Name>Jochen Mainz, Dr.</Name><Name>Lutz Naehrlich</Name><Name>Lutz Naehrlich, Dr.</Name></ContactNames></Trial><Trial Id="156456"><Indications><Indication>Fibrosis</Indication><Indication>Inflammatory disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>AIDS Clinical Trials Group</Company></CompaniesSponsor><Countries><Country>Puerto Rico</Country><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2014-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ACTG A5317</Identifier><Identifier>NCT01928927</Identifier><Identifier>TRAFIC</Identifier><Identifier>UM1AI068636</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>telmisartan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>58</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main goal of this study was to see if a drug called telmisartan would decrease fibrosis (scarring) and inflammation (irritation) in participants who are infected with HIV and doing well on their HIV medications. The study was also being done to see what effects telmisartan has on other signs of disease and inflammation in the body, and to see whether participants who have HIV can take telmisartan safely and without side effects that make them want to stop the drug [ 2065664 ]. The co-primary</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Anthropometric Assessments</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of local/systemic reactions</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Hematological Assessments - Assessment of coagulation markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRAFIC: Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> Adiponectin </BiomarkerName><BiomarkerName> Antigen KI-67 </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> Collagen </BiomarkerName><BiomarkerName> Collagen alpha 1(I) chain </BiomarkerName><BiomarkerName> Collagen alpha-1(VI) chain </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> D-dimer </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Fibronectin </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> HLA-DR Antigens </BiomarkerName><BiomarkerName> High affinity immunoglobulin gamma Fc receptor I </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Hyaluronic acid </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Low affinity immunoglobulin gamma Fc region receptor III </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Lymph node </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14 </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Mothers against decapentaplegic homolog 3 </BiomarkerName><BiomarkerName> Presepsin </BiomarkerName><BiomarkerName> Procollagen type I carboxy terminal peptide </BiomarkerName><BiomarkerName> Scavenger receptor cysteine-rich type 1 protein M130 </BiomarkerName><BiomarkerName> Subcutaneous adipose tissue </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Tissue factor </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Transforming growth factor beta 1 </BiomarkerName><BiomarkerName> Transforming growth factor beta-2 </BiomarkerName><BiomarkerName> Transforming growth factor beta-3 </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Waist circumference </BiomarkerName><BiomarkerName> Waist to Hip Ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Jordan E. Lake, MD, MSc</Name><Name>Netanya Sandler, MD</Name></ContactNames></Trial><Trial Id="150104"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation solid oral</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Cerecor Inc</Company></CompaniesSponsor><DateChangeLast>2013-08-14T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>memantine hydrochloride (lozenge, cough), Cerecor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>83</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this phase IIb, 6-week, randomized, double-blind, placebo-controlled, multicenter study was to evaluate the efficacy of memantine hydrochloride (FP-01) to treat subjects with chronic cough [ 1463459 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase IIb, 6-week, randomized, double-blind, placebo-controlled, multicenter study of memantine hydrochloride (FP-01) to treat subjects with chronic cough</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="148234"><Indications><Indication>Herpesvirus infection</Indication></Indications><DateChangeLast>2014-03-26T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>aciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Trial enrolled 200 non-immunocompromised subjects, aged 18 to 75 years, with histories of recurrent &lt;b&gt;cold&lt;/b&gt; sore outbreaks (3 or more annually)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Device Enhanced Aciclovir For The Treatment of Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="146648"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>BA Research India Ltd</Company><Company>Norwich Clinical Research Associates Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Beech Tree Labs Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-08T00:00:00Z</DateChangeLast><DateEnd>2015-02-28T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>BTL - 2013-06-0161</Identifier><Identifier>HTR - 13-131178</Identifier><Identifier>NCT01902303</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BTL-TML-HSV alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>303</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Clinical history of recurrent &lt;b&gt;cold&lt;/b&gt; sores averaging two or more episodes per year UV exposure is known to cause a &lt;b&gt;cold&lt;/b&gt; sore outbreak... The purpose of this study was to determine if a new drug treatment was effective to block the development of a &lt;b&gt;cold&lt;/b&gt; sore lesion following Ultra Violet (UV) exposure [ 1680487 ], [ 2101776 ]. By July 2013, this phase IIb, 100-patient trial was</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Appearance</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Cold Sore Treatments on UV-Induced Cold Sores</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with HSV-1 infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>C. Fixler</Name><Name>Darcy Randolph</Name><Name>Elsie Kohoot</Name><Name>Gregory Chernish</Name><Name>Jeffrey Berg</Name><Name>Joelle Potrebka</Name><Name>John McMichael, PhD</Name><Name>John Murray</Name><Name>Kim Mitsch</Name><Name>Patricia Henderson</Name></ContactNames></Trial><Trial Id="118199"><Indications><Indication>Diabetic foot ulcer</Indication></Indications><CompaniesSponsor><Company>Dermatools Biotech GmbH</Company></CompaniesSponsor><Countries><Country>Lithuania</Country><Country>Germany</Country><Country>Latvia</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2010-05-21T00:00:00Z</DateStart><Identifiers><Identifier>2010-020437-12</Identifier><Identifier>DT-DP-D2b</Identifier></Identifiers><InterventionsControlDisplay><Intervention>isotonic sodium chloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>DermaPro alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser> considering adverse events, laboratory parameters and vital signs. To characterize the subjective symptoms using Visual Analog Scores (VAS) for pain, itching, and well-being. To evaluate the subjective clinical symptoms (prickling, heat sensation, &lt;b&gt;cold&lt;/b&gt; sensation, numbness, furry feeling, smell, exudation). To investigate the clinical efficacy of Dermapro concerning reduction of wound depth and wound volume during treatment. To investigate the clinical efficacy of DermaPro in terms of fractions of</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Wound Surface Area</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Wound related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DermaPro Versus Isotonic Sodium Chloride Solution in Patients with Diabetic Foot Ulcer</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Foot Diseases - Subjects with diabetic foot ulcers</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Peter Lucker</Name></ContactNames></Trial><Trial Id="115497"><Indications><Indication>Bladder cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer alkylating agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Gel formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>UroGen Pharma Ltd</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Switzerland</Country><Country>Israel</Country><Country>Spain</Country></Countries><DateChangeLast>2019-05-14T00:00:00Z</DateChangeLast><DateEnd>2017-06-30T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01803295</Identifier><Identifier>NMIBC TURBT HG</Identifier><Identifier>OPTIMA</Identifier><Identifier>TAS-4M-CS-0002-0</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mitomycin C (high-dose/sustained release intravesical formulation/RTGel, low grade non-muscle invasive bladder cancer), Urogen Pharma alone</Intervention><Intervention>TC-3 hydrogel plus mitomycin C (high-dose/sustained release intravesical formulation/RTGel, low grade non-muscle invasive bladder cancer), Urogen Pharma</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Carcinoma In Situ (CIS) 'High Grade' urine cytology which is conclusive for HG 'High Grade' tumor results in &lt;b&gt;cold&lt;/b&gt; cup biopsy Tumor located in prostatic urethra Previous systemic chemotherapy in the last two years or pelvic radiotherapy Pregnant or breastfeeding patient Previous treatment with BCG within the last 12 months The patient did not have at least 3 months</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence - Assessment of recurrence rate</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Assessment of tumor dimension</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OPTIMA: Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage I Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Alberto Lapini</Name><Name>Amnon Zisman</Name><Name>Fred Witjes</Name><Name>Fred Witjes, Prof</Name><Name>Ilan Leibovitch</Name><Name>Koby Stav</Name><Name>Stenzl</Name><Name>Stenzl, Prof.</Name><Name>Yuri Vinshtok</Name></ContactNames></Trial><Trial Id="97488"><Indications><Indication>Sepsis</Indication></Indications><CompaniesCollaborator><Company>Maulana Azad Medical College</Company><Company>Vardhman Mahavir Medical College &amp; Safdarjung Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>All India Institute of Medical Sciences</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CAPS</Identifier><Identifier>NCT01723501</Identifier><Identifier>NHKC-Chx2012</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chlorhexidine (0.25%) alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>infants. The secondary objectives were to compare following outcomes in this experiment: Culture-confirmed sepsis within the first week of life. Need for repeat hospital admissions within first 28 days of life. Mortality within first 28 days of life. &lt;b&gt;Cold&lt;/b&gt; stress/hypothermia at 0, 5, 15 and 30 min of intervention. Skin condition at 24 h of life. Colonization rates (subset). Serum levels of chlorhexidine (subset).</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Sepsis - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Sepsis - Assessment of Incidence of Sepsis/Bacteremia</EndpointIndex><EndpointIndex>Sepsis - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Sepsis - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Sepsis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Sepsis - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>CAPS: Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing &lt; 1500 g at Birth</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Subjects at Risk of Skin and Skin Structure Infections</PatientSegment><PatientSegment>Sepsis - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Vinod K Paul, MD, PhD</Name></ContactNames></Trial><Trial Id="95314"><Indications><Indication>Wound healing</Indication></Indications><CompaniesSponsor><Company>Ionmed Ltd</Company></CompaniesSponsor><Countries><Country>Israel</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2014-04-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>BW102</Identifier><Identifier>NCT01709240</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BioWeld1 system alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>was a novel medical device that consists of a Chitosan film and the BioWeld1 plasma ejecting device. The Chitosan film was intended to be applied to the skin incision, while the BioWeld1device was used for welding the Chitosan to the skin by means of &lt;b&gt;cold&lt;/b&gt; plasma technology.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Subjects at Risk of Skin and Skin Structure Infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Drorit Hochner-Celnikier, MD</Name></ContactNames></Trial><Trial Id="91198"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Liposome formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Suspension</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Pacira BioSciences Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-04-11T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>402-C-323</Identifier><Identifier>NCT01683071</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine (extended release/DepoFoam, postoperative pain), Pacira BioSciences/Nuance Biotech alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>278</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>primary unilateral TKA under general or spinal anesthesia American society of anesthesiology (ASA) physical status 1, 2, or 3 Able to demonstrate motor function by performing a 20 m walk, unassisted, and sensory function by exhibiting sensitivity to &lt;b&gt;cold&lt;/b&gt; Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain at Rest</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>30</NumberOfSites><ContactNames><Name>Amy Amman</Name><Name>Anna Brunson</Name><Name>Barbara Bowers</Name><Name>Bruce Davie</Name><Name>Dorinda Casavecchia</Name><Name>E. Dabezies</Name><Name>Elizabeth Clark</Name><Name>Erol Onel, MD</Name><Name>Jacques Chelly</Name><Name>John Bracken</Name><Name>Joy Bonde</Name><Name>Julie Clark</Name><Name>Keith Candiotti</Name><Name>Kenneth Deck</Name><Name>Liz Busby</Name><Name>Maria Antor</Name><Name>Richard Berkowitz</Name><Name>Ronak Desai</Name><Name>Sabry Ayad</Name><Name>Sanjib Adhikary</Name></ContactNames></Trial><Trial Id="86021"><Indications><Indication>Liver injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Ludwig-Maximilians University of Munich</Company><Company>University Hospital Munich</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2010-021333-31</Identifier><Identifier>NCT01564095</Identifier><Identifier>TOP</Identifier><Identifier>TOP2010-LMU</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tacrolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser> Recipient: Chronical terminal liver failure, age&gt; 18 years, first organ transplantation Donor: Donor age&gt; 65 years Macrovesicular steatosis&gt; 40% (macroscopy or biopsy) BMI&gt; 30 Sodium&gt; 165 mmol/l ICU stay and ventilation&gt; 7 days &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 13 h AST&gt; 99 U/l ALT&gt; 105 U/l Bilirubin&gt; 3 mg/dl (&gt; 51 micromol/l) Application of epinephrine</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions - Serum bilirubin assessment</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Serum Creatinine</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TOP: TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an Ex-Vivo Tacrolimus Perfusion</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Liver Transplant Recipients - Primary (first) liver transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Ali Hadian</Name><Name>Andreas Pascher</Name><Name>Frank Ulrich</Name><Name>Hans Schlitt</Name><Name>Karl-Walter Jauch</Name><Name>Marcus Scherer</Name><Name>Martin Angele</Name><Name>Michael Heise</Name><Name>Peter Neuhaus</Name><Name>Peter Schemmer</Name><Name>Sebastian Pratschke</Name><Name>Silvia Wagner</Name><Name>Silvio Nadalin</Name><Name>Thilo Schulte</Name><Name>Wolf Bechstein</Name></ContactNames></Trial><Trial Id="83960"><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Dermatological formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-08-31T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP185</Identifier><Identifier>NCT00860067</Identifier></Identifiers><InterventionsControlDisplay><Intervention>FluMist alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>FluMist Quadrivalent alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1800</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI-3250 ) produced antibody levels similar to those produced by the commercial vaccine, FluMist .</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Judith Falloon, M.D.</Name></ContactNames></Trial><Trial Id="81156"><Indications><Indication>Reperfusion injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Annexin A5 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-06-19T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>8597-CL-0201</Identifier><Identifier>NCT01442337</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dianexin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser> Female subject is pregnant or lactating Donor kidney is anticipated to have &amp;gt; 40 h of &lt;b&gt;cold&lt;/b&gt; ischemia time Donor is&amp;gt; 66 years of age Donor meets both DCD and ECD criteria Subject has previously received, or is receiving an organ transplant other...of &lt;b&gt;cold&lt;/b&gt; ischemia prior to transplantation Donor with terminal serum creatinine&amp;gt; 1.5 mg/dl and any &lt;b&gt;cold&lt;/b&gt; ischemic time up to exclusion limit Female subject is not pregnant and agrees to use an acceptable form of contraception throughout study Male</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - AUC (Area under the concentration curve) of drug/drug metabolites</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of half life of drug (t1/2)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Drug clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Time to maximum concentration (Tmax)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of dialysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Effect of ASP-8597 in Adult Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Non heart beating donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Expanded Criteria Donor (ECD) Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>19</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="81040"><Indications><Indication>Bladder tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF2 gene stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Nucleic acid metabolism modulator</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Adenovirus based gene therapy</Action><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Absorption enhancer</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Intravesical formulation</Technology><Technology>Liposome formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Virus recombinant</Technology><Technology>Weekly dosing</Technology></Technologies><CompaniesSponsor><Company>Cold Genesys Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateStart>2014-03-31T00:00:00Z</DateStart><Identifiers><Identifier>12154</Identifier><Identifier>BOND</Identifier><Identifier>NCT01438112</Identifier></Identifiers><IndicationsAdverse><Indication>Bladder disease</Indication><Indication>Lower back pain</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including gemcitabine , interferon , mitomycin C , valrubicin , valrubicin + mitomycin C + gemcitabine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>CG-0070 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>This integrated phase II/III, open-label, randomized and controlled study was designed to evaluate the safety and efficacy of CG-0070 in patients with non-muscle invasive bladder cancer who have failed BCG. It was hypothized that CG-0070 regimen might be used for patients who have failed current forms of treatment and are recommended for cystectomy.</Teaser><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of surgical rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BOND: Efficacy Study of Recombinant Adenovirus for Non-Muscle Invasive Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 2 Bladder Cancer (G2)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Resectable Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage I Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0a or non-invasive papillary carcinoma (Ta)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0is or carcinoma in situ (Tis)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease - Refractory to BCG therapy</PatientSegment><PatientSegment>Bladder cancer - Subjects with nontransitional cell Bladder cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>7</NumberOfSites><ContactNames><Name>Alex W Yeung, MBBS</Name><Name>Anna Alecci</Name><Name>Daniel Barocas</Name><Name>Gary Steinberg</Name><Name>Karim Chamie</Name><Name>Maxwell Meng</Name><Name>Nazy Zomorodian</Name><Name>Pamela Steele</Name></ContactNames></Trial><Trial Id="80757"><Indications><Indication>Gastrointestinal bleeding</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glutamine synthetase stimulator</Action><Action>Nuclear factor kappa B modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Nitrogen metabolism modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hospital Vall D'Hebron</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-20T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-017819-16</Identifier><Identifier>NCT01434108</Identifier><Identifier>OP_GIB</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MNK-6105 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective was to evaluate the effectiveness of the experimental drug ( OCR-002 ) to reduce plasma ammonia concentration at a dose that is safe and well tolerated. Ammonia usually rises significantly in the hours after gastrointestinal bleeding in patients with cirrhosis of the liver. This increase in the concentration of ammonia facilitates the development of hepatic encephalopathy. Secondary objectives of the trial was to evaluate the development of hepatic encephalopathy and bacterial</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of side-effects/complications</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Other Forms of Anemia - Subjects with anemia due to blood loss</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ammonia</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joan Genescà, MD</Name></ContactNames></Trial><Trial Id="74550"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>University of Cologne</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-01-24T00:00:00Z</DateChangeLast><DateEnd>2010-04-30T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2005-000295-41</Identifier><Identifier>NCT01291199</Identifier><Identifier>Ro-002/05</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vardenafil hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>57</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine whether vardenafil was effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon. The main objectives of the study were to evaluate the efficacy of vardenafil in comparison to placebo on the digital perfusion (laser flux Doppler) and the clinical symptoms (Raynaud Condition Score) of patients suffering from Raynauds disease. Secondary objectives of the trial was adverse events.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Safety and Tolerability - Assessment of adverse effects</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function - Assessment of blood flow</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Stephan Rosenkranz</Name></ContactNames></Trial><Trial Id="73607"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ophthalmological agent</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>FAES Farma SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Charite Universitaetsmedizin Berlin</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2010-019344-39</Identifier><Identifier>BUCUM</Identifier><Identifier>BUCUM 2010</Identifier><Identifier>NCT01271075</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bilastine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> 7, day 28, day 49, and day 70. Overall a maximum of 20 subjects with &lt;b&gt;cold&lt;/b&gt; contact urticaria will be enrolled....severe diseases, especially those affecting the immune system, except urticaria and &lt;b&gt;cold&lt;/b&gt; urticaria The presence of permanent gastrointestinal condition which ...placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with the antihistamine bilastine in patients with &lt;b&gt;cold&lt;/b&gt; contact urticaria (CCU).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes - Assessment of critical stimulation time threshold(CSTT)after cold challenge</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes - Assessment of critical temperature threshold (CTT)after cold challenge</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BUCUM: Bilastine Updosing - Characterization of Underlying Mechanisms</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Histamine </BiomarkerName><BiomarkerName> Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-13 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marcus Maurer, MD</Name></ContactNames></Trial><Trial Id="69769"><Indications><Indication>Restless legs syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>MAO B inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiparkinsonian</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Virginia</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2012-08-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>14630</Identifier><Identifier>NCT01192503</Identifier><Identifier>RAS-RLS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rasagiline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>52</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>visit Use of antidepressants, including TCAs, SSRIs, and SNRIs, except for those permitted as listed above Use of other drugs or supplements contraindicated with rasagiline , including St. John's wort, mirtazapine, cyclobenzaprine, dextromethorphan, &lt;b&gt;cold&lt;/b&gt; products that contain ephedrine, pseudoephedrine Scheduled to undergo elective surgery during the course of the study Active medical or psychiatric illness that requires changes to treatment during the course of the study or jeopardize the subject'</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Fatigue</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Psychiatric Symptoms - Assessment of mood symptoms</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of RLS Symptoms with Protocol Specified Scales - Assessment by International Restless Legs Study Group RLS rating scale</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep - Assessment by Medical Outcomes Study Sleep Scale [MOS-SS]</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep - Assessment of day-time sleepiness</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep - Assessment of sleep quality</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of adverse events</EndpointIndex><EndpointIndex>Restless legs syndrome - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Restless legs syndrome - Patient Reported Outcomes/Quality of Life Assessments - Assessment by RLS Quality of Life Questionnaire (RLSQoL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RAS-RLS: Safety and Efficacy of Rasagiline in Restless Legs Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Restless legs syndrome - Subjects with Moderate to Severe Restless Legs Syndrome</PatientSegment><PatientSegment>Restless legs syndrome - Subjects with Idiopathic Restless Legs Syndrome</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Bernad Ravina, MD. MSCE</Name><Name>Tiffini S Voss, MD</Name></ContactNames></Trial><Trial Id="66863"><Indications><Indication>Cocaine addiction</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estradiol 17 beta dehydrogenase stimulator</Action><Action>Glucocorticoid receptor antagonist</Action><Action>Progesterone receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>New York State Psychiatric Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-21T00:00:00Z</DateChangeLast><DateEnd>2018-02-14T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>6013</Identifier><Identifier>NCT01134198</Identifier><Identifier>RU486 for Cocaine Dependence</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mifepristone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>58</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>insufficiency, or the presence of low pottasium (&amp;lt; 3.5 mEq/l). spot AM cortisol &amp;lt; 5 microg/dl, PM cortisol &amp;lt; 3 microg/dl Participants who cannot comply with study procedures during the initial hospitalization phase Supplemental exclusion criteria for &lt;b&gt;cold&lt;/b&gt; pressor test (CPT): history of frostbite, open cut or sore on foot to be immersed, history of Raynaud's phenomenon. During the testing, if sBP &gt; 190 or dBP &gt; 120, or HR &gt; 160, the test will be interrupted. A second occurrence of these values will stop</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Investigation of Mifepristone (RU-486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients</TitleDisplay><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>92 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Wilfid N Raby</Name></ContactNames></Trial><Trial Id="6549"><Indications><Indication>Familial amyloid neuropathy</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Amyloid protein deposition inhibitor</Action><Action>TTR gene inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>Transthyretin modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>siRNA agent</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Oligonucleotide</Technology><Technology>Oral formulation</Technology><Technology>RNA technology</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>UK</Country><Country>US</Country><Country>France</Country><Country>Spain</Country><Country>Portugal</Country><Country>Argentina</Country><Country>Germany</Country><Country>Sweden</Country></Countries><DateChangeLast>2019-02-12T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>B3461020</Identifier><Identifier>FX-005</Identifier><Identifier>NCT00409175</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Diarrhea</Indication><Indication>Urinary tract infection</Indication><Indication>Vaginal infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>patisiran alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>tafamidis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>128</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>2016, pooled results were presented from three studies (NCT00409175, NCT00791492 and NCT00925002 ). There were no new safety issues or side effects of Fx-1006A were observed in the long-term evaluation of 71 patients. Urinary tract infections (28.2%); &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis, 25.4%); influenza (23.9%); diarrhea (22.5%); headache and pain in an extremity (both 19.7%); back pain (16.9%); upper respiratory tract infection (15.5%); depression and thermal burn (both 14.1%); upper abdominal pain, anxiety, death</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Norfolk Quality of Life Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with gene variants - TTR_HUMAN_rs28933979(A)</PatientSegment><PatientSegment>Pain - Subjects with gene variants - TTR_HUMAN_rs28933979(C)</PatientSegment><PatientSegment>Pain - Subjects with gene variants - TTR_HUMAN_rs28933979(G)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Transthyretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Jeff Packman</Name><Name>Teresa Coelho</Name></ContactNames></Trial><Trial Id="51248"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-05-09T00:00:00Z</DateChangeLast><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-004443-40</Identifier><Identifier>CFAM810B2305</Identifier><Identifier>NCT00878072</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>famciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Outpatient males or females 12 to&amp;lt; 18 years of age General good health with a documented history typical for recurrent herpes labialis Prodromal symptoms or active lesions suggestive of a recurrent episode of herpes labialis (ie, having had &lt;b&gt;cold&lt;/b&gt; sores in the past) , with onset not exceeding 24 h until the time of study drug administration Adolescents participating in PK part of the study may be enrolled without an active herpes labialis recurrence or with onset of signs/symptoms of a recurrent</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-06-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>11</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="48508"><Indications><Indication>Colorectal tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Groupe Cooperateur Multidisciplinaire en Oncologie</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateStart>2004-01-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000453890</Identifier><Identifier>EU-20566</Identifier><Identifier>GERCOR-OPTIMOX2</Identifier><Identifier>GERCOR-OPTIMOX2-2003</Identifier><Identifier>GERCOR-OPTIMOX2-C02-2</Identifier><Identifier>NCT00274872</Identifier><Identifier>Optimox2 Study. C02-2</Identifier><Identifier>SANOFI-GERCOR-OPTIMOX2</Identifier></Identifiers><InterventionsControlDisplay><Intervention>fluorouracil plus leucovorin</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including fluorouracil , leucovorin , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> 6 months No other concurrent anticancer treatment No participation in another clinical trial with any investigational drug within 30 days prior to randomization No other concurrent investigational treatment No concurrent radiotherapy No concurrent &lt;b&gt;cold&lt;/b&gt; cap for prevention of alopecia or iced mouth rinses for prevention of stomatitis</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of tumor resectability</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT-General (FACT-G)</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT-Neurotoxicity (FACT-Ntx)</EndpointIndex><EndpointIndex>Colorectal tumor - Pharmacoeconomic Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Optimox2 Study. C02-2: Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>17</NumberOfSites><ContactNames><Name>Aimery Gramont</Name></ContactNames></Trial><Trial Id="4286"><Indications><Indication>Diabetic neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dihydropyrimidinase related protein 2 modulator</Action><Action>Sodium channel modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>UCB SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2008-07-31T00:00:00Z</DateEnd><DateStart>2004-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00235443</Identifier><Identifier>SP745</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lacosamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>451</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This phase II/III open-label trial was to assess the safety and tolerability of long-term treatment with lacosamide (SPM-927) in subjects with painful diabetic neuropathy. Approximately 525 subjects would be enrolled. To qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging in duration from 6 months to five years must have completed trial SP665 , SP742 , or SP768 and might benefit from long-term administration of lacosamide . Subjects would be titrated to</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Follow-On Trial to Assess the Long-Term Safety and Efficacy of SPM-927 in Painful Distal Diabetic Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>84</NumberOfSites><ContactNames><Name>UCB Call Center</Name></ContactNames></Trial><Trial Id="384977"><Indications><Indication>Cardiogenic shock</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenomedullin ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Cardioprotectant</Action><Action>Protectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesCollaborator><Company>University of Hamburg</Company></CompaniesCollaborator><CompaniesSponsor><Company>German Centre for Cardiovascular Research</Company><Company>Universitätsklinikum Hamburg-Eppendorf</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2020-06-30T00:00:00Z</DateEnd><DateStart>2019-04-04T00:00:00Z</DateStart><Identifiers><Identifier>ACCOST-HH</Identifier><Identifier>NCT03989531</Identifier><Identifier>UHHAMBURG-EPPENDORF</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard of care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>adrecizumab alone</Intervention><Intervention>standard of care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>pressure&amp;lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure &gt; 90 mmHg during systole Signs of left heart insufficiency and/ or pulmonary congestion Signs of impaired organ perfusion with at least one of the following: Altered mental status &lt;b&gt;Cold&lt;/b&gt;, clammy skin Urine output&amp;lt; 30 ml/h Serum lactate&gt;2mmol/l Age &gt; 18 years at time of screening Body weight&amp;lt; 150 kg at time of screening Females/Males who agree to comply with the applicable contraceptive requirements of the protocol</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes - Efficacy parameters</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ACCOST-HH: Adrecizumab in Cardiogenic Shock</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Coronary artery disease - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Carsten Skurk, MD</Name><Name>Dr. Mahir Karakas</Name><Name>Mahir Karakas, MD, MBA</Name><Name>Mirjam Kessler, MD</Name></ContactNames></Trial><Trial Id="382919"><Indications><Indication>Anxiety disorder</Indication><Indication>Parkinsons disease</Indication></Indications><CompaniesCollaborator><Company>The W. Garfield Weston Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of British Columbia</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-06-04T00:00:00Z</DateChangeLast><DateEnd>2020-12-01T00:00:00Z</DateEnd><DateStart>2019-09-01T00:00:00Z</DateStart><Identifiers><Identifier>H18-03083</Identifier><Identifier>NCT03968133</Identifier><Identifier>TAP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Ecologic BARRIER alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma An immune-compromised condition (eg, AIDS, lymphoma, patients undergoing long term corticosteroid treatment) A bleeding disorder Current illness (for example a &lt;b&gt;cold&lt;/b&gt; or flu like symptoms) and infections (for example hepatitis, HIV, gastroenteritis, fungal, or parasitic infections) Allergy to corn starch or corn Concurrent treatment for Parkinson disease with duodopa or deep brain stimulation (DBS)</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Becks Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Fatigue - Assessment by Fatigue Severity Scale (FSS)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Functional Disability/Physical Function - Assessment of motor symptoms</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Psychiatric Symptoms</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Anxiety disorder - Clinical Assessments</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Clinical Symptoms - Assessment of neuropsychiatric symptoms</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part I scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part II scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Fatigue - Assessment by Fatigue Severity Scale (FSS)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Motor Symptoms of Parkinson's Disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Neuropsychological Function - Assessment by Montreal Cognitive Assessment (MoCA)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Non-Motor Symptoms of Parkinson's Disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Parkinsons disease - Clinical Assessments</EndpointIndex><EndpointIndex>Parkinsons disease - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Parkinsons disease - Patient Reported Outcomes/Quality of Life Assessments - Parkinson's Disease Questionnaire (PDQ-39)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TAP: Treating Anxiety in Parkinson's Disease With a Multi‐Strain Probiotic</TitleDisplay><PatientSegmentTerms><PatientSegment>Parkinsons disease - Subjects with Early Stage Parkinson's Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-11-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Petra Uzelman, BSN</Name><Name>Silke Appel-Cresswell, MD</Name></ContactNames></Trial><Trial Id="37892"><Indications><Indication>Lung disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>University Hospital Tubingen</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2013-09-11T00:00:00Z</DateChangeLast><DateEnd>2006-07-31T00:00:00Z</DateEnd><DateStart>2003-08-31T00:00:00Z</DateStart><Identifiers><Identifier>LUFIT</Identifier><Identifier>NCT00204685</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>540</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this study is to determine whether inhalation of recombinant human deoxyribonuclease shortens ventilation time in mechanically ventilated adults.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Pneumonia - Requirement of Ventilatory Support/Intervention</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>35 Months</TrialDuration><NumberOfSites>25</NumberOfSites><ContactNames><Name>Joachim Riethmueller</Name></ContactNames></Trial><Trial Id="377009"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Parul institue of ayurveda</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-04-19T00:00:00Z</DateChangeLast><DateStart>2019-04-23T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2019/04/018536</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Sitopaladi lehya alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Abhay lehya alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> The aim of this study is to assess the ayurvedic medicine for treatment of common &lt;b&gt;cold&lt;/b&gt;.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Ayurvedic Medicine for Treatment of Common Cold</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Meghraj Golare</Name><Name>Rajanish meti</Name></ContactNames></Trial><Trial Id="375467"><Indications><Indication>Schizophrenia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 2D6 inhibitor</Action><Action>NMDA receptor antagonist</Action><Action>Opioid receptor sigma agonist 1</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Anticancer</Action><Action>Antipsychotic</Action><Action>Antitussive</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Avanir Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-08T00:00:00Z</DateChangeLast><DateEnd>2022-07-31T00:00:00Z</DateEnd><DateStart>2019-02-15T00:00:00Z</DateStart><Identifiers><Identifier>18-AVP-786-207</Identifier><Identifier>NCT03896945</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>deudextromethorphan hydrobromide + ultra-low dose quinidine sulfate (neurological/psychiatric disorders), Avanir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>370</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 , as compared with placebo, for the treatment of negative symptoms of schizophrenia.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Subjects with Negative Symptoms</PatientSegment><PatientSegment>Schizophrenia - Subjects with Positive Symptoms</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2022-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>16</NumberOfSites><ContactNames><Name>Nadine Knowles</Name><Name>Sophie Guillaume</Name></ContactNames></Trial><Trial Id="373568"><Indications><Indication>Surgical procedure</Indication></Indications><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><DateChangeLast>2019-03-26T00:00:00Z</DateChangeLast><DateEnd>2022-12-31T00:00:00Z</DateEnd><DateStart>2019-04-01T00:00:00Z</DateStart><Identifiers><Identifier>ASSUITULOTFALLAH</Identifier><Identifier>NCT03876067</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cardioplegic solutions alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cardioplegic solutions plus ozone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33. At this point, the hyper-oxygenated ozonated blood will be mixed with the &lt;b&gt;cold&lt;/b&gt; cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution. Arm 2: patients will receive &lt;b&gt;cold&lt;/b&gt; blood cardioplegia.</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Cardiac Markers</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Other cardiovascular disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other cardiovascular disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other cardiovascular disease - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Other cardiovascular disease - Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ejection fraction </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Troponin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Israa mohamed lotfallah</Name></ContactNames></Trial><Trial Id="369670"><Indications><Indication>Pityriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-10 receptor antagonist</Action><Action>IL-2 receptor antagonist</Action><Action>IL-4 receptor antagonist</Action><Action>Interferon gamma receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mast cell degranulation inhibitor</Action><Action>Topical antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>St Joseph University</Company></CompaniesSponsor><Countries><Country>Lebanon</Country></Countries><DateChangeLast>2019-02-13T00:00:00Z</DateChangeLast><DateEnd>2021-04-01T00:00:00Z</DateEnd><DateStart>2019-03-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03834935</Identifier><Identifier>USJDERM1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pimecrolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> study consists of two arms: Arm 1: patients will receive topical pimecrolimus 1% bid on the affected area for 9 weeks. Sunscreens will not be indicated, and hygienic habits will not be changed. Arm 2: patients will receive placebo (control group), &lt;b&gt;cold&lt;/b&gt; cream bid on the affected area for 9 weeks. Sunscreens will not be indicated, and hygienic habits will not be changed.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Clinical Response - Assessment of body surface area(BSA %) involvement</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Clinical Response - Assessment of pruritus</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Laboratory/Diagnostic Measures - Assessment by other imaging/photography</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Laboratory/Diagnostic Measures - Assessment of scar color/pigmentation/elasticity</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Lesion Count and Characteristics</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other dermatological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba</TitleDisplay><PatientSegmentTerms><PatientSegment>Other dermatological disease - Subjects with specific disease - Subjects with pityriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elio G Kechichian</Name><Name>Elio Kechichian</Name><Name>Josiane Helou</Name></ContactNames></Trial><Trial Id="367446"><Indications><Indication>Respiratory tract infection</Indication></Indications><CompaniesCollaborator><Company>Kantonsspital St Gallen</Company><Company>Lab Medical Center Dr. Risch AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Bioforce Ag Roggwil Tg</Company></CompaniesSponsor><Countries><Country>Switzerland</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2019-05-31T00:00:00Z</DateEnd><DateStart>2018-11-30T00:00:00Z</DateStart><Identifiers><Identifier>5'000'155</Identifier><Identifier>NCT03812900</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Echinacea purpurea alcoholic extract drops alone</Intervention><Intervention>Echinacea purpurea alcoholic extract tablet alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Echinacea purpurea alcoholic extract lozenges alone</Intervention><Intervention>Echinacea purpurea alcoholic extract spray alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>adults will be recruited, of which approximately 300 will develop a common &lt;b&gt;cold&lt;/b&gt; or a influenza-like infection. Two newly developed and two existing Echinacea formulations...preventatively screened and included in the study. If they show acute symptoms of a common &lt;b&gt;cold&lt;/b&gt; or ILI during the study period, they will be instructed to call the study center...pharmaceutical forms (tablets or drops; comparator groups) for the treatment of acute symptoms of the common &lt;b&gt;cold&lt;/b&gt; and/or influenza-like illness (ILI) in adults.</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Roland Schoop, MSc</Name><Name>Werner Albrich, MD</Name></ContactNames></Trial><Trial Id="365131"><Indications><Indication>Hypersensitivity</Indication></Indications><CompaniesCollaborator><Company>Kyung Hee University Hospital</Company><Company>Kyunghee University Medical Center</Company><Company>Sangji University Oriental Medical Center</Company><Company>Semyung University Affiliated Oriental Medical Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Gachon University Gil Oriental Medical Hospital</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2019-02-12T00:00:00Z</DateChangeLast><DateEnd>2020-05-14T00:00:00Z</DateEnd><DateStart>2018-12-11T00:00:00Z</DateStart><Identifiers><Identifier>ISEE_2018_UCHA</Identifier><Identifier>NCT03790033</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bosinji alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>164</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>no &lt;b&gt;cold&lt;/b&gt; Those who have the symptoms of extremely &lt;b&gt;cold&lt;/b&gt; hands in &lt;b&gt;cold&lt;/b&gt; temperature exposure Those who are on the return to a warmer environment, the symptoms of &lt;b&gt;cold&lt;/b&gt; hands is not completely rewarmed Those... The aim is to investigate the efficacy and safety of Ucha-Shinki-Hwan (Bosinji, Shinhwa Pharmaceutical company) on Korean patients with &lt;b&gt;cold&lt;/b&gt; hypersensitivity in the hands and feet.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet (UCHA)</TitleDisplay><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Chan Yong Jun</Name><Name>YOUME KO</Name><Name>Youme Ko</Name></ContactNames></Trial><Trial Id="35797"><Indications><Indication>Familial amyloid neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>Transthyretin modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Argentina</Country><Country>Germany</Country><Country>Brazil</Country><Country>Portugal</Country><Country>Sweden</Country></Countries><DateChangeLast>2016-08-10T00:00:00Z</DateChangeLast><DateEnd>2010-10-31T00:00:00Z</DateEnd><DateStart>2008-07-31T00:00:00Z</DateStart><Identifiers><Identifier>B3461021</Identifier><Identifier>FX-006</Identifier><Identifier>NCT00791492</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tafamidis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> pooled results were presented from three studies ( NCT00409175 , NCT00791492 and NCT00925002 ). There were no new safety issues or side effects of Fx-1006A were observed in the long-term evaluation of 71 patients. Urinary tract infections (28.2%); &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis, 25.4%); influenza (23.9%); diarrhea (22.5%); headache and pain in an extremity (both 19.7%); back pain (16.9%); upper respiratory tract infection (15.5%); depression and thermal burn (both 14.1%); upper abdominal pain, anxiety, death</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of nerve density</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Electrodiagnostic testing</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Central nervous system disease outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Norfolk Quality of Life Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>An Extension Of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients With Transthyretin Amyloid Polyneuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Transthyretin </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Jeff Packman</Name></ContactNames></Trial><Trial Id="355928"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Fungicide</Action><Action>Mucolytic agent</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Inhalant formulation</Technology><Technology>Natural product</Technology><Technology>Oligosaccharide</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Cystic Fibrosis Foundation Therapeutics Inc</Company><Company>European Cystic Fibrosis Society-Clinical Trial Network</Company><Company>Imperial College London</Company><Company>University Hospital of Cologne</Company></CompaniesCollaborator><CompaniesSponsor><Company>AlgiPharma AS</Company></CompaniesSponsor><Countries><Country>Europe</Country></Countries><DateChangeLast>2018-12-24T00:00:00Z</DateChangeLast><DateEnd>2021-06-30T00:00:00Z</DateEnd><DateStart>2019-03-31T00:00:00Z</DateStart><Identifiers><Identifier>3372</Identifier><Identifier>NCT03698448</Identifier><Identifier>SMR3372</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>OligoG CF-5/20 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this randomized, double-blind, placebo-controlled study was to evaluate inhaled oligosaccharide ( Oligo-G ) versus placebo in patients with cystic fibrosis. The study has two parts: Dose-finding part, followed by longer term follow-up (6 months) [ 2095241 ]. As of January 2018, around 120 patients would be included, from around 35 clinical sites mainly in Europe [ 2095241 ].</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment by lung clearance index</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum microbiology</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Dose-finding Study of Inhaled Oligo-G Versus Placebo in Patients With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with respiratory tract infections</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Lung clearance index</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Dr. Silke van Koningsburggen-Rietschel</Name><Name>Hilde Morris, DVM</Name></ContactNames></Trial><Trial Id="336197"><Indications><Indication>Prurigo nodularis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor kappa agonist</Action><Action>Opioid receptor mu antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Trevi Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>France</Country><Country>Europe</Country><Country>Germany</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2018-08-07T00:00:00Z</DateStart><Identifiers><Identifier>2018-001219-53</Identifier><Identifier>NCT03497975</Identifier><Identifier>PRISM</Identifier><Identifier>TR11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nalbuphine (oral extended release tablet, uremic pruritus/prurigo nodularis), Trevi Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this robust, pivotal, randomized, double-blinded, placebo-controlled, two-arm study with an open-label extension period following double-blind treatment study wasd to investigate the anti-pruritic efficacy and safety of nalbuphine ER (NAL ER) tablets in Prurigo Nodularis [ 2077032 ]. Main objective of the trial: To evaluate the effect of NAL ER on itch as assessed by the percentage of Responders (‘response' is defined as a &gt;/= 4-point reduction in the 7-day average Worst Itch-Numerical</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by patient benefit index(PBI)</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PRISM: Study-Pruritus Relief Through Itch Scratch Modulation</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Prurigo Nodularis</PatientSegment><PatientSegment>Pruritus - Subjects with Severe Pruritus</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Clinical Ops Lead</Name><Name>Vicki Duvall</Name></ContactNames></Trial><Trial Id="333917"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Shri Satya Sai Medical College and research institute</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-04-13T00:00:00Z</DateChangeLast><DateStart>2018-04-02T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/03/012834</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lignocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Patients will be randomized into two arms: Arm A: will receive 8 to 10 degrees celcius &lt;b&gt;cold&lt;/b&gt; lignocaine. Arm B: will receive room temperature lignocaine.... The aim of the present study is to assess the effects of precooling the injection site and administration of &lt;b&gt;cold&lt;/b&gt; 2% lignocaine HCl (8 to 10degreeC) in symptomatic irreversible pulpitis of maxillary molars and also to compare the pain on injection</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Assessing the effectiveness of cold local anesthesia in management of acute tooth pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ishwarya Gurucharan</Name><Name>Sekar Mahalaxmi</Name></ContactNames></Trial><Trial Id="328038"><Indications><Indication>Diabetes mellitus</Indication></Indications><CompaniesSponsor><Company>All India Institute of Ayurveda</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-02-11T00:00:00Z</DateChangeLast><DateStart>2018-02-04T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/01/011650</Identifier></Identifiers><InterventionsControlDisplay><Intervention>nishaa aamalki choorna alone</Intervention><Intervention>Variable regimens including aasthaapana basti , anuvaasana basti , triphala taila</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>nishaa aamalki choorna alone</Intervention><Intervention>triphalaa choorna alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>in body) Sayya aasana sawapansukhe ratischa (liking for comfort in lying, sitting, and sleeping) Sitapriyatavam (liking for &lt;b&gt;cold&lt;/b&gt;) Galtalu shosha (dryness of throat and palate) Karpaad daha (burning sensation of hands and feet) Dantadi maladhyadatva...sliminess and heaviness in the limbs) Chikannata deha (unctuouseness in the body) Avayayama (not doing exercise) Atikshuta (excessive hunger) Guru madhura sheeta snigdhoupyega (having heavy, sweet, &lt;b&gt;cold&lt;/b&gt; and oily food) Divasavpana (day sleep)&amp;nbsp;</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of waist to hip ratio</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist to hip ratio</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Obesity - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Obesity - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Diabetic treatment in ayurveda</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with specific disease - Subjects with Prediabetes/Impaired Glucose Tolerance</PatientSegment><PatientSegment>Obesity - Morbid Obesity(Class III) Subjects</PatientSegment><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/obese prediabetics subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Waist to Hip Ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Jitendra Gauttam</Name><Name>Dr Santoshkumar Bhatted</Name></ContactNames></Trial><Trial Id="322841"><Indications><Indication>Hypersensitivity</Indication></Indications><CompaniesCollaborator><Company>Kyung Hee University Gangdong Hospital</Company><Company>Kyunghee University Medical Center</Company><Company>Sangji University Oriental Medical Center</Company><Company>Semyung University second affiliated oriental medical hospital at Chungju</Company></CompaniesCollaborator><CompaniesSponsor><Company>Gachon University Gil Medical Center</Company><Company>Ministry of Health &amp; Welfare, Korea</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2019-02-13T00:00:00Z</DateChangeLast><DateEnd>2019-12-30T00:00:00Z</DateEnd><DateStart>2018-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ISEE_2017_SDT</Identifier><Identifier>KCT0002669</Identifier><Identifier>NCT03374345</Identifier><Identifier>SDT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Sipjeondaebo-tang granule alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>no &lt;b&gt;cold&lt;/b&gt; Those who have the symptoms of extremely &lt;b&gt;cold&lt;/b&gt; hands in &lt;b&gt;cold&lt;/b&gt; temperature exposure Those who are on the return to a warmer environment, the symptoms of &lt;b&gt;cold&lt;/b&gt; hands is not completely rewarmed Those... The aim of this study is to evaluate the efficacy and safety of Sipjeondaebo-tang on Korean patients with &lt;b&gt;cold&lt;/b&gt; hypersensitivity in the hands and feet.</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other immune disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Laboratory/Diagnostic Measures - Assessment of laboratory test abnormalities</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other immune disease - Hematological Assessments</EndpointIndex><EndpointIndex>Other immune disease - Neurological Assessments</EndpointIndex><EndpointIndex>Other immune disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other immune disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>SDT: Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other immune disease - Subjects with specific disease - Subjects with allergic conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Creatine </BiomarkerName><BiomarkerName> Gamma-glutamyltranspeptidase 1 </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Heasol Lee, MA</Name><Name>Jeon Chan Yong</Name><Name>Yeojin Kim, BA</Name><Name>Youme Ko, MA</Name></ContactNames></Trial><Trial Id="321352"><Indications><Indication>Allergy</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Shahrekord University of Medical Sciences and Health Services</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-12-06T00:00:00Z</DateChangeLast><DateStart>2012-06-21T00:00:00Z</DateStart><Identifiers><Identifier>1389-2-3</Identifier><Identifier>IRCT201206106252N2</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cetirizine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cetirizine plus coriander seed extract</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Patients will be randomized to receive either coriander seed extract by barij company 10 to 15 drops every day, tid, before the meal in a cup of &lt;b&gt;cold&lt;/b&gt; wateralong with cetirizine or cetirizine 5 mg po alone and nasoflow spray one puff in each nostril every 12 h. The both groups will be evaluated about their symptoms in the first day and after 3 and 7 days by means of a questionnaire.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The effect of coriander seed extract on respiratory allergic symptoms</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Soroush Amani</Name></ContactNames></Trial><Trial Id="319473"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Cairo University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2018-04-30T00:00:00Z</DateEnd><DateStart>2016-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CEBC-CU-2016-11-167</Identifier><Identifier>NCT03341260</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>diclofenac potassium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with active pain (moderate-to-severe) in mandibular molars Patients with prolonged response to &lt;b&gt;cold&lt;/b&gt; testing and electric pulp tester Patient with the ability to understand and use pain scales Patient with vital coronal pulp tissue on access Patient who accept to enroll to the study</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Pre-operative Diclofenac Potassium on Post-operative Endodontic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment><PatientSegment>Pain - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amatallah H Al-Rawhani, Pos</Name></ContactNames></Trial><Trial Id="317231"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Arak University of Medical Sciences and Health Services</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-04-24T00:00:00Z</DateChangeLast><DateStart>2007-04-21T00:00:00Z</DateStart><Identifiers><Identifier>1/27/1386</Identifier><Identifier>IRCT138903184056N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>zinc sulfate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>112</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Children between 1 to 7 years old diagnosed by a pediatrician as having common &lt;b&gt;cold&lt;/b&gt; based on symptoms Not receiving antibiotics... The aim of this study is to evaluate the efficacy of zinc sulfate in reducing the duration of &lt;b&gt;cold&lt;/b&gt; symptoms in children.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Health Economic Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Effectiveness of zinc sulfate in common cold symptoms in children</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Parsa Yousefi</Name></ContactNames></Trial><Trial Id="317030"><Indications><Indication>Abdominal pain</Indication><Indication>Gastroenteritis</Indication><Indication>Irritable bowel syndrome</Indication><Indication>Psychiatric disorder</Indication></Indications><CompaniesCollaborator><Company>Morinaga Milk Industry Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universiti Sains Malaysia</Company></CompaniesSponsor><Countries><Country>Malaysia</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT03318614</Identifier><Identifier>USM/JEPEM/15040133</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bifidobacterium Infantis M-63 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This trial was designed to study whether Bifidobacterium infantis M-63 improves mental health in irritable bowel syndrome developed after a major flood disaster. The investigators speculated that small intestinal overgrowth (SIBO) is the fundamental basis for the increase in reported cases of acute gastroenteritis and abdominal complaints among flood victims. The investigators further speculated that administration of antibiotics or probiotics could reduce the abdominal symptoms after 3 months.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Irritable bowel syndrome - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Assessment of Clinical Symptoms - Assessment of abdominal pain/discomfort</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Clinical Assessments</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Patient Reported Outcomes/Quality of Life Assessments - Patient Diary</EndpointIndex><EndpointIndex>Irritable bowel syndrome - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster</TitleDisplay><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Yeong Yeh Lee, MD, PhD</Name></ContactNames></Trial><Trial Id="315400"><Indications><Indication>Common cold</Indication><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Shahid Beheshti University of Medical Sciences, Laser Application in Medical Sciences Research Center</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-10-15T00:00:00Z</DateChangeLast><DateStart>2013-08-03T00:00:00Z</DateStart><Identifiers><Identifier>400/8641</Identifier><Identifier>IRCT201307023436N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hydrocortisone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim is to evaluate wheather corticosteroid beneficial for pediatric patients with coryza undergoing anesthesia.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Is corton beneficial for pediatric patients with coryza undergoing anesthesia?</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Babak Gharaei</Name></ContactNames></Trial><Trial Id="315298"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable emulsion</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Babol University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-10-11T00:00:00Z</DateChangeLast><DateStart>2012-06-14T00:00:00Z</DateStart><Identifiers><Identifier>2159/30/ژ/پ</Identifier><Identifier>IRCT201209089874N2</Identifier></Identifiers><InterventionsControlDisplay><Intervention>propofol, AstraZeneca/Fresenius plus succynylcholine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including lidocaine , midazolam hydrochloride , propofol, AstraZeneca/Fresenius , remifentanil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Children with common &lt;b&gt;cold&lt;/b&gt; Cardiorespiratory disease Neuromuscular disease Difficult intubation Other systemic disease</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of tracheal intubation with propofol-remifentanil and propofol-succynylcholine in children 3 to 12 years</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Dr Freshteh Naziri</Name></ContactNames></Trial><Trial Id="315164"><Indications><Indication>General anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Zahedan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-10-10T00:00:00Z</DateChangeLast><DateStart>2013-05-22T00:00:00Z</DateStart><Identifiers><Identifier>91-932</Identifier><Identifier>IRCT2013010612035N1</Identifier></Identifiers><InterventionsControlDisplay><Intervention>succinylcholine plus thiopental</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>remifentanil plus thiopental</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Iranian pregnant female ASA class 1 and 2 Age 18 to 35 years old BMI 18.5 to 2 4.9 Without common &lt;b&gt;cold&lt;/b&gt; Elective cesarean</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Replacement of sux by remifentanil in intubation (GA) in cesarean</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hamed Abdollahi Murchekhort</Name><Name>Hamed Abdollahi Murchekhorti</Name></ContactNames></Trial><Trial Id="313835"><Indications><Indication>Obesity</Indication></Indications><CompaniesCollaborator><Company>Technical University of Munich</Company></CompaniesCollaborator><CompaniesSponsor><Company>Turku University Hospital</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2019-03-21T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2016-08-02T00:00:00Z</DateStart><Identifiers><Identifier>GUTBAT</Identifier><Identifier>NCT03290846</Identifier><Identifier>T153/2016</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>PET/CT alone</Intervention><Intervention>secretin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>23</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>controlled, &lt;b&gt;cold&lt;/b&gt; exposure. This will be done to investigate, whether patients have &lt;b&gt;cold&lt;/b&gt; activated brown adipose tissue. After this, patients will undergo two room temperature condition scans on different days, where patients will be single-blinded and randomised...performed blinded. Satiety score is analzed with SPSS. PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo &lt;b&gt;cold&lt;/b&gt; exposure PET scanning once.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>GUTBAT: Secretin Activates Human Brown Adipose Tissue</TitleDisplay><BiomarkerNames><BiomarkerName>Brown adipose tissue </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Secretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Pirjo R Nuutila, MD,PhD</Name></ContactNames></Trial><Trial Id="305076"><Indications><Indication>Hypothermia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Mashhad University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-31T00:00:00Z</DateChangeLast><DateStart>2015-06-17T00:00:00Z</DateStart><Identifiers><Identifier>IR.MUMS.fm.REC.135.55</Identifier><Identifier>IRCT201606144780N9</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>granisetron alone</Intervention><Intervention>magnesium sulfate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this trial is to compare the effects of magnesium sulfate and granisetron on prevention of shivering during spinal anesthesia in cesarean section.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>Comparison effects of magnesium sulfate and granisetron on prevention of shivering during spinal anesthesia in cesarean section</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ehsan Mahdavi</Name><Name>Mohammad Ali Alipour</Name></ContactNames></Trial><Trial Id="302705"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Biosimilar product</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>International Biotechnology Center Generium LLC</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2017-07-29T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2017-06-23T00:00:00Z</DateStart><Identifiers><Identifier>DRN-CFR-II/III</Identifier></Identifiers><InterventionsControlDisplay><Intervention>dornase alfa alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dornase alfa biosimilar, IBC Generium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>125</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This trial was a comparative study of the clinical efficacy and safety of Tigerase (GENERIUM, Russia) and Pulmozyme (F Hoffmann-La Roche Ltd, Switzerland) as part of the complex therapy of patients with cystic fibrosis.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TitleDisplay>An open, prospective, multicenter, randomized comparative study of the pharmacokinetics, clinical efficacy and safety of Tigerase (GENERIUM, Russia) and Pulmozyme (F.Hoffmann-La Roche Ltd, Switzerland) as part of the complex therapy of patients with cystic fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>18 Months</TrialDuration><NumberOfSites>17</NumberOfSites></Trial><Trial Id="300359"><Indications><Indication>Pain</Indication><Indication>Pulpitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Capsule formulation</Technology><Technology>Dermatological formulation</Technology><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic gel formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Patch formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation systemic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Cairo University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-04-30T00:00:00Z</DateEnd><DateStart>2016-10-31T00:00:00Z</DateStart><Identifiers><Identifier>CEBC-CU-2016-11-167</Identifier><Identifier>NCT03174860</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>diclofenac, Novartis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with active pain (moderate-to-severe) in mandibular molars Patients with prolonged response to &lt;b&gt;cold&lt;/b&gt; testing and electric pulp tester Patient with the ability to understand and use pain scales Patient with vital coronal pulp tissue on access Patient who accept to enroll to the study.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Pre-operative Diclofenac Potassium on Articaine Buccal Infitration Success</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amatallah H Al-Rawhani, Postgraduate</Name><Name>Dr. Suzan AW Amin, PhD</Name><Name>Shaima'a Gawdat, PhD</Name></ContactNames></Trial><Trial Id="299879"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AMP activated protein kinase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiglaucoma agent</Action><Action>Biguanide antidiabetic product</Action><Action>Hypoglycemic agent</Action><Action>Vitamin B12 agonist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Intramuscular formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Liaoning University of Traditional Chinese Medicine</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2017-05-01T00:00:00Z</DateEnd><DateStart>2014-07-21T00:00:00Z</DateStart><Identifiers><Identifier>20140721</Identifier><Identifier>NCT03167918</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Xuefuzhuyu decoction , calcium dobesilate , mecobalamin , metformin hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients who were diagnosed with type 2 diabetes mellitus according to the guidelines of the American Diabetes Association Had no history of smoking, pulmonary disease, &lt;b&gt;cold&lt;/b&gt;, or pulmonary infection within a 2 week period Were not diagnosed with hepatopathy, nephropathy, hyperuricemia, or gastrointestinal disease Were likely to have good compliance and were able to visit our hospital for periodic assessments.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Parallel Assignment</Term></TermsDesign><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pulmonary Function - Assessment of pulmonary function test</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vascular Indices or Parameters - Assessment of hemodynamic parameters</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of fat</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of postprandial glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>Lung Function in Patients With Early Type 2 Diabetes Mellitus</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial Resistance Index </BiomarkerName><BiomarkerName> Blood flow </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Carbon monoxide diffusing capacity </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Glutathione peroxidase </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Malondialdehyde </BiomarkerName><BiomarkerName> Maximal voluntary ventilation </BiomarkerName><BiomarkerName> Peak expiratory flow rate </BiomarkerName><BiomarkerName> Reactive oxygen species </BiomarkerName><BiomarkerName> Superoxide dismutases </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-04-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Xiao-lin Jiang</Name></ContactNames></Trial><Trial Id="299422"><Indications><Indication>Ischemic stroke</Indication></Indications><CompaniesSponsor><Company>Capital Medical University</Company></CompaniesSponsor><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2018-09-16T00:00:00Z</DateEnd><DateStart>2017-06-01T00:00:00Z</DateStart><Identifiers><Identifier>ET-EH</Identifier><Identifier>NCT03163459</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional mechanical thrombectomy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Mechanical thrombectomy alone</Intervention><Intervention>Selective brain cooling alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>stroke under the assistance of micro-guide wire, 50 ml &lt;b&gt;cold&lt;/b&gt; 0.9% saline (4degC) is infused into the ischemic territory at 10 ml/min through the microcatheter, thus allowing the &lt;b&gt;cold&lt;/b&gt; solution to infuse into the ischemic territory prior to reperfusion. After brain cooling procedure, patients will receive mechanical thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. After the recanalization, &lt;b&gt;cold&lt;/b&gt; 0.9% saline (4degC) will be infused into the ischemic</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stroke - Assessment of Cerebrovascular Events - Assessment of infarct lesion volume</EndpointIndex><EndpointIndex>Stroke - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Stroke - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Stroke - Assessment of Hemorrhagic Complications - Assessment of intracerebral hemorrhage (ICH)</EndpointIndex><EndpointIndex>Stroke - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Stroke - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stroke - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Stroke - Assessment of Thrombotic/Thromboembolic Events</EndpointIndex><EndpointIndex>Stroke - Assessment of Vascular Indices or Parameters</EndpointIndex><EndpointIndex>Stroke - Assessment of Vascular Indices or Parameters - Assessment of recanalization</EndpointIndex><EndpointIndex>Stroke - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Stroke - Assessment of complications</EndpointIndex><EndpointIndex>Stroke - Clinical Assessments</EndpointIndex><EndpointIndex>Stroke - Hematological Assessments</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments - Assessment by CT scan</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments - Assessment by Magnetic Resonance Imaging (MRI)</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments - Assessment by angiography</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by National Institute of Health Stroke Scale (NIHSS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Short-duration Selective Brain Cooling for Patients Undergoing Mechanical Thrombectomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Stroke - Post-stroke Subjects</PatientSegment><PatientSegment>Stroke - Subjects with Acute Stroke</PatientSegment><PatientSegment>Stroke - Subjects with Ischemic Stroke</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Hematocrit</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Chuanjie Wu, MD</Name><Name>Xunming Ji, MD</Name></ContactNames></Trial><Trial Id="299175"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Cairo University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2016-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CEBC-CU-2016-10-149</Identifier><Identifier>NCT03163420</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including diclofenac potassium (immediate-release, oral powder for solution), Novartis/Assertio/Tribute , epinephrine , mepivacaine hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Parker Visual Analog Scale (HP- VAS). After 15 min of the initial inferior alveolar nerve block (IANB) of 1.8 ml of 2% mepivacaine hydrochloride with 1:100000 epinephrine , the teeth will be examined using a &lt;b&gt;cold&lt;/b&gt; pulp sensitivity test; in case of lip numbness together with no or mild pain on &lt;b&gt;cold&lt;/b&gt;, the treatment will be initiated. During root canal treatment, no to mild pain response on Heft- Parker Visual Analog Scale (HP- VAS) will be considered success. In case of failure, supplemental anesthesia </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Diclofenac Potassium on IANB Efficacy in Symptomatic Irreversible Pulpitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Khaled M Ezzat, Professor</Name><Name>Suzan AW Amin, PhD</Name></ContactNames></Trial><Trial Id="297682"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication><Indication>Pulpitis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Film coating</Technology><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Cairo University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2016-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CEBD-CU-2015-5-145</Identifier><Identifier>NCT03146481</Identifier></Identifiers><InterventionsControlDisplay><Intervention>inferior alveolar nerve block alone</Intervention><Intervention>epinephrine plus mepivacaine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>inferior alveolar nerve block alone</Intervention><Intervention>Variable regimens including aceclofenac , epinephrine , mepivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>control group (taking a placebo tablet). Each tablet would be taken 1 h before starting treatment. After 15 min of the initial inferior alveolar nerve block (IANB) with 2% mepivacaine containing 100,000 epinephrine, the teeth would be examined using a &lt;b&gt;cold&lt;/b&gt; pulp sensitivity test; in case of no or mild pain, the treatment would be initiated otherwise, additional IANB will be administered. During root canal treatment, no to mild pain response would be considered success. In case of failure, supplemental</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pre-operative Aceclofenac on the Anesthetic Efficacy of IANB in Symptomatic Irreversible Pulpitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Nermeen A Abbas, Postgraduate</Name><Name>Shaimaa Gawdat, PhD</Name><Name>Suzan AW Amin, PhD</Name></ContactNames></Trial><Trial Id="296160"><Indications><Indication>Bleeding</Indication></Indications><CompaniesSponsor><Company>Shiraz University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-03-15T00:00:00Z</DateChangeLast><DateStart>2017-04-16T00:00:00Z</DateStart><Identifiers><Identifier>IR.SUMS.MED.REC.1394.31</Identifier><Identifier>IRCT2017041519470N56</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Ringer alone</Intervention><Intervention>voluven alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>during preparation of CPB. Vital signs will be recorded. After sternotomy and grafting, patient cannulation will be performed by the surgeon and the CPB device is connected. Aorta will be clamped and &lt;b&gt;cold&lt;/b&gt; blood cardioplegia solution with antigrad method will be injected. Cardioplegia solution will be &lt;b&gt;cold&lt;/b&gt; blood type and same in all patients. Simultaneously patient will be cooled to the 34 to 32degC. Distal graft anastomosis will be performed at the time of arrest and warming the patients begins. Patient</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The comparison of effect of voluven versus ringer solution in cardiopulmonary bypass prime on the postoperative bleeding and renal function in coronary artery bypass graft surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - Off pump coronary artery bypass grafting (CABG)</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - On pump coronary artery bypass grafting (CABG)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> International Normalized Ratio </BiomarkerName><BiomarkerName> Partial Thromboplastin Time </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alireza Sadeghi Gilavani</Name><Name>Elahe Alahyari</Name><Name>Elahe allahyari</Name><Name>Farzaneh Masihi</Name></ContactNames></Trial><Trial Id="293752"><Indications><Indication>Labor complication</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hamadan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-11-14T00:00:00Z</DateChangeLast><DateStart>2017-01-29T00:00:00Z</DateStart><Identifiers><Identifier>IR.UMSHA.REC.1395.348</Identifier><Identifier>IRCT201701168768N5</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca plus sufentanil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this randomized, double-blinded, placebo-controlled, one-center, phase II clinical study is to assess the analgesic effects and possible side-effects of two different doses of intrathecal bupivacaine added to sufentanil in women in the first stage of labor. Investigators will compare the analgesic effects and possible side-effects of different dosages of intrathecal bupivacaine (1 and 2 mg).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Pregnancy/Labor related outcomes</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Characterize timecourse of analgesia</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of different doses of bupivacaine in labor spinal analgesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mahshid Nikooseresht</Name><Name>Mahshid Nikooseresht M.D</Name></ContactNames></Trial><Trial Id="292843"><Indications><Indication>Hypothermia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Ahvaz Jundishapur University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-10T00:00:00Z</DateChangeLast><DateStart>2015-12-06T00:00:00Z</DateStart><Identifiers><Identifier>IR.AJUMS.REC.1394.498</Identifier><Identifier>IRCT2016040627258N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ketamine alone</Intervention><Intervention>ondansetron alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>117</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study is a prospective and randomized, double-blind clinical trial. The aim of this study is the comparision between prophylactic low dose ketamine and ondansetron for prevention of shivering after spinal anesthesia for elective cesarean section.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The effect of ketamine and ondansetron for prevention of shivering after surgery</TitleDisplay><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ahmad Reza Mohtadi</Name><Name>Mohammad Reza Gusheh</Name><Name>Nazli Arbabi</Name><Name>Sanaz Nazari</Name></ContactNames></Trial><Trial Id="292559"><Indications><Indication>Cardiac reperfusion injury</Indication></Indications><CompaniesSponsor><Company>Kermanshah University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-01-31T00:00:00Z</DateChangeLast><DateStart>2016-07-22T00:00:00Z</DateStart><Identifiers><Identifier>IRCT2016061428454N1</Identifier><Identifier>KUMS.REC.13940367</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>adenosine alone</Intervention><Intervention>hyperkalemic cardioplegic solution alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> After the heart-lung machine connected to the patient, &lt;b&gt;cold&lt;/b&gt; blood cardioplegia solution (4degC) injected into the aortic root anterograde (15 ml/kg). Arm 1: to immobilize the heart, hyperkalemic cardioplegic solution with adenosine 2 mM will... The aim of this trial is to study the effect of adenosine in &lt;b&gt;cold&lt;/b&gt; blood cardioplegia on cardiac function and ischemia-reperfusion</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Hemodynamic Measurements</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Vital Signs - Blood pressure assessment</EndpointIndex></EndpointIndex><TitleDisplay>The effect of adenosine in cardioplegic solution</TitleDisplay><PatientSegmentTerms><PatientSegment>Other cardiovascular disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Central venous pressure </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Troponin </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Atefeh Asadmobini</Name><Name>Dr Feridoun Sabzi</Name></ContactNames></Trial><Trial Id="291968"><Indications><Indication>Periodontitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Universidade Estadual Paulista (UNESP)</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2017-05-15T00:00:00Z</DateStart><Identifiers><Identifier>HMT+OFD CFA</Identifier><Identifier>NCT03093207</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omega-3 polyunsaturated fatty acids alone</Intervention><Intervention>open flap debridement alone</Intervention><Intervention>Variable regimens including aspirin , chlorhexidine digluconate , dipyrone sodium , epinephrine , mepivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>34</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Johnsons do Brasil SA, Sao Jose dos Campos - SP). Postoperative patients will receive the following postoperative recommendations: do not drink alcoholic beverages; do not touch the surgical wound; do not brush and floss area for 7 days; ingest only &lt;b&gt;cold&lt;/b&gt; liquid (ice cream, yogurt, juices and gelatin) in the first 24 h; mouthwash with 0.12% chlorhexidine digluconate (Periogard) every 12 h for 14 days. Dipyrone sodium 500 mg every 4 h will be prescribed in case of pain. The sutures will be removed after</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments - Assessment of probing pocket depth</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Periodontitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 2 </BiomarkerName><BiomarkerName> C-C motif chemokine 3 </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cássia F Araujo, DDS, MS</Name><Name>Mauro Santamaria, Professor</Name></ContactNames></Trial><Trial Id="291256"><Indications><Indication>Cough</Indication></Indications><CompaniesSponsor><Company>Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-03-22T00:00:00Z</DateChangeLast><DateStart>2017-03-14T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2017/03/008094</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pippali churna alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This study is a single-armed observational clinical trial to study the naimittika rasayana effect of pippali churna in kaphaja kasa (recurrent wet cough) in children of the age group 3 to 7 years.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Pippali churna in prevention of recurrent wet cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arm circumference </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Chest circumference </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Head circumference </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Bahuraj Pundalik Janagond</Name><Name>Dr Reena Kulkarni MD AYU PhD</Name></ContactNames></Trial><Trial Id="28848"><Indications><Indication>Pain</Indication><Indication>Pancreatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company><Company>Radboud University</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aalborg Hospital</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Denmark</Country></Countries><DateChangeLast>2018-07-17T00:00:00Z</DateChangeLast><DateEnd>2010-05-31T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>A0081172/8967</Identifier><Identifier>CPP</Identifier><Identifier>NCT00755573</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>64</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>dermatome T4 compared to placebo group (83 versus −48; p = 0.004, respectively). The difference (change) in &lt;b&gt;cold&lt;/b&gt; pressor task latency and conditioned pain modulation (CPM) response was not significantly different between the study groups [ 1330097 ]. Following...were similar between groups. No statistically significant difference was observed between pregabalin vesus placebo groups for tolerance of &lt;b&gt;cold&lt;/b&gt; pressor task (46 versus 42 s, respectively). Also no significant difference could be found between groups</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC- QLQ</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CPP: Pain and Chronic Pancreatitis - Clinical End Experimental Studies</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with abdominal pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Asbjørn M Drewes, MD, PhD</Name></ContactNames></Trial><Trial Id="287841"><Indications><Indication>Hypotension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2019-09-30T00:00:00Z</DateEnd><DateStart>2017-02-07T00:00:00Z</DateStart><Identifiers><Identifier>NCT03047109</Identifier><Identifier>Phenylephrine Hypotension</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Ringer's lactate solution alone</Intervention><Intervention>ephedrine alone</Intervention><Intervention>phenylephrine alone</Intervention><Intervention>bupivacaine, AstraZeneca plus morphine sulfate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> all participants for anesthesia. Immediately after end of injection of drugs intrathecally, the participant will be placed in the supine position with left uterine displacement. Sensory block will be assessed using loss of sensation in response to &lt;b&gt;cold&lt;/b&gt; sensation using piece of ice along midclavicular line bilaterally every 2 min until reach the level of T5 dermatome. A third monitoring reading of the vital data, maternal non-invasive cardiac output and uterine blood flow will be taken 15 min after</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gynecological disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Ephedrine and Phenylephrine for Spinal Hypotension</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gynecological disorder - Others - Pregnant subjects</PatientSegment><PatientSegment>Other gynecological disorder - Women giving birth/Obstetrics</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial Resistance Index </BiomarkerName><BiomarkerName> Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Cardiac Index </BiomarkerName><BiomarkerName> Cardiac Output </BiomarkerName><BiomarkerName> Ejection fraction </BiomarkerName><BiomarkerName> End diastolic velocity </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Peak systolic velocity </BiomarkerName><BiomarkerName> Pulsatility index </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Stroke volume </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Umbilical artery blood flow </BiomarkerName><BiomarkerName> Umbilical artery pH </BiomarkerName><BiomarkerName> Uterine artery blood flow </BiomarkerName><BiomarkerName> Vascular resistance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>HAMDY A YOUSSEF, MD</Name><Name>HAMDY A. YOUSSEF, MD</Name><Name>MOHAMED F MOSTAFA, ND</Name><Name>MOHAMED F. MOSTAFA</Name><Name>MOHAMED F. MOSTAFA, MD</Name></ContactNames></Trial><Trial Id="285317"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2018-09-30T00:00:00Z</DateEnd><DateStart>2017-01-31T00:00:00Z</DateStart><Identifiers><Identifier>BIER BLOCK</Identifier><Identifier>NCT03021772</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including dexamethasone , lidocaine , midazolam hydrochloride , paracetamol</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including lidocaine , midazolam hydrochloride , neostigmine , paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>motor function (0: normal motor function, 1: reduced motor strength but able to move fingers, 2: complete motor block). Sensation: sensory block (four nerves) was assessed by ice packs using a 3-point scale: 0: normal sensation, 1: loss of sensation of &lt;b&gt;cold&lt;/b&gt; (analgesia), 2: loss of sensation of touch (anesthesia). The standard value of visual analog scale would be set as the score during passive exercise before the surgery. Introperative data: Basic monitoring: heart rate (HR), non-invasive blood pressure</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Morbidity - Assessment of block-related complications</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Neurological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>HAMDY A. YOUSSEF, MD</Name><Name>MOHAMED F. MOSTAFA</Name></ContactNames></Trial><Trial Id="274495"><Indications><Indication>Fatigue</Indication></Indications><CompaniesSponsor><Company>University of Tehran</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-01-29T00:00:00Z</DateChangeLast><DateStart>2010-06-07T00:00:00Z</DateStart><Identifiers><Identifier>20</Identifier><Identifier>IRCT201110127754N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>selenium selenite alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>8</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Having three to four years of exercise experience The absence of any disease in the past month such as to &lt;b&gt;cold&lt;/b&gt; Respiratory infection Hungarian and fever The subjects hadn't ingested any type of sport or vitamin-mineral supplements</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Sport Nutrition</TitleDisplay><BiomarkerNames><BiomarkerName>Hydrocortisone </BiomarkerName><BiomarkerName> Malondialdehyde </BiomarkerName><BiomarkerName> Testosterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Leila Shafiei Neek</Name></ContactNames></Trial><Trial Id="272222"><Indications><Indication>Spinal muscular atrophy</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Neuroprotectant</Action><Action>SMN2 gene modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>PTC Therapeutics Inc</Company><Company>SMA Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Chugai Pharmaceutical Co Ltd</Company><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Serbia</Country><Country>Russian Federation</Country><Country>Germany</Country><Country>Turkey</Country><Country>China</Country><Country>Spain</Country><Country>Switzerland</Country><Country>Brazil</Country><Country>France</Country><Country>US</Country><Country>Poland</Country><Country>Japan</Country><Country>Australia</Country><Country>Croatia</Country><Country>Italy</Country><Country>UK</Country><Country>Belgium</Country><Country>Canada</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2023-09-02T00:00:00Z</DateEnd><DateStart>2016-10-20T00:00:00Z</DateStart><Identifiers><Identifier>2016-000750-35</Identifier><Identifier>BP39055</Identifier><Identifier>JapicCTI-173722</Identifier><Identifier>NCT02908685</Identifier><Identifier>P/284/2017</Identifier><Identifier>SUNFISH</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Nausea</Indication><Indication>Pain</Indication><Indication>Pneumonia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>risdiplam alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>231</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>related to the drug [ 2081347 ]. In May 2019, further results from part 1 of the study were presented. Fever (pyrexia; 41%), cough (33%), vomiting (29%), upper respiratory tract infections (26%), persistent sore throat (oropharyngeal pain; 22%) and &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis; 20%) were the most commonly reported adverse events. Pneumonia was the most common serious adverse event reported in 2/51 (4%) patients. There were no drug-related ophthalmological findings [ 2148413 ], [ 2148661 ], [ 2149928 ], [</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>SUNFISH: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO-7034067 in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with Spinal Muscular Atrophy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Maximal expiratory pressure </BiomarkerName><BiomarkerName> Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Peak cough flow </BiomarkerName><BiomarkerName> Sniff nasal inspiratory pressure </BiomarkerName><BiomarkerName> Survival motor neuron protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>82 Months</TrialDuration><NumberOfSites>56</NumberOfSites><ContactNames><Name>Chugai Pharmaceutical Co., Ltd.</Name><Name>Clinical Trials</Name><Name>Hoffmann-La Roche</Name><Name>Stuart W. Peltz</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="268517"><Indications><Indication>Oral mucositis</Indication></Indications><CompaniesCollaborator><Company>Kyung Hee University</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ministry of Health &amp; Welfare, Korea</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2016-09-20T00:00:00Z</DateChangeLast><DateStart>2016-05-31T00:00:00Z</DateStart><Identifiers><Identifier>HANC</Identifier><Identifier>KCT0002022</Identifier><Identifier>KOMCIRB-150624-HR-022</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Yeoldahanso-tang alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to evaluate the effectiveness and safety of Yeoldahanso-tang on radiation-induced oral mucositis in head and neck cancer patients.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of radiation toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Cancer supportive care - Clinical Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-HN35</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Radiation Induced Toxicity - Assessment of radiation induced mucositis</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Renal Function</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 3 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-HN35</EndpointIndex><EndpointIndex>Head and neck tumor - Protocol Specified Other Endpoints - Assessment of hematological status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HANC: Therapeutic effectiveness of Yeoldahanso-tang on radiation induced oral mucositis in head and neck cancer patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Radiotherapy Related Adverse Events - Radiation induced mucositis</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Anti-Head and Neck Cancer Therapy Associated Toxicity</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Lee Junhee</Name></ContactNames></Trial><Trial Id="267614"><Indications><Indication>Adhesive capsulitis</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Arthritis Australia(AU)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Flinders University of South Australia</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-09T00:00:00Z</DateChangeLast><DateEnd>2018-02-01T00:00:00Z</DateEnd><DateStart>2016-01-01T00:00:00Z</DateStart><Identifiers><Identifier>359.15</Identifier><Identifier>ACTRN12615001378516</Identifier><Identifier>ANZCTR369776</Identifier><Identifier>U1111-1177-5644</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>supra-scapular nerve block alone</Intervention><Intervention>Variable regimens including bupivacaine, AstraZeneca , lidocaine , methylprednisolone , triamcinolone acetonide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Investigators hypothesize that the rate of recovery from frozen shoulder will be faster when current treatment and repeated supra-scapular nerve blocks are done together. The aim of this randomized, double-blind, placebo-controlled trial is to evaluate the benefit of adding supra-scapular nerve block to an evidence informed management regimen (intra-articular corticosteroid injection plus physiotherapy and oral analgesia as appropriate) for the adhesive capsulitis.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The efficacy of supra-scapular nerve block for the treatment of frozen shoulder: a randomized, controlled trial</TitleDisplay><BiomarkerNames><BiomarkerName>Shoulder motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>25 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Michael Shanahan</Name><Name>Tim Morris</Name></ContactNames></Trial><Trial Id="265149"><Indications><Indication>Cryoglobulinemia</Indication><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Gilead Sciences Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Mount Sinai School of Medicine</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-08-12T00:00:00Z</DateChangeLast><DateEnd>2018-02-28T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>GCO 15-2282</Identifier><Identifier>IN-US-337-1716</Identifier><Identifier>NCT02825212</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>with the dosing instructions for study drug administration and able to complete the study schedule of assessments. Note: definition of mixed cryoglobulinemia (patients must meet one of the five overlapping syndromes listed below and the presence of &lt;b&gt;cold&lt;/b&gt;-precipitable immune complexes in blood on two different occasions): Clinical evidence of cryoglobulinemia, overlapping syndromes: Cutaneous vasculitis (Raynaud's phenomenon, purpura, skin ulcers, livedo, acrocyanosis) Glomerulonephritis (hypertension</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Post Liver Transplantation Events - Viral clearance post transplantation</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Infections</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Others - Healthy Subjects</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with cirrhosis</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with hematological disorders</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Peter Gorevic, MD</Name><Name>Susana Seijo, MD-Spain</Name></ContactNames></Trial><Trial Id="25390"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Cytotoxic T-lymphocyte protein-4 modulator</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Protein fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Bristol-Myers Squibb Co</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-12T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2001-03-31T00:00:00Z</DateStart><Identifiers><Identifier>IM103-100</Identifier><Identifier>IM103-100 LTE</Identifier><Identifier>NCT00035555</Identifier></Identifiers><IndicationsAdverse><Indication>Cytomegalovirus infection</Indication><Indication>Diabetes mellitus</Indication><Indication>Infectious disease</Indication><Indication>Lymphoproliferative disease</Indication><Indication>Renal disease</Indication><Indication>Squamous cell carcinoma</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>belatacept alone</Intervention><Intervention>ciclosporin, Novartis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>230</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>receive a second or more renal transplant, those with a history of panel reactive antibody levels &gt; 20%, and those considered by investigators to be at relatively higher risk for acute rejection Human leukocyte antigen-identical donor-recipient pairs &lt;b&gt;Cold&lt;/b&gt; ischemia time &gt; 36 h (donor kidney) Participants who are positive for hepatitis C antibody, on polymerase chain reaction, for hepatitis B surface antigen, and for human immunodeficiency virus A positive purified protein derivative tuberculosis test</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Sub-clinical AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Allograft Nephropathy (CAN)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies - Post transplant lymphoproliferative disorder (PTLD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Non-high density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Very low density lipoprotein cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2004-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>136 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Bristol-Myers Squibb</Name></ContactNames></Trial><Trial Id="249900"><Indications><Indication>Surgical procedure</Indication></Indications><CompaniesSponsor><Company>Montreal General Hospital</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Thailand</Country></Countries><DateChangeLast>2017-03-24T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2016-01-31T00:00:00Z</DateStart><Identifiers><Identifier>MONTREALGH</Identifier><Identifier>NCT02629835</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This Multicentric trial was to compare intravenous (iv) or perineural (PN) dexamethasone for ultrasound-guided axillary brachial plexus blocks (AXBs). Research hypothesis is that PN modality will outlast its iv counterpart.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Intravenous and Perineural Dexamethasone for Ultrasound-guided Axillary Blocks</TitleDisplay><BiomarkerNames><BiomarkerName>Body height </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>De QH Tran, MD, FRCPC</Name></ContactNames></Trial><Trial Id="249434"><Indications><Indication>Fibromyalgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq</Company><Company>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</Company><Company>Fundaçao de Amparo a Pesquisa do Rio Grande do Sul</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital de Clinicas de Porto Alegre</Company></CompaniesSponsor><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-01-31T00:00:00Z</DateEnd><DateStart>2014-12-31T00:00:00Z</DateStart><Identifiers><Identifier>14-0624</Identifier><Identifier>NCT02639533</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>quality index), and resiliency. Then, a fingertapping task would be performed while assessing hemodynamic changes using fNIRS. After that, heat perception would be tested using quantitative sensory testing (QST) and conditioned pain modulation (CPM) with &lt;b&gt;cold&lt;/b&gt;. Also, the pain pressure threshold (PPT) using a digital algometer would be evaluated. Finally, cortical excitability parameters (motor evoked potentials, intracortical facilitation and inhibition, and cortical silent period) would be determined using</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Brain Response to Single Dose of Pregabalin in Fibromyalgia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with fibromyalgia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Brain-derived neurotrophic factor </BiomarkerName><BiomarkerName> Motor evoked potential </BiomarkerName><BiomarkerName> Oxyhemoglobins </BiomarkerName><BiomarkerName> Protein S100-B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Wolnei Caumo, MD, PhD</Name></ContactNames></Trial><Trial Id="248958"><Indications><Indication>Cardiogenic shock</Indication><Indication>Myocardial infarction</Indication></Indications><CompaniesSponsor><Company>China Medical University Hospital</Company></CompaniesSponsor><Countries><Country>Taiwan</Country></Countries><DateChangeLast>2016-11-24T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CMUH104-REC3-058</Identifier><Identifier>NCT02633358</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Therapeutic hypothermia alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Age between 40 to 80 years Acute myocardial infarction Cardiogenic sock including initially systolic blood pressure&amp;lt; 90 mmHg, cardiac index &amp;lt; 2.5 l/m2 and hypoperfusion signs including disturbance consciousness, &lt;b&gt;cold&lt;/b&gt; limbs, decreased urine output and so on</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Acute coronary syndrome - Protocol Specified Other Endpoints - Assessment of other inflammatory biomarkers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of interleukins</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Others - Healthy Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Coronary artery disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cheng-Chieh Lin, PhD</Name><Name>Da-Long Chen, Master</Name></ContactNames></Trial><Trial Id="238729"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Zahedan University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-22T00:00:00Z</DateChangeLast><DateStart>2015-05-22T00:00:00Z</DateStart><Identifiers><Identifier>7030</Identifier><Identifier>IRCT2015041421752N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Biolase diode laser alone</Intervention><Intervention>Laser off therapy alone</Intervention><Intervention>aciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>patients. Treatments will be performed by oral disease specialist. Medical examinations will be daily carried out using head light and a dental mirror. Evaluated parameters will include &lt;b&gt;cold&lt;/b&gt; sore size, amount...5 mm) as number 3. In addition, duration of &lt;b&gt;cold&lt;/b&gt; sore and the time required for its conversion to crust will be recorded. Amount of pain will be evaluated according...who consume medications during the study Patients who do not complete their treatment &lt;b&gt;Cold&lt;/b&gt; sore that have taken &amp;gt; 36 h to form and develop</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Herpesvirus infection - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Comparative Study of the Effect of Laser and Acyclovir on Herpes</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Mariyeh Honarmand</Name><Name>Mariyeh Honarmand</Name></ContactNames></Trial><Trial Id="238625"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Pharmasyntez</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2018-07-31T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2015-08-15T00:00:00Z</DateStart><Identifiers><Identifier>BZ-CF-2-01</Identifier></Identifiers><InterventionsControlDisplay><Intervention>dornase alfa alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dornase alpha conjugate with polysialic acid (Bronhozim), Pharmasyntez alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The aim of this study was to evaluate the efficacy and safety of Bronhozim (Pharmsynthez, Russia), applied once a day, compared with the drug Pulmozyme (Hoffman-La Roche, Switzerland) in patients with cystic fibrosis.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TitleDisplay>A multicenter, open-label, randomized, comparative, two group, two period study with cross-over design to study the efficacy and safety of Bronhozim (Pharmsynthez, Russia) in comparison with the drug Pulmozyme (Hoffman-La Roche, Switzerland) in patients with cystic fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>4</NumberOfSites></Trial><Trial Id="23675"><Indications><Indication>Cervical dysplasia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Intramuscular formulation</Technology></Technologies><CompaniesSponsor><Company>Eisai Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-11T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2005-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00264732</Identifier><Identifier>ZYC1-004</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amolimogene bepiplasmid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>251</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> a cervical cap or diaphragm during the study Not have been treated with any investigational agent within 30 days prior to randomization in this trial Not have had prior gene therapy Be willing to consent to an excisional procedure, such as LEEP or &lt;b&gt;cold&lt;/b&gt;-knife cone procedure, if indicated</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Remission</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Response Rates (RR) - Assessment of progressive disease</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Survival - Assessment of objective response (OR)</EndpointIndex><EndpointIndex>Papillomavirus infection - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Papillomavirus infection - Resolution/Progression of HPV Infections/Lesions</EndpointIndex><EndpointIndex>Papillomavirus infection - Resolution/Progression of HPV Infections/Lesions - Resolution/progression of cervical lesions</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Uterine cervix tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Uterine cervix tumor - Protocol Specified Other Endpoints - Assessment of Risk of Cervical Cancer</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Amolimogene (ZYC-101A) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix</TitleDisplay><PatientSegmentTerms><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions - Subjects with cervical cancer/cervical dysplasia</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions - Subjects with other human Papillomavirus(HPV) related cancers</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Pre-cancerous Lesions - Subjects with cervical intraepithelial neoplasia</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects at risk of developing disease</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Cervical Intraepithelial Neoplasia (CIN) - Subjects with CIN II/moderate to marked dysplasia</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Cervical Intraepithelial Neoplasia (CIN) - Subjects with CIN III/severe dysplasia to carcinoma in situ</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>26</NumberOfSites></Trial><Trial Id="234056"><Indications><Indication>Renal failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hemoglobin modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Blood substitute</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Protein conjugated</Technology></Technologies><CompaniesSponsor><Company>Prolong Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2016-08-31T00:00:00Z</DateEnd><DateStart>2015-08-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02490202</Identifier><Identifier>SGTP-002</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>PEG-bHb-CO (sickle cell anemia/leg ulcers), Prolong Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>renal failure initiated at least 3 months prior to transplantation Subject is to be the recipient of a first kidney transplant from a deceased donor (brain death criteria) Is able to receive intravenous infusions of study drug Anticipated donor organ &lt;b&gt;cold&lt;/b&gt; ischemia time&amp;lt;/= 30 h A calculated prediction of DGF risk of least 25% Females of childbearing potential must agree to use two forms of effective birth control regimen (at least one-barrier method) during the initial 30-day study period Male subjects</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urine (Urinalysis)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of dialysis</EndpointIndex><EndpointIndex>Kidney transplantation - Hematological Assessments</EndpointIndex><EndpointIndex>Kidney transplantation - Imaging/Radiological Assessments - Assessment by echocardiography</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Other Laboratory Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy And Safety Of Sanguinate For Reduction Of Delayed Graft Function In Patients Receiving A Kidney Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>20</NumberOfSites><ContactNames><Name>Hemant Misra, PhD</Name></ContactNames></Trial><Trial Id="233349"><Indications><Indication>Anesthesia</Indication></Indications><CompaniesSponsor><Company>Maharaj Nakorn Chiang Mai Hospital</Company></CompaniesSponsor><Countries><Country>Thailand</Country></Countries><DateChangeLast>2015-11-25T00:00:00Z</DateChangeLast><DateStart>2015-07-01T00:00:00Z</DateStart><Identifiers><Identifier>ID 05-58-22</Identifier><Identifier>TCTR20150624001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The purpose of this study is to compare intravenous and perineural dexamethasone for ultrasound-guided infraclavicular brachial plexus blocks (ICBs). As a precautionary measure, investigators will design the protocol as an equivalency trial and hypothesize that both routes result in similar durations.</Teaser><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Infraclavicular Blocks</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Prangmalee Leurcharusmee</Name><Name>Vanlapa Arnuntasupakul</Name></ContactNames></Trial><Trial Id="230491"><Indications><Indication>Topical anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Hopital Foch</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-05-20T00:00:00Z</DateChangeLast><DateEnd>2019-11-28T00:00:00Z</DateEnd><DateStart>2015-05-21T00:00:00Z</DateStart><Identifiers><Identifier>2013</Identifier><Identifier>2014-000571-50</Identifier><Identifier>2014/07</Identifier><Identifier>NCT02438657</Identifier><Identifier>VMAL</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dextrose alone</Intervention><Intervention>hydrodissection alone</Intervention><Intervention>epinephrine plus lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>52</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this study is to determine the minimum volume of local anesthetic ( lidocaine and epinephrine ) to achieve an ultrasound-guided median nerve block with a dextrose 5% hydrodissection approach.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>VMAL: Ultrasound-Guided Nerve Block: Determination of the Minimal Effective Volume of Local Anesthetic</TitleDisplay><PrimaryCompletionDate type="Actual">2018-11-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Eric Dufour, MD</Name></ContactNames></Trial><Trial Id="223719"><Indications><Indication>Soft tissue sarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Stimulator of interferon genes protein stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Dendritic cell stimulator</Action><Action>Immunostimulant</Action><Action>Radiosensitizer</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Immuno-oncology</Technology><Technology>Intratumoral formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>PharmaEngine Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Nanobiotix</Company></CompaniesSponsor><Countries><Country>Asia</Country><Country>Germany</Country><Country>Philippines</Country><Country>Hong Kong</Country><Country>Spain</Country><Country>Hungary</Country><Country>Poland</Country><Country>France</Country><Country>Norway</Country><Country>Italy</Country><Country>Belgium</Country><Country>South Africa</Country><Country>Europe</Country><Country>Romania</Country><Country>Australia</Country></Countries><DateChangeLast>2019-04-10T00:00:00Z</DateChangeLast><DateEnd>2020-04-30T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>Act.in.sarc</Identifier><Identifier>NBTXR3-301</Identifier><Identifier>NCT02379845</Identifier></Identifiers><InterventionsControlDisplay><Intervention>external beam radiation therapy (50 Gy) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>NBTXR-3 alone</Intervention><Intervention>external beam radiation therapy (50 Gy) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>156</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>, LTK, CD37 and CD22; and signaling pathway T-cell receptor like CD28, CTLA4, CD274, BTLA, TIGIT, CD40LG, CD5, CD3E and ZAP70. A specific adaptive immune pattern was observed after NBTXR-3 + RT treatment, which might contribute to the conversion of &lt;b&gt;cold&lt;/b&gt; tumor into hot tumor, and could be effectively combined with immunotherapeutic agents [ 1931880 ]. In September 2017, results were presented. NBTXR-3 combined with radiation therapy increased the average number of CD8 T cells in eight patient tumors</Teaser><TrialCategories><Category>Radiation therapy</Category><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Protocol Specified Other Endpoints - Assessment of Tumor Burden</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Act.in.sarc: NBTXR-3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall</TitleDisplay><PatientSegmentTerms><PatientSegment>Soft tissue sarcoma - Subjects with High Grade Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Intermediate Grade Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Locally Advanced Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Low Grade Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Relapsed/Recurrent Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Soft Tissue Sarcomas of the Extremities/Trunk</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Unresectable Soft Tissue Sarcoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>60S ribosomal protein L17 </BiomarkerName><BiomarkerName> Antigen peptide transporter 1 </BiomarkerName><BiomarkerName> B- and T-lymphocyte attenuator </BiomarkerName><BiomarkerName> B-cell receptor CD22 </BiomarkerName><BiomarkerName> CD40 ligand </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Cytotoxic T-lymphocyte protein 4 </BiomarkerName><BiomarkerName> Granzyme A </BiomarkerName><BiomarkerName> Integrin alpha-E </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interferon-alpha </BiomarkerName><BiomarkerName> Interleukin-11 </BiomarkerName><BiomarkerName> Interleukin-16 </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Leukocyte antigen CD37 </BiomarkerName><BiomarkerName> Leukocyte tyrosine kinase receptor </BiomarkerName><BiomarkerName> Programmed cell death 1 ligand 1 </BiomarkerName><BiomarkerName> Proto-oncogene tyrosine-protein kinase LCK </BiomarkerName><BiomarkerName> Signal transducer and activator of transcription 4 </BiomarkerName><BiomarkerName> T cell immunoreceptor with Ig and ITIM domains </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-box transcription factor TBX21 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD3 epsilon chain </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD5 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> T-cell-specific surface glycoprotein CD28 </BiomarkerName><BiomarkerName> TAP2 </BiomarkerName><BiomarkerName> Tumor mass </BiomarkerName><BiomarkerName> Tyrosine-protein kinase ZAP-70 </BiomarkerName><BiomarkerName> V(D)J recombination-activating protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>62 Months</TrialDuration><NumberOfSites>44</NumberOfSites><ContactNames><Name>Elsa BORGHI, MD</Name><Name>Mikaela DIMITRIU, PhD</Name><Name>Prof. Sylvia Bonvalot, MD, PhD</Name></ContactNames></Trial><Trial Id="221403"><Indications><Indication>Anesthesia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable emulsion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Ardabil University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-11T00:00:00Z</DateChangeLast><DateStart>2014-05-22T00:00:00Z</DateStart><Identifiers><Identifier>IRCT2014080715795N1</Identifier><Identifier>arums.rec.92.30</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>isoflurane alone</Intervention><Intervention>propofol, AstraZeneca/Fresenius alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Drug allergy Drug addiction Common &lt;b&gt;cold&lt;/b&gt; Heart disease, kidney disease and hypertension Patient dissatisfaction Sedative drugs</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of Inhalation Anesthesia by Isoflurane and Intravenous Anesthesia by Propofol for Laparoscopic Cholecystectomy Surgery</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Masood Entezariasl</Name></ContactNames></Trial><Trial Id="214281"><Indications><Indication>Restless legs syndrome</Indication></Indications><CompaniesCollaborator><Company>King Abdulaziz City For Science &amp; Technology</Company></CompaniesCollaborator><CompaniesSponsor><Company>King Abdulaziz University</Company></CompaniesSponsor><DateChangeLast>2018-01-24T00:00:00Z</DateChangeLast><DateStart>2015-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02256215</Identifier><Identifier>RLSD-1234</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vitamin D alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>106</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed Antinausea drugs (prochlorperazine or metoclopramide) Antipsychotic drugs (haloperidol or phenothiazine derivatives) Anti depressants (SSRIs) Antihistamines as in &lt;b&gt;cold&lt;/b&gt; and allergy medications Patients with current medications or conditions that would interfere with vitamin D absorption: Celiac disease Chron's disease Chronic pancreatitis Cystic fibrosis Weight-loss drug eg, orlistat Cholesterol-lowering drug eg, </Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of RLS Symptoms with Protocol Specified Scales - Assessment by International Restless Legs Study Group RLS rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Vitamin D in the Treatment of Primary Restless Legs Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Restless legs syndrome - Subjects with De-novo Diagnosis of Restless Legs Syndrome</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites></Trial><Trial Id="213456"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Tehran University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-04-04T00:00:00Z</DateChangeLast><DateStart>2014-09-23T00:00:00Z</DateStart><Identifiers><Identifier>112/130/د/93</Identifier><Identifier>112/130/د/93</Identifier><Identifier>IRCT2014090417837N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>13 G specific acupuncture alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>189</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This prospective, randomized, clinical study is aimed to compare the effect of acupuncture in preventing postoperative shivering in patients undergoing elective abdominal hysterectomy in the three groups.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The effect of acupuncture in preventing shivering after abdominal hysterectomy</TitleDisplay><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Mean arterial pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mahdiyeh Hosseinzadeh</Name><Name>Mahin Jaafari Javid MD.</Name><Name>Mahin Jafari Javid MD.</Name></ContactNames></Trial><Trial Id="211360"><Indications><Indication>Immune disorder</Indication><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Chonbuk National University Hospital</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2015-11-27T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2014-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CHE-PI-CM</Identifier><Identifier>NCT02244372</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cordyceps sinensis mycelium culture extract alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Males and females 20 to 80 years old Who had suffered more than twice upper respiratory infection, disorder or common &lt;b&gt;cold&lt;/b&gt; causing URI Able to give informed consent</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract (Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity</TitleDisplay><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-12 </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Eun-Soo Jung, MS</Name></ContactNames></Trial><Trial Id="20836"><Indications><Indication>Liver transplantation</Indication><Indication>Reperfusion injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hemoglobin modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Coagulation inhibitor</Action><Action>NO receptor agonist</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ikaria Inc (pre-2010)</Company><Company>University of Washington</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Alabama at Birmingham</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-14T00:00:00Z</DateChangeLast><DateEnd>2012-10-31T00:00:00Z</DateEnd><DateStart>2008-04-30T00:00:00Z</DateStart><Identifiers><Identifier>F070112003</Identifier><Identifier>NCT00582010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nitric oxide (inhaled), Ikaria alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> oxide and placebo as indicated by center specific analysis. No effect on SICU or hospital length of stay at either center was observed due to nitric oxide . No significant differences with or without Cox regression modeling and adjusting for MELD, &lt;b&gt;cold&lt;/b&gt; ischemic time, weight, BMI, WIT or donor age within each center or when combined were observed in Kaplan-Meier analysis. Complications were observed as 10 and 25% in nitric oxide and placebo groups, respectively, in Center A cohort; whereas in Center</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Liver transplantation - Pharmacoeconomic Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Subjects Awaiting Liver Transplantation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Ceruloplasmin </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Nitrate </BiomarkerName><BiomarkerName> Nitrite </BiomarkerName><BiomarkerName> Prothrombin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Blair Smith</Name><Name>Clark Cross</Name><Name>Devin Eckhoff</Name><Name>John Bynon</Name><Name>John D Lang, MD</Name><Name>Keith Jones</Name><Name>Luc Frenette</Name><Name>Rakesh Patel</Name></ContactNames></Trial><Trial Id="208294"><Indications><Indication>Autism</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>North Carolina Translational and Clinical Sciences Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Duke University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2016-07-31T00:00:00Z</DateEnd><DateStart>2015-08-31T00:00:00Z</DateStart><Identifiers><Identifier>14-1141</Identifier><Identifier>NCT02212275</Identifier><Identifier>Pro00065239</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dextromethorphan hydrobromide (sustained release) alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The investigators overarching aim was to obtain preliminary data to support a larger grant to validate a novel objective, physiologically-based outcome measure for clinical trials in autism spectrum disorders (ASDs) called the cortical metric. Investigators hypothesize that the brain's processing of vibration was similar to its processing of other kinds of information. Investigators also hypothesize that in children with ASD, adjacent groups of neurons work together less well to process information</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Autism - Assessment of Autism Symptoms by Protocol Specified Scales - Assessment by Aberrant Behavior Checklist</EndpointIndex><EndpointIndex>Autism - Assessment of Autism Symptoms by Protocol Specified Scales - Assessment by PDD Behaviour Inventory (PDDBI)</EndpointIndex><EndpointIndex>Autism - Assessment of Functional Disability/Physical Function - Assessment by Social Responsiveness Scale (SRS)</EndpointIndex><EndpointIndex>Autism - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Autism - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Cortical Metrics in Intervention Trials With Autism Spectrum Disorders</TitleDisplay><PatientSegmentTerms><PatientSegment>Autism - Subjects with Autistic Disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Linmarie Sikich, MD</Name></ContactNames></Trial><Trial Id="200504"><Indications><Indication>Osteoarthritis</Indication></Indications><CompaniesCollaborator><Company>Duke University</Company><Company>Duke-NUS Graduate Medical School</Company></CompaniesCollaborator><CompaniesSponsor><Company>Singapore General Hospital Pte Ltd</Company></CompaniesSponsor><Countries><Country>Singapore</Country></Countries><DateChangeLast>2019-01-23T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>COL-01</Identifier><Identifier>COLKOA</Identifier><Identifier>NCT02176460</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>colchicine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>109</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The investigators hypothesized that colchicine would block inflammasome mediated inflammation, thereby improve the signs and symptoms of osteoarthritis (OA), and reduce synovial fluid, serum and urine inflammatory and biochemical joint degradation biomarkers. The aims of the double-blinded, randomized, placebo-controlled study were: To determine whether daily oral colchicine at standard clinical doses (0.5 mg bid), compared to placebo, could decrease the pain of symptomatic OA knee and improve</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function - Assessment of physical function by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain - Assessment of Pain by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Osteoarthritis - Gene variants involved in outcome measures - CYP3A4_HUMAN_Mutation</EndpointIndex><EndpointIndex>Osteoarthritis - Gene variants involved in outcome measures - CYP3A5_HUMAN_Mutation</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Assessment Questionnaire (HAQ) score</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex><EndpointIndex>Osteoarthritis - Protocol Specified Other Endpoints - Assessment of other bio-marker</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COLKOA: Colchicine for Symptom and Inflammation in Knee Osteoarthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects with Osteoarthritis of Knee</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> C-terminal crosslinked telopeptide type II collagen </BiomarkerName><BiomarkerName> Caspase-1 </BiomarkerName><BiomarkerName> Cytochrome P450 3A4 </BiomarkerName><BiomarkerName> Cytochrome P450 3A5 </BiomarkerName><BiomarkerName> Diphosphoric acid </BiomarkerName><BiomarkerName> Glycosaminoglycans </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Matrix metalloproteinase 3/Tissue inhibitor of metalloproteinase 2 ratio </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14 </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Protein carbonyls </BiomarkerName><BiomarkerName> Scavenger receptor cysteine-rich type 1 protein M130 </BiomarkerName><BiomarkerName> Synovial fluid </BiomarkerName><BiomarkerName> Toll-like receptors </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Xanthine dehydrogenase/oxidase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Virginia Kraus, MD, PhD</Name><Name>Ying Y Leung, MBChB</Name></ContactNames></Trial><Trial Id="199544"><Indications><Indication>Prurigo nodularis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor kappa agonist</Action><Action>Opioid receptor mu antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Trevi Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Austria</Country><Country>Poland</Country><Country>US</Country></Countries><DateChangeLast>2018-11-24T00:00:00Z</DateChangeLast><DateEnd>2016-08-31T00:00:00Z</DateEnd><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-005627-17</Identifier><Identifier>NCT02174419</Identifier><Identifier>TR03</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nalbuphine (oral extended release tablet, uremic pruritus/prurigo nodularis), Trevi Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>63</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objectives of this multicenter, randomized, double-blind, placebo-controlled, parallel, three-arm study were to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch numerical rating scale (NRS) in patients with prurigo nodularis and to evaluate the safety and tolerability in the study population [ 1640550 ], [ 1807071 ]. The primary objectives of the study were: To evaluate the effects of two doses of nalbuphine HCl ER tablets on</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Verbal Rating Scale (VRS)</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Prurigo Nodularis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>17 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Clinical Trial Information</Name><Name>Thomas Sciascia, MD</Name></ContactNames></Trial><Trial Id="199526"><Indications><Indication>Prurigo nodularis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor kappa agonist</Action><Action>Opioid receptor mu antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Trevi Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Poland</Country><Country>Austria</Country><Country>Germany</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2017-09-03T00:00:00Z</DateEnd><DateStart>2015-08-15T00:00:00Z</DateStart><Identifiers><Identifier>2013-005628-41</Identifier><Identifier>NCT02174432</Identifier><Identifier>TR03EXT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nalbuphine (oral extended release tablet, uremic pruritus/prurigo nodularis), Trevi Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to evaluate the overall safety and tolerability of nalbuphine ER tablets during a treatment period of up to 50 weeks [ 1946954 ]. Secondary objectives were to: Evaluate the safety of nalbuphine by achieved maintenance dose at the end of treatment week 4. Assess skin lesion improvement using the metrics of the PAS. Change from baseline in patient-reported outcome measures worst and average itch NRS. Change between baseline and final treatment period in PBI-P</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Open-Label, Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis</TitleDisplay><BiomarkerNames><BiomarkerName>Nerve fibers</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-09-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Clinical Trial Information</Name><Name>Thomas Sciascia, MD</Name></ContactNames></Trial><Trial Id="198994"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Reckitt Benckiser plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-11T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-MUC-04</Identifier><Identifier>NCT01537081</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Mucinex alone</Intervention><Intervention>guaifenesin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2810</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Has developed &lt;b&gt;cold&lt;/b&gt; symptoms within 3 days prior to dosing on day 1</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections</TitleDisplay><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>43</NumberOfSites><ContactNames><Name>Reckitt Benckiser LLC</Name></ContactNames></Trial><Trial Id="198734"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ophthalmological agent</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Taiho Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-06-27T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2014-07-01T00:00:00Z</DateStart><Identifiers><Identifier>JapicCTI-142574</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bilastine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to investigate the dose reactivity of TAC-202 , and to verify the superiority of TAC-202 20 mg over placebo in patients with chronic idiopathic urticaria.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase II/III study of TAC-202 in patients with chronic idiopathic urticaria</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Taiho Pharmaceutical Co., Ltd.</Name></ContactNames></Trial><Trial Id="194708"><CompaniesSponsor><Company>National Nutrition and Food Technology Institute</Company></CompaniesSponsor><DateChangeLast>2014-06-11T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00864539</Identifier><Identifier>P/25/47/2027</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>calcium-vitamin D supplement alone</Intervention><Intervention>fortified milk alone</Intervention><Intervention>fortified orange juice alone</Intervention><Intervention>plain milk alone</Intervention><Intervention>plain orange juice alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>585</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> This study was conducted in two phases: At the first phase, the prevalence of vitamin D insufficiency in primary school-children in Tehran is determined during the &lt;b&gt;cold&lt;/b&gt; seasons of 2008. The efficacy of calcium-vitamin D-fortified milk, -orange juice and supplement is compared in six selected primary schools.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of the Efficacy of Calcium-cholecalciferol Foodstuffs and Calcium-cholecalciferol Supplement</TitleDisplay><BiomarkerNames><BiomarkerName>Alkaline phosphatase, bone specific </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Osteocalcin </BiomarkerName><BiomarkerName> Parathyroid hormone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Tirang R. Neyestani, Ph.D.</Name></ContactNames></Trial><Trial Id="190453"><Indications><Indication>Dermatological disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Low molecular weight heparin</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Tehran University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-27T00:00:00Z</DateChangeLast><DateStart>2014-04-21T00:00:00Z</DateStart><Identifiers><Identifier>2597/130/د/92</Identifier><Identifier>IRCT2014040917197N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enoxaparin sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>of &lt;b&gt;cold&lt;/b&gt; compress on the injection site of 60 patients under treatment by sc enoxaparin (60 mg), for 20 min just after every injection in abdomen, over 12 h of injection time, warm compress bag will be placed as well on the same point of injection, ... This study is for comparing the effect of local &lt;b&gt;cold&lt;/b&gt; and warmth upon the size of bruising at the injection site of subcutaneous enoxaparin .</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of the effect of local cold and warmth upon the size of bruising at the injection site of subcutaneous enoxaparin</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sara Amanian</Name><Name>Shokooh Varaie</Name></ContactNames></Trial><Trial Id="189654"><Indications><Indication>Anesthesia</Indication><Indication>General anesthesia</Indication><Indication>Hypothermia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable emulsion</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Mashhad University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-17T00:00:00Z</DateChangeLast><DateStart>2014-06-22T00:00:00Z</DateStart><Identifiers><Identifier>922148</Identifier><Identifier>IRCT2014042917480N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atracurium , bupivacaine, AstraZeneca , ephedrine , fentanyl , nitrous oxide , propofol, AstraZeneca/Fresenius</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study aimed to compare the incidence and severity of hypothermia for general anesthesia and spinal anesthesia in the lower extremities. This is a randomized clinical trial in 60 patients undergoing lower extremity that Imam Reza (AS) visited.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of heat loss during anesthesia</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Mehryar Taghavi Gilani</Name><Name>Dr. Mostafa Delshad</Name></ContactNames></Trial><Trial Id="189331"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor kappa agonist</Action><Action>Opioid receptor mu antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Trevi Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>Poland</Country><Country>US</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2015-07-31T00:00:00Z</DateEnd><DateStart>2014-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-005625-22</Identifier><Identifier>NCT02143648</Identifier><Identifier>TR02</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nalbuphine (oral extended release tablet, uremic pruritus/prurigo nodularis), Trevi Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>360</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objectives of this multicenter, randomized, double-blind, placebo-controlled, parallel, three-arm study were to evaluate the effects of two doses of nalbuphine ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and tolerability in the study population [ 1693904 ], [ 1875417 ]. The secondary objectives of the study were to evaluate the effect of two doses of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of duration and severity of pruritus</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Assessment by skindex score</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects by disease severity - Subjects with Moderate Pruritus</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Systemic Disorders - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Pruritus - Subjects with Severe Pruritus</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>49</NumberOfSites><ContactNames><Name>Clinical Trial Information</Name><Name>Thomas Sciascia, MD</Name></ContactNames></Trial><Trial Id="189265"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor kappa agonist</Action><Action>Opioid receptor mu antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Trevi Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Poland</Country><Country>Romania</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2016-01-31T00:00:00Z</DateEnd><DateStart>2014-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-005626-29</Identifier><Identifier>NCT02143973</Identifier><Identifier>TR02ext</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nalbuphine (oral extended release tablet, uremic pruritus/prurigo nodularis), Trevi Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>184</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to evaluate the overall safety and efficacy of nalbuphine ER tablets during a treatment period of up to 24 weeks. The secondary objective of the study was to evaluate the safety of nalbuphine by achieved dose at the end of treatment period week 3 [ 1946954 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Open-Label, Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Systemic Disorders - Subjects with renal disorders/diseases/dysfunction</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Clinical Trial Information</Name><Name>Thomas Sciascia, MD</Name></ContactNames></Trial><Trial Id="188247"><Indications><Indication>Carpal tunnel syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Bcl 2 binding component 3 stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Apoptosis stimulator</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>University of Alberta</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-09-30T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02141035</Identifier><Identifier>PRO00045538</Identifier><Identifier>RES0021133</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>acetyl-L-carnitine hydrochloride alone</Intervention><Intervention>surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The goal of this randomized, double-blinded, placebo-controlled, pilot study was to test a potentially promising medication, acetyl-L-carnitine (ALCAR). The study hypothesis was that acetyl-L-carnitine increases nerve regeneration in patients with severe carpal tunnel syndrome [ 1761858 ].</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome</TitleDisplay><PrimaryCompletionDate type="Actual">2017-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Ming Chan, MB,ChB</Name></ContactNames></Trial><Trial Id="185303"><Indications><Indication>Cervical dysplasia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TLR-7 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunomodulator</Action><Action>Interferon modulator</Action><Action>Topical dermatological antiviral product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Immuno-oncology</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>United States Naval Medical Center, San Diego</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-05-09T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>CIP#NMCSD.2014.0040</Identifier><Identifier>NCT02130323</Identifier><Identifier>NMCSD.2014.0040</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Cold knife conization (CKC) alone</Intervention><Intervention>Loop electrosurgical excision procedure (LEEP) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>imiquimod alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients will be randomized to either undergo excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP)/&lt;b&gt;cold&lt;/b&gt; knife conization (CKC) or medical therapy with imiquimod 5% (12.5 mg, intravaginally, qw for 16 weeks).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Topical Imiquimod Versus LEEP for Women With Carcinoma In-situ of the Cervix</TitleDisplay><PrimaryCompletionDate type="Actual">2016-12-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Addie N Alkhas, MD</Name><Name>Marthile H Goldman,</Name><Name>Salvador I Doria,</Name></ContactNames></Trial><Trial Id="185016"><Indications><Indication>Renal injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erythropoietin ligand</Action><Action>Erythropoietin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hematopoietic stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Biosimilar product</Technology><Technology>DNA technology</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Hannover Medical School</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-11-21T00:00:00Z</DateChangeLast><DateEnd>2009-11-30T00:00:00Z</DateEnd><DateStart>2007-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2006-002938-38</Identifier><Identifier>MHH - EPONTX - 01/06</Identifier><Identifier>NCT00425698</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>recombinant human erythropoietin alpha biosimilar (anemia), Recpharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>88</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Signed written informed consent Male or female aged 18 to 70 years without restricted legal competence and being able to follow the trial instructions Cadaveric renal transplant, &lt;b&gt;cold&lt;/b&gt; ischemia time below 24 h, and standard immunosuppressive regimen A hemoglobin level &gt; 8 and&amp;lt; 14 g/dl Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF or azathioprine) In patient with diabetes mellitus HbA1c&amp;lt</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of transplant</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with comorbid conditions</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Renal Replacement Therapy - Subjects with history/scheduled for renal transplantation</PatientSegment><PatientSegment>Renal failure - Subjects with Intrarenal Causes for Acute Renal Failure(ARF) - Subjects exposed to nephrotoxins</PatientSegment><PatientSegment>Renal failure - Subjects with Intrarenal Causes for Acute Renal Failure(ARF) - Subjects with tubulointerstitial disease</PatientSegment><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with/at risk of dehydration</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Danilo Fliser, MD</Name></ContactNames></Trial><Trial Id="184338"><Indications><Indication>Atopic dermatitis</Indication></Indications><CompaniesCollaborator><Company>Moscow Health Department "Clinical Oncology Dispensary number 1"</Company><Company>Moscow State Medical and Dental University</Company></CompaniesCollaborator><CompaniesSponsor><Company>JSC "ABBA RUS"</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2018-04-26T00:00:00Z</DateChangeLast><DateEnd>2010-09-30T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>04/09-AVVA RUS</Identifier><Identifier>LF-AD-09</Identifier><Identifier>NCT01124318</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lactofiltrum alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>antibiotics, steroids, immunosuppressive, cytostatic or antimetabolite agents by the time of inclusion into the study Concomitant skin diseases: skin lymphoma, scab, lichen ruber planus, psoriasis Professional activity involving skin injury, exposure to &lt;b&gt;cold&lt;/b&gt;, insolation, ultraviolet radiation Psychoses Application of pre-, probiotics, antibiotics, neuroleptics or tranquilizers 2 weeks before inclusion or during participation in the study Participation in other clinical study 1 month before inclusion or</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dermatitis - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Systemic Function</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Systemic Function - Assessment of hematological/biochemical status</EndpointIndex><EndpointIndex>Dermatitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Scoring Atopic Dermatitis (SCORAD) Index</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Atopic Dermatitis - Patients diagnosed Atopic Dermatitis by Hanifin and Rajka Criteria</PatientSegment><PatientSegment>Atopic Dermatitis - Patients enrolled based on SCORAD Scores - Score of (25-50) &amp; (&gt;50)</PatientSegment><PatientSegment>Atopic Dermatitis - Patients with Moderate to Severe Atopic Dermatitis</PatientSegment><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD) - Subjects with moderate to severe atopic dermatitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bilirubin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Urea</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Anton Dvornikov</Name><Name>Kira Olhovskaya</Name><Name>Larisa Kruglova</Name><Name>Lyudmila Kobeleva, MD, PhD</Name><Name>Nickolay A. Kryuchkov, MD, PhD, MPH</Name><Name>Yuriy Perlamutrov</Name></ContactNames></Trial><Trial Id="173977"><Indications><Indication>Male infertility</Indication></Indications><CompaniesSponsor><Company>Rigshospitalet, Denmark</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-09-04T00:00:00Z</DateChangeLast><DateEnd>2016-05-31T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2010-024588-42</Identifier><Identifier>2010124801</Identifier><Identifier>H-4-2010-138</Identifier><Identifier>NCT01304927</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>calcium plus cholecalciferol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>307</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was designed to evaluate the effect of vitamin D supplementation in infertile men.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex><EndpointIndex>Infertility - Assessment of Semen</EndpointIndex><EndpointIndex>Infertility - Assessment of Underlying Systemic Condition</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Histroy of Infertility - Men with infertility</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial </BiomarkerName><BiomarkerName> Adiponectin </BiomarkerName><BiomarkerName> Adrenocorticotropic hormone </BiomarkerName><BiomarkerName> Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Aldosterone </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Alpha-amylase 1 </BiomarkerName><BiomarkerName> Angiotensin-2 </BiomarkerName><BiomarkerName> Angiotensinogen </BiomarkerName><BiomarkerName> Anti-Muellerian hormone type-2 receptor </BiomarkerName><BiomarkerName> Antinuclear antibodies </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bicarbonates </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> C-peptide </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Calcitonin </BiomarkerName><BiomarkerName> Carcinoembryonic antigen-related cell adhesion molecule 5 </BiomarkerName><BiomarkerName> Collagen type III </BiomarkerName><BiomarkerName> Copeptins </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Estrogens </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Ferritin </BiomarkerName><BiomarkerName> Fibroblast growth factor 23 </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Glucagon-like peptide 1 </BiomarkerName><BiomarkerName> Glucagon-like peptide 2 </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> HLA class I histocompatibility antigen, alpha chain G </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin sensitivity </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Immunoglobulins </BiomarkerName><BiomarkerName> Inhibin B </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Insulin-like growth factor binding protein 3 </BiomarkerName><BiomarkerName> Klotho </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Lean body mass </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lupus coagulation inhibitor </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor </BiomarkerName><BiomarkerName> Natriuretic peptides A </BiomarkerName><BiomarkerName> Natriuretic peptides B </BiomarkerName><BiomarkerName> Osteocalcin </BiomarkerName><BiomarkerName> Osteopontin </BiomarkerName><BiomarkerName> Parathyroid hormone </BiomarkerName><BiomarkerName> Phosphate </BiomarkerName><BiomarkerName> Procalcitonin </BiomarkerName><BiomarkerName> Prolactin </BiomarkerName><BiomarkerName> Prostate-specific antigen </BiomarkerName><BiomarkerName> Renin </BiomarkerName><BiomarkerName> Reticulocytes </BiomarkerName><BiomarkerName> Rheumatoid factor </BiomarkerName><BiomarkerName> Sex hormone-binding globulin </BiomarkerName><BiomarkerName> Skeletal muscle mass </BiomarkerName><BiomarkerName> Somatotropin </BiomarkerName><BiomarkerName> Sperm cells </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Testosterone </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Tumor necrosis factor ligand superfamily member 11 </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Zinc </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>63 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Martin Blomberg Jensen, MD</Name></ContactNames></Trial><Trial Id="173403"><Indications><Indication>IgA nephropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>B-lymphocyte stimulator ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein fusion</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Anthera Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country><Country>South Korea</Country><Country>Thailand</Country><Country>Taiwan</Country><Country>Hungary</Country><Country>UK</Country><Country>Singapore</Country><Country>Spain</Country><Country>South East Asia</Country><Country>Italy</Country><Country>Malaysia</Country><Country>Philippines</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>Sweden</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-06-30T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>15507</Identifier><Identifier>2013-CT0107</Identifier><Identifier>2014-001365-26</Identifier><Identifier>AN-IGN3321</Identifier><Identifier>BRIGHT-SC</Identifier><Identifier>DRKS00008810</Identifier><Identifier>HKCTR-1752</Identifier><Identifier>NCT02062684</Identifier><Identifier>NMRR-13-269-15507</Identifier><Identifier>PHRR141028-000672</Identifier><Identifier>UW 13-250</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Rhinopharyngitis</Indication><Indication>Skin rash</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>blisibimod alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>58</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In June 2016, interim-data results were presented. Blisibimod was generally well-tolerated with common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, back pain, mild rash at the injection site as most common adverse events [ 1776880 ]. Similar results were presented in August 2017 [ 1956653 ]. In August 2017, results were presented. More patients in placebo group discontinued treatment compared to blisibimod group. Nasopharyngitis was the most common adverse event reported with blisibimod. No incidences</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Disease Progression</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At Home Treatment by Subcutaneous Administration</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Glomerular Disorder</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 1 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Proteinuria/Albuminuria</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> CD40 ligand </BiomarkerName><BiomarkerName> Complement C3 </BiomarkerName><BiomarkerName> Complement C4 </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Immunoglobulin A </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M </BiomarkerName><BiomarkerName> Plasma cells </BiomarkerName><BiomarkerName> Urinary protein </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Bill Shanahan, MD</Name><Name>Colin Hislop, MD</Name><Name>James Pennington</Name><Name>Jeanne Bayaca, MD</Name><Name>Josephine Valdez, MD</Name><Name>Ma. Theresa Bad-Ang</Name><Name>Marieta De Luna, MD</Name><Name>Richad Hizon, MD</Name><Name>Romina Danguilan, MD</Name></ContactNames></Trial><Trial Id="162576"><Indications><Indication>Drug withdrawal syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute on Drug Abuse</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Kentucky</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>09-0489</Identifier><Identifier>NCT00980044</Identifier><Identifier>R01DA027068</Identifier></Identifiers><IndicationsAdverse><Indication>Hot flashes</Indication><Indication>Insomnia</Indication><Indication>Lacrimation disorder</Indication><Indication>Miosis</Indication><Indication>Muscle disease</Indication><Indication>Rhinorrhea</Indication><Indication>Sneezing</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tramadol hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>tramadol 200 mg on ratings of insomnia, lacrimation, muscular tension, and sneezing compared to placebo. Miosis was observed only in phase 1 of tramadol 600 mg. In phase 2, higher peak ratings of rhinorrhea, irritable, depressed, heavy/sluggish, and hot/&lt;b&gt;cold&lt;/b&gt; flashes was observed in tramadol 600 mg than placebo. No serious adverse events and no signal of abuse liability for tramadol was reported [ 1505400 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of dependency potential</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michelle Lofwall</Name></ContactNames></Trial><Trial Id="158633"><Indications><Indication>Coronary artery disease</Indication></Indications><CompaniesSponsor><Company>Universitatsklinikum Essen</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-12-05T00:00:00Z</DateChangeLast><DateEnd>2012-10-01T00:00:00Z</DateEnd><DateStart>2008-07-31T00:00:00Z</DateStart><Identifiers><Identifier>08-3683</Identifier><Identifier>DRKS00009418</Identifier><Identifier>NCT01406678</Identifier><Identifier>RIPC-CCA</Identifier><Identifier>WDHZ-TC-0801</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Remote ischemic preconditioning (RIPC) alone</Intervention><Intervention>isoflurane plus sufentanil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>500</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was to assess protection of heart, brain and kidney by RIPC under crystalloid cardioplegic arrest and also assessed safety and clinical outcome.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Troponin I (TnI) elevation</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Cerebrovascular accident /Transient Ischemic Attack</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RIPC-CCA: Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - On pump coronary artery bypass grafting (CABG)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Multiple Vessel CAD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Mitochondrial DNA </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Eva Kottenberg, M.D., PhD.</Name><Name>Gerd Heusch, M.D., PhD.</Name><Name>Matthias Thielmann, MD, PhD</Name><Name>Matthias Thielmann, MD., PhD.</Name></ContactNames></Trial><Trial Id="158290"><Indications><Indication>Tonsillitis</Indication></Indications><CompaniesSponsor><Company>Birjand University</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-07-20T00:00:00Z</DateChangeLast><DateStart>2012-11-20T00:00:00Z</DateStart><Identifiers><Identifier>125/85044</Identifier><Identifier>IRCT2012120211637N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ampicillin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>138</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>and would recommended to refer in any case of complications and intense pain. 7 days after the surgery patients would visited again for evaluation of their improvement and data would be recorded. Both groups received washing with &lt;b&gt;cold&lt;/b&gt; NS (normal saline) and the same &lt;b&gt;cold&lt;/b&gt; liquid diet [ 1489607 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Antibiotic Therapy on Recovery After Tonsillectomy and Adenotonsillectomy Complications</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Asghar Zarban</Name><Name>Dr Golboie, ENT specialist</Name><Name>Golboie</Name><Name>Mohammadreza Mofateh</Name><Name>Seyed Mousavi</Name></ContactNames></Trial><Trial Id="155970"><Indications><Indication>Acute stress disorder</Indication><Indication>Inflammatory disease</Indication></Indications><CompaniesCollaborator><Company>Puleva Biotech SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Granada</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-04-26T00:00:00Z</DateChangeLast><DateEnd>2011-04-30T00:00:00Z</DateEnd><DateStart>2008-04-30T00:00:00Z</DateStart><Identifiers><Identifier>C3565-00</Identifier><Identifier>C3565-00</Identifier><Identifier>NCT01947426</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Fish oil alone</Intervention><Intervention>docosahexaenoic acid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>concretely of colostrum (2 to 3 postpartum days) and of mature (ripe) milk to 1, 2, 3 months. The samples would be preserved in freezer of -80degC and sent to the different laboratories due preserved participants in order that there does not break the &lt;b&gt;cold&lt;/b&gt; chain (dry ice). In the first year of life of the child there would be practised tests of motive and cognitive development (Bayley's test and Fagan's test) in order to evaluate the influence of the dietetic intervention on the mother in the development</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Mother DHA Supplementation on Term Newborn</TitleDisplay><BiomarkerNames><BiomarkerName>Bone formation rate </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Fatty acids </BiomarkerName><BiomarkerName> Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Julio J Ochoa</Name></ContactNames></Trial><Trial Id="149660"><Indications><Indication>Dysmenorrhea</Indication></Indications><CompaniesSponsor><Company>Reckitt Benckiser plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-11-13T00:00:00Z</DateChangeLast><DateEnd>2009-06-30T00:00:00Z</DateEnd><DateStart>2009-01-02T00:00:00Z</DateStart><Identifiers><Identifier>Dysmenorrhoea Efficacy Study</Identifier><Identifier>EudraCT: 2008-006762-29</Identifier><Identifier>ISRCTN42521357</Identifier><Identifier>NL0804</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>acetaminophen + ibuprofen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>85</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to assess the efficacy of fixed dose combination tablets of 200 mg ibuprofen plus 500 mg acetaminophen, administered as one or two tablets (two tablets equivalent to 400 mg ibuprofen plus 1,000 mg acetaminophen) in comparison to placebo among patients experiencing moderate to severe pain due to primary dysmenorrhoea, in terms of total analgesic effect [ 1463150 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Dysmenorrhoea Efficacy Study: Dysmenorrhea Efficacy Study: Fixed Dose Combination Tablets of Ibuprofen and Acetaminophen for Primary Dysmenorrhoea</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with dysmenorrhoea</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ronald Eccles</Name></ContactNames></Trial><Trial Id="142172"><Indications><Indication>Liver transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PGI2 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antihypertensive</Action><Action>Platelet aggregation inhibitor</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>University of Pittsburgh</Company></CompaniesCollaborator><CompaniesSponsor><Company>United Therapeutics Corp</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01884038</Identifier><Identifier>RIV-LT-301</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>treprostinil alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser> Receiving a living done liver transplant Receiving a donor liver with a &lt;b&gt;cold&lt;/b&gt; ischemia time&amp;lt; 6 h Receiving a donor liver with macrosteatosis &gt; 30% Receiving any investigation drug with the except of alemtuzamab (Camphath) Failed liver transplant in previous 180 days Prior organ transplant or cell infusion Undergoing multi-organ</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Liver transplantation - Pharmacoeconomic Assessments</EndpointIndex><EndpointIndex>Liver transplantation - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Perioperative Remodulin in Orthotopic Liver Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Cadaveric Donor Liver Transplant (CDLTx) Recipients</PatientSegment><PatientSegment>Liver transplantation - Liver Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2010-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amadeo Marcos, MD</Name><Name>Raman Venkataramanan, Ph.D, F.C.P.</Name></ContactNames></Trial><Trial Id="141915"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Georgetown University Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>Evered</Identifier><Identifier>IIRPCRAD001AUS183T</Identifier><Identifier>NCT01878786</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>corticosteroid therapy alone</Intervention><Intervention>Variable regimens including everolimus , mycophenolate mofetil , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Safety Issues</Reason></ReasonForTrialDiscontinuation><Teaser> &lt;b&gt;Cold&lt;/b&gt; ischemic time (CIT)&gt; 30 h Patients who are ABO incompatible transplants, or T, or B cell crossmatch positive transplant Patients with a known hypersensitivity to any of the study drugs or to drugs of similar chemical class Non-controlled DCD Donor </Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Evered: A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Non heart beating donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Others - Eligible renal donors</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Matthew Cooper</Name></ContactNames></Trial><Trial Id="129220"><Indications><Indication>Cancer pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>KCNQ voltage-gated potassium channel stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Relevare Pharmaceuticals Ltd</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>Germany</Country></Countries><DateChangeLast>2018-07-05T00:00:00Z</DateChangeLast><DateStart>2011-10-18T00:00:00Z</DateStart><Identifiers><Identifier>2011-001202-99</Identifier><Identifier>CNSB015CP01</Identifier></Identifiers><InterventionsControlDisplay><Intervention>opioids therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>flupirtine (adjunctive, neuropathic pain), Relevare alone</Intervention><Intervention>opioids therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>duration Pain with neuropathic characteristics that include one or more of the following: Throbbing Shooting Stabbing Sharp Cramping Gnawing Hot-burning Aching Heavy Tender Splitting Tiring-exhausting Sickening Fearful Punishing-cruel Electric-shock &lt;b&gt;Cold&lt;/b&gt;-freezing Piercing Caused by light touch Itching Tingling or 'pins and needles' Numbness Pain inadequately relieved despite active management including strong opioids Currently taking morphine, oxycodone, hydromorphone, buprenorphine, or transdermal</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain - Assesment of Brief Pain Inventory Short-Form (BPI-SF)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=30% response</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Solid tumor - Assessment of pain</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI) (AS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase IIb/III, Double-Blind, Placebo-Controlled, Randomized Study Investigating the Safety, Tolerability and Efficacy of Flupirtine as Adjunct to Opioids When Administered to Cancer Subjects Who Are Experiencing Pain With Neuropathic Features</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Cancer/Treatment-related Pain</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Pain - Subjects with Cancer Related Pain</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Intractable Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Vice President Clinical Operations</Name></ContactNames></Trial><Trial Id="12694"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Norepinephrine uptake inhibitor</Action><Action>Vasoconstrictor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Omeros Corp</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-20T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2007-12-31T00:00:00Z</DateStart><Identifiers><Identifier>C07-004</Identifier><Identifier>C07-004</Identifier><Identifier>NCT00624845</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ketoprofen + amitriptyline + oxymetazoline (pain) Omeros Medical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>prescription serotonergic or histaminic drug within 14 days More than two doses of any oral, parenteral, or intravenous steroids (eg, dexamethasone for antiemetic prophylaxis) within 3 months More than two doses of oxymetazoline or other nasal decongestant/&lt;b&gt;cold&lt;/b&gt;/cough/allergy medication (including loratadine) within 7 days More than two doses of ketoprofen or other NSAID (including COX-2 inhibitors) within 7 days (except for piroxicam, as indicated below) Subject who has taken more than two doses of opioid</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>C07-004: Double-Blind, Multicenter Study Comparing the Efficacy and Safety of OMS-103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Scott Houston</Name></ContactNames></Trial><Trial Id="126755"><Indications><Indication>Liver injury</Indication></Indications><CompaniesSponsor><Company>Chonbuk National University Hospital</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-11-29T00:00:00Z</DateChangeLast><DateEnd>2012-01-31T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>INS-LF-CURCUMA</Identifier><Identifier>NCT01634256</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Fermented turmeric alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>serious adverse events were reported. A total of five subjects were reported for adverse events. In placebo group, mild enteritis and ureterolith, respectively, were observed in two patients. In FTP group, chronic gastritis, gout-induced pain, and common &lt;b&gt;cold&lt;/b&gt; were reported in three patients, respectively.These adverse events were unlikely related to the study protocol. The above reported adverse events were mild and were pre-existing complaints before the initiation of treatment with FTP or placebo. Between</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury</TitleDisplay><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sang-Wook Kim, MS</Name></ContactNames></Trial><Trial Id="117736"><Indications><Indication>Acute sinusitis</Indication></Indications><CompaniesSponsor><Company>Bionorica SE</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2009-05-29T00:00:00Z</DateEnd><DateStart>2009-01-28T00:00:00Z</DateStart><Identifiers><Identifier>2008-002794-13</Identifier><Identifier>ARhiSi-1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BNO-1016 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>moderate persistent asthma) within the last 4 weeks prior to study inclusion Treatment with decongestant preparations, analgesics (except paracetamol), mucolytics/secretolytics, antihistamines, or alternative medicine preparations for treatment of common &lt;b&gt;cold&lt;/b&gt; like symptoms or with immunomodulating properties within the last 7 days prior to study inclusion Patients requiring antibiotic treatment for any condition at study entry Pregnancy or lactation Severe somatopathic, neurological and/or psychiatric diseases</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Assess The Efficacy and Safety of Two Different Dosages of A Herbal Medicinal Product (Dry Extract BNO-1016) in Patients with Acute Rhinosinusitis</TitleDisplay><PrimaryCompletionDate/><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="113744"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Adverse Drug Reactions, Advice and Consulting ADR-AC</Company><Company>CTU Bern</Company><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Hospital Inselspital, Berne</Company></CompaniesSponsor><Countries><Country>Switzerland</Country></Countries><DateChangeLast>2018-07-10T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>199/10</Identifier><Identifier>CIGE025ECH04T</Identifier><Identifier>NCT01803763</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age&amp;lt; 18 or &gt; 70 years Patients with pure physical or &lt;b&gt;cold&lt;/b&gt; urticaria, delayed pressure or cholinergic urticaria Patients with a clearly defined allergic urticaria (food, drugs etc) Previous treatment with omalizumab within one year prior to randomization Known hypersensitivity to omalizumab or any of its components</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures - Hematologic/blood chemistry assessment</EndpointIndex><EndpointIndex>Urticaria - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Chronic Urticaria Quality of Life (CU-Q2oL) Scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Prospective, Double-blind, Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> CD63 antigen </BiomarkerName><BiomarkerName> High affinity immunoglobulin epsilon receptor subunit beta </BiomarkerName><BiomarkerName> Interleukin-3</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Oliver Hausmann</Name></ContactNames></Trial><Trial Id="110569"><Indications><Indication>Ischemic stroke</Indication></Indications><CompaniesCollaborator><Company>National Institute of Neurological Disorders and Stroke</Company><Company>University of Texas Health Science Center Houston</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of California San Diego</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Switzerland</Country><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2010-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ICTuS2/3</Identifier><Identifier>ICTuS2/3</Identifier><Identifier>NCT01123161</Identifier><Identifier>P50NS044148</Identifier><Identifier>P50NS044227</Identifier></Identifiers><InterventionsControlDisplay><Intervention>normothermia alone</Intervention><Intervention>t-PA alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Celsius Control System alone</Intervention><Intervention>hypothermia alone</Intervention><Intervention>surface warming alone</Intervention><Intervention>buspirone plus meperidine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>but randomization will not be delayed for neuroimaging other than initial scan to exclude hemorrhage Known contra-indications to hypothermia, such as known hematological dyscrasias that affect thrombosis (cryoglobulinemia, Sickle cell disease, serum &lt;b&gt;cold&lt;/b&gt; agglutinins), or vasospastic disorders such as Raynaud's or thromboangiitis obliterans Known co-morbid conditions that are likely to complicate therapy in the opinion of the investigator Heart failure (NYHA class III and IV) Uncompensated arrhythmia</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stroke - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Activities of Daily Living scale (ADL)</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Barthel Activities of Daily Living Index</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by National Institute of Health Stroke Scale (NIHSS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ICTuS2/3: The Intravascular Cooling in the Treatment of Stroke 2/3 Trial</TitleDisplay><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>James C. Grotta, MD</Name><Name>Patrick D. Lyden, MD</Name><Name>Thomas M. Hemmen, MD, PhD</Name></ContactNames></Trial><Trial Id="10554"><Indications><Indication>Empyema</Indication><Indication>Pleural disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action><Action>Urokinase plasminogen activator modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>F Hoffmann-La Roche AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Azienda Ospedaliera di Padova</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2013-09-14T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>1372P</Identifier><Identifier>DUKE</Identifier><Identifier>NCT00502632</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa plus urokinase</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>94</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to determine whether intrapleural treatment with dornase alfa plus urokinase improves clinical outcome compared to urokinase alone in children with complicated parapneumonic effusions.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Antimicrobial Usage/ Prescription Changes</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pneumonia - Requirement of Ventilatory Support/Intervention</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>DUKE: Dornase Alfa and Urokinase for Kids With Pleural Empyema a Randomized Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects at risk of developing disease - Subjects with pre-existing lung diseases</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Alessandro Inserra, MD</Name><Name>Eleonora Cesca, MD</Name><Name>Giorgio Stefanutti</Name><Name>Maurizio Cheli, MD</Name><Name>PierGiorgio Gamba</Name><Name>PierGiorgio Gamba, MD</Name><Name>Sonia Viale, MD</Name></ContactNames></Trial><Trial Id="97796"><Indications><Indication>Chronic lymphocytic leukemia</Indication><Indication>Lymphoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Btk tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>B-lymphocyte adhesion inhibitor</Action><Action>B-lymphocyte migration inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Chemotaxis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>Janssen Research &amp; Development LLC</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pharmacyclics Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>US</Country><Country>Australia</Country><Country>Ukraine</Country><Country>Spain</Country><Country>Canada</Country><Country>Belgium</Country><Country>Germany</Country><Country>Turkey</Country><Country>Ireland</Country><Country>China</Country><Country>New Zealand</Country><Country>Israel</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>UK</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-003967-23</Identifier><Identifier>NCT01722487</Identifier><Identifier>PCYC-1115</Identifier><Identifier>PCYC-1115-CA</Identifier><Identifier>RESONATE-2</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Atrial fibrillation</Indication><Indication>Bleeding</Indication><Indication>Cough</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Hematoma</Indication><Indication>Hypertension</Indication><Indication>Musculoskeletal pain</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Pneumonia</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>chlorambucil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ibrutinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>269</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>without alternative etiology, or increased absolute reticulocytosis (above ULN) or bone marrow erythropoiesis in the absence of bleeding) and at least one marker of direct or indirect autoimmune mechanism (positive direct antiglobulin for IgG or C3d, &lt;b&gt;cold&lt;/b&gt; agglutinins) (Ding 2007); Immune thrombocytopenia is defined by platelets&amp;lt;/= 100,000/microl and increased megakaryocytes on the bone marrow exam Eastern Cooperative Oncology Group (ECOG) performance score = 1 or 2 Diagnosis of CLL/SLL that meets</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Anemia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Anemia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of hematologic improvement</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of treatment utilization/alterations</EndpointIndex><EndpointIndex>Anemia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of hospitalization</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Bone Marrow</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Co-morbidity - Assessment of hematologic diseases/disorders</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Co-morbidity - Assessment of premalignant/malignant diseases/disorders</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Laboratory/Diagnostic Measures - Assessment using imaging modalities</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Transfusions</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of adverse events</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Hematological Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptom control</EndpointIndex><EndpointIndex>Leukemia - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Leukemia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Leukemia - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D (EuroQoL)</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACIT-F TOI</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Lymphoma - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Lymphoma - Hematological Assessments - Assessment of hematologic reconstitution</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D (EuroQoL)</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQol EQ-5D-5L Questionnaire</EndpointIndex><EndpointIndex>Lymphoma - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex><EndpointIndex>Thrombocytopenia - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Bone Marrow</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Laboratory/Diagnostic Measures - Assessment using imaging modalities</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Morbidity Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Transfusions</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of adverse events</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Thrombocytopenia - Clinical Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Hematological Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptom control</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RESONATE-2: Open-label, Phase III BTK Inhibitor Ibrutinib Versus Chlorambucil Patients &gt;/= 65 Years or Older With Treatment-naive CLL or SLL</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with autoimmune hemolytic anemia</PatientSegment><PatientSegment>Anemia - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Anemia - Subjects with specific disease - Subjects with Cancer/Cancer Chemotherapy Induced Anemia</PatientSegment><PatientSegment>Idiopathic thrombocytopenic purpura - Subjects with comorbid conditions</PatientSegment><PatientSegment>Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)</PatientSegment><PatientSegment>Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with small lymphocytic/prolymphocytic lymphoma</PatientSegment><PatientSegment>Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Cancer/Chemotherapy Induced Thrombocytopenia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Immune (Idiopathic) Thrombocytopenia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 </BiomarkerName><BiomarkerName> ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> B-lymphocyte antigen CD19 </BiomarkerName><BiomarkerName> B-lymphocytes </BiomarkerName><BiomarkerName> Beta-2-microglobulin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> C-C chemokine receptor type 7 </BiomarkerName><BiomarkerName> CD27 antigen </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> CD8-Positive T-Lymphocytes </BiomarkerName><BiomarkerName> Cellular tumor antigen p53 </BiomarkerName><BiomarkerName> Deoxyribonucleic acid </BiomarkerName><BiomarkerName> HLA-DR Antigens </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Immunoglobulin heavy locus </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Interleukin-7 receptor subunit alpha </BiomarkerName><BiomarkerName> Leukocyte common antigen </BiomarkerName><BiomarkerName> Low affinity immunoglobulin gamma Fc region receptor III </BiomarkerName><BiomarkerName> Lymph node </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Memory T-Lymphocytes </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14 </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Myeloid-derived suppressor cells </BiomarkerName><BiomarkerName> Natural killer T-cells </BiomarkerName><BiomarkerName> Natural killer cells </BiomarkerName><BiomarkerName> Neural cell adhesion molecule 1 </BiomarkerName><BiomarkerName> Programmed cell death protein 1 </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> Spleen </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Thyroid-stimulating hormone </BiomarkerName><BiomarkerName> Thyroxine </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 6 </BiomarkerName><BiomarkerName> Tyrosine-protein kinase BTK</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>225</NumberOfSites><ContactNames><Name>Alessandra Tedeschi</Name><Name>Deepali Suri</Name><Name>Jan Burger</Name><Name>Lori Styles, MD</Name><Name>Medical Monitor</Name><Name>Peter Hillmen</Name></ContactNames></Trial><Trial Id="96618"><Indications><Indication>Empyema</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Fibrinolysis stimulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Inhalant formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>BC Children's Hospital</Company><Company>CHU de Quebec-Universite Laval</Company><Company>Canadian Institutes of Health Research</Company><Company>Childrens Hospital of Eastern Ontario (CHEO)</Company><Company>McMaster Children's Hospital</Company><Company>Physicians' Services Incorporated Foundation</Company><Company>St Michaels Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital for Sick Children</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>1000033767</Identifier><Identifier>DTPA trial</Identifier><Identifier>NCT01717742</Identifier></Identifiers><InterventionsControlDisplay><Intervention>alteplase alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>alteplase plus dornase alfa</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this multicenter, randomized, controlled trial was to compare the time to discharge from hospital after chest drain insertion in previously well children who present with pleural empyema, treated with intrapleural DNase (dornase alfa) ( Pulmozyme ) and tissue plasminogen activator (tPA) (alteplase) ( Cathflo ) by chest drain for three doses over 48 h compared with three doses over 48 h of alteplase alone. Other outcomes related to effectiveness, safety and cost would be assessed as</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Pneumonia - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pneumonia - Requirement of Ventilatory Support/Intervention</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>DTPA trial: Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects with Severe/Very Severe Pneumonia</PatientSegment><PatientSegment>Pneumonia - Subjects with disease related complications - Subjects with empyema</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Eyal Cohen, MD, MSc</Name></ContactNames></Trial><Trial Id="9651"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Thymidine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Transport Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-04T00:00:00Z</DateChangeLast><DateEnd>2006-03-31T00:00:00Z</DateEnd><DateStart>2005-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00230867</Identifier><Identifier>TPI-203</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aciclovir (transdermal, iontophoretic), Transport Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1800</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>by &lt;b&gt;cold&lt;/b&gt; sores which might affect the normal course of &lt;b&gt;cold&lt;/b&gt; sores (eg, eczema, psoriasis, albinism, or chronic vesiculobullous disorders) Subject is currently enrolled in another clinical trial or has used...multi-centered, double-blind, placebo-controlled trial to evaluate the safety and efficacy of acyclovir (SoloVir), delivered via a novel iontophoretic device, for the treatment of &lt;b&gt;cold&lt;/b&gt; sores in patients with recurrent herpes labialis lesions [ 604945 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Development in aborted lesion</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Christopher M Hull, MD</Name></ContactNames></Trial><Trial Id="96131"><Indications><Indication>Colonoscopy</Indication></Indications><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2010-10-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-01</Identifier><Identifier>NCT01073930</Identifier><Identifier>SEE CLEAR I</Identifier></Identifiers><IndicationsAdverse><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including HalfLytely , HalfLytely + bisacodyl , bisacodyl</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>PicoPrep alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>608</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy). Each PicoPrep pouch would be reconstituted by mixing the contents in a cup with 5 oz of &lt;b&gt;cold&lt;/b&gt; water. The first pouch would be taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects would consume five 8 oz glasses of clear liquids over the next few hours. The second pouch would be taken approximately 5 h before</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEE CLEAR I: Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep</TitleDisplay><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="96017"><Indications><Indication>Colonoscopy</Indication></Indications><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2010-10-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-02</Identifier><Identifier>NCT01073943</Identifier><Identifier>SEE CLEAR II</Identifier></Identifiers><IndicationsAdverse><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including HalfLytely , HalfLytely + bisacodyl , bisacodyl</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>PicoPrep alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>603</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>would receive PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of two pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 oz of &lt;b&gt;cold&lt;/b&gt; water. Subjects randomized to the PicoPrep group will begin treatment (first sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (second sachet) at least 6 h later, between 10:00 PM and 12:00 AM. Subjects would</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of colon cleansing/bowel preparation</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Satisfaction Questionnaire (PSQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEE CLEAR II: Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep</TitleDisplay><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="95693"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2012-10-26T00:00:00Z</DateChangeLast><DateEnd>2009-06-30T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>HotDogVienna</Identifier><Identifier>NCT00772460</Identifier></Identifiers><InterventionsControlDisplay><Intervention>BairHugger alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>HotDog alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to compare two patient warming systems with 40 patients each in a convective warming group (BairHugger, Arizant) and in a conductive warming group (HotDog, Augustine Biomedical). The patients would undergo small to medium trauma surgery and would be warmed with the randomized device. The study hypothesize that the area under the standardized core temperature/time curve would be significantly greater in the conductive warming group. Secondary outcome would be the mean</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery</TitleDisplay><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Oliver Kimberger, M.D.</Name></ContactNames></Trial><Trial Id="95165"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin receptor 17A antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Amgen Inc</Company></CompaniesSponsor><Countries><Country>Portugal</Country><Country>Austria</Country><Country>Spain</Country><Country>France</Country><Country>Canada</Country><Country>Australia</Country><Country>Hungary</Country><Country>Poland</Country><Country>Netherlands</Country><Country>Czech Republic</Country><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateStart>2012-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-000656-34</Identifier><Identifier>20120103</Identifier><Identifier>AMAGINE-2</Identifier><Identifier>NCT01708603</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ustekinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>brodalumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1831</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>In November 2014, results were published. Common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, headache and joint pain were the most common adverse events that occurred in the brodalumab arms (more than 5 percent of subjects in either group). In 1% of subjects in the 210 mg group, 1.2% of subjects in the weight-based group, and 2.1% of subjects in the 140 mg group compared with 1.3% for ustekinumab and 2.6% for placebo, serious adverse events occurred during the placebo-controlled period. In the brodalumab</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>AMAGINE-2: Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Epidermis </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Integrin alpha-X </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17C </BiomarkerName><BiomarkerName> Interleukin-17F </BiomarkerName><BiomarkerName> Interleukin-23 subunit alpha </BiomarkerName><BiomarkerName> Keratin, type I cytoskeletal 16 </BiomarkerName><BiomarkerName> Keratinocytes </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lysosome-associated membrane glycoprotein 3 </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>159</NumberOfSites><ContactNames><Name>IHQ Medical Info - Clinical Trials</Name><Name>MD</Name></ContactNames></Trial><Trial Id="95140"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin receptor 17A antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Amgen Inc</Company><Company>MedDerm Associates</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Australia</Country><Country>Greece</Country><Country>Hungary</Country><Country>Latvia</Country><Country>US</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Belgium</Country><Country>Italy</Country><Country>Poland</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-000667-24</Identifier><Identifier>20120104</Identifier><Identifier>AMAGINE-3</Identifier><Identifier>NCT01708629</Identifier><Identifier>NCT02786732</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Candida infection</Indication><Indication>Cerebrovascular trauma</Indication><Indication>Common cold</Indication><Indication>Depression</Indication><Indication>Headache</Indication><Indication>Ischemic heart disease</Indication><Indication>Neutropenia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ustekinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>brodalumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1881</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>In November 2014, results were presented. In the brodalumab arms (&gt; 5% of patients in either group) the most common adverse events that occurred were common &lt;b&gt;cold&lt;/b&gt;, joint pain, upper respiratory tract infection and headache. In 1.4%, 1.6%, 0.6%, 1.0% of patients, in 210, 140 mg, ustekinumab and placebo group serious adverse events occurred respectively [ 1611190 ]. In March 2015, results were presented. In placebo, ustekinumab, brodalumab 140 and 210 mg groups, 48.6, 53.7, 52.6 and 56.8% of any grade</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>AMAGINE-3: Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Epidermis </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Integrin alpha-X </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17C </BiomarkerName><BiomarkerName> Interleukin-17F </BiomarkerName><BiomarkerName> Interleukin-23 subunit alpha </BiomarkerName><BiomarkerName> Keratin, type I cytoskeletal 16 </BiomarkerName><BiomarkerName> Keratinocytes </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lysosome-associated membrane glycoprotein 3 </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>170</NumberOfSites><ContactNames><Name>Dip. Regolatorio</Name><Name>IHQ Medical Info - Clinical Trials</Name><Name>MD</Name></ContactNames></Trial><Trial Id="94794"><Indications><Indication>Chronic sinusitis</Indication></Indications><CompaniesSponsor><Company>Bionorica SE</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Germany</Country><Country>Belgium</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2017-10-25T00:00:00Z</DateChangeLast><DateEnd>2014-07-14T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-003623-35</Identifier><Identifier>CRS-02</Identifier><Identifier>NCT01706484</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BNO-1016 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>927</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>decongestant preparations (alpha-sympathomimetics), analgesics (including systemic non-steroidal anti inflammatory drugs [NSAIDs], except paracetamol), mucolytics/secretolytics, antihistamines, or alternative medicine preparations for treatment of common &lt;b&gt;cold&lt;/b&gt; like symptoms or with immunomodulating properties within the last 7 days prior to V1 Patients with gastric or duodenal ulcer Other diseases within five years prior to V1, which in the opinion of the investigator disqualifies the patient for trial enrollment</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy And Safety Of Two Dosages Of A Herbal Medicinal Product (Dry Extract BNO-1016) in Chronic Rhinosinusitis</TitleDisplay><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Claus Bachert, Prof. Dr.</Name><Name>Senior Clinical Research Manager</Name></ContactNames></Trial><Trial Id="93607"><Indications><Indication>Sleep apnea</Indication></Indications><CompaniesSponsor><Company>Stanford University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>1R01 HS019738-01</Identifier><Identifier>COMET</Identifier><Identifier>NCT01461473</Identifier><Identifier>SU-10182011-8536</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oral appliance alone</Intervention><Intervention>positive airway pressure therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>131</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>need for treatment for hypertension) which is currently untreated or taking medication for the treatment of hypertension Stable medication regimen for 2 months prior to the baseline testing visit. As-needed medications such as those used for allergy, &lt;b&gt;cold&lt;/b&gt;, or minor pain symptoms may be used at the discretion of the Clinical Center physician</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Vascular Endothelial Function - Flow-mediated dilatation (FMD)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms - Assessment of daytime fatigue</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Functional Disability/Physical Function - Assessment by Functional Outcomes of Sleep Questionnaire</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Neuropsychological Function - Assessment of attention/concentration</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Psychiatric Symptoms - Assessment of mood symptoms</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Sleep - Assessment of day-time sleepiness</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vascular Indices or Parameters - Assessment of endothelial function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of Well-Being Self-Administered Scale (QWB-SA)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Sleep Apnea Quality of Life Index (SAQLI) questionaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COMET: Comparative Outcomes Management With Electronic Data Technology (COMET) Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects on Hypertensive Treatment</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with obstructive sleep apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Obstructive Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Severe Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Subjects co-morbid with hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Brachial artery </BiomarkerName><BiomarkerName> Mean arterial pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Allan Pack, MD</Name><Name>Clete A Kushida, MD, PhD</Name><Name>Ruth Benca, MD</Name><Name>Susan Redline, MD</Name></ContactNames></Trial><Trial Id="92782"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Nanoparticle formulation dermatological</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>BlueWillow Biologics</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NB-001-010</Identifier><Identifier>NCT01695187</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NB-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>362</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>more &lt;b&gt;cold&lt;/b&gt; sore recurrences on the lips and/or skin surrounding the lips in the previous year. The majority of their &lt;b&gt;cold&lt;/b&gt; sore recurrences proceeded by a...the duration of the &lt;b&gt;cold&lt;/b&gt; sore recurrence Be willing to refrain from participation in another clinical trial Be willing and able to use phone or internet to obtain... The purpose of this phase III study is to test the hypothesis that time to healing of a &lt;b&gt;cold&lt;/b&gt; sore will be lower </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NB-001 Treatment of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>12</NumberOfSites></Trial><Trial Id="92762"><Indications><Indication>Bleeding</Indication></Indications><CompaniesSponsor><Company>Massachusetts Eye &amp; Ear Infirmary</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2011-11-30T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>10-03-016</Identifier><Identifier>NCT01415583</Identifier></Identifiers><IndicationsAdverse><Indication>Bleeding</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>314</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> family history of any bleeding disorder will be excluded Subjects currently on oral corticosteroids for other medical conditions or have recently taken any oral corticosteroid within 2 weeks of surgery Patients with tonsillectomy performed using a &lt;b&gt;cold&lt;/b&gt; knife technique, microdebrider, coblation or plasma knife due to surgeon or parent preference Where appropriate subjects who do not have informed consent or child assent signed will be excluded Children&amp;lt; 3 years old will be excluded due to the fact</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Morbidity</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy</TitleDisplay><PrimaryCompletionDate type="Actual">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christopher Hartnick, MD</Name></ContactNames></Trial><Trial Id="92245"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-5 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Research &amp; Development Ltd</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>France</Country><Country>Australia</Country><Country>UK</Country><Country>Mexico</Country><Country>Czech Republic</Country><Country>Netherlands</Country><Country>Poland</Country><Country>Germany</Country><Country>Canada</Country></Countries><DateChangeLast>2019-05-22T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>115575</Identifier><Identifier>2012-001497-29</Identifier><Identifier>MEA115575</Identifier><Identifier>NCT01691508</Identifier><Identifier>SIRIUS</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Bronchitis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>mepolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>135</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Among the corticosteroid-dependent severe eosinophilic asthma (n = 45) subjects who previously used omalizumab for a median duration of 8 months, 82% of subjects discontinued use due to lack of efficacy. The primary exacerbation cause was allergy and &lt;b&gt;cold&lt;/b&gt; air in the prior omalizumab group and was respiratory infection in the no prior omalizumab group. Similar po corticosteroid reduction and exacerbation rate reduction (33 versus 29%) was observed in subjects previously treated with omalizumab when compared</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Glucose evaluations</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination - Cardiac evaluation</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Change in rescue medication use</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SIRIUS: Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with poorly controlled/not well controlled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with uncontrolled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>47</NumberOfSites><ContactNames><Name>Alfredo Gazca-Aguilar</Name><Name>Amal Assa'ad</Name><Name>Andrea Ludwig-Sengpiel</Name><Name>Anneke Brinke</Name><Name>Antoine Magnan</Name><Name>Arnaud Bourdin</Name><Name>Bronislava Novotna</Name><Name>Catherine Lemiere</Name><Name>Catherine Weiler</Name><Name>Charles Fogarty</Name><Name>Cheri Hudson</Name><Name>Dagmar Kindlova</Name><Name>Dante Hernandez-Colin</Name><Name>David Spencer</Name><Name>Dimitar Sajkov</Name><Name>Ekkehard Beck</Name><Name>Elisabeth Bel</Name><Name>Frederic Blay</Name><Name>GSK Clinical Trials</Name><Name>Geoffrey Chupp</Name><Name>Gert-Jan Braunstahl</Name><Name>Grazyna Pulka</Name><Name>Ian Pavord</Name><Name>James Martin</Name><Name>Jan Chlumsky</Name><Name>Jaromir Bystron</Name><Name>Jo Douglass</Name><Name>Kevin Mortimer</Name><Name>Mario Castro</Name><Name>Martin Hoffmann</Name><Name>Mathias Rolke</Name><Name>Michel Laviolette</Name><Name>Michel Aubier</Name><Name>Norbert Pauk</Name><Name>Oliver Kornmann</Name><Name>Parameswaran Nair</Name><Name>Peter Gibson</Name><Name>Peter Howarth</Name><Name>Philip Thompson</Name><Name>Piotr Kuna</Name><Name>Robert Mroz</Name><Name>Rohit Katial</Name><Name>Sabine Ballenberger</Name><Name>Sally Wenzel</Name><Name>Siegrid Hofmann</Name><Name>Stephanie Korn</Name><Name>Steven Meltzer</Name><Name>Vitezslav Kolek</Name><Name>Winfried Schroeder-Babo</Name><Name>Yves Donazzolo</Name><Name>Zenon Siergiejko</Name></ContactNames></Trial><Trial Id="91764"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-06-26T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01686646</Identifier><Identifier>RH01361</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>caffeine alone</Intervention><Intervention>paracetamol alone</Intervention><Intervention>caffeine plus paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>of &lt;b&gt;cold&lt;/b&gt; for&amp;lt; 96 h, rating of at least '2' on malaise at least 4 other symptoms of &lt;b&gt;cold&lt;/b&gt; No history of clinically significant perennial rhinitis, no recent antibiotic, anti-histamine or &lt;b&gt;cold&lt;/b&gt; treatment, no caffeine in the previous...This study would investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from common &lt;b&gt;cold&lt;/b&gt;, when taking a novel paracetamol and caffeine combination versus paracetamol alone.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Two Doses of a Common Cold Treatment on Alertness</TitleDisplay><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="91028"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Somatostatin receptor agonist</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>University of Miami</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>20110126</Identifier><Identifier>NCT01680861</Identifier></Identifiers><InterventionsControlDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Thymoglobulin alone</Intervention><Intervention>basiliximab alone</Intervention><Intervention>everolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Previously received or is receiving an organ transplant other than a kidney Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemic time&gt; 48 h ABO incompatible donor kidney Recipients of T cell, or B cell cross-match positive transplant Panel reactive antibody (PRA)&gt; 30% HIV or hepatitis C virus, or hepatitis B virus anti-genemia Current malignancy or a history of malignancy</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Tacrolimus/Everolimus Versus Tacrolimus/Enteric Coated Mycophenolate Sodium</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gaetano Ciancio, M.D.</Name></ContactNames></Trial><Trial Id="89855"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Respicopea Limited</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>BC1036-001</Identifier><Identifier>NCT01656668</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AG-1321001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>288</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to investigate the effect of BC-1036 (theobromine) on cough-related quality of life and cough severity following 2 weeks treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of the Safety and Effectiveness of BC-1036 Capsules to Treat Frequent Long-Term Cough</TitleDisplay><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Alan Jackson, MB, BS</Name><Name>Alun George, MA MBBS, DRCOG, DCH, MRCGP</Name><Name>Alyn Morice, BA(Hons) MB.B.Chir MA FRCP</Name><Name>Bernard Higgins, MB ChB, MRCP, MD</Name><Name>Chris Strang, MB BS, D. Obst, RCOG M</Name><Name>Damien McNally, MB,BCh,BAO,DRCOG,DMH,MRCGP</Name><Name>Fan Chung, MB, BS, MD, FRCP, DSc (PI)</Name><Name>Ian Pavord, MB BS, MRCP, FRCP, DM</Name><Name>Lorcan McGarvey, MBBCh,BAOHons,MRCP,MD,CCST(PI)</Name><Name>Philip Marazzi, MB, BS</Name><Name>Richard Oliver, MB ChB, MRCGP</Name><Name>Surinder Birring, BSc,MBChB(Hons),MRCP,MD(PI)</Name><Name>Warwick Coulson, BSc, MBBS, DipRCOG, MRCGP</Name></ContactNames></Trial><Trial Id="89313"><Indications><Indication>Hypercholesterolemia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>HMG CoA reductase inhibitor</Action><Action>Proprotein convertase PC9 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antihypertriglyceridemic agent</Action><Action>Cardioprotectant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antihypertriglyceridemic agent</Action><Action>Cardioprotectant</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Cell culture technique</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-31T00:00:00Z</DateChangeLast><DateEnd>2014-04-30T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC11568</Identifier><Identifier>NCT01644175</Identifier><Identifier>ODYSSEY Combo I</Identifier><Identifier>U1111-1121-4356</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>atorvastatin alone</Intervention><Intervention>lipid modifying therapy alone</Intervention><Intervention>rosuvastatin alone</Intervention><Intervention>simvastatin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>lipid modifying therapy alone</Intervention><Intervention>Variable regimens including alirocumab , atorvastatin , rosuvastatin , simvastatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>316</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Greater number of injection site reactions were observed in patients receiving alirocumab. These patients had more reports of associated symptoms. Also, these patients had reactions of longer average duration than patients receiving placebo. Common &lt;b&gt;cold&lt;/b&gt; and flu or flu-like symptoms are the other common adverse events occurring more frequently in patients with alirocumab than placebo [ 1680323 ]. In September 2015, pooled analysis of ten phase III trials in the ODYSSEY program ( LONG TERM , FH I , </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Low-density lipoprotein cholesterol (LDL-C) levels</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ODYSSEY Combo I: Efficacy and Safety of Alirocumab (SAR-236553/REGN-727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Hyperlipidemia/dyslipidemia</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Stable Coronary Artery Disease</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Primary Hypercholesterolemia</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with past or present history of coronary heart disease</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Primary Hypercholesterolemia</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Apolipoprotein A-I </BiomarkerName><BiomarkerName> Apolipoprotein B-100 </BiomarkerName><BiomarkerName> Apolipoprotein(a) </BiomarkerName><BiomarkerName> Conserved oligomeric Golgi complex subunit 2 </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lipoproteins </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Non-high density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>75</NumberOfSites><ContactNames><Name>Clinical Sciences &amp; Operations</Name></ContactNames></Trial><Trial Id="89149"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hanmi Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-07-13T00:00:00Z</DateChangeLast><DateEnd>2013-02-28T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>HM-MOLZ-301</Identifier><Identifier>KCT0000484</Identifier><Identifier>MOLZ</Identifier><Identifier>NCT01640535</Identifier></Identifiers><InterventionsControlDisplay><Intervention>levocetrizine alone</Intervention><Intervention>montelukast sodium alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>levocetirizine plus montelukast sodium</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>283</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>anomaly History of acute, chronic sinusitis within 30 days of visit 1 History of intranasal/eye surgeries within 3 months of visit 1 Initiation of immunotherapy or dose modification within 1 month prior to visit 1 Upper respiratory infections including &lt;b&gt;cold&lt;/b&gt; and systemic infections within 3 weeks of visit 1 Chronic use of tricyclic antidepressants, beta agonists, bronchodilators, etc, that may affect the efficacy of study drug At visit 2, patients who recorded Daytime Nasal Symptom Scores for fewer than</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of daytime symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of night time symptom score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MOLZ: Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Kyungmi Park</Name><Name>Minsook Jung</Name><Name>Yoan Park</Name></ContactNames></Trial><Trial Id="88355"><Indications><Indication>Idiopathic pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF-1 antagonist</Action><Action>FGF receptor antagonist</Action><Action>FGF1 receptor antagonist</Action><Action>FGF2 receptor antagonist</Action><Action>FGF3 receptor antagonist</Action><Action>Flt3 tyrosine kinase inhibitor</Action><Action>Lck tyrosine kinase inhibitor</Action><Action>Lyn tyrosine kinase inhibitor</Action><Action>PDGF receptor alpha antagonist</Action><Action>PDGF receptor antagonist</Action><Action>PDGF receptor beta antagonist</Action><Action>Src tyrosine kinase inhibitor</Action><Action>VEGF receptor antagonist</Action><Action>VEGF-1 receptor antagonist</Action><Action>VEGF-2 receptor antagonist</Action><Action>VEGF-3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Fibrosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Immuno-oncology</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>UK</Country><Country>Israel</Country><Country>Spain</Country><Country>China</Country><Country>Ireland</Country><Country>Germany</Country><Country>South Korea</Country><Country>Turkey</Country><Country>Australia</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Chile</Country><Country>Italy</Country><Country>Portugal</Country><Country>France</Country><Country>US</Country><Country>Belgium</Country><Country>Netherlands</Country><Country>Mexico</Country><Country>India</Country><Country>Greece</Country><Country>Japan</Country><Country>Finland</Country></Countries><DateChangeLast>2019-05-21T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2012-06-06T00:00:00Z</DateStart><Identifiers><Identifier>1199.33</Identifier><Identifier>2011-002766-21</Identifier><Identifier>CTRI/2013/01/003290</Identifier><Identifier>INPULSIS-ON</Identifier><Identifier>JapicCTI-121989</Identifier><Identifier>NCT01619085</Identifier><Identifier>UKCRN 12148</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Dyspnea</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Weight loss</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nintedanib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>752</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>-1120 were the most frequent AEs and leading to drug discontinuation in 5% (2.3 and 9.5% of patients continuing or initiating therapy, respectively) [ 1698764 ], [ 1700118 ]. In November 2015, results were presented. Diarrhea, nausea, cough, common &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis), bronchitis, difficult or labored breathing (dyspnea), IPF disease progression, decreased appetite, weight decreased and vomiting were the most common adverse events. IPF was the most frequent serious adverse event reported which </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Laboratory/Diagnostic Measures - Assessment of blood biochemistry</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Interstitial lung disease - Clinical Assessments - Assessment of liver function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>INPULSIS-ON: Extension Trial of the Long-term Safety of BIBF-1120 in Patients With Idiopathic Pulmonary Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Pancreatic alpha-amylase </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-07-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>85 Months</TrialDuration><NumberOfSites>192</NumberOfSites><ContactNames><Name>Aloke Ghosal</Name><Name>Anand Pendse</Name><Name>Ashish Kumar</Name><Name>Boehringer Ingelheim</Name><Name>Mahendra Kawedia</Name><Name>Parag Khatavkar</Name><Name>Partha Gokhale</Name><Name>Parthiv Mehta</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Sathish Shivappa</Name><Name>Virendra Singh</Name></ContactNames></Trial><Trial Id="88056"><Indications><Indication>Multiple sclerosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cannabinoid CB1 receptor modulator</Action><Action>Cannabinoid CB2 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Muscle relaxant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Drug combination</Technology><Technology>Formulation aerosol</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GW Pharmaceuticals plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-03-05T00:00:00Z</DateChangeLast><DateEnd>2005-02-28T00:00:00Z</DateEnd><DateStart>2001-07-31T00:00:00Z</DateStart><Identifiers><Identifier>GWMS0001 EXT</Identifier><Identifier>NCT01610687</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nabiximols, GW Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>137</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>improvements recorded and dosage taken remained stable. In 25 patients (of 62 approached) planned, sudden interruption of CBM for two weeks did not cause a consistent withdrawal syndrome, although at least one of--tiredness, interrupted sleep, hot and &lt;b&gt;cold&lt;/b&gt; flushes, mood alteration, reduced appetite, emotional lability, intoxication or vivid dreams was reported by11 (46%) patients [ 1531549 ]</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Pain - Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Spasticity</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple sclerosis - Subjects with Primary Progressive Multiple Sclerosis (PPMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Progressive Relapsing Multiple Sclerosis (PRMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Secondary Progressive Multiple Sclerosis (SPMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with spasticity</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with urinary bladder dysfunction</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Derick Wade, FRCP MD</Name></ContactNames></Trial><Trial Id="87326"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Centre Hospitalier Universitaire D Amiens</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2017-05-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-001385-18</Identifier><Identifier>CIME</Identifier><Identifier>NCT01595984</Identifier><Identifier>PI10-PR-CHOUKROUN</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ciclosporin, Novartis plus enteric-coated mycophenolate sodium, Novartis</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Patient receiving a kidney from a heart attack donor, or an ABO incompatible donor or a donor with a positive T-cross match Patient with a maximum PRA&gt; 20% twice &lt;b&gt;Cold&lt;/b&gt; ischemic time&gt; 36 h Patients with thrombocytopenia (&amp;lt; 75,000/mm3), neutropenia (&amp;lt; 1500/mm3), leukopenia (&amp;lt; 2500/mm3) or a hemoglobin concentration &amp;lt; 8 g/dl, at inclusion visit Patient with severe hyperlipidemia: total cholesterol &gt;/= 9 mmol/l (&gt;/= 3.50</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CIME: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI) Versus a CNI-free Treatment in Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>2</NumberOfSites></Trial><Trial Id="87068"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Poland</Country></Countries><DateChangeLast>2012-05-07T00:00:00Z</DateChangeLast><DateStart>2001-01-15T00:00:00Z</DateStart><Identifiers><Identifier>SCO30002</Identifier><Identifier>SFCT01</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication><Indication>Rhinitis</Indication><Indication>Sinusitis</Indication><Indication>Tracheitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>387</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Safety results showed that adverse events (AEs) were reported in 55, 56 and 48% of patients from the SFC, FP and placebo groups, respectively. The most commonly reported AEs were COPD exacerbation (79, 72 and 59%), influenzal syndrome (3, 2 and 2%), &lt;b&gt;cold&lt;/b&gt; (3, 2 and 2%), rhinitis (2, 3 and &amp;lt; 1%), bronchitis (2, 2 and 2%), tracheitis (2, 0 and 0%), oral candidiasis (2, &amp;lt; 1 and &amp;lt; 1%), and sinusitis (2, 0 and 2%), in the respective groups. Treatment-related non-fatal or fatal serious AEs (SAEs)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the safety and efficacy of fluticasone propionate/salmeterol combination 500/50 microg bid compared to fluticasone propionate 500 microg bid in the treatment of chronic obstructive pulmonary disease (COPD)</TitleDisplay><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate </BiomarkerName><BiomarkerName> Vital capacity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="86988"><ActionsSecondaryInterventionsPrimary><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Subunit vaccine</Action><Action>Toxoid vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable emulsion</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Merck &amp; Co Inc</Company></CompaniesSponsor><Countries><Country>Taiwan</Country></Countries><DateChangeLast>2017-08-09T00:00:00Z</DateChangeLast><DateEnd>2003-08-31T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>001-02</Identifier><Identifier>2004_079</Identifier><Identifier>NCT00092469</Identifier><Identifier>V441-001</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Fever</Indication><Indication>Gastroenteritis</Indication><Indication>Pediatric varicella zoster virus infection</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Hexavac alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>151</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of all systemic AEs was mostly mild and transient with the most prevalent AE being fever, followed by the second most prevalent AE of infections. Upper respiratory tract infection was the most common event observed with other events such as common &lt;b&gt;cold&lt;/b&gt;, chicken pox, and candidiasis. The most affected system in all reported AEs was body as a whole (fever and infection) followed by digestive system (gastroenteritis). Approximately 48% of the reported systemic AEs (89/184 events) were diagnosed as drug-related</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-diphtheria antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-hepatitis B antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-pertussis antibody seroprotection (PT)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-polio virus antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-polyribosyl-ribitol-phosphate antibody seroprotection (PRP)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-tetanus antibody seroprotection</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Assessment of anti-polio antibody concentration</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)</TitleDisplay><PatientSegmentTerms><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior hepatitis B vaccination(HBV)</PatientSegment><PatientSegment>Polio Vaccine - Subjects with Prior Other Vaccination</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2003-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Medical Monitor</Name></ContactNames></Trial><Trial Id="86920"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Isotechnika Pharma Inc</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>CTR20130372</Identifier><Identifier>INSPIRE</Identifier><Identifier>ISA10-12</Identifier><Identifier>NCT01586845</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tacrolimus alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>voclosporin alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>, HBV, HCV or tuberculosis Subjects receiving a a kidney from a non-heart beating donor Subjects receiving paired (en bloc or paired) kidney transplants Transplantation of multiple grafts (eg, kidney and pancreas) Subjects receiving a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 30 h Subjects receiving any transplanted organ other than a kidney Recipients of a bone marrow or stem cell transplant Any systemic infections requiring continued therapy at the time of entry into this study (prophylaxis against CMV </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>INSPIRE: Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2015-12-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chen</Name></ContactNames></Trial><Trial Id="86462"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>France</Country><Country>Germany</Country><Country>Spain</Country><Country>Belgium</Country><Country>Switzerland</Country><Country>UK</Country></Countries><DateChangeLast>2019-06-18T00:00:00Z</DateChangeLast><DateEnd>2015-10-13T00:00:00Z</DateEnd><DateStart>2012-01-16T00:00:00Z</DateStart><Identifiers><Identifier>2011-005154-57</Identifier><Identifier>CACZ885D2307E1</Identifier><Identifier>D2307E1</Identifier><Identifier>NCT01576367</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Dermatological disease</Indication><Indication>Diarrhea</Indication><Indication>Ear disease</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Gastroenteritis</Indication><Indication>Gastrointestinal disease</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Injury</Indication><Indication>Molluscum contagiosum infection</Indication><Indication>Ocular disease</Indication><Indication>Pneumonia</Indication><Indication>Poison intoxication</Indication><Indication>Respiratory disorder</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Vascular disease</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> In June 2016, results were presented. Out of 17 patients included, 12, 4, and 1 were found to be of muckle-wells syndrome (MWS), neonatal-onset multisystem inflammatory disease (NOMID), and familial &lt;b&gt;cold&lt;/b&gt; auto-inflammatory syndrome (FCAS) phenotypes, respectively. A total of 14 patients completed the study. Due to lack of therapeutic effect, two patients discontinued. By end of study (EOS), a total of 15 attained complete response (88.2%) at week 80</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of change in the overall condition of urticaria</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Overall therapeutic response</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety and Tolerability of ACZ-885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Others - Children and adolescents</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-10-13T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Information&amp;Communication Médicale</Name><Name>Inma Bosch</Name><Name>Medical Information Services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="86381"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Emulsion dermatological</Technology><Technology>Nucleoside synthesis</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesCollaborator><Company>TKL Research Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Meda Pharmaceuticals Ltd</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-04-10T00:00:00Z</DateChangeLast><DateEnd>2013-02-01T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>MP 800</Identifier><Identifier>NCT01574612</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aciclovir + hydrocortisone (dermatological), Medivir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to test the safety of Xerese (acyclovir + hydrocortisone) cream 5/1% for the treatment of recurrent &lt;b&gt;cold&lt;/b&gt; sores in children ages 6 to 11 years after 5 days of treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>An Open-label, Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6 to 11 Years Old</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Caroline Giullo</Name><Name>Claudia Cisneros</Name><Name>David Ginsburg, D.O.</Name><Name>Ellen Frankel</Name><Name>James Borders</Name><Name>Karen Hanna</Name><Name>Matthew Davis</Name><Name>Pierre Blemur</Name><Name>Robert Ford</Name><Name>Theresa Dayton</Name></ContactNames></Trial><Trial Id="8620"><Indications><Indication>Adult varicella zoster virus infection</Indication><Indication>Diabetic neuropathy</Indication><Indication>Neuropathic pain</Indication><Indication>Postherpetic neuralgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Grunenthal GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-07-03T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2006-12-31T00:00:00Z</DateStart><Identifiers><Identifier>796838</Identifier><Identifier>NCT00414349</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine transdermal patch (PHN/pain), Endo/Teikoku/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>sensomotor polyneurpathy of the lower extremities for&gt;/= 3 months (below the knees on both extremities) with at least 2 of the following symptoms present: burning, sensation, tingling or prickling, numbness from time to time, painful heat or &lt;b&gt;cold&lt;/b&gt; sensation (eg, warm or &lt;b&gt;cold&lt;/b&gt; water) Subjects with PHN and neuropathic pain present for&gt;/= 3 months after healing of the herpes zoster skin rash Without neurolytic neurosurgical therapy for their condition</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and safety of topical versus systemic treatment in post-herpetic neuralgia and diabetic poly-neuropathic pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ralf Baron</Name><Name>Ralf Baron, Prof. Dr.</Name></ContactNames></Trial><Trial Id="85802"><Indications><Indication>Fibromyalgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ocular antihistamine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Indiana University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-12-21T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>1106005839 (1106-01)</Identifier><Identifier>KetoforFMS</Identifier><Identifier>NCT01553318</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ketotifen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>51</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>medication that effects the central nervous system, eg, benzodiazepines, sedative/hypnotic, etc) during the 10-week study period unless medically necessary Must report all medication including herbal supplements and over-the-counter medications, eg, &lt;b&gt;cold&lt;/b&gt; medication, eye drops, etc, that he/she is currently taking to a member of the research team Must be willing to maintain a medication diary provided to him/her during the 10-week study period Must be willing to abstain any fibromyalgia related medication</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Fibromyalgia Impact Questionnaire (FIQ)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Musculoskeletal Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>KetoforFMS: Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with fibromyalgia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 2 </BiomarkerName><BiomarkerName> Eotaxin </BiomarkerName><BiomarkerName> Interleukin-8</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dennis C. Ang, MD</Name><Name>Janna Hilligoss</Name><Name>Melody Strickling</Name></ContactNames></Trial><Trial Id="8552"><Indications><Indication>Peripheral vascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Albumin modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Cardiovascular diagnostic agent</Action><Action>Endocrine diagnostic agent</Action><Action>MRI imaging agent</Action><Action>Neoplasm diagnostic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Intravenous formulation</Technology></Technologies><CompaniesCollaborator><Company>Bayer Schering Pharma AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>EPIX Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2008-03-18T00:00:00Z</DateChangeLast><DateEnd>2003-07-10T00:00:00Z</DateEnd><DateStart>2002-07-25T00:00:00Z</DateStart><IndicationsAdverse><Indication>Paresthesia</Indication><Indication>Taste disorder</Indication><Indication>Temperature disorder</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>gadofosveset alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Adverse events possibly or probably related to gadofosveset were generally mild and transient. The most common adverse events were paresthesia (7.3%), taste perversion (4.2%) and flushing, dry mouth, and feeling &lt;b&gt;cold&lt;/b&gt;, (each 2.1%) [ 496607 ].</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III study of gadofosveset for the detection of vascular disease in the pedal arteries</TitleDisplay><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Gregory Sorenson</Name></ContactNames></Trial><Trial Id="85409"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farmaceutica SA</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Norway</Country><Country>Brazil</Country><Country>Turkey</Country><Country>Argentina</Country><Country>Germany</Country><Country>France</Country><Country>Poland</Country><Country>Hungary</Country><Country>Sweden</Country><Country>US</Country><Country>Italy</Country><Country>Spain</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2018-09-24T00:00:00Z</DateEnd><DateStart>2012-08-17T00:00:00Z</DateStart><Identifiers><Identifier>2010-024381-21</Identifier><Identifier>CRAD001A2314</Identifier><Identifier>NCT01544491</Identifier><Identifier>P/006/2012</Identifier><Identifier>P/105/2011</Identifier><Identifier>P/105/2014</Identifier><Identifier>P/207/2010</Identifier></Identifiers><IndicationsAdverse><Indication>Infectious disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>steroid therapy alone</Intervention><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>everolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>106</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> At baseline: Recipients of kidneys from donors with known renal disease (such as diabetes nephropathy, nephrosclerosis), at the time of transplant Recipients of a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 24 h History of hypersensitivity or contraindications to any of the study drugs or to drugs of similar chemical classes, or to any of the excipients History of malignancy of any organ system treated or untreated, carrying possible risk</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, tolerability and safety of early introduction of everolimus, reduced calcineurin inhibitors and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in pediatric renal transplant recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Estradiol </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Inhibin B </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Testosterone </BiomarkerName><BiomarkerName> Thyroid-stimulating hormone </BiomarkerName><BiomarkerName> Thyroxine </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Triiodothyronine </BiomarkerName><BiomarkerName> Urinary protein </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-10-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Departamento médico (ICRO)</Name><Name>Drug Regulatory Affairs</Name><Name>Information&amp;Communication Médicales</Name><Name>Medical Competence Center</Name><Name>Medical Information Servcies</Name><Name>Medical information</Name><Name>Medisinsk Informasjon</Name><Name>Novartis Pharmaceuticals</Name><Name>Public Information Desk</Name><Name>clinical Trial Information Desk</Name></ContactNames></Trial><Trial Id="85047"><Indications><Indication>Male hypogonadism</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Androgen receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Repros Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01534208</Identifier><Identifier>ZA-300</Identifier></Identifiers><IndicationsAdverse><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Muscle spasm</Indication><Indication>Thromboembolism</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>testosterone (MD-lotion), Eli Lilly/Acrux alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>enclomifene citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>499</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In September 2013, results showed that thromboembolism was the only SAE reported in one subject. As the study was conducted during the &lt;b&gt;cold&lt;/b&gt;, flu and allergy season the most common AEs were those related to the upper respiratory tract infections (11.6%). Headache (6.6%), muscle spasms (4%), and fatigue (2.8%) were the other AEs reported. Only 0.2% of men experienced changes in visual acuity but 1.4% of men experienced transient blurred vision. The drug was well-tolerated and there were no dose response</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypogonadism - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of FSH and/or LH Levels</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Hormone Levels - Assessment of testosterone levels</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hypogonadism - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Hypogonadism - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypogonadism - Subjects with Secondary Hypogonadism</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Testosterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>Joseph S Podolski</Name><Name>Michele Rosner</Name></ContactNames></Trial><Trial Id="85018"><Indications><Indication>Premature labor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel inhibitor L-type</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Class IV antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>MemorialCare Health System</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>464-07</Identifier><Identifier>NCT00641784</Identifier></Identifiers><InterventionsControlDisplay><Intervention>magnesium sulfate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>nifedipine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>This study was designed to contemporarily assess the efficacy of oral nifedipine versus iv magnesium sulfate in the acute management of preterm labor in women with singleton gestations, in terms of defined early and late neonatal measures.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Tocolytics Trial: intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population</TitleDisplay><BiomarkerNames><BiomarkerName>Fibronectin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kenneth Chan, MD</Name><Name>Vineet K Shrivastava, MD</Name></ContactNames></Trial><Trial Id="84951"><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Danish Cancer Society</Company><Company>Eli Lilly &amp; Co</Company><Company>Herlev Hospital Region Hovedstaden</Company><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Danish Breast Cancer Cooperative Group</Company></CompaniesSponsor><DateChangeLast>2015-09-09T00:00:00Z</DateChangeLast><DateStart>2010-11-29T00:00:00Z</DateStart><IndicationsAdverse><Indication>Infectious disease</Indication><Indication>Neutropenia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>docetaxel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including docetaxel , docetaxel + gemcitabine , gemcitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>337</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This was a phase III, randomized study to compare safety and efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with predominantly human epidermal growth factor receptor (HER) 2-negative locally advanced or metastatic breast cancer [ 1262490 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III, randomized study to compare safety and efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer</TitleDisplay><BiomarkerNames><BiomarkerName>Metalloproteinase inhibitor 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="84925"><Indications><Indication>Diabetic peripheral neuropathy</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-03T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>E05-CL-3004</Identifier><Identifier>NCT01533428</Identifier><Identifier>STEP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>369</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>discontinuations due to drug-related TEAEs were reported [ 1694723 ]. In January 2017, results were published. Comparing two groups, except application site reactions all other treatment -emergent adverse events were similar. Sensory perception of sharp, &lt;b&gt;cold&lt;/b&gt;, warm, or vibration stimuli showed no indications of deterioration among groups [ 1900363 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Daily Pain Rating Scale (DPRS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STEP: A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8% Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic polyneuropathy</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>33</NumberOfSites><ContactNames><Name>Clinical Study Manager</Name></ContactNames></Trial><Trial Id="84352"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-5 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company><Company>The Netherlands Asthma Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Academic Medical Center, University of Amsterdam</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2019-03-14T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>MATERIAL</Identifier><Identifier>MATERIAL</Identifier><Identifier>NCT01520051</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mepolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aims of this mepolizumab study were to: To investigate whether interleukin(IL)-5 neutralization reduces the inflammatory response to viral airway infections in allergic asthma patients. To investigate whether IL-5 neutralization prevents or reduces asthma symptoms during virus-induced asthma exacerbations. To investigate whether IL-5 neutralization affects the cellular immune response to viral airway infections in allergic asthma patients. The hypothesis was that neutralization of IL-5 during</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Bronchial Biopsy/Bronchoalveolar Lavage (BAL) Markers - BAL fluid cell count</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum cytokines/interleukins/chemokines</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Antibody assays</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MATERIAL: Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects at risk of developing disease - Ex-Smokers</PatientSegment><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Intermittent/Episodic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Stable Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Asthma - Subjects without Asthma Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> C-C motif chemokine 20 </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Fractional concentration of exhaled nitric oxide </BiomarkerName><BiomarkerName> Immunoglobulin A </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-1 receptor antagonist protein </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Natural killer cells </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> T-lymphocytes </BiomarkerName><BiomarkerName> Tryptase </BiomarkerName><BiomarkerName> Vascular endothelial growth factor A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elisabeth H Bel, MD, PhD</Name><Name>Koenraad F van der Sluijs, PhD</Name><Name>Peter J Sterk, PhD</Name><Name>René Lutter, PhD</Name><Name>Suzanne M Bal, PhD</Name></ContactNames></Trial><Trial Id="83614"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Ecuador</Country><Country>Hungary</Country><Country>South Africa</Country><Country>Malaysia</Country><Country>Mexico</Country><Country>South Korea</Country><Country>Georgia</Country><Country>Ukraine</Country><Country>Czech Republic</Country><Country>Brazil</Country><Country>Slovakia</Country><Country>Poland</Country><Country>Taiwan</Country><Country>Spain</Country><Country>US</Country></Countries><DateChangeLast>2018-03-21T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022743-37</Identifier><Identifier>HEC2</Identifier><Identifier>NCT01500213</Identifier><Identifier>TS-P04833</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Constipation</Indication><Indication>Dyspepsia</Indication><Indication>Febrile neutropenia</Indication><Indication>Headache</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , placebo + granisetron + dexamethasone , rolapitant (oral), TESARO , rolapitant + granisetron + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>555</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patient receiving highly emetogenic chemotherapy (HEC) [ 1745904 ]. Main objective of the trial was to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt; 24 to 120 h) of CINV compared with administration of placebo with granisetron and dexamethasone in patients receiving HEC. The primary outcome would be based on</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HEC2: Phase III, Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment><PatientSegment>Cancer supportive care - Nausea and Vomiting - Highly emetic chemotherapy</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Ira Oliff</Name><Name>Joy Jardincino</Name><Name>Lorraine Hughes</Name><Name>Project Manager</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="83613"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Ukraine</Country><Country>Belarus</Country><Country>Spain</Country><Country>Portugal</Country><Country>Italy</Country><Country>Ecuador</Country><Country>Czech Republic</Country><Country>Mexico</Country><Country>Puerto Rico</Country><Country>South Korea</Country><Country>Taiwan</Country><Country>Bulgaria</Country><Country>Hong Kong</Country><Country>Argentina</Country><Country>Romania</Country><Country>Russian Federation</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Peru</Country><Country>Latvia</Country><Country>South Africa</Country><Country>France</Country><Country>US</Country><Country>Poland</Country><Country>Slovakia</Country><Country>Chile</Country><Country>Georgia</Country></Countries><DateChangeLast>2019-01-23T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022746-24</Identifier><Identifier>NCT01500226</Identifier><Identifier>TS-P04834</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Constipation</Indication><Indication>Dizziness</Indication><Indication>Dyspepsia</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Stomatitis</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>dexamethasone plus granisetron</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , rolapitant (oral), TESARO</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1369</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patients receiving moderately emetogenic chemotherapy (MEC). Rolapitant or placebo would be administered orally 1 to 2 h prior to the initiation of chemotherapy on day 1 [ 1279872 ], [ 1745904 ]. The primary objective of the study was: To determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt; 24 to 120 h) of CINV</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase III, Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>29</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Ira Oliff</Name><Name>Joy Jardincino</Name><Name>Lorraine Hughes</Name><Name>Project Manager</Name><Name>Project Manger</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="83578"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pharm Olam de México, S. de R.L. de C.V.</Company></CompaniesCollaborator><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country><Country>Chile</Country><Country>Thailand</Country><Country>Puerto Rico</Country><Country>Philippines</Country><Country>Canada</Country><Country>Portugal</Country><Country>Bulgaria</Country><Country>Argentina</Country><Country>Italy</Country><Country>Spain</Country><Country>Romania</Country><Country>Peru</Country><Country>Latvia</Country><Country>Belgium</Country><Country>Russian Federation</Country><Country>US</Country><Country>Hungary</Country><Country>Mexico</Country><Country>Belarus</Country><Country>France</Country><Country>Guatemala</Country></Countries><DateChangeLast>2018-03-21T00:00:00Z</DateChangeLast><DateEnd>2014-05-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022742-25</Identifier><Identifier>HEC1</Identifier><Identifier>NCT01499849</Identifier><Identifier>TS-P04832</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Constipation</Indication><Indication>Dyspepsia</Indication><Indication>Headache</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>dexamethasone plus granisetron</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , placebo + granisetron + dexamethasone , rolapitant (oral), TESARO , rolapitant + granisetron + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>532</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patients receiving HEC. Rolapitant or placebo would be administered prior to initiation of chemotherapy on day 1 with granisetron and dexamethasone. Patients would record all events of emesis and use of rescue medication for established nausea and/or vomiting, and would indicate the severity of nausea they experienced in each of the previous 24 h in the Nausea and Vomiting (NV</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HEC1: Phase III, Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy</TitleDisplay><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>27 Months</TrialDuration><NumberOfSites>44</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Lorraine Hughes</Name><Name>Lynnann Waggoner</Name><Name>Project Manager</Name><Name>Ricardo Uribe</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="8286"><Indications><Indication>Seizure disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action><Action>Glutamate release inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Europe</Country><Country>Australia</Country><Country>US</Country></Countries><DateChangeLast>2014-01-17T00:00:00Z</DateChangeLast><DateStart>1997-12-31T00:00:00Z</DateStart><Identifiers><Identifier>105-123</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Viral infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamotrigine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>169</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled study of lamotrigine in children and young adults with Lennox-Gastaut syndrome [ 438112 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Epilepsy - Assessment of Epilepsy Syndromes</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Generalized Seizures</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Response Rates (RR) - Assessment of response rate</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency</EndpointIndex><EndpointIndex>Epilepsy - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Epilepsy - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Lennox-Gastaut Quality of Life Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A randomized, double-blind, placebo-controlled study of lamotrigine in children and young adults with Lennox-Gastaut syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Epilepsy - Subjects with Lennox-Gastaut Syndrome</PatientSegment><PatientSegment>Epilepsy - Subjects with Primarily Generalized Seizures - Subjects with absence seizures</PatientSegment><PatientSegment>Epilepsy - Subjects with Primarily Generalized Seizures - Subjects with tonic-clonic seizures</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="82638"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>Ukraine</Country><Country>UK</Country><Country>Belgium</Country><Country>Italy</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Germany</Country><Country>Spain</Country><Country>Europe</Country><Country>Netherlands</Country><Country>France</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2014-02-27T00:00:00Z</DateEnd><DateStart>2011-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016458-42</Identifier><Identifier>E05-CL-3002</Identifier><Identifier>NCT01478607</Identifier><Identifier>PACE</Identifier></Identifiers><IndicationsAdverse><Indication>Edema</Indication><Indication>Erythema</Indication><Indication>Fatigue</Indication><Indication>Influenza virus infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>standard of Care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention><Intervention>standard of Care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>468</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> for majority of tests at EoS across all treatment arms. Numerically greater improvements were observed in the reporting of ‘normal' sharp (on ball of foot), warm and &lt;b&gt;cold&lt;/b&gt; sensation in arms 1 and 2 versus arm 3. In all arms, there was a reduction in the percentage of patients experiencing ‘absence' sharp (on ball of foot) warm, &lt;b&gt;cold&lt;/b&gt; and vibration by EoS. Arm 2 had greatest numerical change in the ‘absent' category with these tests. At EoS, only fewer patients in all three arms had ‘absent' or ‘markedly</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Liver Functions - Alanine aminotransferase (ALT)/Serum glutamic-pyruvic transaminase (SGPT)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Liver Functions - Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Renal Function - Assessment of Blood Urea Nitrogen (BUN)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Diabetic Complications &amp; Events - Diabetic neuropathy</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Liver Functions - Alanine aminotransferase (ALT)/Serum glutamic-pyruvic transaminase (SGPT)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Liver Functions - Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Renal Function - Assessment of Blood Urea Nitrogen (BUN)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PACE: A Study to Evaluate the Long-Term Safety of Repeated Qutenza Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic polyneuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>27 Months</TrialDuration><NumberOfSites>86</NumberOfSites><ContactNames><Name>Senior Clinical Study Manager</Name><Name>Service Desk</Name></ContactNames></Trial><Trial Id="82247"><Indications><Indication>Bone disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Parathyroid hormone ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bone metabolism modulator</Action><Action>Bone synthesis stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Aarhus University Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aarhus University</Company><Company>Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-05-25T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-004465-32</Identifier><Identifier>2011/386</Identifier><Identifier>NCT01466829</Identifier><Identifier>PAATH</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to compare healing time and quality of newly formed bone in cardiac surgery patients treated with parathyroid hormone (PTH) post-surgically and a control group treated with saline.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Male</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PAATH: Treatment With PTH After Sternotomy in Cardiac Surgery Patients</TitleDisplay><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Per Nielsen, MD</Name></ContactNames></Trial><Trial Id="82176"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation stimulator</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Glycoprotein</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Protein recombinant</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Novo Nordisk A/S</Company></CompaniesSponsor><Countries><Country>Japan</Country><Country>South America</Country><Country>US</Country><Country>Europe</Country><Country>Taiwan</Country><Country>UK</Country><Country>France</Country><Country>Croatia</Country><Country>Canada</Country><Country>Asia</Country><Country>Malaysia</Country><Country>Brazil</Country><Country>North America</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2019-02-09T00:00:00Z</DateChangeLast><DateEnd>2023-11-30T00:00:00Z</DateEnd><DateStart>2012-05-16T00:00:00Z</DateStart><Identifiers><Identifier>11093</Identifier><Identifier>2011-000826-31</Identifier><Identifier>JapicCTI-121877</Identifier><Identifier>NCT01467427</Identifier><Identifier>NMRR-12-109-11093</Identifier><Identifier>NN7999-3774</Identifier><Identifier>P/292/2010</Identifier><Identifier>U1111-1119-5013</Identifier><Identifier>UKCRN 12600</Identifier><Identifier>paradigm 5</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Contusion</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Eosinophilia</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nonacog beta pegol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of the trial was to evaluate safety, efficacy and pharmacokinetics of NNC-0156-0000-0009 (nonacog beta pegol, N9-GP) in previously treated patient with hemophilia B. This trial was conducted in Asia, Europe and North America [ 1497246 ], [ 1725602 ], [ 2021695 ]. The primary objective was to evaluate immunogenicity of glycopegylated recombinant coagulation factor IX (NNC-0156-0000-0009; N9-GP). The secondary objectives were: To evaluate safety other than immunogenicity of N9-GP. To evaluate</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Hemostatic Efficacy</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development - Assessment of development of factor IX inhibitor</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of number of bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>paradigm 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment><PatientSegment>Hemophilia - Subjects with Moderate Hemophilia</PatientSegment><PatientSegment>Hemophilia - Subjects with Severe Hemophilia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-Coagulation factor IX antibodies </BiomarkerName><BiomarkerName> Coagulation factor IX</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>138 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Clinical Disclosure (1452)</Name><Name>Faraizah Abdul Karim</Name><Name>Lene  Hasselriis</Name><Name>Marianne  Fridberg</Name><Name>Miss Teh Huiping</Name><Name>Ms Tan Enn Swan</Name><Name>Novo Nordisk</Name><Name>Paula  Persson</Name></ContactNames></Trial><Trial Id="81688"><Indications><Indication>Factor VIII deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor VIII agonist</Action><Action>Factor VIII modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood clotting modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Ireland</Country><Country>South Africa</Country><Country>Germany</Country><Country>US</Country><Country>Hong Kong</Country><Country>Italy</Country><Country>India</Country><Country>Austria</Country><Country>Poland</Country><Country>Australia</Country><Country>Israel</Country><Country>China</Country><Country>Japan</Country><Country>Russian Federation</Country><Country>Brazil</Country><Country>France</Country><Country>Turkey</Country><Country>Portugal</Country><Country>Chile</Country><Country>Belgium</Country><Country>Switzerland</Country><Country>Sweden</Country><Country>UK</Country><Country>Netherlands</Country><Country>New Zealand</Country><Country>Canada</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-003072-37</Identifier><Identifier>8HA01EXT</Identifier><Identifier>ASPIRE</Identifier><Identifier>CCRN 767</Identifier><Identifier>CTRI/2012/07/002772</Identifier><Identifier>NCT01454739</Identifier><Identifier>P/077/2014</Identifier><Identifier>UKCRN 11705</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Dental caries</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Hernia</Indication><Indication>Hot flashes</Indication><Indication>Influenza virus infection</Indication><Indication>Joint disease</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>efmoroctocog alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>to rFVIIIFc [ 1635451 ]. In August 2015, results were published. Safety results were consistent with the general hemophilia A population across the age groups. Serious allergic reactions and vascular clots were not observed. Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), arthralgia (joint pain) and upper respiratory infection with an incidence of &gt;/= 5% were the most commonly observed adverse events [ 1685091 ]. In December 2015, pooled results from NCT01027377 and NCT01454739 studies were presented. In patients </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of annualised bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term></TermsPatientSelection><TitleDisplay>ASPIRE: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia A</PatientSegment><PatientSegment>Hemophilia - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>108</NumberOfSites><ContactNames><Name>Alok Srivastava</Name><Name>Anjali Nagpal</Name><Name>Cecil Ross</Name><Name>Joseph John</Name><Name>Medical Director</Name><Name>Naresh Gupta</Name><Name>Non Disponibile</Name><Name>Not available</Name><Name>Ritika Bajaj</Name><Name>Shashikant Apte</Name><Name>non disponibile</Name></ContactNames></Trial><Trial Id="81180"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Helsinn Healthcare SA</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Estonia</Country><Country>Chile</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>France</Country><Country>Argentina</Country><Country>Romania</Country><Country>UK</Country><Country>Peru</Country><Country>Serbia</Country><Country>Poland</Country><Country>Ukraine</Country><Country>Hungary</Country><Country>US</Country><Country>Bulgaria</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-04-05T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2010-022872-30</Identifier><Identifier>DRKS00003925</Identifier><Identifier>NCT01442376</Identifier><Identifier>PALO-10-20</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ondansetron alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>palanosetron hydrochloride alone</Intervention><Intervention>palonosetron (high dose) alone</Intervention><Intervention>palonosetron (low dose) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>502</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>practice and if deemed appropriate by the investigator Dimenhydrinate; hydroxyzine; domperidone; lorazepam; cyclizine; cannabinoids;  scopolamine; trimetobenzamide Hcl; meclizine hydrochloride; pseudoephedrine Hcl Over the counter (OTC) antiemetics, OTC &lt;b&gt;cold&lt;/b&gt; or OTC allergy medications Herbal preparations containing ephedra or ginger Patient aged&amp;lt;/= 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age group and any indication) within</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>68</NumberOfSites><ContactNames><Name>Adriana Berretta</Name><Name>Alexander Moskalenko</Name><Name>Alicja Chybicka</Name><Name>Ana Guerra</Name><Name>Anca Colita</Name><Name>Angelina Stoyanova</Name><Name>Anna Balcerska</Name><Name>Antonio Aptowitzer</Name><Name>Armando Picon</Name><Name>Bohumir Blazek</Name><Name>Christopher Frantz</Name><Name>Clarke Anderson</Name><Name>Claudio Chamorro</Name><Name>Claudio Sandoval</Name><Name>Cristian La Rosa</Name><Name>Danuse Dembicka</Name><Name>Danuta Perek</Name><Name>Dragan Bobev</Name><Name>Edita Kabickova</Name><Name>Elena Basharova</Name><Name>Emilia Mihut</Name><Name>Francisco Cifuentes</Name><Name>Gabor Kovacs</Name><Name>Georgy Mentkevich</Name><Name>Hryhorii Klymniuk</Name><Name>Ingrith Miron</Name><Name>Irene Cherrick</Name><Name>Irene Slavc</Name><Name>Ivan Zhurylo</Name><Name>J. Johnston</Name><Name>Jacqueline Kraveka</Name><Name>Janic Dragana</Name><Name>Jeffrey Schwartz</Name><Name>Jerzy Kowalczyk</Name><Name>Jochen Roessler</Name><Name>John Geil</Name><Name>Juan Bustos</Name><Name>Juan Leon</Name><Name>Kadri Saks</Name><Name>Kateryna Vilchevska</Name><Name>Lauren Akers</Name><Name>Ljiljana Pejcic</Name><Name>Manisha Bansal</Name><Name>Margaret Macy</Name><Name>Margarita Belogurova</Name><Name>Mariusz Wysockl</Name><Name>Mark Ranalli</Name><Name>Miklos Garami</Name><Name>Milena Cickovic</Name><Name>Monica Dragomir</Name><Name>Monica Makiya</Name><Name>Nicolas Sirvent</Name><Name>Oleksandr Dudnichenko</Name><Name>Ramamoorthy Nagasubramanian</Name><Name>Rinat Galiulin</Name><Name>Robert Saylors</Name><Name>Ruth Ladenstein</Name><Name>Sandor Turi</Name><Name>Sirje Mikkel</Name><Name>Svetlana Gorbatykh</Name><Name>Thorsten Simon</Name><Name>Tomas Votava</Name><Name>Valerya Kaleva</Name><Name>Vladimir Lebedev</Name><Name>Wojciech Mlynarski</Name></ContactNames></Trial><Trial Id="81133"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology></Technologies><CompaniesCollaborator><Company>Swedish Orphan Biovitrum AB</Company></CompaniesCollaborator><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Biogen Inc</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>UK</Country><Country>US</Country><Country>Netherlands</Country><Country>South Africa</Country><Country>Ireland</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-003076-36</Identifier><Identifier>9HB02PED</Identifier><Identifier>Kids B-LONG</Identifier><Identifier>NCT01440946</Identifier><Identifier>P/123/2011</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Factor IX plus eftrenonacog alfa</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> the study due to an adverse event [ 1637201 ]. In February 2017, results were presented. rFIXFc was well tolerated and adverse events (AEs) observed were typical of the pediatric hemophilia B population. The most common AEs were found to be common &lt;b&gt;cold&lt;/b&gt; (23%) and fall (20%).  Four participants experienced serious AEs, all of which were assessed as unrelated to rFIXFc by the investigators. There were no reports of anaphylaxis or serious hypersensitivity reactions to rFIXFc, no vascular thrombotic events</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of annualised bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Kids B-LONG: Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB-029, in Previously Treated Pediatric Participants With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment><PatientSegment>Hemophilia - Subjects with Severe Hemophilia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Medical Director</Name><Name>Roshni Kulkarni</Name><Name>not available</Name></ContactNames></Trial><Trial Id="81011"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Mundipharma Research GmbH &amp; Co. KG</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>UK</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Hungary</Country><Country>Spain</Country><Country>Germany</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-002901-31</Identifier><Identifier>NCT01439100</Identifier><Identifier>OXN2504</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>oxycodone + naloxone (prolonged release tablet, pain), Mundipharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>172</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>benefit from WHO step III opioid therapy for the duration of the study Subjects must not have received opioid containing medication in the last 6 months on a regular basis (ie, prescribed medication or more than occasional self medication use for cough, &lt;b&gt;cold&lt;/b&gt; etc.)  Receiving stable treatment for Parkinson's disease for at least 4 weeks prior to randomization, the dose of which is expected to remain consistent throughout the double-blind phase  In the Investigator's opinion, the subject does not have visual</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Central nervous system disease outcomes</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of Life (Unspecified)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Non-Motor Symptoms of Parkinson's Disease - Assessment of sensory function</EndpointIndex><EndpointIndex>Parkinsons disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of Life (QOL) questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Placebo-Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Psychogenic Pain</PatientSegment><PatientSegment>Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment><PatientSegment>Parkinsons disease - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>Attila Csanyi</Name><Name>Bernard Boothman</Name><Name>Ernest Balaguer</Name><Name>Joseph Classen</Name><Name>Julia Lajtos</Name><Name>Kallol Chaudhuri</Name><Name>Karis Eggert</Name><Name>Reinhard Ehret</Name><Name>Simon Ellis</Name><Name>Valeria Albu</Name></ContactNames></Trial><Trial Id="80946"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-08T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>ALO-02-10-3001</Identifier><Identifier>B4531001</Identifier><Identifier>NCT01428583</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Myocardial infarction</Indication><Indication>Nausea</Indication><Indication>Pneumonia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>oxycodone + naltrexone (abuse-resistant), Pfizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>395</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was designed to provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules ( ALO-02 ) in a chronic non-cancer pain population.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of dependency potential</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Non-Cancer Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>67</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="80828"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Sustained release formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>France</Country><Country>Finland</Country><Country>Czech Republic</Country><Country>Denmark</Country><Country>China</Country><Country>India</Country><Country>Australia</Country><Country>Hungary</Country><Country>Netherlands</Country><Country>New Zealand</Country><Country>Japan</Country><Country>Bulgaria</Country><Country>Slovenia</Country><Country>Germany</Country><Country>Guatemala</Country><Country>Canada</Country><Country>South Korea</Country><Country>Turkey</Country><Country>Portugal</Country><Country>Mexico</Country><Country>US</Country><Country>Estonia</Country><Country>Italy</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-11-26T00:00:00Z</DateChangeLast><DateEnd>2013-09-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>1237.5</Identifier><Identifier>2009-010668-40</Identifier><Identifier>CTRI/2012/04/002557</Identifier><Identifier>JapicCTI-111687</Identifier><Identifier>NCT01431274</Identifier><Identifier>TONADO 1</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiovascular disease</Indication><Indication>Cerebrovascular disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Pneumonia</Indication><Indication>Respiratory disease</Indication><Indication>Stroke</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>olodaterol alone</Intervention><Intervention>tiotropium bromide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2624</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>5 microg: 74.7%; tiotropium 5 microg: 73.3%; tiotropium 2.5 microg: 73.4%; olodaterol 5 microg: 76.6% [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies (NCT01431274 and NCT01431287). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ]. In January 2017, pooled results were published from two 52-week phase III trials (NCT01431274 and  NCT01431287 ). In the total population as well as in patient</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TONADO 1: Tiotropium plus Olodaterol Fixed-Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>197</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>George Dsouza</Name><Name>Jenny Gullberg</Name><Name>Mahesh</Name><Name>Manuel Quaresma</Name><Name>Pradyut Waghray</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Raj Bhagat</Name><Name>Satish</Name><Name>Sharad Thikkiwal</Name><Name>Shoma Das</Name><Name>Sundeep Salvi</Name><Name>Virendra Singh</Name><Name>V Pattabhiraman</Name></ContactNames></Trial><Trial Id="80827"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Sustained release formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim AB</Company><Company>Boehringer Ingelheim GmbH</Company><Company>Boehringer Ingelheim International GmbH</Company><Company>Boehringer Ingelheim Ltd</Company><Company>SCS Boehringer Ingelheim Comm.V</Company></CompaniesSponsor><Countries><Country>Slovakia</Country><Country>China</Country><Country>US</Country><Country>Spain</Country><Country>Canada</Country><Country>Hungary</Country><Country>South Africa</Country><Country>Austria</Country><Country>Norway</Country><Country>Russian Federation</Country><Country>Turkey</Country><Country>Belgium</Country><Country>Serbia</Country><Country>Taiwan</Country><Country>Brazil</Country><Country>India</Country><Country>Romania</Country><Country>Sweden</Country><Country>Colombia</Country><Country>Germany</Country><Country>Japan</Country><Country>Croatia</Country><Country>Ireland</Country><Country>UK</Country><Country>Peru</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2013-11-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>111688</Identifier><Identifier>1237.6</Identifier><Identifier>2009-010669-22</Identifier><Identifier>CCRN 438</Identifier><Identifier>CTRI/2012/04/002554</Identifier><Identifier>NCT01431287</Identifier><Identifier>TONADO 2</Identifier><Identifier>TONADO TM 2</Identifier><Identifier>UKCRN 11670</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiovascular disease</Indication><Indication>Cerebrovascular disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Pneumonia</Indication><Indication>Respiratory disease</Indication><Indication>Stroke</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>olodaterol alone</Intervention><Intervention>tiotropium bromide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2539</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> microg: 74.7%; tiotropium 5 microg: 73.3%; tiotropium 2.5 microg: 73.4%; olodaterol 5 microg: 76.6% [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies ( NCT01431274 and NCT01431287). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ]. In January 2017, pooled results were published from two 52-week phase III trials ( NCT01431274 and NCT01431287). In the total population as well as in patient</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC post bronchodilator administration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TONADO TM 2: Tiotropium + Olodaterol Fixed-Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>223</NumberOfSites><ContactNames><Name>Aloke Ghosal</Name><Name>B. Mutha</Name><Name>Boehringer Ingelheim</Name><Name>Jenny Gullberg</Name><Name>Manish Jain</Name><Name>Parag Khatavkar</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Rajesh Swaranakar</Name><Name>Roland Buh</Name><Name>S. Balamurugan</Name><Name>Shoma Das</Name><Name>Sujeet Rajan</Name><Name>Tushar Sahastrabuddhe</Name></ContactNames></Trial><Trial Id="80695"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology></Technologies><CompaniesCollaborator><Company>Swedish Orphan Biovitrum AB</Company></CompaniesCollaborator><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Italy</Country><Country>France</Country><Country>Panama</Country><Country>Brazil</Country><Country>Australia</Country><Country>Sweden</Country><Country>Belgium</Country><Country>Canada</Country><Country>UK</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Japan</Country><Country>Germany</Country><Country>Hong Kong</Country><Country>India</Country><Country>China</Country><Country>Ireland</Country><Country>South Africa</Country><Country>US</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2011-12-08T00:00:00Z</DateStart><Identifiers><Identifier>2011-003075-11</Identifier><Identifier>9HB01EXT</Identifier><Identifier>B-YOND</Identifier><Identifier>CTRI/2012/05/002708l</Identifier><Identifier>NCT01425723</Identifier><Identifier>P/303/2014</Identifier><Identifier>UKCRN 11703</Identifier></Identifiers><IndicationsAdverse><Indication>Allergy</Indication><Indication>Common cold</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hematuria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>eftrenonacog alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>common &lt;b&gt;cold&lt;/b&gt; and vomiting were the most common adverse events (incidence of &amp;gt;/= 5%) for adults and adolescents. Whereas, falls, common &lt;b&gt;cold&lt;/b&gt; and seasonal allergy were the most common adverse events for &amp;nbsp;children aged &amp;lt; 12 years [ 1686917...2017 [ 1899444 ]. In March 2017, interim&amp;nbsp;results were presented. rFIXFc was found to be well-tolerated and headache (12.1%), common &lt;b&gt;cold&lt;/b&gt; (11.2%) were the most common AEs unrelated to rFIXFc. A total of 39 serious AEs (SAEs) were reported in 23 patients</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of number of bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term></TermsPatientSelection><TitleDisplay>B-YOND: Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>65</NumberOfSites><ContactNames><Name>Alok Srivastava</Name><Name>Anjali Nagpal</Name><Name>Cecil Ross</Name><Name>John Pasi, MD, PhD</Name><Name>Medical Director</Name><Name>ND</Name><Name>Not available</Name><Name>Ritika Bajaj</Name><Name>Shashikant Apte</Name></ContactNames></Trial><Trial Id="80267"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-08-08T00:00:00Z</DateChangeLast><DateStart>1994-01-13T00:00:00Z</DateStart><Identifiers><Identifier>FLUTI/AH92/N114</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Headache</Indication><Indication>Hoarseness</Indication><Indication>Infectious disease</Indication><Indication>Influenza virus infection</Indication><Indication>Rhinopharyngitis</Indication><Indication>Throat disease</Indication><Indication>Tooth disease</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate (fixed) alone</Intervention><Intervention>fluticasone propionate (step-down) alone</Intervention><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>332</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Across treatment periods, the most frequent adverse events (AEs) reported in the fluticasone propionate step-down and fluticasone propionate fixed groups were headache, acute nasopharyngitis, sore throat, influenza, chest infection, asthma, hoarseness, &lt;b&gt;cold&lt;/b&gt; symptoms, exacerbation of asthma, toothache, cough and upper respiratory tract infection [ 1217186 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, multicenter, double-blind, parallel-group study to compare the efficacy, safety and tolerability of a high-dose treatment regimen of fluticasone propionate (2.0 mg reducing to 0.5 mg daily) with a fixed-dose of fluticasone propionate (0.5 mg daily) in maintaining the control attained following oral corticosteroid therapy for an acute severe exacerbation of asthma in adult patients</TitleDisplay><BiomarkerNames><BiomarkerName>Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="80072"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Ahn-Gook Pharmaceuticals Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-04-09T00:00:00Z</DateChangeLast><DateEnd>2011-05-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>AG1321001_ACP3</Identifier><Identifier>NCT01416480</Identifier></Identifiers><InterventionsControlDisplay><Intervention>levodropropizine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>AG-1321001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>332</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this clinical trial was to evaluate the antitussive effect of theobromine capsule 300 mg in patients with acute bronchitis.</Teaser><TrialCategories><Category>Borderline product</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical Trial to Evaluate the Safety and Efficacy of 'Theobromine Capsule' as an Antitussive in Acute Cougher</TitleDisplay><PrimaryCompletionDate type="Actual">2011-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jae Yeol Kim, M.D.</Name><Name>Jung Hyun chang, M.D.</Name><Name>Ki-Suck Jung, M.D.</Name><Name>Kwan Ho Lee, M.D.</Name><Name>Soo-Taek Uh, M.D.</Name><Name>Sung Soon Lee, M.D.</Name><Name>Yong Bum Park, M.D.</Name><Name>Young Kyoon Kim, M.D.</Name></ContactNames></Trial><Trial Id="80017"><Indications><Indication>Essential hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha adrenoceptor antagonist</Action><Action>Beta adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Antioxidant agent</Action><Action>Cardiac agent</Action><Action>Class II antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2011-08-16T00:00:00Z</DateChangeLast><DateStart>1989-03-31T00:00:00Z</DateStart><Identifiers><Identifier>105517/132</Identifier><Identifier>CAR-UK-104</Identifier></Identifiers><IndicationsAdverse><Indication>Bradycardia</Indication><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Migraine</Indication><Indication>Nausea</Indication><Indication>Orthostatic hypotension</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>carvedilol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>232</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Results were published in September 2005. The most commonly observed adverse events (AEs) were relating to dizziness and/or postural hypotension, fatigue, headache/migraine, shortness of breath, nausea/vomiting, &lt;b&gt;cold&lt;/b&gt;/influenza, and malaise. The serious AEs observed were relating to dizziness and/or postural hypotension, bradycardia, nausea, vomiting and diarrhea, raised liver function tests and glucose [ 1215236 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, double-blind, multicenter, parallel group study to evaluate the efficacy and safety of carvedilol in the elderly patients with mild to moderate essential hypertension</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="79174"><Indications><Indication>Psoriatic arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>Australia</Country><Country>Italy</Country><Country>Bulgaria</Country><Country>Germany</Country><Country>Canada</Country><Country>US</Country><Country>UK</Country><Country>Belgium</Country><Country>Brazil</Country><Country>Slovakia</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Russian Federation</Country><Country>Singapore</Country><Country>Argentina</Country><Country>Philippines</Country><Country>Thailand</Country><Country>Romania</Country></Countries><DateChangeLast>2019-06-27T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-000276-34</Identifier><Identifier>CAIN457F2306</Identifier><Identifier>F2306</Identifier><Identifier>FUTURE 1</Identifier><Identifier>NCT01392326</Identifier><Identifier>UKCRN ID: 11416</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Candida infection</Indication><Indication>Crohns disease</Indication><Indication>Headache</Indication><Indication>Hypercholesterolemia</Indication><Indication>Infectious disease</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>606</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>a stroke (0.6/100 patient-years), and two had a myocardial infarction (0.3/100 patient-years), throughout the study as compared with no patients in the placebo group [ 1699501 ]. In November 2015, results were presented. Nasopharyngitis (the common &lt;b&gt;cold&lt;/b&gt;, 19.6%), upper respiratory tract infection (19.1%) and back pain (8.9%) were the most common adverse events (AEs) for either secukinumab dose. Serious adverse event (SAE) rates were and 11.0% for secukinumab 150 and 75 mg, respectively [ 1710928 ],</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 20 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 70 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Joint Disease Progression</EndpointIndex><EndpointIndex>Psoriatic arthritis - Imaging/Radiological Assessments - Van der Heijde modified sharp score (vdHS)</EndpointIndex><EndpointIndex>Psoriatic arthritis - Patient Reported Outcomes/Quality of Life Assessments - Disability index of the health assessment questionnaire (HAQDI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>FUTURE 1: Efficacy at 24 Weeks and Long-term Safety, Tolerability and Efficacy up to Two Years of Secukinumab (AIN-457) in Patients With Active Psoriatic Arthritis (PsA)</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis - Subjects with moderate psoriatic arthritis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis - Subjects with severe psoriatic arthritis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with Diagnosis of Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-cyclic citrullinated peptides antibodies </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness </BiomarkerName><BiomarkerName> Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>119</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>DRA dept.</Name><Name>Dr Anita Lim Yee Nah</Name><Name>Dr Leung Ying Ying</Name><Name>Dr Yoon Kam Hon</Name><Name>Dr. Proton Rahman</Name><Name>Drug Regulatory Affairs</Name><Name>Informační služba - klin. hodnocení</Name><Name>Medical Dept - Desislava Uzunova</Name><Name>Medical information services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="79144"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-03-03T00:00:00Z</DateChangeLast><DateEnd>2001-02-18T00:00:00Z</DateEnd><DateStart>1995-09-08T00:00:00Z</DateStart><Identifiers><Identifier>LB-04</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Acute sinusitis</Indication><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Eczema</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Jaundice</Indication><Indication>Pharyngitis</Indication><Indication>Pneumonia</Indication><Indication>Pruritus</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamivudine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In August 2005, results were published. Insomnia (10%), cough (10%), headache (15%), asthenopia, buzzing, dull headache, upper abdominal pain, lower abdominal pain on left side, &lt;b&gt;cold&lt;/b&gt;-like symptoms, joint pain, lassitude, listlessness of the lower limbs, generalized pruritus, pneumonia, jaundice, eczema of external auditory meatus, acute pharyngitis, acute sinusitis, occipital headache left side, fever, and sputum each in 5% of patients were the commonly observed adverse events up to week 260 in the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of HBV Viral Response - Assessment of HBV viral load</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Histological Changes in Liver</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Liver Functions - Alanine transaminase (ALT) levels</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBeAg changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, single-center, open-label, study to evaluate the safety and efficacy of long-term treatment of lamivudine in patients with chronic hepatitis B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - Subjects with Chronic Hepatitis B Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>65 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="79117"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-03-04T00:00:00Z</DateChangeLast><DateEnd>1997-01-31T00:00:00Z</DateEnd><DateStart>1995-05-31T00:00:00Z</DateStart><Identifiers><Identifier>LB-03</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Ascites</Indication><Indication>Chill</Indication><Indication>Common cold</Indication><Indication>Drowsiness</Indication><Indication>Drug eruption</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Liver failure</Indication><Indication>Liver tumor</Indication><Indication>Skin rash</Indication><Indication>Thyroid tumor</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamivudine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results from a safety population of 133 patients were published. The most commonly observed adverse events in the study were headache (12.8, 13.5, and 0.8%), sleepiness (12.0, 12.0, and 0%), dull headache (3.8, 3.8, and 0%), rash (3.8, 4.5, and 0%), &lt;b&gt;cold&lt;/b&gt;-like symptoms (2.3, 5.3, and 1.5%), malaise (2.3, 4.5, and 1.5%), light headedness (1.5, 1.5, and 0%), chills (1.5, 1.5, and 0%), tension of neck muscle (0.8, 0.8, and 0%), anorexia (0, 0.8, and 1.5%), ascites (0, 0.8, and 1.5%), and eruption (0, 0.8</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of HBV Viral Response - Assessment of HBV viral load</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Liver Functions - Alanine transaminase (ALT) levels</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBeAg changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, multicenter, open-label study to evaluate the long-term safety and efficacy of lamivudine in patients with chronic hepatitis B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - Subjects with Chronic Hepatitis B Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="78613"><Indications><Indication>Common cold</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><DateChangeLast>2011-12-29T00:00:00Z</DateChangeLast><DateStart>1994-11-30T00:00:00Z</DateStart><Identifiers><Identifier>FLNL39</Identifier><Identifier>FNM40137</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>after onset of the common &lt;b&gt;cold&lt;/b&gt; for 6 days [ 1203654 ].... Results were published in June 1998. The duration of common &lt;b&gt;cold&lt;/b&gt; symptoms was equal in both...common &lt;b&gt;cold&lt;/b&gt; were significantly more severe during days 1 to 10 (p &amp;lt; 0.05) in subjects found to have positive cultures for S pneumoniae, H influenzae</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, double-blind, placebo-controlled trial to study the effect of fluticasone propionate (FP) in subjects with common cold</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="78537"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2012-04-27T00:00:00Z</DateChangeLast><DateStart>1990-06-30T00:00:00Z</DateStart><Identifiers><Identifier>FLUTI/AH89/J78</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Dyspnea</Indication><Indication>Flatulence</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Nausea</Indication><Indication>Throat disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>budesonide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>197</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>reported in the fluticasone propionate group were sore throat (22.9% of patients), headache (17.7%), cough (17.7%), and &lt;b&gt;cold&lt;/b&gt; (9.4%). A total of 68 patients receiving budesonide had AEs throughout treatment. The most common AEs reported in the budesonide...dyspnea, dry throat, flatulence and worsening of asthma were some of the SAEs observed in patients. Headache, cough, &lt;b&gt;cold&lt;/b&gt;, back ache, chest infection, wheeziness, sputum production and nausea were some of the AEs occurred frequently in patients [ 1202924</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, multicenter, open-label, parallel-group study to compare the efficacy, safety and tolerability of fluticasone propionate and budesonide administered via a metered dose inhaler in adult patients with moderate to severe symptomatic asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="78418"><Indications><Indication>Dengue virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Sanofi Pasteur</Company><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>Malaysia</Country><Country>Vietnam</Country><Country>Thailand</Country><Country>Indonesia</Country><Country>Philippines</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2017-11-21T00:00:00Z</DateEnd><DateStart>2011-06-03T00:00:00Z</DateStart><Identifiers><Identifier>2014-001708-24</Identifier><Identifier>6463</Identifier><Identifier>CYD14</Identifier><Identifier>NCT01373281</Identifier><Identifier>NMRR-10-672-6463</Identifier><Identifier>PHRR121114-000015</Identifier><Identifier>U1111-1116-4957</Identifier><Identifier>UTN: U1111-1116-4957</Identifier></Identifiers><IndicationsAdverse><Indication>Infectious disease</Indication><Indication>Injury</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Dengvaxia alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10275</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of &lt;b&gt;cold&lt;/b&gt; clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse. Independent Data Monitoring Committee (IDMC) severity criteria. The severity of VCD cases was assessed by an Independent IDMC using pre-defined standardized</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</TitleDisplay><PatientSegmentTerms><PatientSegment>Dengue Vaccine - Subjects with Dengue Fever - People living in endemic areas</PatientSegment><PatientSegment>Dengue virus infection - Subjects at Risk of Dengue Fever - People living in endemic areas</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti Dengue virus antibodies </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Dr. Maria Rosario Capeding</Name><Name>Evon Chew Yeah Yoong</Name><Name>Hussain Imam B MD Ismail</Name><Name>Mary Noreen CHUA</Name><Name>Medical Director</Name><Name>Revathy Nallusamy</Name></ContactNames></Trial><Trial Id="78238"><Indications><Indication>Dengue virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanofi Pasteur Inc</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>Colombia</Country><Country>Mexico</Country><Country>Puerto Rico</Country><Country>Honduras</Country></Countries><DateChangeLast>2019-04-18T00:00:00Z</DateChangeLast><DateEnd>2018-03-05T00:00:00Z</DateEnd><DateStart>2011-06-08T00:00:00Z</DateStart><Identifiers><Identifier>2014-001716-19</Identifier><Identifier>CYD15</Identifier><Identifier>NCT01374516</Identifier><Identifier>UTN: U1111-1116-4986</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Polyneuropathy</Indication><Indication>Urticaria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Dengvaxia alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20869</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to assess the efficacy of sanofi pasteur's CYD dengue vaccine ( Dengvaxia ) in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America. The primary objective of this study was to assess the efficacy of CYD dengue vaccine after three vaccinations at 0, 6 and 12 months in preventing symptomatic virologically-confirmed dengue cases, regardless of the severity, due to any of the four serotypes in children and adolescents aged 9 to</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America</TitleDisplay><PatientSegmentTerms><PatientSegment>Dengue Vaccine - Subjects with Dengue Fever - People living in endemic areas</PatientSegment><PatientSegment>Dengue virus infection - Subjects at Risk of Dengue Fever - People living in endemic areas</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti Dengue virus antibodies </BiomarkerName><BiomarkerName> Anti-Yellow fever virus antibodies </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>80 Months</TrialDuration><NumberOfSites>21</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="77559"><Indications><Indication>Ankylosing spondylitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Mexico</Country><Country>US</Country><Country>Peru</Country><Country>Netherlands</Country><Country>UK</Country><Country>France</Country><Country>Taiwan</Country><Country>Belgium</Country><Country>Italy</Country><Country>Turkey</Country><Country>Russian Federation</Country><Country>Bulgaria</Country><Country>Canada</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024529-18</Identifier><Identifier>CAIN457F2305</Identifier><Identifier>CCRN 620</Identifier><Identifier>F2305</Identifier><Identifier>MEASURE 1</Identifier><Identifier>NCT01358175</Identifier><Identifier>UKCRN ID: 11043</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Lipid metabolism disorder</Indication><Indication>Neutropenia</Indication><Indication>Pharyngitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Solid tumor</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>371</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>adverse events. Improvements with secukinumab were sustained regardless of the anti-TNF status. Overall, secukinumab was well-tolerated with a safety profile through two years [ 1709789 ]. In November 2015, results were presented. Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;; 24.3%), diarrhea (13.8%), headache (12.2%) and pharyngitis (sore throat; 11.6%) were the most common adverse events (AEs) observed in patients treated with secukinumab 150 mg at Week 104. Patiwnts (86.7%) experienced an AE and 12.2% experienced a </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Bath ankylosing spondylitis metrology index (BASMI)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Pharmacoeconomic Assessments</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 20</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 40</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MEASURE 1: A 16-Week Efficacy and Two-Year Long-Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Active Ankylosing Spondylitis</PatientSegment><PatientSegment>Ankylosing spondylitis - Moderate Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Severe Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Anti-TNF therapy</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - NSAIDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with anti-TNF therapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase, bone specific </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> C-terminal telopeptide of collagen type I </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness </BiomarkerName><BiomarkerName> Osteocalcin </BiomarkerName><BiomarkerName> Procollagen Type I N-terminal peptide </BiomarkerName><BiomarkerName> Procollagen type I carboxy terminal peptide </BiomarkerName><BiomarkerName> Sclerostin </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 11B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>85</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Dr. Atul Deodhar</Name><Name>Dr. Proton Rahman</Name><Name>Drug Regulatory Affairs</Name><Name>Medical Information Services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharma Services AG</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="77484"><Indications><Indication>Gout</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Dermatological formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Nasal formulation local</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Hungary</Country><Country>Lithuania</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-11-09T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024173-39</Identifier><Identifier>CACZ885H2361</Identifier><Identifier>NCT01356602</Identifier></Identifiers><IndicationsAdverse><Indication>Aortitis</Indication><Indication>Cardiac failure</Indication><Indication>Constipation</Indication><Indication>Delirium</Indication><Indication>Migraine</Indication><Indication>Muscle injury</Indication><Indication>Pain</Indication><Indication>Staphylococcus infection</Indication><Indication>Unstable angina</Indication><Indication>Viral respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention><Intervention>canakinumab-LYO alone</Intervention><Intervention>canakinumab-PFS alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>397</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Use of the following therapies (within varying protocol defined timeframes): corticosteroids, narcotics, topical ice/&lt;b&gt;cold&lt;/b&gt; packs, chronic opiate treatment, NSAID (such as aspirin), colchicine Hemodialysis Live vaccine within 3 months before first dose Donation or loss of &gt;/= 400 ml within 3 months before first dose Gout brought on by other factors such as chemotherapy,</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gout - Assessment of disease flare</EndpointIndex><EndpointIndex>Gout - Assessment of disease flare - Proportion of subjects requiring treatment for gout flares</EndpointIndex><EndpointIndex>Gout - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Gout - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Gout - Patient Reported Outcomes/Quality of Life Assessments - Physician patient questionnaire(PPQ)</EndpointIndex><EndpointIndex>Gout - Physician Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Musculoskeletal disease related outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Gout - Hyperuricemic Subjects with Gout</PatientSegment><PatientSegment>Gout - Subjects with Acute Gout - Subjects with acute gout flares</PatientSegment><PatientSegment>Gout - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment><PatientSegment>Gout - Subjects with Treatment Resistant Disease - Subjects with colchicine resistant disease</PatientSegment><PatientSegment>Gout - Subjects with Use of Anti-Gout Medications</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>99</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="77110"><Indications><Indication>Raynauds disease</Indication><Indication>Scleroderma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HETE modulator</Action><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacao de Amparo a Pesquisa do Estado Sao Paulo</Company></CompaniesCollaborator><CompaniesSponsor><Company>Federal University of Sao Paulo</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2018-11-15T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2011-04-30T00:00:00Z</DateStart><Identifiers><Identifier>FAPESP 2011/00012-3</Identifier><Identifier>NCT01347008</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sildenafil citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results were published in October 2017 [ 2013083 ]. In October 2017, further results were published. Patients in sildenafil compared to placebo group reported a significantly higher mean percentage change from baseline in FBF before &lt;b&gt;cold&lt;/b&gt; stimulus (p = 0.026) and after &lt;b&gt;cold&lt;/b&gt; stimulus (p = 0.028) at 8 weeks, respectively. Patients in sildenafil group compared to placebo showed significant improvement in the percentage change from baseline to week 8 in the RP VAS score. No changes were seen in VEGF levels</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular endothelial growth factor (VEGF)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Laboratory/Diagnostic Measures - Assessment of endothelial progenitor cells</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Wound Healing - Assessment of ulcer healing</EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Endothelial progenitor cells </BiomarkerName><BiomarkerName> Hematopoietic progenitor cell antigen CD34 </BiomarkerName><BiomarkerName> Prominin-1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando V Andrigueti, MD</Name></ContactNames></Trial><Trial Id="77013"><Indications><Indication>Rhinovirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Leukotriene C4 antagonist</Action><Action>Leukotriene D4 antagonist</Action><Action>Leukotriene E4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><DateChangeLast>2011-05-02T00:00:00Z</DateChangeLast><DateStart>1999-05-11T00:00:00Z</DateStart><Identifiers><Identifier>9188US/0020</Identifier></Identifiers><IndicationsAdverse><Indication>Insomnia</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>zafirlukast alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this phase III, double-blind, placebo-controlled trial was to evaluate the safety and efficacy of zafirlukast for the treatment of symptoms associated with rhinovirus infection [ 1187565 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, double-blind, placebo-controlled trial to evaluate the safety and efficacy of zafirlukast for the treatment of symptoms associated with rhinovirus infection</TitleDisplay><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="76298"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation stimulator</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Glycoprotein</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Protein recombinant</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Novo Nordisk A/S</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>France</Country><Country>US</Country><Country>Malaysia</Country><Country>Russian Federation</Country><Country>Hungary</Country><Country>Germany</Country><Country>Thailand</Country><Country>Macedonia, The Former Yugoslav Republic of</Country><Country>Japan</Country><Country>UK</Country><Country>Canada</Country><Country>Netherlands</Country><Country>South Africa</Country><Country>Turkey</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2013-03-31T00:00:00Z</DateEnd><DateStart>2011-04-27T00:00:00Z</DateStart><Identifiers><Identifier>2010-023069-24</Identifier><Identifier>JapicCTI-111644</Identifier><Identifier>NCT01333111</Identifier><Identifier>NMRR-11-493-9528</Identifier><Identifier>NN7999-3747</Identifier><Identifier>Paradigm 2</Identifier><Identifier>U1111-1119-6415</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nonacog beta pegol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>74</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this 52-week, single-blinded, randomized trial was to evaluate the safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 (nonacog beta pegol) when used for treatment and prophylaxis of bleeding episodes in patients with hemophilia B [ 1427308 ], [ 1496839 ], [ 1725602 ], [ 2021695 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Clinical Symptoms - Assessment of bleeding episodes</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Paradigm 2: Safety and Efficacy of NNC-0156-0000-0009 in Hemophilia B Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Coagulation factor IX</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>Chua Swee Choo @ Justine Chua</Name><Name>Global Clinical Registry (GCR, 1452)</Name><Name>Novo Nordisk</Name><Name>Shantini Evelyn Chelliah</Name></ContactNames></Trial><Trial Id="76048"><Indications><Indication>Varicella zoster virus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>EMS SA</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-04-21T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>F500EMS1010</Identifier><Identifier>NCT01327144</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Drowsiness</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>aciclovir alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>famciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>177</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In July 2018, results were published. Headache, diarrhea, nausea, back pain, &lt;b&gt;cold&lt;/b&gt;, and drowsiness were the most common adverse events in both the groups, but were reported to be clinically insignificant [ 2060920 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Felipe Pinho</Name><Name>Joyce Silva</Name></ContactNames></Trial><Trial Id="75744"><Indications><Indication>Herpesvirus infection</Indication></Indications><CompaniesSponsor><Company>BlueWillow Biologics</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2012-01-31T00:00:00Z</DateEnd><DateStart>2011-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NB-001-004</Identifier><Identifier>NCT01321359</Identifier><Identifier>SHaRCS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NB-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>907</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>eligibility criteria would be randomized in the study. Subjects would begin treatment as soon as they experience the onset of &lt;b&gt;cold&lt;/b&gt; sore symptoms. Treatment would be applied five times daily, approximately 3 to 4 h apart while awake. Treatment would...by a history of three or more &lt;b&gt;cold&lt;/b&gt; sore recurrences on the lips and/or skin surrounding the lips in the previous 12 months Have the majority of their &lt;b&gt;cold&lt;/b&gt; sore recurrences proceeded by a well defined history of prodromal symptoms</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Development in aborted lesion</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHaRCS: A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>35</NumberOfSites><ContactNames><Name>Ginger Callison</Name><Name>Helen Chao</Name><Name>Janis Caldwell</Name><Name>Karen Breisinger</Name><Name>Kim Cruz</Name><Name>Michele Abernethy</Name><Name>Randi Derner</Name><Name>Roberto Aguirre</Name><Name>Sherri Chatham</Name><Name>Sue Denson</Name></ContactNames></Trial><Trial Id="74997"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Oncology</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Switzerland</Country><Country>UK</Country><Country>Ireland</Country><Country>Spain</Country><Country>France</Country><Country>Belgium</Country><Country>Germany</Country></Countries><DateChangeLast>2019-07-02T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016859-22</Identifier><Identifier>CACZ885D2307</Identifier><Identifier>D2307</Identifier><Identifier>NCT01302860</Identifier><Identifier>P/208/2011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>months of age at the time of the screening visit Body weight&gt;/= 2.5 Kg Parent or legal guardian's written informed consent is required before any assessment is performed for patients At study entry, patients should have a clinical diagnosis of familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome (FCAS), muckle-wells syndrome (MWS), or neonatal onset multisystem inflammatory disease (NOMID) and symptoms requiring pharmacological intervention. Prior agreement between the investigator and Novartis for study eligibility</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability - Assessment of serious/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Overall therapeutic response</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Urticaria - Clinical Assessments</EndpointIndex><EndpointIndex>Urticaria - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety and Tolerability of ACZ-885 in Pediatric Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Others - Children and adolescents</PatientSegment><PatientSegment>Other neurological disease - Others - Neonates</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with gene variants - NLRP3_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Chief Scientific Officer</Name><Name>Medical Information Services</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="74356"><Indications><Indication>Parkinsons disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel modulator</Action><Action>Dopamine receptor agonist</Action><Action>MAO B inhibitor</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action><Action>Antiparkinsonian</Action><Action>Dopamine uptake inhibitor</Action><Action>Glutamate release inhibitor</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Newron Pharmaceuticals SpA</Company></CompaniesSponsor><DateChangeLast>2018-12-04T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2006-005861-21</Identifier><Identifier>NCT01286935</Identifier><Identifier>NW-1015/018/III/2006</Identifier></Identifiers><IndicationsAdverse><Indication>Depression</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>safinamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>544</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> chronic pain and to confirm the positive effects observed after 6 months of treatment. When compared to placebo, safinamide showed significant improvements in the PDQ-39 items 37 ('painful cramps or spasm'; p = 0.0074) and 39 ('unpleasantly hot or &lt;b&gt;cold&lt;/b&gt;'; p = 0.0209) and reductions in the number of concomitant pain treatments by 26.2% (p = 0.005). After two years of treatment, significantly greater proportion of patients treated in the safinamide group were not using pain drugs (p = 0.0478) [ 2042299</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part II scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part IV scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Dyskinesia</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of OFF state of Parkinson's disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of ON state of Parkinson's disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Sleep - Assessment of sleep parameters</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 18-Month Study of Long-Term Efficacy and Safety of Safinamide as Add-On Therapy in Patients With Mid-Late Stage PD</TitleDisplay><PatientSegmentTerms><PatientSegment>Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment><PatientSegment>Parkinsons disease - Subjects with Motor Symptoms of Parkinson's Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>See Study 016 for details</Name></ContactNames></Trial><Trial Id="7435"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Italy</Country><Country>Germany</Country><Country>Spain</Country></Countries><DateChangeLast>2016-11-22T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2004-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-001052-36</Identifier><Identifier>CRAD001A2411</Identifier><Identifier>NCT00150046</Identifier><Identifier>RAD2411</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ciclosporin, Novartis plus mycophenolate mofetil</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ciclosporin, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>176</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> or treatment within 1 month prior to randomization Patients receiving induction therapy which is not standard per local practice Patients with donor &gt; 60 years and/or with known donor coronary or heart disease at the time of transplant Donor heart &lt;b&gt;cold&lt;/b&gt; ischemic time &gt; 6 h Patients with panel reactive antibodies &gt; 20% Patients who are recipients of ABO incompatible transplants Patients with platelet count&amp;lt; 50,000/mm3 at the evaluation before randomization Presence of severe hypercholesterolemia</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Efficacy parameters - unspecified</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Basel Novartis Pharma AG</Name></ContactNames></Trial><Trial Id="73782"><Indications><Indication>Bronchitis</Indication><Indication>Upper respiratory tract infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Expectorant</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ewha Womans University</Company><Company>Hanyang University</Company><Company>Inha University</Company><Company>Konkuk University</Company><Company>Kyung Hee University</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ahn-Gook Pharmaceuticals Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-01-23T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>2010-02-28T00:00:00Z</DateStart><Identifiers><Identifier>AG NPP_P3</Identifier><Identifier>EudraCT: 2007-003272-19</Identifier><Identifier>NCT01151202</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AG-NPP709 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>236</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess therapeutic confirmation of AG-NPP709 syrup to evaluate the safety and efficacy in patients with acute upper respiratory tract infection and chronic inflammatory bronchitis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Cure rates/success rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG-NPP709 Syrup</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Dae-Hyun Lim</Name><Name>Ho-Joo Yoon</Name><Name>Jung Han</Name><Name>Sun-Hee Choi</Name><Name>Young-ho Na, PhD, MD</Name></ContactNames></Trial><Trial Id="73266"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Australia</Country><Country>US</Country><Country>New Zealand</Country><Country>Singapore</Country><Country>Switzerland</Country><Country>Germany</Country><Country>Poland</Country></Countries><DateChangeLast>2018-04-20T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2010-022784-35</Identifier><Identifier>GA00889</Identifier><Identifier>GLACIAL</Identifier><Identifier>NCT01264939</Identifier><Identifier>Q4883g</Identifier><Identifier>UKCRN ID: 10115</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract inflammation</Indication><Indication>Urticaria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>336</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>agent within 30 days of day-14 Weight&amp;lt; 20 kg (44 lbs) Clearly defined underlying etiology for chronic urticarias other than CIU (main manifestation being physical urticaria). This includes the following urticarias: acute, solar, cholinergic, heat, &lt;b&gt;cold&lt;/b&gt;, aquagenic, delayed pressure or contact and as well as the following diseases as these diseases may have symptoms of urticaria or angioedema: urrticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>GLACIAL: A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1-Antihistamines, H2-Blockers, and/or Leukotriene Receptor Antagonists</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Subjects with chronic idiopathic urticaria(CIU)</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> Histamine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>73</NumberOfSites><ContactNames><Name>Dr Derrick Aw Chen Wee</Name><Name>Dr Tay Yong Kwang</Name><Name>Edward R. Conner, M.D.</Name></ContactNames></Trial><Trial Id="71013"><ActionsSecondaryInterventionsControl><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Finland</Country><Country>Germany</Country></Countries><DateChangeLast>2017-08-07T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>Eudract number 2007-003786-41</Identifier><Identifier>NCT00644059</Identifier><Identifier>NCT01015885</Identifier><Identifier>V70P5</Identifier><Identifier>V70P5TER</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Agrippal S1 alone</Intervention><Intervention>Fluarix alone</Intervention><Intervention>meningococcal C conjugate vaccine alone</Intervention><Intervention>tick-borne encephalitis vaccine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Fluad alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4902</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>and participation in another clinical trial during the present study Experience of a severe acute infectious disease in the month prior to study start or experience of a mild acute infection disease in the week prior the study start (untreated common &lt;b&gt;cold&lt;/b&gt; is acceptable). The severity of the infectious disease occurred will be based on the investigator's judgment Any severe acute respiratory disease and infection requiring systemic antibiotic or antiviral therapy ongoing or resolved within 2 days prior</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Influenza/Influenza Like Illness</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Influenza/Influenza Like Illness</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Immune Response - Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of local reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of systemic reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Protocol Specified Other Endpoints - Unspecified efficacy assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to &lt; 72 Months) Versus Control Vaccines</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>102</NumberOfSites><ContactNames><Name>Novartis Vacccines and Diagnostics</Name></ContactNames></Trial><Trial Id="7011"><Indications><Indication>Carpal tunnel syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Endo Health Solutions Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2007-01-01T00:00:00Z</DateEnd><DateStart>2005-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EN3272-301</Identifier><Identifier>NCT00266214</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine patch, Immune Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>210</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>severe CTS as defined by electrodiagnostic findings Have had steroid injections for CTS in the previous 3 months Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (eg, ultrasound, iontophoresis, &lt;b&gt;cold&lt;/b&gt; laser) in the past 2 weeks Require sleep medications Are using a lidocaine-containing product that cannot be discontinued during the study Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>PPD</Name></ContactNames></Trial><Trial Id="6983"><Indications><Indication>Insomnia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>GABA A receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Hypnotic</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2017-08-06T00:00:00Z</DateChangeLast><DateEnd>2007-06-27T00:00:00Z</DateEnd><DateStart>2006-02-28T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0007</Identifier><Identifier>JapicCTI-060278</Identifier><Identifier>NCT00283946</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hypertension</Indication><Indication>Nausea</Indication><Indication>Palpitation</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>zolpidem (immediate-release, insomnia), Sanofi alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>876</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &gt;/= 45 min per night within 4 weeks before the start of the run-in period according to the health check sheet Patients who had a washout period before the start of the run-in period, when given antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedy, except for eye-drops, nose drops or external medicine), hypnotics, or anxiolytic or antidepressant drugs for sleep Patients aged between 20 and 65 when their informed consent was obtained Patients who had an ability to fill in the sleep diary</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of early morning awakening</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of total sleep time (TST)</EndpointIndex><EndpointIndex>Insomnia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Double-Blind, Group-Comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Astellas Pharma Inc.</Name><Name>Central Contact</Name></ContactNames></Trial><Trial Id="69746"><Indications><Indication>Schizoaffective disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Quintiles Malaysia Sdn Bhd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Janssen Scientific Affairs</Company><Company>Ortho-McNeil Janssen Scientific Affairs, LLC</Company></CompaniesSponsor><Countries><Country>US</Country><Country>South Africa</Country><Country>Malaysia</Country><Country>Romania</Country><Country>India</Country><Country>Philippines</Country><Country>Ukraine</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-017271-17</Identifier><Identifier>6795</Identifier><Identifier>CR016618</Identifier><Identifier>CTRI/2011/091/000008</Identifier><Identifier>NCT01193153</Identifier><Identifier>NMRR-10-753-6795</Identifier><Identifier>R092670SCA3004</Identifier></Identifiers><IndicationsAdverse><Indication>Akathesia</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Pain</Indication><Indication>Rhinopharyngitis</Indication><Indication>Tremor</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>paliperidone (open-label period) alone</Intervention><Intervention>paliperidone palmitate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>667</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>were published in May 2014. Weight gain (8.5% in paliperidone palmitate versus 4.7% in placebo), insomnia (4.9 versus 7.1%), worsening of schizoaffective disorder (3.1 versus. 5.9%), headache (5.5 versus 3.5%) and nasopharyngitis, which is the common &lt;b&gt;cold&lt;/b&gt; (5.5 versus 3.5%) were the adverse events observed in &gt; 5% of patients. Akathisia (3.0% in paliperidone palmitate  versus 1.8% in placebo) and tremor (1.2 versus 2.4%) were the most common movement disorders observed. Increase in body weight (&gt;/= 7%</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Functional Disability/Physical Function - Assessment of subjects by Personal and Social Performance Scale (PSP)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Therapy Related Outcomes - Assessment of relapse/exacerbation</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Medication Satisfaction Questionnaire (MSQ)</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of subjects by CGI-S scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Subjects at risk of developing disease - Subjects with schizophrenia spectrum disorder</PatientSegment><PatientSegment>Schizophrenia - Subjects with Other Neuro-psychiatric Diseases/Disorders - Subjects with other psychotic disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Prolactin </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>81</NumberOfSites><ContactNames><Name>Anil Nischal</Name><Name>Dong-Jing Fu, M.D., PhD</Name><Name>Hitendra Gandhi</Name><Name>Janssen Scientific Affairs, LLC Clinical Trial</Name><Name>Sangha Mitra Patnaik</Name><Name>Shoibal Mukherjee</Name><Name>Suarn Singh</Name><Name>Venu Jhanwar</Name><Name>Vinay Barhale</Name><Name>Vishal Indla</Name><Name>Yeoh Sin Yee</Name></ContactNames></Trial><Trial Id="69435"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Veloxis Pharmaceuticals A/S</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Italy</Country><Country>Brazil</Country><Country>Poland</Country><Country>Spain</Country><Country>Sweden</Country><Country>Argentina</Country><Country>New Zealand</Country><Country>Mexico</Country><Country>Serbia</Country><Country>France</Country><Country>US</Country><Country>Australia</Country><Country>Singapore</Country><Country>South Korea</Country></Countries><DateChangeLast>2019-01-03T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2008-003241-89</Identifier><Identifier>DRKS00006514</Identifier><Identifier>LCP-Tacro-3002</Identifier><Identifier>LCPTacro3002</Identifier><Identifier>NCT01187953</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Edema</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Tremor</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including basiliximab , mycophenolate mofetil , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , mycophenolate mofetil , tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>543</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>positive serological test result for HIV-1, HBV or HCV Donor with history of malignant disease (current or historical) Centers for disease control and prevention high-risk donor Patients with mental dysfunction or inability to cooperate with the study &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 30 h Non-heart-beating donor</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioavailability</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints - Frequency of treatment failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Double-Blind, Double-Dummy, Efficacy/Safety, LCP-Tacro versus Prograf, Prevention Rejection, De Novo Adult Kidney Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Transaminases </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>89</NumberOfSites><ContactNames><Name>Alan Glicklich</Name><Name>Dr Terence Kee Yi Shern</Name><Name>Dr Vathsala Anatharaman</Name><Name>Ronald Guido</Name></ContactNames></Trial><Trial Id="69163"><Indications><Indication>Autoimmune hemolytic anemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2016-01-08T00:00:00Z</DateEnd><DateStart>2011-03-03T00:00:00Z</DateStart><Identifiers><Identifier>2008-008255-42</Identifier><Identifier>NCT01181154</Identifier><Identifier>P080704</Identifier><Identifier>RAHIA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rituximab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>immunosuppressive drugs Any other associated cause congenital or acquired hemolytic anemia (except thalassemia trait or heterozygous sickle cell anemia) Negative DAT or DAT positive with isolated anti-C3d pattern related to the presence of a monoclonal Ig M with &lt;b&gt;cold&lt;/b&gt; agglutinin properties Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen (HbsAg) Neutrophils count&amp;lt; 1000/mm3 at inclusion Impaired renal function as indicated by a serum creatinine level&gt; 2 mg/</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of cumulative treatment</EndpointIndex><EndpointIndex>Anemia - Assessment of Transfusions - Assessment of red blood cell transfusions</EndpointIndex><EndpointIndex>Anemia - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Splenectomy</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Transfusions - Assessment of red blood cell transfusions</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Therapy Related Outcomes - Assessment of number of transfusions</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RAHIA: Rituximab in Autoimmune Hemolytic Anemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with autoimmune hemolytic anemia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Immune (Idiopathic) Thrombocytopenia - Subjects with autoimmune thrombocytopenia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>58 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marc MICHEL, MD</Name></ContactNames></Trial><Trial Id="68905"><Indications><Indication>Breast tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Auckland City Hospital</Company></CompaniesSponsor><DateChangeLast>2010-08-06T00:00:00Z</DateChangeLast><DateStart>1995-09-30T00:00:00Z</DateStart><IndicationsAdverse><Indication>Allergy</Indication><Indication>Anemia</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Hypersensitivity</Indication><Indication>Infectious disease</Indication><Indication>Leukopenia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>docetaxel alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>527</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This open-label, randomized, phase III trial was to evaluate the safety and efficacy of docetaxel in patients with unresectable locally advanced or metastatic breast cancer [ 745828 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An open-label, randomized, phase III trial to evaluate the safety and efficacy of docetaxel in patients with unresectable locally advanced or metastatic breast cancer</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="6849"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>China</Country><Country>Hong Kong</Country><Country>India</Country><Country>Chile</Country><Country>Czech Republic</Country><Country>Japan</Country><Country>Russian Federation</Country><Country>Philippines</Country></Countries><DateChangeLast>2016-11-21T00:00:00Z</DateChangeLast><DateEnd>2011-02-28T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>A0081107</Identifier><Identifier>JapicCTI-101173</Identifier><Identifier>NCT00407745</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Edema</Indication><Indication>Fatigue</Indication><Indication>Insomnia</Indication><Indication>Vision disorder</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>220</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate if pregabalin relieves nerve pain associated with spinal cord injury, compared with placebo. This study would also evaluate the safety of pregabalin in this patient population.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Daily Pain Rating Scale (DPRS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>64</NumberOfSites><ContactNames><Name>Pfizer Call Center</Name><Name>Pfizer Japan Inc.</Name></ContactNames></Trial><Trial Id="6844"><Indications><Indication>Bipolar disorder</Indication><Indication>Insomnia</Indication><Indication>Schizophrenia</Indication></Indications><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-09-21T00:00:00Z</DateChangeLast><DateEnd>2008-06-30T00:00:00Z</DateEnd><DateStart>2006-08-31T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0008</Identifier><Identifier>JapicCTI-060330</Identifier><Identifier>NCT00374777</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Depression</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Eczema</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>nitrazepam alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &gt;/= 45 min per night within 4 weeks before the start of the run-in period according to the health check sheet Patients who had a washout period before the start of the run-in period, when given antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedy, except for eye-drops, nose drops or external medicine), hypnotics, or anxiolytic or antidepressant drugs for sleep Patients aged between 20 and 65 years when their informed consent was obtained Patients who had an ability to fill in the sleep</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Anthropometric Assessments</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures - Assessment of hematological parameters</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of mean wake time</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of night awakenings</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of total sleep time</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of early morning awakening</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of total sleep time (TST)</EndpointIndex><EndpointIndex>Insomnia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of adverse events(AEs)/side effects</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of discontinuations due to adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of neuropsychiatric adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Sleep</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Double-Blind, Group-Comparison, Phase III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment><PatientSegment>Insomnia - Subjects with comorbid conditions - Subjects co-morbid with mood disorders</PatientSegment><PatientSegment>Schizophrenia - Subjects with Other Neuro-psychiatric Diseases/Disorders - Subjects with other psychotic disorders</PatientSegment><PatientSegment>Schizophrenia - Subjects with comorbid conditions - Subjects with mood disorders</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Astellas Pharma Inc.</Name><Name>Use Central Contact</Name></ContactNames></Trial><Trial Id="67877"><Indications><Indication>Cystic fibrosis</Indication><Indication>Sinusitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Genentech Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pennsylvania State University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-06-30T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>IRB#33344</Identifier><Identifier>NCT01155752</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>The hypothesis is that the intranasal use of Pulmozyme will decrease the severity of sinusitis in cystic fibrosis (CF) and lead to an improved quality of life.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by quality of life (short form-36 and chronic respiratory questionnaire)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Pulmozyme in Cystic Fibrosis With Sinusitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cathy Mende, NP</Name><Name>Timothy Craig</Name><Name>Timothy Craig, DO</Name></ContactNames></Trial><Trial Id="67378"><Indications><Indication>Respiratory disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>University of Aberdeen</Company><Company>University of Leicester</Company></CompaniesCollaborator><CompaniesSponsor><Company>Queen Mary University of London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>08/43/03</Identifier><Identifier>2009-015626-11</Identifier><Identifier>NCT01142505</Identifier><Identifier>WAIT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>montelukast sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1358</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The patients would receive 4 mg po, qd granules of montelukast or mannitol for 10 days given alone or with &lt;b&gt;cold&lt;/b&gt; or warm food from the onset of a &lt;b&gt;cold&lt;/b&gt; or wheezing attack....given montelukast and 50% would be given dummy medication. Parents would start the trial medication whenever their child develops a &lt;b&gt;cold&lt;/b&gt;, and stop the medication when wheeze resolve. Parents would also be able to give the trial medication for wheeze</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Asthma - Assessment of Wheeze</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>WAIT: Wheeze and Intermittent Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jonathan Grigg</Name></ContactNames></Trial><Trial Id="66158"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Muscle relaxant</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Army Research and Referral hospital</Company><Company>Postgraduate Institute of Medical Education and Research</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-12-21T00:00:00Z</DateChangeLast><DateEnd>2010-05-01T00:00:00Z</DateEnd><DateStart>2009-11-30T00:00:00Z</DateStart><Identifiers><Identifier>B22:A15:PGI/DM/EC/40/7.11.2007</Identifier><Identifier>NCT01117298</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tadalafil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>66</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>between the ages of 18 and 60 years will be selected for the study if they have a clinical diagnosis of Raynauds phenomenon secondary to systemic sclerosis (scleroderma) despite being on vasodilator therapy. Raynauds phenomenon is defined as a history of &lt;b&gt;cold&lt;/b&gt; sensitivity associated with color changes of cyanosis or pallor, as well as a history of at least four attacks per week during 2 week pre-trial period even with treatment with other vasodilators. The diagnosis of scleroderma is defined by the American</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function - Assessment of flow mediated dilatation</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Wound Healing - Assessment of ulcer healing</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynauds Phenomenon in Scleroderma</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Aman Sharma</Name><Name>Darshan S Bhakuni, MD</Name><Name>Darshan Singh Bhakuni</Name><Name>Parasar Ghosh</Name></ContactNames></Trial><Trial Id="65812"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-24T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2010-03-31T00:00:00Z</DateStart><Identifiers><Identifier>LAIV</Identifier><Identifier>MI-CP208</Identifier><Identifier>NCT01091246</Identifier></Identifiers><InterventionsControlDisplay><Intervention>FluMist alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>MEDI-8662 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2312</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to demonstrate the immunological noninferiority of Q/LAIV compared to FluMist in children 2 to 17 years of age by comparing the strain-specific post-dose geometric mean titers (GMTs) of hemagglutination inhibition (HAI) antibodies.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>LAIV: A Study to Evaluate the Immunogenicity Composed of Four Vaccine Strains in a Live Influenza Vaccine in Children (LAIV)</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-plasminogen activator inhibitor 1 antibodies</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>110</NumberOfSites><ContactNames><Name>Judith Falloon</Name></ContactNames></Trial><Trial Id="65706"><Indications><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2017-10-03T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-003491-69</Identifier><Identifier>CACZ885DCA01</Identifier><Identifier>NCT01105507</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>any assessment is performed for patients&amp;lt; 18 years of age Patients with a diagnosis of CAPS: familial &lt;b&gt;cold&lt;/b&gt;-induced urticaria (FCAS/FCU), muckle-wells syndrome (MWS) or chronic infantile neurological cutaneous and articular syndrome (NOMID...Familial &lt;b&gt;Cold&lt;/b&gt; Autoinflammatory Syndrome (FCAS)/Familial &lt;b&gt;Cold&lt;/b&gt; Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID)/Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). To</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="65310"><Indications><Indication>Urinary incontinence</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Acetylcholine receptor antagonist</Action><Action>p130Cas associated protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antiarrhythmic agent</Action><Action>Antidepressant</Action><Action>Neuromuscular blocking agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drying</Technology><Technology>Formulation powder</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology><Technology>Toxin</Technology></Technologies><CompaniesCollaborator><Company>Ethica Clinical Research Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sunnybrook Health Sciences Centre</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-12-19T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>0922006</Identifier><Identifier>NCT01091727</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Depression</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hematuria</Indication><Indication>Insomnia</Indication><Indication>Muscle spasm</Indication><Indication>Muscle weakness</Indication><Indication>Nausea</Indication><Indication>Urinary tract infection</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>onabotulinumtoxinA alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>57</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>associated with an augment in detrusor pressure of &gt; 102 cm H2O. This was deemed possibly treatment related. Urinary tract infection (57 and 55% of patients), headache (21 and 17%), nausea with or without vomiting (21 and 7%), sweating (18 and 0%), common &lt;b&gt;cold&lt;/b&gt; (14 and 7%), muscle spasms (14 and 7%), muscle weakness (11 and 0%), depression (11 and 0%), dizziness (7 and 3%), hematuria (7 and 7%), insomnia (7 and 0%) and back pain (7 and 3%) were some of the AEs observed in &gt;/= 5% of patients in the Botox and</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics - Change from baseline in incontinence episodes</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics - Change from baseline in micturition or catheterization frequency</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments - International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms Quality of life (ICIQ-LUTSqol) questionnaire</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments - Urinary Incontinence Quality of Life Scale (I-QOL)</EndpointIndex><EndpointIndex>Urinary incontinence - Assessment of Incontinence Using Voiding Diary - Assessment of filling symptoms</EndpointIndex><EndpointIndex>Urinary incontinence - Assessment of Urodynamics - Assessment of cystometric outcome</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - Dowell-Bryant incontinence cost index(DBICI)</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - Incontinence quality of life(I-QoL)</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - International consultation on incontinence questionnaire (ICIQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with urinary bladder dysfunction</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Urinary incontinence - Subjects at risk of developing disease - Subjects with history of neurological disorders</PatientSegment><PatientSegment>Urinary incontinence - Subjects with History of/Scheduled for drug Therapy</PatientSegment><PatientSegment>Urinary incontinence - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Urinary incontinence - Subjects with Urge Incontinence/Overactive Bladder - Subjects with neurogenic urge incontinence</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sender Herschorn</Name></ContactNames></Trial><Trial Id="65141"><Indications><Indication>Uveitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>South Korea</Country><Country>Austria</Country><Country>Turkey</Country><Country>Taiwan</Country><Country>Hong Kong</Country><Country>Germany</Country><Country>Tunisia</Country><Country>Spain</Country><Country>US</Country><Country>Jordan</Country><Country>Singapore</Country><Country>Israel</Country><Country>Egypt</Country><Country>Greece</Country><Country>France</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2010-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-013901-33</Identifier><Identifier>CAIN457C2303E1</Identifier><Identifier>NCT01093846</Identifier><Identifier>SHIELD</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>59</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>procedures Any medical or psychiatric condition which, in the investigator's opinion would preclude the participant from adhering to the protocol or completing the study per protocol Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior Visit 16 that in the opinion of the study investigator or sponsor that would be a contraindication to additional treatment with AIN-457 Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Uveitis - Assessment of Medication Use</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of anterior chamber cells</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of vitreous haze</EndpointIndex><EndpointIndex>Uveitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Uveitis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Uveitis - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Uveitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHIELD: A 38 Week Extension Study to CAIN457C2303</TitleDisplay><PatientSegmentTerms><PatientSegment>Uveitis - Subjects with History of/Scheduled for Therapy</PatientSegment><PatientSegment>Uveitis - Subjects with Intermediate Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Posterior Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with Panuveitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="64874"><Indications><Indication>Keratosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Fungicide</Action><Action>Photosensitizer</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>photonamic GmbH &amp; Co KG</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2007-11-30T00:00:00Z</DateEnd><DateStart>2006-03-31T00:00:00Z</DateStart><Identifiers><Identifier>AK 04</Identifier><Identifier>EudraCT No. 2005-003556-36</Identifier><Identifier>NCT00308867</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Alacare alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>349</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>interfere with response evaluation of study treatment Skin sun sensitivity type V or VI according to Fitzpatrick Known intolerance to one or more of the ingredients of the study medication Known adverse reactions to cryosurgery (including &lt;b&gt;cold&lt;/b&gt; urticaria and &lt;b&gt;cold&lt;/b&gt; intolerance) Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent Simultaneous participation in another clinical study or participation in another clinical study</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Actinic keratosis - Clinical Assessments - Complete clearance of actinic keratoses</EndpointIndex><EndpointIndex>Actinic keratosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PDP-506A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK</TitleDisplay><PatientSegmentTerms><PatientSegment>Actinic keratosis - Subjects with clinically visible actinic keratosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Rolf-Marcus Szeimies, Professor MD</Name></ContactNames></Trial><Trial Id="64636"><Indications><Indication>Atrophy</Indication><Indication>Fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-12-13T00:00:00Z</DateChangeLast><DateEnd>2012-06-01T00:00:00Z</DateEnd><DateStart>2009-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-011473-33</Identifier><Identifier>CERTITEM</Identifier><Identifier>CRAD001AFR10</Identifier><Identifier>NCT01079143</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Corticosteroids , basiliximab , ciclosporin, Novartis , enteric-coated mycophenolate sodium, Novartis , everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>194</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Recipient of a primary or secondary deceased or living (related or not) donor kidney transplant and who requires basiliximab induction therapy &lt;b&gt;Cold&lt;/b&gt; ischemia time&amp;lt; 30 h Women of child-bearing age, even those with a history of infertility, must have had a negative pregnancy test during the 7 days before screening or at the time of screening, and must use a recognized and reliable method of contraception</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Degree of inflammation and fibrosis in renal biopsies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CERTITEM: Progression of Renal Interstitial Fibrosis/Tubular Atrophy (IF/TA) According to Epithelial-Mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>23</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="62655"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Elastase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Expectorant</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Edmond Pharma</Company></CompaniesSponsor><Countries><Country>Slovakia</Country><Country>Italy</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>France</Country><Country>Romania</Country><Country>Denmark</Country><Country>Bulgaria</Country><Country>UK</Country><Country>Belgium</Country></Countries><DateChangeLast>2018-02-22T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-008192-34</Identifier><Identifier>ERD-01-08/EP</Identifier><Identifier>NCT01032304</Identifier><Identifier>RESTORE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>erdosteine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>492</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of the study was to evaluate the effect of erdosteine , compared to placebo, on exacerbation rate over a 12-month treatment period in patients with moderate to severe COPD. Moreover, the effects of erdosteine on pulmonary function parameters, clinical symptoms, quality of life, exercise performance, disease-related costs and the long-term safety of erdosteine would be assessed.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RESTORE: The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>49</NumberOfSites><ContactNames><Name>Medical Department</Name></ContactNames></Trial><Trial Id="62127"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>South Africa</Country><Country>Australia</Country><Country>Italy</Country><Country>Sweden</Country><Country>Spain</Country><Country>Germany</Country><Country>Peru</Country><Country>Chile</Country><Country>Denmark</Country><Country>US</Country><Country>UK</Country><Country>Mexico</Country><Country>Canada</Country><Country>Netherlands</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2011-10-17T00:00:00Z</DateEnd><DateStart>2009-09-25T00:00:00Z</DateStart><Identifiers><Identifier>102970</Identifier><Identifier>2009-013064-40</Identifier><Identifier>HZC102970</Identifier><Identifier>NCT01017952</Identifier></Identifiers><InterventionsControlDisplay><Intervention>vilanterol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1635</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Main objective of the trial was to evaluate safety and efficacy of fluticasone furoate + GW-642444 (FF/GW-642444) 50 microg/25 microg qd and FF/GW-642444 100 microg/25 microg qd and FF/GW-642444 200 microg/25 microg qd versus GW-642444 25 microg qd on the annual rate of moderate and severe exacerbations in subjects with COPD over a 52 week treatment period. This study would evaluate the contribution of the ICS on reducing the rate of exacerbations when used in combination with a fixed dose of the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of time to first exacerbation</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate Annual Rate of Exacerbations and Safety of Three Dosage Strengths of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease - Subjects with dyspnea</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>185</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="61703"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Glaxo Group Research Ltd</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Mexico</Country><Country>Canada</Country><Country>Argentina</Country><Country>US</Country><Country>South Africa</Country><Country>Sweden</Country><Country>Italy</Country><Country>UK</Country><Country>Germany</Country><Country>Peru</Country><Country>Chile</Country><Country>Estonia</Country><Country>Australia</Country><Country>Philippines</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2011-10-31T00:00:00Z</DateEnd><DateStart>2009-09-25T00:00:00Z</DateStart><Identifiers><Identifier>102871</Identifier><Identifier>HZC102871</Identifier><Identifier>NCT01009463</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Bronchitis</Indication><Indication>Candida infection</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Headache</Indication><Indication>Pneumonia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>vilanterol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1626</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the efficacy and safety of three strengths of the fluticasone furoate + GW-642444 inhalation powder in patient with chronic obstructive pulmonary disease (COPD). Main objective of the trial was to evaluate safety and efficacy of FF/GW-642444 50/25 microg qd and FF/GW-642444 100/25 microg qd and FF/GW-642444 200/25 microg qd versus GW-642444 25 microg qd on the annual rate of moderate and severe exacerbations in patients with COPD over a 52 week treatment</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of time to first exacerbation</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease - Subjects with dyspnea</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>193</NumberOfSites><ContactNames><Name>Anthony De Soyza</Name><Name>GSK Clinical Trials</Name><Name>Giuseppe Mazza</Name><Name>Miguel E Trevino</Name><Name>Neil D Levine</Name><Name>Paul M Friedman</Name><Name>Peter M Calverley</Name><Name>Yasser Ahmed</Name></ContactNames></Trial><Trial Id="61265"><Indications><Indication>Insomnia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA A receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypnotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2007-07-05T00:00:00Z</DateEnd><DateStart>2006-03-31T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0006</Identifier><Identifier>JapicCTI-184447</Identifier><Identifier>JapicCTI-R140535</Identifier><Identifier>NCT00999219</Identifier></Identifiers><IndicationsAdverse><Indication>Amnesia</Indication><Indication>Atrial fibrillation</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Erythema</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention><Intervention>zolpidem (immediate-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &amp;lt; 30 Patient considered able to undertake a washout period before start of the screening examination, period 1 administration, and period 2 administration, where medication in question is an antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedies, not including eye-drops, nasal or topical preparations), an hypnotic, or an anxiolytic or antidepressant drug used for hypnotic effect Patients who had an ability to fill in the sleep check sheet It does not matter whether the patients are</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of wake time after sleep onset (WASO)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment with sleep questionnaires</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of FK1-99B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with Chronic Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with Primary Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with Sleep Maintenance Insomnia - Subjects with middle insomnia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Use Central Contact</Name></ContactNames></Trial><Trial Id="61112"><Indications><Indication>Uveitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Brazil</Country><Country>Israel</Country><Country>Saudi Arabia</Country><Country>US</Country><Country>Spain</Country><Country>Italy</Country><Country>Hungary</Country><Country>Austria</Country><Country>Jordan</Country><Country>Turkey</Country><Country>Egypt</Country><Country>Taiwan</Country><Country>Hong Kong</Country><Country>France</Country><Country>Singapore</Country><Country>Greece</Country><Country>Switzerland</Country><Country>South Korea</Country><Country>India</Country><Country>Tunisia</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-011237-27</Identifier><Identifier>CAIN457C2303</Identifier><Identifier>CTRI/2009/091/000874</Identifier><Identifier>NCT00995709</Identifier><Identifier>SHIELD</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>intravenously or subcutaneously within 3 months prior to screening and no prior treatment with AIN-457 Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil) Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) Underlying metabolic, hematological, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and/or places the patient at an unacceptable risk for participation in an immunomodulatory</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Macular edema - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Macular edema - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Macular edema - Assessment of adverse events</EndpointIndex><EndpointIndex>Macular edema - Patient Reported Outcomes/Quality of Life Assessments - Visual function questionnaire(VFQ)</EndpointIndex><EndpointIndex>Uveitis - Assessment of Medication Use</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of anterior chamber cells</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of vitreous haze</EndpointIndex><EndpointIndex>Uveitis - Assessment of Underlying Systemic Disease</EndpointIndex><EndpointIndex>Uveitis - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Uveitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Uveitis - Patient Reported Outcomes/Quality of Life Assessments - Visual function questionnaire(VFQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHIELD: Phase III Study in Refractory Behcet's Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Macular edema - Subjects at risk of developing disease - Subjects with history of uveitis</PatientSegment><PatientSegment>Uveitis - Subjects Contraindicated for Steroid Therapy</PatientSegment><PatientSegment>Uveitis - Subjects with Acute Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with History of/Scheduled for Therapy - Subjects with history/scheduled for immunosuppressants</PatientSegment><PatientSegment>Uveitis - Subjects with Intermediate Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Non-Infectious Uveitis - Subjects with autoimmune disorder associated uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Posterior Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Recurrent Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with Panuveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with retinal vasculitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anterior chamber </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Macula retinae </BiomarkerName><BiomarkerName> Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>60</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="60891"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2012-02-29T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-003490-15</Identifier><Identifier>CACZ885D2308</Identifier><Identifier>JapicCTI-090930</Identifier><Identifier>NCT00991146</Identifier></Identifiers><IndicationsAdverse><Indication>Acne</Indication><Indication>Bronchitis</Indication><Indication>Conjunctivitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Epstein Barr virus infection</Indication><Indication>Gastroenteritis</Indication><Indication>Hypertension</Indication><Indication>Nervous system development disorder</Indication><Indication>Pain</Indication><Indication>Parvovirus infection</Indication><Indication>Pharyngitis</Indication><Indication>Pneumonia</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Rhinorrhea</Indication><Indication>Stomatitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was to assess the efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes (CAPS). This study would allow access for Japanese patients to a new potentially efficacious treatment for CAPS patients with a convenient dosing regimen. The objectives of this study were to assess the presence of protective antibody levels following immunization with non-live vaccines, proportion of patients with vaccination-associated reactions and the safety if</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase</TitleDisplay><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Novartis</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="60606"><Indications><Indication>Iron overload</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Ferritin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Blood system agent</Action><Action>Fungicide</Action><Action>Iron chelator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Children's Hospital of Los Angeles</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2009-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CICL670AUS30T</Identifier><Identifier>NCT00981370</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>deferasirox alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>secondary objective(s) were to: Determine if the magnitude of endothelial-dependant vasodilation was related to the degree of iron overload. Determine if the degree of change in cardiac beat to beat variability in response to hypoxic exposure or to &lt;b&gt;cold&lt;/b&gt; exposure ('&lt;b&gt;cold&lt;/b&gt;-face-test') was related the magnitude of iron overload. The primary measure of iron overload would be MRI determination of liver iron concentration.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Anemia - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Survival</EndpointIndex><EndpointIndex>Anemia - Assessment of iron status - Assessment of iron overload</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of reticulocyte count</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical Importance of Treating Iron Overload in Sickle Cell Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia</PatientSegment><PatientSegment>Anemia - Subjects with Sickle Cell Anemia</PatientSegment><PatientSegment>Anemia - Subjects with Thalassemia - Subjects with beta thalassemia major/cooley's anemia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Thomas D. Coates, M.D.</Name></ContactNames></Trial><Trial Id="59385"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP206</Identifier><Identifier>MI-CP206</Identifier><Identifier>NCT00952705</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Fever</Indication><Indication>Myalgia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>FluMist alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>MEDI-8662 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1800</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>0.2 ml into a single nostril. Each dose contained 10(7.0 +/- 0.5) fluorescent focus units (FFU) of each of four &lt;b&gt;cold&lt;/b&gt;-adapted, temperature-sensitive, attenuated, 6: 2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A...III: participants would receive FluMist -B/Victoria intranasally using a BD Accuspray device. A total volume of 0.2 ml would be administered intranasally (approximately 0.1 ml into each nostril). Each dose contained 10(7.0 +/- 0.5 FFU) of each of three &lt;b&gt;cold&lt;/b&gt;-adapted, temperature-sensitive</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MI-CP206: A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI-8662) in Adults 18 to 49 Years of Age</TitleDisplay><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Anita Chaudhary</Name><Name>Anne Cutter</Name><Name>Donald Brandon</Name><Name>Jill Bergers</Name><Name>Joseph Sliman, M.D., MPH</Name><Name>Karina Arencibia</Name><Name>Laurence Chu</Name><Name>Lorraine Boggs</Name><Name>Matthew Davis</Name><Name>Stephen Bowman</Name></ContactNames></Trial><Trial Id="58607"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>MediQuest Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2009-06-30T00:00:00Z</DateStart><Identifiers><Identifier>09-001</Identifier><Identifier>NCT00934427</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MQX-503 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>for 1 day before certain planned &lt;b&gt;cold&lt;/b&gt; exposures, once just before same planned &lt;b&gt;cold&lt;/b&gt; exposures, and, if needed, right after the start of symptoms during same planned &lt;b&gt;cold&lt;/b&gt; exposures....Raynaud's events during a typical winter day Must be willing to apply creams to fingers Must be willing to undergo &lt;b&gt;cold&lt;/b&gt; temperature exposure Must be willing and able to stop certain medications Must be willing to use effective contraception, if applicable</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Vascular disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Time to cardiovascular event</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Patients with claudication pain</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2010-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Jeff Gregory, MD</Name></ContactNames></Trial><Trial Id="58128"><Indications><Indication>Amyloidosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>Transthyretin modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>FoldRx Pharmaceuticals Inc</Company><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>Germany</Country><Country>US</Country><Country>Portugal</Country><Country>France</Country><Country>Sweden</Country><Country>Italy</Country><Country>Brazil</Country></Countries><DateChangeLast>2019-03-06T00:00:00Z</DateChangeLast><DateEnd>2021-12-31T00:00:00Z</DateEnd><DateStart>2009-08-05T00:00:00Z</DateStart><Identifiers><Identifier>2009-011535-12</Identifier><Identifier>B3461023</Identifier><Identifier>FX1A-303</Identifier><Identifier>NCT00925002</Identifier></Identifiers><IndicationsAdverse><Indication>Angina</Indication><Indication>Cardiac failure</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Sepsis</Indication><Indication>Skin burns</Indication><Indication>Transient ischemic attack</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tafamidis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>93</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>, pooled results were presented from three studies ( NCT00409175 , NCT00791492 and NCT00925002). There were no new safety issues or side effects of Fx-1006A were observed in the long-term evaluation of 71 patients. Urinary tract infections (28.2%); &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis, 25.4%); influenza (23.9%); diarrhea (22.5%); headache and pain in an extremity (both 19.7%); back pain (16.9%); upper respiratory tract infection (15.5%); depression and thermal burn (both 14.1%); upper abdominal pain, anxiety, death</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TitleDisplay>Safety and Efficacy Evaluation of FX-1006A in Subjects With Transthyretin Amyloidosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Total body mass </BiomarkerName><BiomarkerName> Transthyretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>148 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="57108"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>MediQuest Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-09-10T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>2004-11-30T00:00:00Z</DateStart><Identifiers><Identifier>MQT 03-001</Identifier><Identifier>NCT00253331</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MQX-503 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to &lt;b&gt;cold&lt;/b&gt; temperatures. Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a &lt;b&gt;cold&lt;/b&gt; chamber, and then blood flow and skin temperature are monitored for the next 2 h. Each patient will receive multiple doses on different</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Assessment of blood flow to return cold exposure.</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Time required for skin temperature to return after cold exposure</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Indices or Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Lab Study of MQX-503 in Treatment of Raynaud's</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Carin Dugowson, MD, MPH</Name><Name>Laura K Hummers, MD</Name></ContactNames></Trial><Trial Id="57022"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Endo Health Solutions Inc</Company></CompaniesSponsor><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2004-03-31T00:00:00Z</DateEnd><DateStart>2003-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EN3202-028</Identifier><Identifier>NCT00911287</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxymorphone ER, Endo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>129</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>test (females only) History of or active asthma or emphysema Clinically significant hepatic impairment Received any of the following medications within 48 hours prior to dosing: Dextromethorphan-containing medications (over-the-counter [OTC] cough and &lt;b&gt;cold&lt;/b&gt; preparations, such as Vicks Formula 44) St. John's Wort&gt; 1000 mg/day Received monoamine oxidase inhibitor (MAOI) drugs within 2 weeks prior to dosing Are not stabilized on the following medications for at least 4 weeks prior to dosing: Tricyclic antidepressant</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2004-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Study Director</Name></ContactNames></Trial><Trial Id="5521"><Indications><Indication>Raynauds disease</Indication><Indication>Vascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Rho associated protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Johns Hopkins University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-03T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NA_00002801</Identifier><Identifier>NCT00498615</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fasudil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> a new vasodilator called fasudil , a rho-kinase inhibitor. The study hypothesized that fasudil would prevent vasoconstriction of digital and cutaneous arteries during a standard laboratory based &lt;b&gt;cold&lt;/b&gt; exposure and would therefore improve digital blood flow and skin temperature recovery time following &lt;b&gt;cold&lt;/b&gt; challenge.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Time to cardiovascular event</EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Rho-Kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fredrick M Wigley, M.D.</Name><Name>Fredrick Wigley</Name></ContactNames></Trial><Trial Id="5411"><Indications><Indication>Insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin ligand</Action><Action>Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Human insulin intermediate acting product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Peptide</Technology><Technology>Powder formulation inhalant</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2014-09-30T00:00:00Z</DateChangeLast><DateEnd>2000-09-30T00:00:00Z</DateEnd><DateStart>1999-09-30T00:00:00Z</DateStart><Identifiers><Identifier>217-106</Identifier><Identifier>NCT00424437</Identifier></Identifiers><IndicationsAdverse><Indication>Aphasia</Indication><Indication>Coma</Indication><Indication>Confusion</Indication><Indication>Cough</Indication><Indication>Dizziness</Indication><Indication>Headache</Indication><Indication>Hyperglycemia</Indication><Indication>Hypoglycemia</Indication><Indication>Hypothermia</Indication><Indication>Nausea</Indication><Indication>Pharyngitis</Indication><Indication>Respiratory tract infection</Indication><Indication>Rhinitis</Indication><Indication>Seizure disorder</Indication><Indication>Tremor</Indication><Indication>Unconsciousness</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including NPH insulin , regular insulin , sc insulin (regular + NPH insulin)</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Exubera + Ultralente , NPH insulin , Ultralente , insulin (inhaled), Pfizer , regular insulin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine, in patients with type 1 diabetes mellitus, whether glycemic control could be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin ( Exubera ) plus a single bedtime ultralente injection as with a conventional sc insulin regimen involving two to three mixed regular/NPH insulin injections per day. The study also aimed to determine the tolerability and safety of Exubera therapy and its effects after 6 months, if any, on</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of postprandial plasma glucose (PPPG)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Hypoglycemic Episodes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Insulin Dose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A 6-month clinical trial assessing efficacy and safety of inhaled insulin in type 1 diabetes mellitus</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>36</NumberOfSites><ContactNames><Name>Pfizer Call Center</Name></ContactNames></Trial><Trial Id="53913"><Indications><Indication>Acute lymphoblastic leukemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Abl tyrosine kinase inhibitor</Action><Action>Bcr protein inhibitor</Action><Action>Kit tyrosine kinase inhibitor</Action><Action>PDGF receptor antagonist</Action><Action>Signal transduction inhibitor</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Fibrosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>St Jude Children's Research Hospital</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-12-21T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2000-07-08T00:00:00Z</DateStart><Identifiers><Identifier>F32CA141762</Identifier><Identifier>NCT00137111</Identifier><Identifier>P30CA021765</Identifier><Identifier>R37CA036401</Identifier><Identifier>TOTXV</Identifier><Identifier>Total XV</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>methotrexate alone</Intervention><Intervention>Variable regimens including 6-Mercaptopurine , L-asparaginase , anthracycline , cyclophosphamide , cytarabine , daunorubicin , dexamethasone , doxorubicin , etoposide phosphate , imatinib , leucovorin , methotrexate , prednisone , vincristine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>501</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The primary objective was to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate. The secondary objectives were: To determine if CNS irradiation can be safely omitted in the context of the systemic therapy used in the protocol. To identify whether prolonged (24 h) iv infusions of HDMTX produce greater methotrexate polyglutamate (MTXPG) accumulation than short (4</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Leukemia - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Leukemia - Assessment of Disease Progression - Assessment of risk for disease progression</EndpointIndex><EndpointIndex>Leukemia - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures - Neurological function assessment</EndpointIndex><EndpointIndex>Leukemia - Assessment of Markers of Tumor Growth and Progression - Assessment of prognostic markers</EndpointIndex><EndpointIndex>Leukemia - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of antibody response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of radiological response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability - Treatment emergent adverse events (TEAEs)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Leukemia - Hematological Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Leukemia - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Leukemia - Protocol Specified Other Endpoints - Assessment of Antileukemia Activity/Anti-Tumor Activity</EndpointIndex><EndpointIndex>Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Mortality/Death Rates - Assessment of treatment-related mortality/non-relapse mortality</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Remission</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of infections</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Survival - Assessment of Recurrence/Relapse Free Survival</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Protocol Specified Other Endpoints - Assessment of disease activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Leukemia - Pediatric Leukemia Subjects</PatientSegment><PatientSegment>Leukemia - Subjects with Acute Leukemia Unspecified Type</PatientSegment><PatientSegment>Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Caspase-1 </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> L-asparaginase </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lipoproteins </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>244 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Ching-Hon Pui, M.D.</Name></ContactNames></Trial><Trial Id="53895"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-05T00:00:00Z</DateChangeLast><DateEnd>2005-02-28T00:00:00Z</DateEnd><DateStart>2004-07-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP112</Identifier><Identifier>NCT00192335</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Abscess</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Nasal congestion</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>890</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to demonstrate equivalent immunogeniticity of CAIV-T / FluMist . The secondary objective of this study was to assess the safety and tolerability of CAIV-T / FluMist .</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FluMist in Healthy Participants</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Kunitz-type protease inhibitor 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Luis Angles, MD</Name></ContactNames></Trial><Trial Id="53894"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><DateChangeLast>2017-12-02T00:00:00Z</DateChangeLast><DateEnd>2002-11-01T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>D153-P504</Identifier><Identifier>NCT00192400</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2160</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and &amp;lt; 36 months.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Robert Walker, MD</Name></ContactNames></Trial><Trial Id="5292"><Indications><Indication>Diabetic neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dihydropyrimidinase related protein 2 modulator</Action><Action>Sodium channel modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>UCB BIOSCIENCES GmbH</Company><Company>UCB SA</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Belgium</Country><Country>Germany</Country><Country>Hungary</Country><Country>Italy</Country><Country>Austria</Country><Country>Romania</Country><Country>Spain</Country><Country>Finland</Country><Country>Bulgaria</Country><Country>Poland</Country><Country>France</Country><Country>Serbia</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000551-42</Identifier><Identifier>NCT00546351</Identifier><Identifier>SP746</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lacosamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>621</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this trial was to assess the tolerability and safety of long-term lacosamide administration in subjects with painful distal diabetic neuropathy. The secondary objective was to evaluate the efficacy of long-term use of lacosamide in this indication. Trial sub-study: A double-blind, randomized withdrawal of lacosamide in subjects with painful diabetic neuropathy-subtrial to SP746. The primary objective of this subtrial was to demonstrate the efficacy of lacosamide in subjects</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Imaging/Radiological Assessments - Assessment by echocardiography</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Imaging/Radiological Assessments - Assessment by echocardiography</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>80 Months</TrialDuration><NumberOfSites>65</NumberOfSites><ContactNames><Name>UCB Clinical Trial Call Center</Name></ContactNames></Trial><Trial Id="51993"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA helicase inhibitor</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>DNA intercalator</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Fonden til Fremme af Eksperimentel Cancerforskning</Company><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Danish Breast Cancer Cooperative Group</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2007-003126-15</Identifier><Identifier>DBCG 07-READ</Identifier><Identifier>NCT00689156</Identifier><Identifier>READ</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Myalgia</Indication><Indication>Nausea</Indication><Indication>Peripheral neuropathy</Indication><Indication>Stomatitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including cyclophosphamide , docetaxel , docetaxel + cyclosphosphamide , epirubicin , epirubicin + docetaxel + cyclosphosphamide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2015</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The Danish Breast Cancer Cooperative Group (DBCG) designed this study to clarify if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin and cyclophosphamide followed by docetaxel in patients with TOP2A (Topoisomerase [DNA] II Alpha [170 kD]) normal and operable breast cancer.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>READ: Epirubicin or Not in Patients With TOP2A (Topoisomerase [DNA] II Alpha [170 kD]) Normal Early Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Others - Subjects with node positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>DNA topoisomerase 2-alpha</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Bent Ejlertsen, M.D.</Name><Name>Henning T. Mouridsen, M.D.</Name></ContactNames></Trial><Trial Id="51387"><Indications><Indication>Adenocarcinoma</Indication><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Erbb4 tyrosine kinase receptor inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Puma Biotechnology Inc</Company><Company>Wyeth Pharmaceuticals</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>Poland</Country><Country>Turkey</Country><Country>Lebanon</Country><Country>Chile</Country><Country>Germany</Country><Country>Sweden</Country><Country>Israel</Country><Country>South Korea</Country><Country>New Zealand</Country><Country>Greece</Country><Country>Colombia</Country><Country>Hong Kong</Country><Country>China</Country><Country>Denmark</Country><Country>UK</Country><Country>Jordan</Country><Country>Portugal</Country><Country>Czech Republic</Country><Country>Taiwan</Country><Country>Bulgaria</Country><Country>Bahamas</Country><Country>France</Country><Country>Mexico</Country><Country>Brazil</Country><Country>Italy</Country><Country>Belgium</Country><Country>Malaysia</Country><Country>Malta</Country><Country>Singapore</Country><Country>Slovakia</Country><Country>Croatia</Country><Country>Hungary</Country><Country>Peru</Country><Country>US</Country><Country>Argentina</Country><Country>Saudi Arabia</Country><Country>Serbia</Country><Country>Switzerland</Country><Country>Canada</Country><Country>Spain</Country><Country>Australia</Country><Country>Japan</Country><Country>Netherlands</Country><Country>Lithuania</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2009-07-09T00:00:00Z</DateStart><Identifiers><Identifier>2008-007345-31</Identifier><Identifier>3144A2-3004</Identifier><Identifier>3144A2-3004 / B1891004</Identifier><Identifier>3144A2-3004(B1891004)</Identifier><Identifier>3144A2-3004-WW</Identifier><Identifier>7006</Identifier><Identifier>B1891004</Identifier><Identifier>ExteNET</Identifier><Identifier>JapicCTI-101217</Identifier><Identifier>NCT00878709</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Appetite loss</Indication><Indication>Arthralgia</Indication><Indication>Cerebral edema</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Dyspepsia</Indication><Indication>Emesis</Indication><Indication>Epistaxis</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hepatotoxicity drug-induced</Indication><Indication>Influenza virus infection</Indication><Indication>Jaundice</Indication><Indication>Liver disease</Indication><Indication>Muscle spasm</Indication><Indication>Nail disease</Indication><Indication>Nausea</Indication><Indication>Paronychia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Skin rash</Indication><Indication>Stomach tumor</Indication><Indication>Stomatitis</Indication><Indication>Urinary tract infection</Indication><Indication>Weight loss</Indication><Indication>Xerosis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>neratinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2840</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this multicenter, randomized, double-blind, placebo-controlled, phase III trial was to investigate whether neratinib could further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab [ 1665435 ], [ 1228385 ], [ 1782156 ], [ 1782157 ], [ 1790152 ], [ 1797854 ], [ 1918107 ], [ 1945729 ], [ 1945624 ], [ 1961588 ], [ 1989379 ], [ 2069325 ], [ 2102197 ], [ 2102199 ], [ 2130663 ], [ 2130860 ], [ 2158805 ]. Main</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>ExteNET: Study Evaluating the Effects of Neratinib After Adjuvant Trastuzumab in Women With Early Stage Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Others - Subjects with node positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIB Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIC Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alpha-amylase 1 </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Epidermal growth factor receptor </BiomarkerName><BiomarkerName> Estrogen receptor </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Myc proto-oncogene protein </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </BiomarkerName><BiomarkerName> Progesterone receptor </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> Receptor tyrosine-protein kinase erbB-3 </BiomarkerName><BiomarkerName> Receptor tyrosine-protein kinase erbB-4 </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Transaminases</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>136 Months</TrialDuration><NumberOfSites>594</NumberOfSites><ContactNames><Name>Personal</Name><Name>Pfizer Japan Inc.</Name><Name>Puma</Name></ContactNames></Trial><Trial Id="49488"><Indications><Indication>Diabetic neuropathy</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Antidepressant</Action><Action>Anxiolytic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><DateChangeLast>2010-09-21T00:00:00Z</DateChangeLast><DateStart>2003-11-30T00:00:00Z</DateStart><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Constipation</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Hyperhidrosis</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>duloxetine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>348</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>severity on the 11-point Likert scale (from the patient diary prior to randomization), and stable glycemic control Concomitant medication inclusions (chronic and episodic) were antacids, antiasthma agents, aminophylline, birth control medication, cough/&lt;b&gt;cold&lt;/b&gt; preparations (that did not contain dextromethorphan), diuretics, inhaled and topical steroids, hypoglycemics, insulin, laxatives, theophylline, anticoagulants, antibiotics, antidiarrheals, and antihistamines. Medications including angiotensin-converting</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, 12-week, multicenter, randomized, double-blind, placebo-controlled parallel study of duloxetine in patients with diabetic neuropathy</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="49419"><Indications><Indication>Periodontal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Collagenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Tetracycline</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>TOLMAR Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-02-08T00:00:00Z</DateChangeLast><DateStart>1997-03-21T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>doxycycline (subgingival delivery: Atridox), Atrix alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The drug was generally well tolerated. Side effects were similar to those of placebo. The most common side effects observed were headache, common &lt;b&gt;cold&lt;/b&gt;, gum discomfort, pain or soreness, toothache, and tooth sensitivity [ 327938 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A 9-month, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the safety and efficacy of Atridox in patients with moderate to severe periodontal disease</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="47935"><Indications><Indication>Bladder cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Cancer Institute of Canada</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2012-01-01T00:00:00Z</DateEnd><DateStart>2006-04-30T00:00:00Z</DateStart><Identifiers><Identifier>BL11</Identifier><Identifier>CAN-NCIC-BL11</Identifier><Identifier>CDR0000486873</Identifier><Identifier>NCT00352079</Identifier></Identifiers><InterventionsControlDisplay><Intervention>BCG alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>BCG plus gefitinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>tumor(s) Carcinoma in situ (Tis) At least grade 2 tumor that invades the subepithelial connective tissue (T1) Has undergone TUR of all visible bladder lesions within the past 21 to 60 days with biopsy of the underlying bladder wall for all tumors and &lt;b&gt;cold&lt;/b&gt;-cup biopsy of all suspicious areas No metastatic disease as confirmed by negative radiology within the past 16 weeks, including the following: Chest x-ray Imaging of the upper urinary tract by one of the following methods: CT scan, MRI, or ultrasound</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Clinical Response - Assessment of Time-to-Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 2 Bladder Cancer (G2)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>68 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Louis Lacombe, MD</Name></ContactNames></Trial><Trial Id="47928"><Indications><Indication>Premature labor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development</Company></CompaniesCollaborator><CompaniesSponsor><Company>The George Washington University Biostatistics Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>HD21410</Identifier><Identifier>HD27860</Identifier><Identifier>HD27869</Identifier><Identifier>HD27915</Identifier><Identifier>HD27917</Identifier><Identifier>HD34116</Identifier><Identifier>HD34136</Identifier><Identifier>HD34208</Identifier><Identifier>HD36801</Identifier><Identifier>HD36801 SCAN</Identifier><Identifier>HD40485</Identifier><Identifier>HD40500</Identifier><Identifier>HD40512</Identifier><Identifier>HD40544</Identifier><Identifier>HD40545</Identifier><Identifier>HD40560</Identifier><Identifier>NCT00439374</Identifier><Identifier>U10HD021410</Identifier><Identifier>U10HD027860</Identifier><Identifier>U10HD027869</Identifier><Identifier>U10HD027915</Identifier><Identifier>U10HD027917</Identifier><Identifier>U10HD034116</Identifier><Identifier>U10HD034136</Identifier><Identifier>U10HD034208</Identifier><Identifier>U10HD036801</Identifier><Identifier>U10HD040485</Identifier><Identifier>U10HD040500</Identifier><Identifier>U10HD040512</Identifier><Identifier>U10HD040544</Identifier><Identifier>U10HD040545</Identifier><Identifier>U10HD040560</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hydroxyprogesterone caproate (long-acting, preterm birth prevention), Adeza alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>657</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>planned cervical cerclage Congenital Mullerian abnormality of the uterus Contraindication to intra-muscular injections Hypertension requiring medication Diabetes managed with insulin or oral hypoglycemic agents DES exposure Cervical surgery such as &lt;b&gt;cold&lt;/b&gt; knife conization Planned indicated preterm delivery Participation in another interventional study that influences age at delivery Participation in this trial in a previous pregnancy Prenatal care or delivery planned outside a MFMU Network center</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term></TermsPatientSelection><TitleDisplay>RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix</TitleDisplay><BiomarkerNames><BiomarkerName>Birth weight</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>56 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Menachem Miodovnik, MD</Name><Name>William Grobman, MD, MBA</Name></ContactNames></Trial><Trial Id="45807"><Indications><Indication>Neuropathy</Indication><Indication>Neurotoxicity drug-induced</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Apoptosis inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><DateChangeLast>2019-03-29T00:00:00Z</DateChangeLast><DateEnd>2004-05-31T00:00:00Z</DateEnd><DateStart>2002-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC4972</Identifier><Identifier>NCT00272051</Identifier><Identifier>SR57746A</Identifier><Identifier>XENOX</Identifier></Identifiers><IndicationsAdverse><Indication>Anxiety disorder</Indication><Indication>Diarrhea</Indication><Indication>Insomnia</Indication><Indication>Tinnitus</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin , xaliproden</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>620</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> not reveal any differences. Diabetic compared to non-diabetic patients, no differences was observed between the two groups in terms of acute oxaliplatin-induced neurological symptoms including laryngeal dysthesia (p = 0.707), jaw pain (p = 0.743), &lt;b&gt;cold&lt;/b&gt;-induced dysthesia (p = 0.600) or muscle pain (p =  0.506). Moreover, there was no difference observed between the two groups in parameters of the highest grade of paresthesia (p = 0.498), incidence of long-term oxaliplatin-induced paresthesia (p = </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of clinical/pathological response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>XENOX: XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>22 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Gerard SAID</Name></ContactNames></Trial><Trial Id="4579"><Indications><Indication>Heart transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Australia</Country><Country>Germany</Country><Country>Canada</Country><Country>Italy</Country><Country>Brazil</Country><Country>US</Country><Country>Austria</Country></Countries><DateChangeLast>2017-06-30T00:00:00Z</DateChangeLast><DateEnd>2007-01-08T00:00:00Z</DateEnd><DateStart>2004-08-09T00:00:00Z</DateStart><Identifiers><Identifier>2004-000541-38</Identifier><Identifier>CRAD001A2403</Identifier><Identifier>NCT00098007</Identifier><Identifier>RAD/Certican</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ciclosporin, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>199</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with donor hearts &gt; 60 years of age and/or with a &lt;b&gt;cold&lt;/b&gt; ischemia time of more than 6 h and/or donor hearts which have obvious coronary disease or are known to have heart disease at time of transplant Patients who are recipients of multiple solid organ transplants, or who are previously received transplanted</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR associated with hemodynamic compromise (HDC)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure - Incidence of graft loss</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability - Withdrawal/discontinuation of the drug due to toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Safety, Tolerability and Efficacy of Certican in de Novo Heart Transplant (Tx) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Subjects with History of/on Currently on Heart Transplant Therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>28</NumberOfSites></Trial><Trial Id="45479"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-04T00:00:00Z</DateChangeLast><DateEnd>2006-12-01T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP134</Identifier><Identifier>NCT00325481</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to assess the safety of a bivalent vaccine of two new influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine ( FluMist ) containing them.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Study To Evaluate the Safety of Bivalent Vaccine</TitleDisplay><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Maria Allende, M.D.</Name></ContactNames></Trial><Trial Id="44938"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Europe BV</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>Netherlands</Country><Country>France</Country><Country>Germany</Country><Country>Switzerland</Country><Country>UK</Country><Country>Spain</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2007-08-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000520-32</Identifier><Identifier>FG-506-02-42</Identifier><Identifier>JapicCTI-184472</Identifier><Identifier>JapicCTI-R140562</Identifier><Identifier>NCT00296309</Identifier><Identifier>SENIOR</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Simulect , mycophenolate mofetil , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>267</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patient has an immunological high risk &lt;b&gt;Cold&lt;/b&gt; ischemia time &gt; 30 h Patient has significant liver disease Patient is allergic or intolerant to study medication Patient or donor is known to be HIV positive Patient with malignancy or history of malignancy Patient has significant, uncontrolled concomitant</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Dysfunction</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for antidiabetic agents</EndpointIndex><EndpointIndex>Kidney transplantation - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - Hyperglycemia</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SENIOR: Comparing Efficacy and Safety of Tacrolimus and MMF With/Without Induction in the Elderly Following Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Compatible Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>34</NumberOfSites><ContactNames><Name>Medical Physician</Name></ContactNames></Trial><Trial Id="44935"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company><Company>Sanofi Genzyme</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Inc</Company><Company>Australian Government Department of Health and Ageing</Company><Company>Fujisawa GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Poland</Country><Country>Spain</Country><Country>Austria</Country><Country>France</Country><Country>Czech Republic</Country><Country>Netherlands</Country><Country>Sweden</Country><Country>Romania</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Australia</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2006-07-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000457-34</Identifier><Identifier>ACTRN12611001224910</Identifier><Identifier>FG-506-02-40</Identifier><Identifier>JapicCTI-184471</Identifier><Identifier>JapicCTI-R140561</Identifier><Identifier>NCT00296361</Identifier><Identifier>RESTORE</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>sirolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>634</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patient has a high immunological risk, defined as a PRA grade &gt; 50% in the previous 6 months and / or having a previous graft survival&amp;lt; 1 year due to immunological reason Patient is receiving a graft from a non-heart-beating donor &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney &gt; 30 h Patient has significant liver disease, defined as having during the past 30 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Clinically-confirmed AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Freedom from acute rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Leucopenia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/Aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for antidiabetic agents</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for lipid lowering drugs</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - Hyperkalaemia</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RESTORE: To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2006-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>59</NumberOfSites><ContactNames><Name>Medical Physician</Name></ContactNames></Trial><Trial Id="44746"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma KK</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-08-13T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2008-02-29T00:00:00Z</DateStart><Identifiers><Identifier>A1202</Identifier><Identifier>A1202E1</Identifier><Identifier>A1202E1</Identifier><Identifier>CRAD001A1202</Identifier><Identifier>CRAD001A1202E1</Identifier><Identifier>JapicCTI-080593</Identifier><Identifier>JapicCTI-090710</Identifier><Identifier>NCT00658320</Identifier><Identifier>NCT00856466</Identifier></Identifiers><IndicationsAdverse><Indication>Acne</Indication><Indication>Constipation</Indication><Indication>Cytomegalovirus infection</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hyperlipidemia</Indication><Indication>Hypertension</Indication><Indication>Hyperuricemia</Indication><Indication>Insomnia</Indication><Indication>Iron deficiency anemia</Indication><Indication>Renal disease</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including ciclosporin, Novartis , everolimus , everolimus + Neoral , mycophenolate mofetil , mycophenolate mofetil + Neoral</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>122</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> prior to randomization are acceptable, otherwise these tests should be performed within two weeks prior to randomization Recipients of organs from donors who test positive for Hepatitis B surface antigen, HCV or HIV are excluded Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 24 h Donor age &gt; 65 years Patients with platelet count&amp;lt; 100,000/mm at baseline before transplantation Patients with an absolute neutrophil count of&amp;lt; 1500/mm3 or white blood cell count of &amp;lt; 4500/mm3 at baseline before transplantation</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Calculated GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using Nankivell formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure - Incidence/proportion of patients with graft loss</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Dose-adjusted trough concentration (C0/Dose)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints - Frequency of treatment failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Novartis</Name><Name>Novartis Pharma KK</Name></ContactNames></Trial><Trial Id="4434"><Indications><Indication>Cardiovascular disease</Indication><Indication>Heart disease</Indication><Indication>Raynauds disease</Indication><Indication>Vascular disease</Indication></Indications><CompaniesSponsor><Company>National Heart Lung and Blood Institute</Company></CompaniesSponsor><DateChangeLast>2016-04-16T00:00:00Z</DateChangeLast><DateStart>1992-09-30T00:00:00Z</DateStart><Identifiers><Identifier>73</Identifier><Identifier>NCT00000530</Identifier><Identifier>RTS</Identifier></Identifiers><IndicationsAdverse><Indication>Edema</Indication><Indication>Headache</Indication><Indication>Tachycardia</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nifedipine (once-daily controlled-release), Pfizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>313</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the &lt;b&gt;cold&lt;/b&gt; season months of November through February in 1993 and 1994 (cohort 1) and 200 were enrolled during the 1994 and 1995 &lt;b&gt;cold&lt;/b&gt; season months (cohort 2) [ 1152064 ]....Patients completed at least 75% of the required 1-month basline record of attacks No contraindications to the study treatments Patients who reported at least two attacks on an average day during the previous &lt;b&gt;cold&lt;/b&gt; season</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RTS: Raynaud's Treatment Study (RTS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Bruce Thompson</Name></ContactNames></Trial><Trial Id="44232"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Hungary</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Slovakia</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2004-08-31T00:00:00Z</DateEnd><DateStart>2003-02-28T00:00:00Z</DateStart><Identifiers><Identifier>DISTAMP</Identifier><Identifier>FG-506-02-CEE-01</Identifier><Identifier>JapicCTI-184504</Identifier><Identifier>JapicCTI-R140599</Identifier><Identifier>NCT00693381</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including methylprednisolone , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>152</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>squamous cell carcinoma of the skin that has been treated successfully Patient has significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, or active peptic ulcer Patient is receiving a graft from a non-heart-beating donor &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney&gt;/= 40 h</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Clinically-confirmed AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Freedom from acute rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Severity of AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Anemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Gastrointestinal adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Urinary tract infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DISTAMP: Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2004-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Central Contact</Name></ContactNames></Trial><Trial Id="43935"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2007-01-01T00:00:00Z</DateEnd><DateStart>2004-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000330000</Identifier><Identifier>NCI-2012-02556</Identifier><Identifier>NCT00070122</Identifier><Identifier>S0303</Identifier><Identifier>U10CA032102</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , capecitabine , fluorouracil , leucovorin calcium , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>therapeutic anticoagulation Prophylactic anticoagulation of central venous lines allowed Low-dose prophylactic enoxaparin or heparin allowed No concurrent cimetidine No concurrent sorivudine or its related analogs (eg, brivudine) No concurrent use of a &lt;b&gt;cold&lt;/b&gt; cap or iced mouth rinses</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers - Assessment of markers of DNA repair</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Response - Assessment of Time to Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of growth factors</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of angiogenesis</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of markers of drug resistance/metabolism</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT-C TOI</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Recurrent/Relapsed Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM Stage I/Dukes A Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Charles Blanke</Name></ContactNames></Trial><Trial Id="43792"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateStart>2001-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CCHI621ADE01</Identifier><Identifier>NCT00228020</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including ciclosporin, Novartis , mycophenolate mofetil , prednisone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , ciclosporin, Novartis , mycophenolate mofetil , prednisone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>212</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients who are recipients of HLA-identical renal transplants. Patients whose donor kidney &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT) is &gt; 36 h. Patients whose transplant kidney is obtained from a non-heart beating donor Other protocol-defined exclusion criteria may apply</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - First AGR episode</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Sub-clinical AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival - Survival Rates (Kaplan-Meier analysis)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-01-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="41370"><Indications><Indication>Neurotoxicity drug-induced</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Apoptosis inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>Chile</Country><Country>Canada</Country><Country>Italy</Country><Country>Germany</Country><Country>US</Country><Country>Brazil</Country><Country>Argentina</Country><Country>UK</Country><Country>Australia</Country><Country>Hungary</Country><Country>Spain</Country><Country>Poland</Country><Country>Portugal</Country></Countries><DateChangeLast>2019-03-29T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2005-12-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC5505</Identifier><Identifier>EUDRACT : 2005-002570-30</Identifier><Identifier>NCT00305188</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin , xaliproden</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>879</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> not reveal any differences. Diabetic compared to non-diabetic patients, no differences was observed between the two groups in terms of acute oxaliplatin-induced neurological symptoms including laryngeal dysthesia (p = 0.707), jaw pain (p = 0.743), &lt;b&gt;cold&lt;/b&gt;-induced dysthesia (p = 0.600) or muscle pain (p =  0.506). Moreover, there was no difference observed between the two groups in parameters of the highest grade of paresthesia (p = 0.498), incidence of long-term oxaliplatin-induced paresthesia (p = </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Evaluation of the Efficacy of Xaliproden (SR-57746A) in Preventing the Neurotoxicity of Oxaliplatin/5FU/LV Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Clinical Sciences &amp; Operations</Name></ContactNames></Trial><Trial Id="41217"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>US</Country></Countries><DateChangeLast>2017-09-14T00:00:00Z</DateChangeLast><DateEnd>2007-03-31T00:00:00Z</DateEnd><DateStart>2000-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CRAD001AB351</Identifier><Identifier>NCT00098241</Identifier><Identifier>RAD/Certican</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>everolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; ischemia time &gt; 40 h Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs Patients with panel reactive T-cell antibodies of 50 % or higher at the last assessment before transplantation</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Incidence/rate of infections</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Other Laboratory Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety And Efficacy of Certican in Pediatric De Novo Renal Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>81 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="40943"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>UK</Country><Country>Taiwan</Country><Country>Spain</Country><Country>Belgium</Country><Country>Austria</Country><Country>US</Country><Country>Germany</Country><Country>New Zealand</Country><Country>France</Country><Country>Puerto Rico</Country><Country>Italy</Country><Country>Argentina</Country><Country>Australia</Country><Country>Canada</Country></Countries><DateChangeLast>2018-07-05T00:00:00Z</DateChangeLast><DateEnd>2011-07-31T00:00:00Z</DateEnd><DateStart>2006-01-31T00:00:00Z</DateStart><Identifiers><Identifier>-</Identifier><Identifier>2005-003413-32</Identifier><Identifier>CRAD001A2310</Identifier><Identifier>NCT00300274</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including ciclosporin, Novartis , everolimus , mycophenolate mofetil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>721</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>melanoma skin lesions) Patients with a known hypersensitivity to similar drugs and to the components of the formulations Patients with donor greater than 65 years and/or with known donor coronary or heart disease at the time of transplant Donor heart &lt;b&gt;cold&lt;/b&gt; ischemic time &gt; 6 h Patients who are treated with drugs strong inducers or inhibitors of cytochrome P450 3A4. (See appendix 4) Patients who are unable to take oral medication by mouth (short- term NG administration allowed no longer than Day 5) Existence</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR associated with hemodynamic compromise (HDC)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure - Incidence of graft loss</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Loss to follow up</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Re-transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>-: Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with cardiopulmonary disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Carotid artery intima-media </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>66</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="39802"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Grunenthal GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ortho-McNeil Janssen Scientific Affairs, LLC</Company></CompaniesSponsor><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2008-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CR015040</Identifier><Identifier>KF5503/49</Identifier><Identifier>NCT00814580</Identifier><Identifier>R331333PAI3022</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxycodone IR alone</Intervention><Intervention>tapentadol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>382</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>least 3 days post-operatively. Patients who continue to meet all study criteria post-operatively would be randomized prior to PACU discharge and would be sent home with study medication (Visit 2). All patients would be prescribed a standard regimen of &lt;b&gt;cold&lt;/b&gt; pack application to the surgical shoulder. Patients would be instructed to take the first dose of study medication as their first oral analgesic when they have at least moderate pain (prior to discharge or at home). Patients would be reminded about</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=30% response</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=50% response</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of Health Services Utilization</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="39117"><Indications><Indication>Hypertension</Indication></Indications><ActionsPrimaryInterventionsControl><Action>ACE inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antihypertensive</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Takeda Europe R&amp;D Centre Ltd</Company><Company>Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Bulgaria</Country><Country>Slovakia</Country><Country>Finland</Country><Country>Estonia</Country><Country>Germany</Country><Country>Netherlands</Country><Country>Serbia</Country><Country>Sweden</Country><Country>Poland</Country></Countries><DateChangeLast>2017-03-07T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>01-06-TL-491-020</Identifier><Identifier>2007-002583-10</Identifier><Identifier>NCT00760214</Identifier><Identifier>U1111-1113-8982</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ramipril alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>azilsartan medoxomil potassium (hypertension), Takeda/ Arbor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>885</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>that alter blood pressure, including: Tricyclic antidepressants Monoamine oxidase inhibitors Lithium Phosphodiesterase type 5 inhibitors Diet medications Amphetamines or their derivatives Chronically used (defined as more than 3 doses per week) common &lt;b&gt;cold&lt;/b&gt; medications or nonsteroidal anti-inflammatory, including aspirin greater than 300 mg/day or cyclooxygenase-2 inhibitors Systemic use of corticosteroids (topical or inhaled is acceptable) Thiazolidinediones Herbal medications Is hypersensitive to angiotensin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - DBP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - SBP control rate</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>16</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="386874"><Indications><Indication>Tooth disease</Indication></Indications><CompaniesSponsor><Company>Personal Products Co</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2014-05-31T00:00:00Z</DateEnd><DateStart>2014-03-31T00:00:00Z</DateStart><Identifiers><Identifier>KOXDHY0009</Identifier><Identifier>NCT02113579</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Crest alone</Intervention><Intervention>mouth rinse 12027-033 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>375</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>process, complete a medical/dental history, and be evaluated for tactile sensitivity to Yeaple probe and response to a &lt;b&gt;cold&lt;/b&gt; air stimulus. Participants who qualify through screening would begin a run-in period that will last approximately 2 weeks. The...recession A minimum of two eligible teeth (premolars, canines and/or incisors) with a screening (-2 weeks baseline) and baseline &lt;b&gt;cold&lt;/b&gt; air stimulus Visual Analogue Scale (VAS) score of 40 to 80 mm on a 100 mm VAS scale, tactile sensitivity score between</Teaser><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity</TitleDisplay><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Michael Lynch</Name></ContactNames></Trial><Trial Id="386262"><Indications><Indication>Common cold</Indication><Indication>Nasal congestion</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Prostaglandin synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AFT Pharmaceuticals Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-07-01T00:00:00Z</DateChangeLast><DateEnd>2017-03-17T00:00:00Z</DateEnd><DateStart>2015-11-10T00:00:00Z</DateStart><Identifiers><Identifier>2015-002385-23</Identifier><Identifier>AFT-MXCF-03</Identifier></Identifiers><InterventionsControlDisplay><Intervention>phenylephrine hydrochloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Maxiclear alone</Intervention><Intervention>acetaminophen and ibuprofen (oral formulation, pain), AFT Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>275</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser> Male and/or female aged &gt;/= 18 years Presents &lt;b&gt;cold&lt;/b&gt; symptoms which began within 96 h of the study entry Has a minimum score of 2 from the list of the following URTI symptoms: runny nose, blocked nose, sore throat and cough For females: must be sterile or using adequate contraception Has a baseline NAR</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III clinical study to study the effects of different doses of phenylephrine hydrochloride in combination with paracetamol and/or ibuprofen, in people with blocked nose due to the common cold</TitleDisplay><BiomarkerNames><BiomarkerName>Specific airway conductance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ioana Stanescu</Name></ContactNames></Trial><Trial Id="386022"><Indications><Indication>Adenocarcinoma</Indication><Indication>Anal tumor</Indication><Indication>Cervical dysplasia</Indication><Indication>Papillomavirus infection</Indication><Indication>Uterine cervix tumor</Indication><Indication>Vaginal cancer</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Protein recombinant</Technology><Technology>Suspension</Technology><Technology>Viral coat protein</Technology></Technologies><CompaniesSponsor><Company>MSD R&amp;D (China) Co Ltd</Company><Company>Merck &amp; Co Inc</Company><Company>Merck Sharp &amp; Dohme BV</Company><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2027-02-01T00:00:00Z</DateEnd><DateStart>2019-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CTR20190587</Identifier><Identifier>NCT03998254</Identifier><Identifier>V503-023</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Gardasil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Gardasil 9 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>6000</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V-503 ) vaccine in Chinese women 20 to 45 years of age. The safety and tolerability of the V-503 vaccine is evaluated. Using the qHPV vaccine as a control, whether the V-503 vaccine inoculated reduces the HPV 31, 33, 45, 52, and 58-related cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) is observed in Phases I and II of the study). The incidence of adenocarcinoma and cervical cancer</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 11) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 16) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 18) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 31) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 33) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 45) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 52) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 58) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 6) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Morbidity</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of adverse events</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Human Papillomavirus Infection - Assessment of frequency/incidence/persistence of human papillomavirus infection</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Clinical Assessments</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy, Immunogenicity and Safety of V-503 in Chinese Women Aged 20 to 45 Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Human Papillomavirus Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-human papillomavirus type 11 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 16 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 18 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 31 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 33 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 45 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 52 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 58 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 6 antibodies</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2027-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>91 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Li Guohua</Name><Name>Li Honghua</Name><Name>Ma Xiang</Name><Name>Medical Director</Name><Name>Mo Zhaojun</Name><Name>Ren Sibiao</Name><Name>Shi Shaodong</Name><Name>Su Ruiping</Name><Name>Yin Peng</Name><Name>Zhao Wei</Name><Name>Zhu Xiaoping</Name></ContactNames></Trial><Trial Id="384911"><Indications><Indication>Cold agglutinin disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Apellis Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2019-06-19T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>Patients with &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD)... This is a phase III trial of APL-2 in patients with &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD) [ 2164236 ]. In June 2019, Apellis Pharmaceuticals Inc planned to commence this trial in early 2020 [ 2164236 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A Phase III trial of APL-2 in patients with cold agglutinin disease (CAD)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="383733"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>NeRRe Therapeutics Ltd</Company></CompaniesSponsor><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>This is a phase III study of orvepitant for cough [ 2160349 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III study of orvepitant for Cough</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="380991"><Indications><Indication>Bordetella pertussis infection</Indication><Indication>Clostridium tetani infection</Indication><Indication>Corynebacterium diphtheriae infection</Indication><Indication>Haemophilus influenzae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology></Technologies><CompaniesSponsor><Company>Beijing Minhai Biotechnology Co Ltd</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-05-29T00:00:00Z</DateChangeLast><Identifiers><Identifier>2016L05247</Identifier><Identifier>CTR20182419</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Cell-free white-breaking Haemophilus influenzae type b vaccine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Haemophilus influenzae type b (Hib) vaccine (freeze-dried), Beijing Minhai Biotechnology alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1710</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>of cell-free white broken combination vaccine: 0.5 ml per dose, 0.5 ml per human dose, the cell-free pertussis vaccine titer will be not less than 4.0 IU, the diphtheria vaccine titer will be not less than 30 IU, broken. The vaccine efficacy of the &lt;b&gt;cold&lt;/b&gt; vaccine will be not less than 40 IU; Hemophilus influenzae type b conjugate vaccine: 0.5 ml per bottle, 0.5 ml per human dose, and no less than 10 microg of Hemophilus influenzae type b capsular polysaccharide. Intramuscular injection, vaccination </Teaser><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibody concentration</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Adsorption of cell-free baibai broken freeze dry Haemophilus influenzae type b combined vaccine III</TitleDisplay><PatientSegmentTerms><PatientSegment>Haemophilus Influenzae Type B Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Li Dahan</Name><Name>Li Guifan</Name><Name>Liang Shu</Name><Name>Liang Shuming, Bachelor of Medicine</Name><Name>Sun Guangwei</Name></ContactNames></Trial><Trial Id="38023"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farma SpA</Company><Company>Novartis Oncology</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Turkey</Country><Country>UK</Country><Country>India</Country><Country>France</Country><Country>US</Country><Country>Italy</Country><Country>Spain</Country><Country>Germany</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-02-21T00:00:00Z</DateChangeLast><DateEnd>2010-04-30T00:00:00Z</DateEnd><DateStart>2008-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-004367-22</Identifier><Identifier>CACZ885D2306</Identifier><Identifier>NCT00685373</Identifier></Identifiers><IndicationsAdverse><Indication>Abscess</Indication><Indication>Arthralgia</Indication><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Spontaneous abortion</Indication><Indication>Tonsillitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>166</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>required before any assessment is performed for patients&amp;nbsp;&amp;lt;18 years of age Diagnosis of familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome, Muckle-Wells syndrome or Muckle-Wells syndrome with overlapping symptoms of neonatal onset multisystem inflammatory disease...studies or newly identified patients with the following cryopyrin-associated periodic syndromes (CAPS): familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome, Muckle-Wells syndrome or Muckle-Wells syndrome with overlapping symptoms of neonatal onset multisystem</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability - Assessment of serious/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by urticaria severity score</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Clinical Assessments</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of ACZ-885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>28</NumberOfSites></Trial></SearchResults></trialResultsOutput>